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Background
Despite the success of checkpoint blockade immunotherapy in
characteristically immunogenic cancers such as melanoma, these
antibodies remain ineffective against poorly T cell-infiltrated malig-
nancies including prostate cancer. Sensitizing these “cold” tumors to
immunotherapy will require interventions which enhance tumor anti-
gen presentation and T cell priming, while suppressing microenviron-
mental signals which constrain T cell expansion, survival, and effector
function independent of coinhibitory signaling. We investigated
whether intratumoral administration of either the STING agonist c-di-
GMP (CDG) or dendritic cell (DC) growth factor Flt3-ligand can po-
tentiate the therapeutic effects of T cell checkpoint modulation with
αCTLA-4, αPD-1, and α4-1BB in a bilateral subcutaneous model of
prostate adenocarcinoma. Additionally, we tested whether intratu-
moral delivery of low-dose checkpoint modulators with CDG at a sin-
gle lesion can achieve abscopal control of distal lesions.
Methods
Male C57BL/6 mice were challenged subcutaneously on both flanks
with TRAMP-C2 prostate adenocarcinoma, and treatment was admin-
istered intraperitoneally and/or intratumorally for 3 doses every
4 days, beginning on day 14 post-implantation for survival experi-
ments or day 31 for flow analysis experiments.
Results
Intratumoral delivery of STING agonist CDG alone potently rejects
all injected TRAMP-C2 tumors, but fails to generate systemic con-
trol of uninjected lesions. Systemic administration of αCTLA-4,
αPD-1, and α4-1BB cures 40 % of mice with bilateral TRAMP-C2,
and concurrent administration of CDG at one or both flanks en-
hances survival to 75 %. Similar effects are observed with© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeintratumoral Flt3L, although administration at both flanks is re-
quired for full effect. Intratumoral low-dose αCTLA-4, αPD-1, and
α4-1BB at a single flank induces abscopal effects in 20 % of mice,
and concurrent administration of CDG enhances systemic immun-
ity to cure up to 50 % of mice. We observe that the level of
STING activation required to mediate rejection without inducing
ulcerative toxicity is proportional to initial tumor size. Function-
ally, local STING activation complements intratumoral checkpoint
modulation to reduce local MDSC infiltration, enhance CD8:Treg
ratios, and downregulate the M2 macrophage marker CD206. In
contrast, local Flt3L robustly enhances immune infiltration of
injected and distal tumors, but therapeutic benefit is attenuated
due to concomitant induction of FoxP3+ Treg.
Conclusions
Intratumoral STING activation via CDG or DC expansion with Flt3L
potentiates the therapeutic effects of systemically-delivered αCTLA-4,
αPD-1, and α4-1BB against multi-focal TRAMP-C2 prostate cancer.
The abscopal potential of CDG alone is weak, in contrast to prior ob-
servations, but combining CDG with low-dose checkpoint blockade
intratumorally can induce systemic immunity, suggesting an alterna-
tive approach for clinical implementation of combination immuno-
therapies at reduced doses.
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Background
Induction of immune responses against multiple antigens expressed
from conventional vector platforms is often ineffective for reasons
not well understood. Common methods of expressing multiple anti-
gens within a single vector construct include the use of fusion pro-
teins, endoprotease cleavage sites, or internal ribosome entry sites.
These methods often lead to decreased expression of antigens-of-le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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encoded antigens. Circumventing these limitations, we have devel-
oped a novel production process for our integration-deficient, den-
dritic cell-targeting lentiviral vector platform, ZVex, enabling highly
flexible and effective multigene delivery in vivo, making it possibly
the most versatile vector platform in the industry.
Methods
Up to five vector genome plasmids, each encoding one full-length
antigen or immuno-modulator, were mixed with four constant plas-
mids, each encoding vector particle proteins, prior to transfection of
production cells. Due to the propensity of lentiviruses forming gen-
omic reassortants, the resulting vector preparations hypothetically
contain a mix of homozygous and heterozygous vector particles.
qRT-PCR was used to determine total and antigen-specific titers of
ZVex-Multi vectors, defined as vector genome counts. Mice were im-
munized with ZVex-Multi vectors or monozygous vectors expressing
multiple antigens from the same backbone to compare immunogen-
icity via intracellular cytokine staining. Two tumor models were used
to evaluate therapeutic efficacy: 1) a B16 melanoma model, where
tumor cells were inoculated in the flank and measured 2–3 times per
week; and 2) a metastatic CT26 colon carcinoma model, where tumor
cells were inoculated intravenously, and lung nodules were enumer-
ated 17–19 days post-tumor inoculation.
Results
Titrations by qRT-PCR of multiple ZVex-Multi vector lots demon-
strated that production yields of ZVex-Multi expressing up to four dif-
ferent tumor-associated antigens (e.g., NY-ESO-1, MAGE-A3) and two
immuno-modulators (e.g., IL-12, anti-CTLA-4 or anti-PD-L1) were
highly reproducible. Compared to mice immunized with vectors ex-
pressing multiple antigens from the same backbone, mice immu-
nized with ZVex-Multi vectors consistently developed T cells against
all targeted TAAs and exhibited improved tumor growth control and
survival.
Conclusions
ZVex-Multi is a next generation DC-tropic vector platform designed
to overcome limitations of single-genome vector platforms with re-
spect to efficient co-expression of any combination of desired genes.
Unlike other vector platforms, ZVex-Multi eliminates multiple cloning
steps modifying the vector backbone, which can often result in un-
predictable expression patterns of coded gene products. Its versatility
and agility makes ZVex-Multi potentially the best-in-class vector plat-
form for co-expression of multiple tumor antigens and immuno-
modulators for enhanced cancer immunotherapy against a broad
range of tumors.
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Background
Monalizumab (IPH2201) is a first-in-class humanized IgG4 target-
ing NKG2A, which is expressed as heterodimer with CD94 on the
surface of NK, γδT and tumor infiltrating CD8+ T cells. This inhibi-
tory receptor binds to HLA-E in humans and to Qa-1b in mice.
HLA-E is frequently up-regulated on cancer cells, protecting from
killing by NKG2A+ cells. Monalizumab blocks binding of CD94-
NKG2A to HLA-E, reducing inhibitory signaling thereby enhancing
NK and T cell responses. PD-1/PD-L1 inhibitors are successfully
being used to treat patients with a wide variety of cancers. Com-
bined blockade of NKG2A/HLA-E and PD-1/PD-L1 may be a prom-
ising strategy to better fight cancer by activating both the
adaptive and innate immune systems.Methods
To assess the effect of combined blockade of NKG2A/HLA-E and
PD-1/PD-L1 in vivo, anti-mouse NKG2A and PD-1 antibodies were
used in mice engrafted with A20 mouse B lymphoma cell line.
For in vitro assays, anti-PD-L1 antibody durvalumab, and monali-
zumab were tested in human PBMC staphylococcal enterotoxin b
assays.
Results
When cultured in vitro, the A20 cells express ligands for PD-1 but not
for NKG2A. Exposure to IFN-γ in vitro, or subcutaneous injection into
mice, induced expression of Qa-1b, resulting in a tumor model co-
expressing PD-L1 and Qa-1b. Monotherapy with PD-1 or NKG2A
blockers resulted in moderate anti-tumor efficacy while treatment
with combination of NKG2A and PD-1 blockers resulted in a signifi-
cantly higher anti-tumor immunity, and an increased rate of
complete tumor regression. Depletion of either NK, or CD8+ T cells,
or IFN-γ was enough to abrogate the efficacy of PD-1 and NKG2A
blockade, indicating that both of these effector populations contrib-
ute to the efficacy of the combination treatment. To further explore
this possibility and to assess the potential therapeutic relevance in
humans, well-validated PBMC-based assays were used which showed
that blocking both axes with a combination of durvalumab and mon-
alizumab led to increased production of cytokines by both T and NK
cells. Furthermore, the magnitude of the increase in cytokine secre-
tion was dependent on the production of high levels of IFN-γ. Since
IFN-γ is known to induce HLA-E this suggests that blockade of
NKG2A could have a beneficial role in activation of immune cells
through the combined blockade of PD-1/PD-L1.
Conclusions
Together, these data indicate that blocking NKG2A in conjunction
with PD-1/PD-L1 checkpoint inhibitors provides increased anti-tumor
efficacy mediated by IFN-γ and support the rationale for assessing
this combination in clinical trials.
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Background
The pharmacokinetics of pembrolizumab given as monotherapy
are well characterized. Consistent with other monoclonal
Fig. 2 (abstract P192). Observed pembrolizumab serum
concentrations from patients with melanoma treated with
pembrolizumab plus ipilimumab in relation to the predicted
concentration interval (gray) for pembrolizumab 2 mg/kg Q3W
monotherapy (log scale)
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ited central (3.53 L) and peripheral (3.85 L) volume of distribu-
tion, and low variability in the central volume of distribution
(19 % coefficient of variation). Pembrolizumab monotherapy has
low immunogenicity potential, with an observed incidence of
treatment-emergent anti-drug antibodies (ADA) of < 1 %. We
present data on the pharmacokinetics and immunogenicity of
pembrolizumab when given in combination with ipilimumab in
the phase I KEYNOTE-029 study.
Methods
KEYNOTE-029 included 2 cohorts that assessed the safety and
antitumor activity of pembrolizumab plus ipilimumab: a safety
run-in that included patients with advanced melanoma or renal
cell carcinoma (RCC) (N = 22) and a melanoma expansion cohort
(N = 153). In both cohorts, patients received 4 doses of pembroli-
zumab 2 mg/kg plus ipilimumab 1 mg/kg Q3W followed by
pembrolizumab 2 mg/kg Q3W for up to 2 years. Pembrolizumab serum
concentration was quantified with an electrochemiluminescence-based
immunoassay (lower limit of quantitation, 10 ng/mL). A validated bridg-
ing electrochemiluminescence immunoassay using a standard 3-
tiered approach (drug tolerance level, 124 μg/mL) was used to
detect ADA in serum.
Results
Across cohorts, 175 patients received pembrolizumab plus ipili-
mumab: 165 with melanoma and 10 with RCC. At least 1 evalu-
able sample for pharmacokinetic assessment was available for all
10 patients with RCC and 162 patients with melanoma. The pre-
dose serum concentration versus time profiles for pembrolizumab
were similar in patients with RCC and melanoma (Fig. 1). Ob-
served serum concentrations were within the range predicted for
pembrolizumab 2 mg/kg Q3W given as monotherapy (Fig. 2). Of
the 160 patients with melanoma who provided postdose ADA
samples, 156 (97.5 %) were negative, 2 (1.3 %) were inconclusive,
and 2 (1.3 %) were positive for treatment-emergent ADA. Best
overall response in the ADA-positive patients was stable disease
in one and progressive disease in the other. No patient with RCC
had treatment-emergent ADA.
Conclusions
The addition of ipilimumab does not appear to impact pembrolizu-
mab serum concentration or increase the risk of developing ADA in
patients with advanced melanoma or RCC.
Trial Registration
ClinicalTrials.gov identifier NCT02089685.Fig. 1 (abstract P192). Arithmetic mean (SE) predose serum
concentration-time profile of pembrolizumab following multiple
doses of pembrolizumab plus ipilimumab (linear-linear scale)P193
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Background
Talimogene laherparepvec (T-Vec) is the first oncolytic virus to be
U.S. Food and Drug Administration (FDA) approved for the treat-
ment of cancer. T-Vec, a modified herpes simplex type I (HSV I)
virus, has two proposed mechanisms of action: direct cell lysis
and immune activation. Combination immunotherapy using T-Vec
and checkpoint blockade has shown promise in clinical trials. In
preliminary work, our laboratory has shown that T-Vec causes up-
regulation of programmed cell death protein 1 (PD-1) on infiltrat-
ing T cells in mice, suggesting potential synergy of T-Vec and
anti-PD-1 (αPD-1).
Methods
In a temporally and spatially regulated murine model of BRAFCA
PTEN−/− spontaneous melanoma [1], tumors are induced on right
flank. When tumors reach >5 mm in diameter, mice are random-
ized into 6 treatment groups comparing combinations of BRAF
inhibition (BRAFi), αPD-1, and T–Vec (Table 1). Tumor growth is
measured twice a week until end of study. Flow cytometry is per-
formed on tumor, lymph node, and spleen to assess immune
microenvironment.
Fig. 4 (abstract P193). Survival comparison of treatment groups
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Mean tumor volume and survival was plotted to compare
groups (Figs. 3 and 4). Mice treated with triple combination
have decreased tumor growth. Mice treated with combination
T-Vec + BRAFi with or without αPD-1 have longer survival com-
pared to mice treated with control or single drug arms. Flow
cytometry shows increase in percent CD3+/CD45+ cells in tu-
mors of mice treated with combination αPD-1 + T-Vec compared
to the control and single drug arms. Percent CD8+/CD3+ cells
in tumors treated with immunotherapy appears to be increased
compared to the control and BRAFi only group (Fig. 5). Add-
itionally, percent of FOXP3+/CD4+ cells in tumors appears to be
decreased in groups receiving T-Vec (Fig. 6) while no change in
FOXP3+/CD4+ populations was observed in tumors from groups
receiving αPD-1 without T-Vec or in draining lymph node or
spleen.
Conclusions
Initial findings show that combination therapy of BRAFi + αPD-1
+ T-Vec is more effective than any single treatment.
Combination immunotherapy increases infiltration of T cells into
tumor. Furthermore, oncolytic virus appears to decrease
regulatory T cells infiltrating tumor. This study is ongoing and
further analysis will continue as we further evaluate the
immune microenvironment using flow cytometry and
immunohistochemistry.
Acknowledgements
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41:544–552.Table 1 (abstract P193). Treatment groups
Group Treatment
Group 1 (Red) Control Chow + IP 2A3 + IT PBS
Group 2 (Orange) BRAFi Chow + IP 2A3 + IT PBS
Group 3 (Yellow) BRAFi Chow + Ip α-PD1 + IT PBS
Group 4 (Green) BRAFi Chow + IP 2A3 + IT T-Vec
Group 5 (Blue) BRAFi Chow + IP α-PD1 + IT T-Vec
Group 6 (Purple) Control Chow + IP α=PD1 + IT T-Vec
IP intraperitoneal, IT intratumoral, BRAFi brief inhibiotor, α-PD1 anti
programmed cell death 1, T-Vec talimogene Leherparepvec
Fig. 3 (abstract P193). Tumor volume comparison of all mice
Fig. 5 (abstract P193). Flow cytometry data of CD8+ cells per CD3
+ cell populations
Fig. 6 (abstract P193). Flow cytometry data of CD4+/FOXP3+ cells
per CD4+ cell populations
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Background
Phosphatidylserine (PS) is a phospholipid that is exposed on the sur-
face of apoptotic cells, some tumor cells and tumor endothelium. PS
has been shown to promote anti-inflammatory and immunosuppres-
sive signals in the tumor microenvironment. Antibodies that target
PS have been shown to reactivate anti-tumor immunity by repolariz-
ing tumor associated macrophages to a M1-like phenotype, reducing
the number of MDSCs in tumors and promote the maturation of den-
dritic cells into functional APCs. In a B16 melanoma model, targeting
PS in combination with immune checkpoint blockade has been
shown to have a significantly greater anti-cancer effect than either
agent alone. This combination was shown to enhance CD4+ and
CD8+ T cell infiltration and activation in the tumors of treated ani-
mals. Radiation therapy is an effective focal treatment of primary
solid tumors, but is less effective in treating metastatic solid tumors
as a monotherapy. There is evidence that radiation induces immuno-
genic tumor cell death and enhances tumor-specific T cell infiltration
in irradiated tumors. In addition, the abscopal effect, a phenomenon
in which tumor regression occurs outside the site of radiation ther-
apy, has been observed in both preclinical and clinical trials with the
combination of radiation therapy and immunotherapy.
Methods
We examined the effects of combining tumor radiation therapy with
an antibody that targets PS (1 N11) and an immune checkpoint
blockade (anti-PD-1) using the mouse B16 melanoma model. Tumor
surface area and overall survival of mice were used to determine effi-
cacy of the combinations.
Results
We examined the expression of PS on immune cells infiltrating B16
melanomas. CD11b +myeloid cells expressed the highest levels of PS
on their surface whereas T cells and B16 tumor cells express little to
no PS. These data suggest that targeting PS in B16 melanoma would
induce a pro-inflammatory myeloid tumor microenvironment. We
hypothesize that therapies that induce apoptotic cell death on tumor
cells would enhance the activity of PS-targeting antibodies. We
therefore examined the effects of combining a PS-targeting antibody
with local tumor radiation. We found that the PS-targeting antibody
synergizes with both anti-PD-1 and radiation therapy to improve
anti-cancer activity and overall survival. In addition, the triple com-
bination of the PS-targeting antibody, tumor radiation and anti-PD-1
treatment displayed even greater anti-cancer and survival benefit.
Conclusions
This finding highlights the potential of combining these three agents
to improve outcome in patients with advanced-stage melanoma and
may inform the design of future clinical trials with PS targeting in
melanoma and other cancers.
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In the tumor microenvironment, T cell inhibitory checkpoint recep-
tors trigger signals that suppress T cell effector function, resulting in
tumor immune evasion. Clinical antibodies blocking one of these re-
ceptors, PD-1, yield positive responses in multiple cancers; however,
their efficacy is limited. Simultaneously targeting more than one in-
hibitory checkpoint receptor has emerged as a promising therapeutic
strategy. In support of this concept, mice deficient in PD-1 and LAG-
3, an inhibitory checkpoint receptor often co-expressed with PD-1 in
the tumor microenvironment, exhibit enhanced anti-tumor activity.
Here, we demonstrate increased anti-tumor efficacy of a combined
anti–human PD-1 (hPD-1) and anti–human LAG-3 (hLAG-3) therapy
using fully human monoclonal antibodies in dual humanized PD-1 x
LAG-3 mice. The pharmacokinetics and toxicology of the novel anti-
hLAG-3 antibody were assessed in non-human primates to support
clinical development.
Methods
REGN2810, a high affinity anti-hPD-1 monoclonal antibody that
blocks PD-1 interaction with PD-L1 and PD-L2, and a novel high
affinity monoclonal anti–hLAG-3 antibody, which blocks the LAG-
3/MHC II interaction were generated. Dual humanized PD-1 x
LAG-3 mice were engineered by replacing the extracellular do-
mains of mouse Pdcd1 and Lag3 with the corresponding regions
of hPD-1 and hLAG-3 and were used for testing antibody efficacy
in a MC38.ova syngeneic tumor model. Expression of humanized
PD-1 and LAG-3 were analyzed by flow cytometry. Binding of
hLAG-3 to mouse MHC II was confirmed with a cell adhesion
assay, and binding of hPD-1 to mouse PD-L1 was confirmed
using surface plasmon resonance. The pharmacokinetics of anti-
hLAG-3 antibody following a single i.v. dose, and the safety pro-
file in a 4-week weekly i.v. dose regimen of up to 50 mg/kg/
dose, were determined in cynomolgus monkeys.
Results
Treatment of MC38.ova tumor-bearing humanized mice with a com-
bination of anti-hPD-1 and anti-hLAG-3 antibodies triggered activa-
tion of intratumoral and peripheral T cells. Importantly, the
combination treatment exhibited an additive, dose dependent anti-
tumor effect compared to the respective monotherapies. Anti-hLAG-
3 antibody pharmacokinetics in cynomolgus monkeys followed a
standard mean concentration-time profile characterized by an initial
brief distribution phase and a linear beta elimination phase. Exposure
to anti-hLAG-3 increased in a dose-proportional manner, with elimin-
ation half-lives ranging from 10.8 to 11.5 days. Anti-hLAG-3 antibody
was well tolerated, and no-observed-adverse-effect level (NOAEL)
could be established up to 50 mg/kg.
Conclusions
Preclinical anti-tumor efficacy of combined REGN2810 and anti-
hLAG-3 antibody treatment, together with favorable pharmacokinetic
and safety data for anti-hLAG-3 antibody in cynomolgus monkeys,
support clinical development of this cancer combination
immunotherapy.
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Background
The immunological escape of tumors represents one of the main ob-
stacles to the treatment of malignancies. The blockade of PD-1 or
CTLA-4 receptors represented a milestone in the history of
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effective in specific cohorts of patients. It has been proposed that
their efficacy relies on the presence of an immunological response.
Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would
synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry
analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to
combination immunotherapy. However, with a more aggressive
schedule, tumors with a lower burden were more susceptible to the
combination of PeptiCRAd and PD-L1 blockade. The therapy signifi-
cantly increased the median survival of mice (Fig. 7). Interestingly,
the reduced growth of contralaterally injected B16F10 cells sug-
gested the presence of a long lasting immunological memory also
against non-targeted antigens. Concerning the functional state of
tumor infiltrating lymphocytes (TILs), we found that all the immune
therapies would enhance the percentage of activated (PD-1pos TIM-
3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos
TIM-3pos) cells compared to placebo. As expected, we found that
PeptiCRAd monotherapy could increase the number of antigen spe-
cific CD8+ T cells compared to other treatments. However, only the
combination with PD-L1 blockade could significantly increase the ra-
tio between activated and exhausted pentamer positive cells (p =
0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could
decrease the amount of dysfunctional antigen specific T cells. We ob-
served that the anatomical location deeply influenced the state of
CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in-
creased by 2 fold on TILs compared to splenic and lymphoid T cells.
In the CD8+ compartment, the expression of PD-1 on the surface
seemed to be restricted to the tumor micro-environment, while CD4
+ T cells had a high expression of PD-1 also in lymphoid organs.
Interestingly, we found that the levels of PD-1 were significantly
higher on CD8+ T cells than on CD4+ T cells into the tumor micro-
environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check-
point inhibitors might be strongly enhanced by their combination
with cancer vaccines. PeptiCRAd was able to increase the number of
antigen-specific T cells and PD-L1 blockade prevented their exhaus-
tion, resulting in long-lasting immunological memory and increased
median survival.Fig. 7 (abstract P196). Survival of C57 mice bearing B16OVA
tumors and treated on day 6 post-implantation with either PBS,
PDL1 blockade, OVA-targeting PeptiCRAd or the combination of
PDL1-blockade and OVA-PeptiCRAd.P197
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Background
In vitro characterization of reagent efficacy in the context of can-
cer immunotherapy is a necessary step before moving to more
expensive animal models and clinical studies. However, current
in vitro assays like Chromium-51, ATP-based luminescence or flow
cytometry are either difficult to implement in high throughput
environments or are mainly based on endpoint methodologies
that are unable to capture the full dynamic of the immune re-
sponse. Here, we present the adaptation of an impedance-based
platform to monitor cytotoxic activity of immune cells activated
trough different means.
Methods
Impedance technology detects cell death and proliferation of ad-
herent cells by measuring changes in conductance of microelec-
trodes embedded in 96 and 384-wells cell culture plates. We
utilized adherent and B cell leukemia/lymphoma cell lines as well
as primary tumor cells as in vitro models for immunotherapy re-
agent evaluation. We seeded the cells on electrodes coated 96-
well plates and monitored cell adhesion and proliferation for
24 hours. The following day effector cells were added at multiple
effector:target ratios in presence of BiTEs antibodies and/or anti
PD-1/PD-L1 antibodies. Impedance signal was monitored for up
to seven days. Control wells were set up with effector cells only
or with target plus effector cells but without antibodies. We
adapted such adhesion-based technology to monitor non-
adherent B-leukemia/lymphoma cells, by developing a strategy
where the wells are coated with an anti-CD40 antibody. The coat-
ing allows specific adhesion and retention of B cells and meas-
urement of changes in impedance that are proportional to cell
number.
Results
Using increasing concentrations of EpCAM/CD3 BiTE, we demon-
strated the suitability of an impedance-based approach to quantita-
tively monitor the efficacy of immune cells-mediated cancer cell
killing both under different effector:target ratios and antibody con-
centrations. Combination treatments with checkpoint reduced timing
and increased amount of killed cancer cells. Similar results were also
obtained with engineered CAR-T cells against CD19 or NK cell lines,
demonstrating specific killing of tumor B cells at very low effector:tar-
get ratios. The results were also confirmed by flow cytometry.
Conclusions
Overall, our results demonstrate the value of an impedance-based
approach in measuring the cytotoxic response across the temporal
scale, an aspect that is otherwise very difficult to assess with more
canonical end point assays. Furthermore, the availability of 384-well
format and minimal sample handling place the technology in an
ideal spot for applications in large reagent validation screening or
personalized medicine, like therapeutic protocol validation directly
on patient samples.
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Because of the immunosuppressive tumor microenvironment, the im-
mune system is unable to develop effective responses against tumor
cells. This phenomenon also acts against the effectiveness of adop-
tive T cell therapy. In order to overcome this situation in the tumor,
an attractive therapeutic combination is the combination of oncolytic
viruses and immune checkpoint inhibitors. In this case, besides the
last two therapies mentioned above, combinations with T cell ther-
apy were also included. The virus used was engineered to express
tumor necrosis factor α (TNFα) and interleukin (IL)-2, two cytokines
that will boost the immunogenicity of the virus and thus its antitu-
mor properties. On the other hand, the use of anti-PD-1 will avoid ex-
haustion on tumor infiltrating T cells and hence remove the barriers
that could dampen the desired immune response against the tumor.
Methods
In the study of the antitumor effect of this three armed treat-
ment we used an in vivo model of subcutaneous B16-OVA
melanoma-bearing mice. Two experiments were carried out; the
first one (n = 47) to establish the differences between the triple,
double, and single armed combination therapies and the second
experiment (n = 84) was focused on study the differences be-
tween the groups that showed the best outcomes in the first
one and also optimize viral and anti-PD-1 administration regimes.
Results
Preliminary results show a statistically significant positive effect com-
ing out from the combination of virus therapy and immune check-
point blockade with regard to both tumor progression and overall
survival, with up to 43 % complete tumor regression achieved in
some of the groups after 96 days post treatment. On the other hand,
the effect of adoptive cell therapy in this combination is not com-
pletely clear. More results will be presented after analyzing biological
samples collected during both experiments.
Conclusions
Preclinical studies are a key step to detect which combinations are
more suitable for success in human trials. In this study we developed
a rationale for the combination relying on two concepts: to make si-
lent tumors more visible to the immune system and to counter im-
munosuppressive mechanisms to unleash the full potential of T cells
against the tumor, rendering in a modification of the tumor micro-
environment that makes it more susceptible for T cell mediated kill-
ing. According to the results displayed from these experiments, the
combination of this genetically modified adenovirus and PD-1 block-
ade is an efficient combination to be considered for future applica-
tion in humans.
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Background
IMM-101, a heat-killed borate-buffered whole cell product of Myco-
bacterium obuense has been shown to enhance cell mediated cyto-
kine responses and innate immune responses involving NK and
gamma delta cells [1]. Complete responses (CR) in patients with mel-
anoma lung metastases demonstrated. Follow up of original publica-
tion [2] has shown a 30 % 5-year survival. Combined with
gemcitabine in metastatic pancreatic cancer a significant survival
advantage over gemcitabine monotherapy is seen [3].
Methods
We present 3 patients with metastatic melanoma, progressed
after initial stabilisation with IMM-101, who showed CR after
check point inhibitors (CPI) ipilimumab (n = 2), pembrolizumab
(n = 1). Patient 1: 2006 46 M melanoma left forearm, BT 3.7 mm,
1 positive lymph node. Recurrent disease treated with surgery,
Aldara and low dose IL-2. 2010 pulmonary mets, commencedIMM-101, no response (initial SD). 2011 given Ipilimumab. Patient
2: 2011 50 F axillary lump removed, melanoma (no primary).
Concomitant mediastinal, lung, gastric and peritoneal deposits.
Gastric surgery, decarbazine. Commenced IMM-101 with cyber-
knife to lung lesion. 2013 Small bowel obstruction from new dis-
ease. Started ipilimumab. Patient 3: 2014 79 M melanoma, left
cheek, BT 2.4 mm. Regional lymph node recurrence, treated with
a left neck dissection in April 2014. Developed paracardiac
nodes, adrenal, lung and multiple large subcutaneous deposits.
Commenced IMM-101 with initial shrinkage. However, new large
subcutaneous lesions. Commenced pembrolizumab.
Results
Patient 1 - CR on Pet CT, maintained through 2016. Patient 2 - CR
maintained for 2 years. Patient 3 - CR of subcutaneous deposits four
days after first injection.
Conclusions
The CR rate to CPI’s is disappointing, < 1 % for Ipilimumab. PDL-1 ex-
pression is predictive for PD-1 responses and although CPI combina-
tions are clearly needed, most are very toxic. IMM-101 is relatively
free of toxicity, enhances PD-1 expression in pre-clinical models but
may also prime tumour response to check point inhibitors by its ac-
tion on macrophage function. Based on these observations, we
speculate that IMM-101 primes for CPI’s and propose a trial priming
with IMM-101, followed by anti-PD-1 antibodies.
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Background
AGS-003 is an individualized, autologous, tumor antigen-loaded,
dendritic cell (DC) immunotherapy currently in phase III develop-
ment for the treatment of metastatic renal cell carcinoma (mRCC)
in combination with standard-of-care. Antibodies to PD-1 on acti-
vated T cells or PD-L1 expressed on APCs have now been ap-
proved for treatment of several cancer indications including RCC.
While there is a strong mechanistic rationale for the potential
synergy of these agents in combination, data supporting the im-
portance of sequencing the administration of these agents are
limited. Since the DC-based immunotherapy, AGS-003, expresses
high levels of PD-L1, combinations with checkpoint blockade may
remove a critical signal protecting DCs during the early CTL acti-
vation phase in vivo. Concurrent administration of checkpoint in-
hibitors with AGS-003 may, therefore, impede the proposed
mechanism of action of AGS-003, which is the induction of
tumor-specific CTL responses. Results derived from in vitro model-
ing of DCs inducing T cell responses can demonstrate how to
better mobilize the immune system to overcome the immunosup-
pressive environment of cancer. Therefore, it was of interest to
test anti-PD-1/anti-PD-L1 antibody therapy in vitro in combination
with DCs representative of AGS-003, to observe the effects com-
bination therapy would have on antigen-specific CTL proliferation
and functional responses.
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DCs derived from monocytes were co-electroporated with MART-1
RNA and CD40 ligand RNA to represent AGS-003 DC products. In vitro
co-cultures were set up with autologous CTLs and MART-1/CD40L
DCs in the presence of anti-PD-1 or anti-PD-L1 antibodies. In some
instances, PD-1 expression was hyper expressed on CTLs by electro-
porating MART-1-specfic CTLs with PD-1 RNA. Subsequent expansion
of MART-1-specific CTLs and multi-functional responses in the pres-
ence of checkpoint blockade were mapped using multi-color flow
cytometry.
Results
Combination with anti-PD-1 antibody did not did not negatively
affect the expansion of MART-1-specific CTL responses; however, if
PD-1 was hyper-expressed on previously stimulated MART-1-specific
CTLs responses were diminished. Anti-PD-1 antibody blocking re-
stored CTL function in the presence of high levels of PD-1 expression.
Interestingly, anti-PD-L1 antibody blocking resulted in suppression of
early MART-1-specific CTL expansion and subsequent downstream ef-
fector function.
Conclusions
Our results suggest that the sequencing of AGS-003 therapy and
checkpoint blockade is important to allow full CTL activation by the
DCs prior to anti-PD-1/PD-L1 therapy. Moreover the high expression
of PD-L1 on DCs may serve as a “don’t kill the messenger” signal, crit-
ical to prevent deletion of the DC prior to full signal delivery during
early phases of CTL activation.
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Background
Osteosarcoma (OS) is a primary bone malignancy, commonly cul-
minating into aggressive pulmonary metastasis. Despite chemo-
therapy advances, the 5-year survival of pulmonary metastatic OS
remains 25-30 %. Immunotherapy is one of the promising novel
approaches to target minimal residual and relapsed disease. The
objective of this study is to determine if blocking the PD-1/PD-L1
immunosuppressive signaling pathway using a PD-1 checkpoint
inhibitor will have an effect in OS lung metastasis. Anti-PD-1 and
anti-PD-L1 antibodies have exhibited therapeutic benefit in mel-
anoma, and non-small cell lung carcinoma. We hypothesize that
disruption of the PD-1/PD-L1 signaling pathway using anti-PD-1
antibody has an effect against OS lung metastasis and improves
overall survival.
Methods
Flow cytometry and western blotting were used to analyze PD-L1
expression in 7 different OS cell lines. Immunohistochemistry
(IHC) analysis was used to determine PD-L1 expression in OS lung
metastases from patients and mice. LM7 human OS mouse model
was used to test the effect of blocking murine PD-1 in OS lung
metastases. Therapeutic effect of anti-PD-1 treatment was mea-
sured by the number of macro and micro-metastases. IHC was
used to measure cell proliferation (Ki-67), apoptosis (TUNEL) and
cleaved-caspase 3 expression in addition to NK cells and macro-
phages infiltration. Western blotting was used to address the
downstream components of the signaling pathway such as p-
Stat3 and p-Erk1/2. The Simple PCI software was used to quantify
the IHC data.
Results
Our studies revealed surface and total PD-L1 expression in five
out of seven human OS cell lines. Primary and metastatic OS
lung tumor samples from patients demonstrated membranous
and cytoplasmic PD-L1 expression. Using a human OS mouse
model we demonstrated therapeutic effect of anti-PD-1 therapy
as the number of macro and micro-metastases decreased in theanti-PD-1 treated group as compared to the untreated. Anti-PD-1
treatment led to a significant increase in the number of NK cells
and macrophages in the OS lung tumors suggesting these cells
to have a potential therapeutic benefit against OS lung metasta-
ses. In addition, anti-PD-1 therapy caused a decrease in PD-L1 ex-
pression in the lung tumors, possibly due to a decrease in p-
ERK1/2 and p-Stat3 expression.
Conclusions
We conclude that targeting the PD-1/PD-L1 axis could be used to
treat OS lung metastasis. Therapeutic efficacy of anti-PD-1 may be
due to an increased activity of NK cells and/or macrophages in the
lung tumors and that inhibition of the p-Stat3/PD-L1 pathway may
be the mechanism implicated in OS lung metastases after anti-PD-1
treatment.
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Background
Cancer immunotherapy requires effective recognition and elimin-
ation of tumor cells identified as non-self; however, tumors can
evade host immune surveillance through multiple mechanisms,
including epigenetic silencing of genes involved in antigen pro-
cessing and immune recognition. Epigenetic therapy with histone
deacetylase (HDAC) inhibitors has shown limited benefit as a
monotherapy in patients with solid tumors; however, recent re-
ports suggest the potential for synergy when combined with im-
munotherapy. Entinostat is a class I-HDAC inhibitor undergoing
trials for the treatment of various cancers, while vorinostat is a
pan-HDAC inhibitor approved in the United States for the treat-
ment of cutaneous T cell lymphoma. The aim of this study was
to extensively evaluate the effects of entinostat and vorinostat on
human peripheral immune cell subsets in order to examine the
potential for combination of HDAC inhibitors with cancer
immunotherapy.
Methods
Peripheral blood mononuclear cells (PBMCs) from metastatic
breast cancer patients (n = 7) were exposed in vitro for 48 hours
to clinically relevant exposures of entinostat, vorinostat, or ve-
hicle control. PBMCs were then analyzed by multicolor flow cy-
tometry using 27 unique markers to identify 123 immune cell
subsets, which included 9 classic cell types [CD4+ and CD8+ T
cells, regulatory T cells (Treg), B cells, conventional dendritic
cells (cDC), plasmacytoid dendritic cells (pDC), natural killer cells
(NK), natural killer T cells (NKT), and myeloid derived suppressor
cells (MDSC)], and 114 refined subsets relating to their matur-
ation and function.
Results
Treatment with entinostat and vorinostat induced several notable al-
terations in peripheral immune cells, suggesting mainly immune acti-
vating properties. Exposure to entinostat increased the frequency of
activated CD4+ T cells, activated mature NK cells, antigen presenting
cells (cDCs), and highly immature MDSCs, as well as decreased total
Tregs and those with a suppressive phenotype. Exposure to vorino-
stat induced fewer changes than entinostat, including increasing the
frequency of activated CD4+ T cells, highly immature MDSCs, and
NKT cells.
Conclusions
These findings show that while entinostat and vorinostat have overall
immune activating properties, entinostat induced a greater number
changes than vorinostat. This study supports the combination of
HDAC inhibitors with immunotherapy, including therapeutic cancer
vaccines and/or checkpoint inhibitors.
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Background
We report a novel role for semaphorin 4D (SEMA4D, CD100) in
modulating the tumor microenvironment (TME) to exclude activated
antigen presenting cells and cytotoxic T lymphocytes so as to pro-
mote tumor growth. Antibody blockade reduces expansion of MDSC,
shifts the balance of M1/M2, T effector/T regulatory cells and associ-
ated cytokines and chemokines, and augments tumor rejection with
immune checkpoint inhibition.
Methods
Anti-SEMA4D antibodies were evaluated, alone and in combination
with immune checkpoint antibodies. Immune response was charac-
terized by immunohistochemistry, flow cytometry, functional assays,
and cytokine, chemokine and gene expression analysis. Anti-tumor
activity was evaluated in various preclinical models. A phase I trial for
single agent VX15/2503 was completed.
Results
SEMA4D restricts migration of macrophages and promotes expan-
sion of suppressive myeloid cells in vitro. Strong expression of
SEMA4D at the invasive margins of actively growing tumors
in vivo modulates the infiltration and polarization of leukocytes in
the TME. Antibody neutralization facilitated recruitment of acti-
vated APCs and T lymphocytes into the TME in preclinical
models. M-MDSCs were significantly reduced in both tumor and
blood following treatment. This was accompanied by a significant
shift towards increased Th1 cytokines and CTL-recruiting chemo-
kines, with concurrent reduction in Treg-, MDSC-, and M2-
macrophage promoting chemokines (CCL2, CXCL1, CXCL5).
Accordingly, an increase in Teff:Treg ratio (3x, p < 0.005) and CTL
activity (4x, p < 0.0001) was observed. NanoString gene expression
analysis of on-treatment tumors confirms an increase in the
gamma-inflammatory gene signature (Ribas, ASCO 2015), includ-
ing significant increases in CXCL9, Gzmb, CCR5, Stat1, Lag3, Ptprc,
Ciita, Pdcd1 (PD-1), and Itga1. These coordinated changes in the
tumoral immune context are associated with durable tumor rejec-
tion and immunologic memory in preclinical colon, breast, and
melanoma models. Importantly, anti-SEMA4D antibody can further
enhance activity of immune checkpoint inhibitors and chemother-
apy. Strikingly, the combination of anti-SEMA4D with anti-CTLA-4
acts synergistically, with maximal increase in survival (p < 0.01)
and complete tumor regression in 100 % of mice, as compared
to 22 % with monotherapy (p < 0.01). SEMA4D antibody treat-
ment was well tolerated in nonclinical and clinical studies; includ-
ing a phase I multiple ascending dose trial in patients with
advanced refractory solid tumors. Patients with the longest dur-
ation of treatment, 48–55 weeks, included colorectal, breast, and
a papillary thyroid patient, who had a partial response by RECIST.
Conclusions
Inhibition of SEMA4D represents a novel mechanism and therapeutic
strategy to promote functional immune infiltration into the tumorand inhibit tumor progression. Phase Ib/IIa trials of combination ther-
apy with immune checkpoint inhibition are planned.
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Background
Regulatory T cells (Treg) modulate anti-tumor immunity by suppress-
ing T cell activation. Treg are induced and maintained by immunoreg-
ulatory receptors, such as PD-L1, and respond to homing signals
within the inflamed tumor microenvironment that include the endo-
thelial cell protein, E-selectin, and the CXCR4 ligand, SDF-1. GMI-1359
is a small molecule glycomimetic beginning clinical evaluation with
dual inhibitory activity against E-selectin and SDF-1. The aim of the
current study was to determine if GMI-1359 alone or in combination
with anti-mPD-L1 antibody affected the in vivo growth of CT26 colon
carcinoma and to assess percentages of infiltrative intratumoral cells
expressing immune markers.
Methods
Female Balb/c mice were implanted subcutaneously with 5x105
CT26.WT tumor cells. Three days post tumor injection, mice (n =
15/group) were treated with saline, GMI-1359 (40 mg/kg for 12
consecutive days), isotype control antibody (anti-KLH) or anti-
mPD-L1 antibody (10 F.9G2, 10 mg/kg on days 3, 6, 10, 13, and
17), or the combination of GMI-1359 and anti-mPD-L1 or anti-
KLH. On day 15, tumors and spleens (n = 5/group) were excised
and T cells (total CD4+ and CD8+, and CCR7+/CD62L+ subsets of
each), regulatory T cells (Treg; CD4/CD25/FoxP3), and myeloid de-
rived suppressor cells (MDSC; CD11b+/Gr1+) were determined by
flow cytometry. The remaining mice were followed for tumor
response.
Results
Treatments were well tolerated. Mice in control groups and single
agent GMI-1359 were all identified with progressive disease. In
contrast, treatment with anti-mPD-L1 alone or in combination with
GMI-1359 produced a 40 % complete response (CR) rate. The median
time to CR was shorter when anti-mPD-L1 was combined with GMI-
1359 compared to anti-mPD-L1 alone (14 vs. 23 days, respectively, p <
0.0471). Evaluation of tumor infiltrating cells showed that combination
therapy with GMI-1359 and anti-mPD-L1 reduced the percentage of
Treg compared to treatment with saline, GMI-1359 or anti-mPD-L1 as
single treatments (0.9 % vs. 3.3 %, 2.9 % and 1.9 %, respectively). No
other T cell subsets were affected. In spleens, the median percentage
of Treg were unaffected by any of the treatments and suggest that the
reduction in intratumoral Treg by combined treatment with anti-PD-L1
and GMI-1359 was an attenuated response to maintenance and hom-
ing signals in the tumor microenvironment.
Conclusions
In conclusion, these studies demonstrate that the dual E-selectin/
CXCR4 antagonist, GMI-1359, in combination with anti-mPD-L1 anti-
body attenuates the induction and distribution of intratumoral Treg
and this reduction in Treg is associated with a more rapid immuno-
therapeutic anti-tumor response.
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Background
Phosphatidylserine (PS) is a phospholipid normally residing in the
inner leaflet of the plasma membrane that becomes exposed on vas-
cular endothelial cells and tumor cells in the tumor microenviron-
ment, particularly in response to chemotherapy and irradiation.
Binding of antibodies targeting PS induces the recruitment of im-
mune cells and engages the immune system to destroy tumor and
associated vasculature and by blocking the immunosuppressive ac-
tion of PS. Recent studies have demonstrated that PS-targeting anti-
bodies enhance the anti-tumor activity of immune checkpoint
antibody blockade to CTLA-4 and PD-1 in mouse breast and melan-
oma tumor models. Ibrutinib is an approved anticancer drug target-
ing B cell malignancies that is a selective, covalent inhibitor Bruton's
tyrosine kinase (BTK) in B cell tumors. Data from recent mouse tumor
studies demonstrate that ibrutinib in combination with anti-PD-1
antibody blockade inhibits growth of solid tumors, lacking BTK ex-
pression, suggesting that ibrutinib may inhibit interleukin-2 inducible
T cell kinase (ITK) and promote Th1 anti-tumor responses.
Methods
The present study was conducted to evaluate a combination therapy
including PS-targeting antibody mch1N11, ibrutinib and anti-PD-1
antibody in C57Bl/6 mice bearing triple negative E0771 breast tu-
mors. Tumors were staged to an initial volume of ~100 mm3 and ran-
domized to treatment groups (N = 10) with mch1N11 or isotype
control at 10 mg/kg qw, anti-PD-1 at 2.5 mg/kg qw or ibrutinib
6 mg/kg or vehicle qd x 8. Tumor volumes were measured twice per
week to determine tumor growth inhibition (TGI) relative to control
treated animals. The in vitro sensitivity of E0771 tumor cells to ibruti-
nib was compared to the drug sensitive Jeko-1 cell line in a 72 hour
growth and viability assay.
Results
The E0771 cell line is resistant in vitro to 10 mM ibrutinib. Tumor bear-
ing mice treated with mch1N11, ibrutinib or anti-PD-1 alone had
22.2 %, 23.5 % and 32.6 % TGI respectively. The TGI for mch1N11 and
ibrutinib was 30.5 %, ibrutinib and anti-PD-1 was 34.5 %, mch1N11 and
anti-PD-1 was 36.1 %. The triple combination therapy had statistically
greater TGI compared to control treated mice (59.9 %, p = 0.0084).
Conclusions
Treatment of solid tumors with a combination of inhibitors that target PS,
ITK and the PD-1/PD-L1 axis in the tumor microenvironment provides a
novel treatment for solid tumors, including triple negative breast cancer.
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Background
The excitement in the field of immuno-oncology over the last several
years, driven largely by the clinical success of the first-wave of checkpoint
inhibitors, is tempered by the fact that only 10-40 % of patients respond
to these drugs given as monotherapy. It is widely believed that
to improve efficacy and patient outcome, new approaches that
combine treatments with more than one functionality are
needed. Novel approaches that provide combination therapy in a
single product, will likely lead the way.Methods
We have developed a next generation cellular vaccine platform – re-
ferred to as ComPACT (COMbination Pan-Antigen Cytotoxic Therapy),
that incorporates a tumor antigen chaperone (gp96-Ig) with T cell
costimulation (Fc-OX40L), into a single tumor cell line that secretes
them both (recently published in Cancer Immunology Research 2016).
Results
The current data extend these findings in additional preclinical settings.
Specifically, ComPACT is capable of priming antigen-specific CD8+ T cells
(peak: 13.3 % of total CD8+), even more so than a leading OX40 agonist
antibody (8.4 %) or vaccine alone (5.6 %), and this is associated with in-
creased CD127 + KLRG-1- memory precursor cells and antigen-specific
CD4+ proliferation, with reduced off-target inflammation. Importantly,
vaccine-expressed Fc-OX40L stimulated IFNγ+, TNFα+, granzyme-b + and
IL-2+ by antigen-specific CD8+ T cells. This pharmacodynamic signature
of an anti-tumor immune response predicted enhanced rejection of
established MC38, CT26 and B16.F10 tumors. Additionally, tetramer ana-
lysis of antigen-specific CD8+ T cells (in all 3 tumor models), identified
significant accumulation of tumor infiltrating lymphocytes (TIL), suggest-
ing that ComPACT is not only capable of amplifying antigen-specific T
cells, but these T cells can efficiently target and eliminate tumors. We
have expanded our repertoire of ‘ComPACT’ vaccines to secrete gp96-Ig
along with either Fc-TL1A, Fc-4-1BBL or Fc-ICOSL. Each costimulator/vac-
cine has a unique functionality, which may be context or tumor
dependent. We are currently exploring these mechanistic differences.
Conclusions
Taken together, we show that the magnitude and specificity of vac-
cination can be enhanced by locally secreted costimulatory mole-
cules when delivered within a single product. This may simplify
clinical translation and importantly, provide significant patient bene-
fit by improving safety and lowering costs.
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Background
Chromatin deacetylation is a major determinant in epigenetic silen-
cing of immune-associated genes, a key factor in tumor evasion of
host immune surveillance. Deregulation of epigenetic enzymes, in-
cluding aberrant expression of histone deacetylases (HDACs), has
been associated with poor prognosis in several cancer types, includ-
ing of prostate and lung origin. Vorinostat is a pan-HDAC inhibitor
currently approved in the United States for the treatment of cutane-
ous T cell lymphoma. Entinostat is a class I HDAC inhibitor under clin-
ical investigation for the treatment of various malignancies. HDAC
inhibitors have been shown to delete immunosuppressive elements
and promote synergistic antitumor effects in combination with vari-
ous immunotherapies. Checkpoint inhibitors targeting PD-1/PD-L1 in-
teractions are promising immunotherapies shown to elicit objective
responses against multiple tumors. Avelumab is a fully human IgG1
mAb monoclonal antibody that inhibits PD-1/PD-L1 interaction by
targeting PD-L1, and mediates ADCC against PD-L1-expressing tumor
cells in vitro. We examined the sensitivity of human lung and pros-
tate carcinoma cells to avelumab-mediated ADCC following clinically-
relevant exposure to vorinostat or entinostat.
Methods
Carcinoma cells were exposed daily to vorinostat (3uM) or DMSO for 4
consecutive days, or to entinostat (500 nM) or DMSO for 72 h, prior to
being examined for (a) cell-surface PD-L1 expression or (b) used as
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as effectors. To examine the effect of HDAC inhibitors on PD-L1 expres-
sion in vivo, female nu/nu mice were implanted with NCI-H460 (lung)
or PC-3 (prostate) carcinoma cells. When tumors reached 0.5-
1 cm3, animals received 4 daily doses of DMSO or vorinostat
(150 mg/kg, p.o.). Alternatively, animals received a single dose of
entinostat (20 mg/kg, p.o.) or DMSO 72 h prior to tumor excision.
Frozen specimens were examined for cell-surface expression of
PD-L1 by immunofluorescence.
Results
Our results show that 1) vorinostat and entinostat significantly increase
the sensitivity of human lung and prostate carcinoma cells to ADCC
mediated by avelumab; 2) the anti-CD16 neutralizing mAb significantly
decreases avelumab-mediated lysis of target cells exposed to either
HDAC inhibitor; 3) both HDAC inhibitors can enhance tumor PD-L1 ex-
pression in vitro and in vivo in prostate and/or lung xenograft models;
4) increased avelumab-mediated ADCC of tumor targets exposed to
HDAC inhibitors can occur without increased tumor PD-L1 expression.
Conclusions
These studies provide a rationale for combining vorinostat or entino-
stat with mAbs targeting PD-L1, including for patients that have
failed monotherapy regimens with HDAC or checkpoint inhibitors.
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Background
Our previous work demonstrated that the addition of phosphatidylserine
(PS) targeting antibodies to anti-programmed death ligand 1 (PD-1) ther-
apy in murine triple negative breast cancers (TNBC) significantly en-
hanced immune system activation and tumor growth inhibition. In these
studies, NanoString immune profile analysis showed that intratumoral
levels of lymphocyte activation gene 3 (LAG3) mRNA increased in re-
sponse to PS and PD-1 treatments. This suggests LAG3 may act to at-
tenuate T cell activation in TNBC during I/O therapeutic regimens;
however, it is unknown if PD-1 and LAG3 function cooperatively in regu-
lating T cell anergy, and whether adding PS blocking antibodies can fur-
ther enhance the effectiveness of LAG3 and/or LAG3 + PD-1 therapies.
Methods
Animal studies utilized C57bl/6 mice implanted with the murine TNBC
model E0771. Immunoprofiling analysis was performed by flow cytom-
etry and the NanoString nCounter® PanCancer Immune Profiling Panel.
Antibody treatments utilized a specific phosphatidylserine targeting
antibody (ch1N11), anti-PD-1, or anti-LAG3 alone or in combination. All
statistical analysis utilized the student t-test (significant with p < 0.05).
Results
LAG3 and PD-1 were co-expressed on T cells in E0771. Mice treated
with antibodies targeting PS, PD-1, and LAG3 alone in combination
with each other demonstrated that the addition of PS blocking anti-
bodies to anti-PD-1 therapy or LAG3 had significantly greater anti-
tumor activity than either single agent. Comparison of PD-1 + LAG3
combinational therapy vs. single PD-1 or LAG3 treatments showed
moderately more anti-tumor activity than single treatments; however,
the addition of PS blocking antibodies to either checkpoint inhibitor
was as equally effective in inhibiting tumor growth as observed in the
combination of LAG3 + PD-1 treatment. Further comparison of PD-1 +
LAG3 vs. PS + PD-1 + LAG3 treatments demonstrated that the addition
of PS blocking antibodies resulted in a significant decrease in tumor
growth accompanied by complete tumor regression in a greater num-
ber of animals than observed in the PD-1 + LAG3 treatment group.
FACS and NanoString immunoprofiling analysis on each treatment
group showed that the addition of PS blocking antibodies to all check-
point treatment groups, including the combination of PD-1 + LAG3, re-
sulted in enhanced tumor infiltrating lymphocytes (TILs), a reduction ofmyeloid derived suppressor cells (MDSCs), and enhanced cytokines as-
sociated with immune system activation.
Conclusions
Overall, our data demonstrate that while PS, LAG3, and PD-1 therapies
each have efficacy in TNBC as single agents, I/O treatments that include
PS blocking antibodies offer significantly improved growth inhibition
and are capable of increasing TILs compared to single and combin-
ational treatments by T cell checkpoint targeting inhibitors alone.
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Background
Strategies to re-activate exhausted anti-tumor immune responses with
antibody blockade of key T cell co-inhibitory receptors such as PD-1/
PD-L1 or CTLA-4 have demonstrated transformational potential in the
clinic. TIGIT (a PVR-nectin family member) is a dominant immuno-
inhibitory receptor on tumor-specific T and NK cells, shown to regulate
anti-tumor immunity. Activation of TIGIT on T and NK cells limits prolif-
eration, effector cytokine production, and killing of target tumor cells.
The high affinity receptor for TIGIT is PVR, and the counter agonist re-
ceptor is CD226, all of which are members of the PVR-nectin family.
TIGIT is elevated in the tumor microenvironment in many human tu-
mors and coordinately expressed with other checkpoint immune recep-
tors such as PD-1. However, the spatial and coordinate expression of
these receptors and ligands required for these functions, and the cell-
types involved in anti-tumor immunity, remains unknown.
Methods
TIGIT, CD226 and PD-L1 blockade will be assessed in preclinical syn-
geneic tumor model CT26 and MC38. To determine which immune
cells are important for allowing tumor progression early and late in
disease mice with cell-specific gene ablation for these family mem-
bers were challenged with tumors. Tumor growth was determined
and tumor sections labeled and probed by fluorescence microscopy
to assess TIGIT, CD226 and PVR cellular expression.
Results
In mouse models of both cancer, antibody co-blockade of TIGIT and
PD-L1 enhanced CD8+ T cell effector function, resulting in significant
tumor clearance. TIGIT is expressed on CD8+ T cell, Treg and NK cells.
Specific ablation of TIGIT on CD8+ T cells resulted in tumor clearance,
and was dependent on PVR in the host tissue. Immunofluorescence
studies will be presented.
Conclusions
Therapeutic blockade of TIGIT may result in improved eradication of
malignancies when used in conjunction with other anti-cancer therap-
ies including those that modulate anti-tumor immune responses, and is
currently being tested in phase I clinical trials. Models indicate that in-
hibition of TIGIT with a blocking mAb may release CD226 to activate
tumor-specific T cells. Another mechanism could involve regulation of T
cell suppression by TIGIT on regulatory T cells. A better understanding
of the coordinate interaction between these receptors and ligands in
tumors will be informative for the appropriate application of
checkpoint-therapy combinations.
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Fig. 8 (abstract P211). USP6 Expression in RD-ES Cell Line. USP6 was
expressed in a doxycycline-inducible in the patient derived Ewing sar-
coma cell line. Clonal lines that express high or medium amounts of
USP6 were isolated from the initial pooled population. Expression of
USP6 increased Jak1 levels and activation of downstream effectors STAT1
and STAT3 in an USP6 dose dependent manner. Note: Similar lines were/
are being created for other sarcomas. RD-ES is used as an example
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CC-122 binds the E3 ubiquitin ligase CRL4CRBN resulting in the degrad-
ation of the transcription factor Aiolos and activation of T cells. Preclinical
and clinical data obtained in hematologic malignancies indicate that CC-
122 exerts immunomodulatory activity through enhanced antibody
dependent cell-mediated cytotoxicity and a shift in T cell subsets from a
naïve to effector and memory subsets. CC-122 is in clinical development
in multiple hematologic diseases and in solid tumors such as hepatocellu-
lar carcinoma (HCC) as a single agent (NCT01421524) and in combination
with nivolumab (nivo). The effects of combining CC-122 with immune
checkpoint antibodies in in vitro models of T cell activation and immune
co-culture models with HCC cells were examined.
Methods
Carboxyfluorescein succinimidyl ester (CFSE) based proliferation,
cytokine production and immune co-culture assays were performed
with stimulated peripheral blood mononuclear cells (PBMC) from
healthy donors followed by drug treatment. Drug combinations were
investigated in mixed lymphocyte reactions (MLR) with monocyte de-
rived dendritic cells and T cells from separate donors. Apoptosis was
measured via Annexin V/ToPro3 staining. Synergy calculations were
performed with the fractional product method.
Results
In a 3-day CD3-stimulated PBMC assay, CC-122 (1-10 μM) treatment ele-
vated HLA-DR, a marker of T cell activation, by 3.4-5.5 and 3.2-5.3 fold
in CD4+ and CD8+ T cells, respectively. Proliferation of CD4+ and CD8+
T cells from CD3-stimulated PBMC treated with vehicle, CC-122 (50nM),
nivo (50 μg/ml) or the combination was assessed via CFSE staining. The
percentage of proliferating vehicle-treated CD4+ and CD8+ cells was
37 % and 40 %, compared to nivo (45 % and 47 %), CC-122 (54 % and
68 %) and the combination (61 % and 74 %). SEB stimulated PBMC
were treated with CC-122 (40nM), and nivo or α-PD-L1 (0.1-100 μg/ml)
resulting in secretion of 424, 160 and 154 ng/ml IL-2, respectively. The
combination of CC-122 with either nivo or α-PD-L1 (10 μg/ml) resulted
in synergistic IL-2 secretion levels of 873 and 813 ng/ml, respectively. In
an MLR assay, the combination of CC-122 (100nM) with nivo (10 μg/ml)
or α-PD-L1 (10 μg/ml) resulted in synergistic IL-2 and IFNγ secretion. Fi-
nally, the combination of CC-122 and nivo or CC-122 and α-PD-L1 sig-
nificantly increased PBMC-mediated cytotoxicity of HCC cells compared
to either single agent or isotype control (p≤ 0.05).
Conclusions
CC-122 in combination with nivo or anti-PD-L1 antibodies results in syn-
ergistic activation of T cells and significantly enhanced immune mediated
cytotoxicity against HCC cells. Given the novel mechanism of immuno-
modulation by CC-122 and synergistic combination with checkpoint
blockade, clinical investigation in HCC is currently in progress.
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Background
Bone and soft tissue tumors (BSTTs) represent a heterogeneous class
of neoplasms that disproportionately affect children. Compared to
other malignancies, BSTTs are poorly understood, which has ham-
pered the development of effective therapies. Our lab previously dis-
covered that the oncogenic de-ubiquitylating enzyme USP6 is the
key etiologic agent in several benign BSTTs, and is selectively overex-
pressed in multiple sarcomas, a malignant class of BSTTs [1]. USP6
drives tumorigenesis by directly de-ubiquitylating the Jak1 kinase,
leading to its stabilization and activation of STAT transcription factors
[2]. Since the Jak1-STAT pathway is a central mediator of interferon
(IFN) signaling, we hypothesized that USP6 overexpression in sarco-
mas would render them hypersensitive to the immune stimulatory
effects of IFN, which could be exploited for therapeutic benefit.Methods
USP6 was expressed in a doxycycline-inducible manner in various
patient-derived sarcoma cell lines, including Ewing sarcoma, rhabdomyo-
sarcoma, leiomyosarcoma, and liposarcoma. USP6 expression levels were
confirmed to approximate those in primary patient tumor samples.
Results
USP6 conferred exquisite sensitivity of sarcoma cells to the immuno-
modulatory effects of IFN. Activation of STAT1 and STAT3 were both en-
hanced and prolonged in sarcoma cells expressing USP6 upon IFN treat-
ment. RNA-sequencing confirmed that USP6 induces an IFN response
signature by itself, and that it synergizes with IFN to dramatically induce
interferon-stimulated gene (ISG) expression. The ISGs synergistically induced
by USP6 and IFN include a large group of anti-tumor and immunomodula-
tory genes: the pro-apoptotic ligand TRAIL was dramatically elevated and
mediated apoptosis of USP6-expressing sarcoma cells. Immunomodulatory
factors synergistically induced by USP6 and IFN included chemokines and
cytokines that drive migration and differentiation of T cells.
Conclusions
USP6 overexpression sensitized sarcoma cells to IFN, simultaneously in-
ducing TRAIL-mediated death and stimulating sarcoma cells to produce
immune stimulatory/anti-tumorigenic chemokines and cytokines. This
dual mechanism of action may position IFN as an extremely effective
therapeutic agent for treatment of sarcomas that overexpress USP6.
References
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Fig. 9 (abstract P211). USP6 Sensitizes Cells to IFN-Induced Death.
RD-ES were treated with 1000 U/mL IFNa, IFNB, or IFNy for 24 hours
with or without USP6 expression. IFNB was most effective in inducing
death (~50%). Death was monitored via trypan blue exclusion
Fig. 10 (abstract P211). USP6 Expression Determines Sensitivity to
IFN-Induced Death. RD-ES, RD-ES/USP6(Med), and RD-ES/USP6(High)
were treated with 1000 U/mL IFNB overnight. Higher USP6 increases
the sensitivity of the cells to IFNB induced death. Death was
monitored by PARP cleavage
Fig. 11 (abstract P211). USP6 Synergizes with IFN to Massively
Upregulate TRAIL. RD-ES were treated with 1000 U/mL IFNa, IFNB, or
IFNy for 24 hours with or without USP6 expression. TRAIL was found
to be synergistically induced by IFN in the presence of USP6. IFNB
was the most potent at nearl5 5000-fold over baseline
Fig. 12 (abstract P211). USP6 Synergizes with IFNy to Increase
Chemokine Expression. RD-ES, RD-ES/USP6(Med), and RD-ES/
USP6(High) were treated with 10 U/mL IFNy overnight. The chemokine
CXCL10 was synergistically induced in an USP6 dose-dependent
manner. Similar expression patterns were seen for other chemokines
like CXCL9 and CXCL11
Fig. 13 (abstract P211). USP6 Induces an IFN-Response In Vitro.
RNA-sequencing was performed on RD-ES/USP6(Pooled) were
treated with or without dox. The resulting gene expression data was
analyzed using Gene Sequencing Enrichment Analysis (GSEA) using
the Hallmark dataset (the hallmark dataset contains curated gene
sets that are known to be part of key cellular pathways). USP6
induces a strong IFN-response and Jak-STAT gene expression
Fig. 14 (abstract P211). USP6 Induces an IFN-Response In Vivo
(Ewings Sarcoma). The Ewing sarcoma patient microarray dataset
(GSE37371) was sorted based on USP6 expression and the top 5
USP6 expressing patient samples were compared to the bottom 5
using GSEA. Similar to the in vitro results, high USP6 expression
correlates with activation of Jak-STAT and an IFN-response signature
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Fig. 15 (abstract P211). USP6 Induces an IFN-Response In Vivo
(Rhabdomyosarcoma). The Ewing sarcoma patient microarray dataset
(GSE66533) was sorted based on USP6 expression and the top 5
USP6 expressing patient samples were compared to the bottom 5
using GSEA. Similar to the in vitro results, high USP6 expression
correlates with activation of Jak-STAT and an IFN-response signature
Fig. 16 (abstract P211). USP6 Potentiates IFN Signaling In Vitro.
RD_ES/USP6(Pooled) or RD-ES lines were treated with 1000 U/mL
IFNa of IFNB for the indicated time period. USP6 extended the
duration and amplified the magnitude of STAT1 and STAT3 activation
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Background
Elevated extracellular adenosine in the tumor microenvironment is
immunosuppressive promoting tumor growth and metastasis
through signaling via A2AR on immune cells. CPI-444 is a potent,
oral, selective A2AR antagonist that has been well tolerated in phase
I/Ib studies.
Methods
Preclinical studies were performed with MC38 mouse tumor models
and primary human PBMCs. Based on these results, we have initiated
a phase Ib trial to examine safety, tolerability, biomarkers, and effi-
cacy of CPI-444 as single agent and in combination with anti-PD-L1
antibody, atezolizumab, in patients with selected solid tumors. Per-
ipheral blood and tumor biopsies are collected pre- and post-
treatment for biomarker analysis.
Results
Pre-clinical studies demonstrated cross-talk between adenosine and
PD-1/PD-L1 pathways, providing rationale for combination therapy.
In MC38, anti-PD-L1 treatment resulted in elevated CD39 and CD73
expression on T cells, consistent with increased capacity to generate
adenosine. The adenosine analog NECA inhibited TCR-mediated ERK
phosphorylation and production of IL-2 and IFNγ in human PBMCs;
these inhibitory effects were blocked by CPI-444. Treatment of MC38with CPI-444 led to inhibition of tumor growth, with tumor elimin-
ation in ~30 % of mice. Combining CPI-444 with anti-PD-L1 syn-
ergistically inhibited tumor growth and eliminated tumors in
90 % of mice. When cured mice were re-challenged with MC38,
tumors were uniformly rejected, indicating CPI-444 induced sys-
temic anti-tumor memory. CD8+ depletion abrogated efficacy of
CPI-444 ± anti-PD-L1 treatment. Biomarker results from the on-
going phase Ib trial demonstrate CPI-444 neutralizes A2AR signal-
ing and activates markers of an immune response. To measure
A2AR inhibition, peripheral blood samples were activated with
NECA and pCREB quantified using flow cytometry. A2AR signaling
was robustly inhibited in 8 of 9 patients in an exposure
dependent manner. Of the patients evaluated so far, immune ac-
tivation was observed by flow cytometry analysis of PD-1/CD8
frequency in all continuously treated patients and a subset of pa-
tients on the 14 day schedule. IHC and gene expression of path-
way markers in serial tumor biopsies will be discussed.
Conclusions
In total, this shows that CPI-444 exhibits functional inhibition of ad-
enosine signaling, and treatment is associated with activation of
markers of anti-tumor immunity. This is the first demonstration of im-
mune modulation in cancer patients receiving an adenosine
antagonist.
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Background
Immunotherapy has transformed cancer treatment by unleashing po-
tent and durable anti-tumor immunity against many cancers. However,
because many of the same mechanisms control anti-tumor immunity
and self-tolerance, these therapies can also induce systemic auto-
immunity by activating autoreactive T cells in normal tissues. Combina-
tions of checkpoint inhibitors targeting PD-1 and CTLA-4 increase
clinical response rates, but similarly increase toxicities, thereby reducing
their clinical potential. New approaches are therefore needed that pro-
vide anti-tumor activity without dysregulating systemic immunity.
Methods
CytomX has developed Probody therapeutics (Pb-Tx) that are
proteolytically-activated antibodies designed to widen the thera-
peutic index by minimizing drug interaction with normal tissue while
retaining anti-tumor activity. Pb-Tx are “masked” to attenuate bind-
ing to target in healthy tissue, but can become “unmasked” in the
tumor microenvironment by tumor-specific protease activity.
Results
In vitro, the masked PD-1 Pb-Tx had reduced affinity for mouse PD-1
relative to the parental antibody. Binding affinity was completely re-
stored following addition of appropriate proteases. In mice, single-
agent antibodies to CTLA-4 and to PD-1, and the PD-1 Pb-Tx induced
10 %, 30 %, and 20 % complete tumor regressions (CRs) against
established MC38 tumors, respectively. In combination with anti-
CTLA-4, both PD-1 antibody and Pb-Tx induced 80 % CRs and gener-
ated effective T cell memory against tumor re-challenge. In 10-week-
old NOD mice, a 1 or 10 mpk single dose of anti-PD-1 antibody in-
duced diabetes in 43 % and 57 % of mice, respectively, while a 10
mpk dose of PD-1 Pb-Tx yielded only 14 % disease incidence with
delayed onset. In younger NOD mice, the CTLA-4/PD-1 antibody
combination induced diabetes in 50 % of mice. In contrast, mice ad-
ministered the PD-1 Pb-Tx/CTLA-4 antibody combination were com-
pletely protected. Similar data were generated with a PD-L1-targeted
Pb-Tx.
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A PD-1 targeted Pb-Tx provided equivalent anti-tumor efficacy in mice
to that of its parental antibody while protecting from anti-PD-1-medi-
ated autoimmunity, both as a single agent and in combination with a
CTLA-4 antibody. These results demonstrate that PD-1 Pb-Tx retain
anti-tumor efficacy with improved safety profiles preclinically and
therefore have promise to enable safer combination immunotherapies.
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Background
Immunotherapy has historically been successful in highly antigenic tu-
mors but mostly failed in non-antigenic tumors. Our studies in auto-
immunity have shown that increased antigen load within a tissue
enhances immune reactivity against it. We hypothesize that enhancing
protein target expression on breast tumors can increase the efficacy of
targeted immunotherapy. Lactation proteins have recently been shown
to be effective immunotherapeutic targets on breast tumors. Since lac-
tation proteins are negatively regulated by signaling via the estrogen
receptor (ER), we hypothesize that target lactation protein expression
on breast tumors can be increased by antagonism of the ER in order to
enhance efficacy of antigen specific immunotherapy/vaccination.
Methods
Enhancement of target protein expression in human breast tumors was
tested in vitro by treatment of ER+ (MCF7 cells) and ER + PR+ (T47D cells)
with different doses of the clinically approved ER modulator, tamoxifen.
In vivo modulation of target antigen expression was tested by inoculating
6–7 week old Balb/cJ female mice with 4 T1 breast tumors followed by
oral treatment with tamoxifen. Increase in lactation protein expression
(e.g. alpha lactalbumin) was assayed by in vitro Luciferase assays followed
by confirmation by immunoblotting and immunohistochemistry at differ-
ent time points post treatment. Effect of increased antigen expression on
efficacy of targeted immunotherapy was assessed by antigen specific
immunization of 4 T1 tumor bearing mice with or without tamoxifen ad-
ministration and comparing tumor growth.
Results
Our in vitro studies on human tumors and in vivo murine studies
show that antagonism of the ER via tamoxifen treatment can sub-
stantially increase expression of target lactation proteins such as
alpha lactalbumin on breast tumors. We show that whereas at least a
2–3 fold increased expression of the target protein can be achieved
on tumors, normal breast tissue remains unaffected. Tumor progres-
sion studies revealed that in spite of increased target expression, no
enhancement in efficacy of immunotherapy was achieved via active
immunization protocols. However, efficacy of cell based targeted im-
munotherapies can possibly be enhanced when applied in combin-
ation with our proposed strategy to increase target expression.
Conclusions
Singular increase in target antigen expression on tumors is not effective
in enhancing efficacy of immunotherapy probably due to associated
limiting factors such as DC trafficking, antigen presentation and effect-
ive priming. However, the efficacy of cell-based targeted immunothera-
peutic strategies that circumvent the limitations around active priming
can be enhanced by using our combinatorial strategy of enhancing
antigen expression on tumors via hormone receptor antagonism.
Acknowledgements
The PhRMA Foundation for funding support.P215
Dose escalation/confirmation results of ENCORE 601, a phase Ib/II,
open-label study of entinostat (ENT) in combination with
pembrolizumab (PEMBRO) in patients with non-small cell lung
cancer (NSCLC)
Melissa L Johnson1, Alex A Adjei2, Mateusz Opyrchal3, Suresh
Ramalingam4, Pasi A Janne5, George Dominguez6, Dmitry Gabrilovich6,
Laura de Leon7, Jeannette Hasapidis7, Scott J Diede8, Peter Ordentlich7,
Scott Cruickshank7, Michael L Meyers9, Matthew D Hellmann10
1Sarah Cannon Research Institute, Nashville, TN, USA; 2Mayo Clinic,
Rochester, MN, USA; 3Roswell Park Cancer Institute, Buffalo, NY, USA;
4Emory University, Atlanta, GA, USA; 5Dana-Farber Cancer Institute,
Boston, MA, USA; 6The Wistar Institute, Philadelphia, PA, USA; 7Syndax
Pharmaceuticals, Inc., Waltham, MA, USA; 8Merck Research Laboratories,
North Wales, PA, USA; 9Syndax Pharmaceuticals, Inc., New York, NY, USA;
10Department of Medicine, Memorial Sloan Kettering Cancer Center,
New York, NY, USA
Correspondence: Melissa L Johnson (mjohnson@tnonc.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P215
Background
ENT is an oral, class I selective histone deacetylase (HDAC) inhibi-
tor shown in animal models to reduce immunosuppressive
myeloid derived suppressor cells (MDSCs) and regulatory T cells
(Tregs) and produce synergistic anti-tumor responses when com-
bined with immune checkpoint inhibition. ENCORE 601 is a phase
Ib/II study designed to evaluate ENT plus PEMBRO in patients
with advanced NSCLC. The objective of the phase Ib dose escal-
ation/confirmation portion was to determine the recommended
phase II dose (RP2D).
Methods
Patients with stage III/IV NSCLC (previous anti-PD-1/PD-L1 therapy
was permitted) were enrolled in a 3 + 3 dose escalation phase. ENT
3 mg and 5 mg QW PO + PEMBRO 200 mg Q3W IV in 21-day cycles
were explored to determine the safety and RP2D, followed by a
dose-confirmation cohort (n = 9). Pre-treatment biopsies were re-
quired. Correlative studies included tumor PD-L1 expression and
phenotypic and functional evaluation of immune cell subsets in per-
ipheral blood and tumor tissue.
Results
Twenty-two NSCLC patients (9 of which progressed on prior anti-
PD-1/PD-L1 therapy) were treated with ENT plus PEMBRO; 13 in
the dose escalation phase (6 at ENT 3 mg and 7 at ENT 5 mg)
and 9 in the dose confirmation phase (ENT 5 mg). Of 20 patients
with PD-L1 expression results, 7 patients (35 %) had PD-L1 < 1 %,
8 (40 %) had PD-L1 1-49 %, and 5 (25 %) had PD-L1 ≥ 50 %. Dur-
ing dose escalation, 1 patient previously treated with anti-PD-1
therapy experienced a DLT at Cycle 2 Day 15 (ENT 3 mg, Grade
3 immune-mediated hepatitis), and no other DLTs were observed.
Among all 22 patients treated, Grade 3/4 treatment-related AEs
included hypophosphatemia (9 %), neutropenia (5 %), anemia
(5 %), acute respiratory failure (5 %), elevated alkaline phosphat-
ase (5 %) and immune-mediated hepatitis (5 %). Of 6 evaluable
patients previously exposed to anti-PD-1/PD-L1, best response in-
cludes 3 SD and 3 PD. Of 11 evaluable anti-PD-1/PD-L1 naïve pa-
tients, best response includes 1 PR, 1 SD and 9 PD. A reduction
in peripheral MDSC levels was observed between pre-treatment
and Cycle 2 Day 1 in 7 of 11 patients assessed (median decrease
of 40.7 % PMN-MDSCs; 67.3 % M-MDSCs).
Conclusions
5 mg ENT weekly combined with PEMBRO has a manageable safety
profile, expected pharmacodynamic effects on reducing MDSCs, and
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Background
Since the infiltration of tumor tissues with effector CD8+ T cells
(CTLs) is associated with improved clinical outcomes and predicts
patients’ responsiveness to checkpoint blockers, we developed a
combinatorial approach to selectively enhance the production of
CTL chemokines in tumor lesions, while avoiding the activation of
healthy tissues. Our preliminary data from human ex vivo tissue
culture models demonstrate that a) TLR3-based combinatorial ad-
juvants selectively induce CTL-attracting chemokines in tumor-
associated stromal and myeloid cells, while avoiding undesirable
activation of cancer cells and surrounding non-tumor tissues; b)
combination of TLR3 ligands with IFNa synergistically amplifies
the production of CTL-attracting chemokines and allows to uni-
formly induce their production in all tumor lesions; and c) that
the inclusion of COX2 blockers prevents the induction of Treg-
attractants.
Methods
Based on these preclinical data, we developed a phase I/II clinical
trial (UPCI 10-131/NCT01545141) to determine the safety and local
effectiveness of intravenous infusion of rintatolimod (Ampligen; se-
lective TLR3 ligand) combined with Intron A and oral celecoxib, in
patients with resectable recurrent colorectal cancer. Our phase I/II
trial UPCI 11–128 (NCT02432378) evaluates the safety, feasibility and
local effectiveness of the intraperitoneal delivery of rintatolimod and
Intron A (with oral celecoxib) in cisplatin-treated patients with recur-
rent ovarian cancer.
Results
In the completed phase I of UPCI 10–131, we observed very
good safety profile of this combination and, in accordance with
our expectations, selective disappearance of CTL-, TH1- and NK
cell markers from circulation, lasting 24–48 hours after rintatoli-
mod/Intron A infusion. Comparison of the resected tumors dem-
onstrated enhanced intratumoral ratios of CXCL10 (CTL-attractant)
to CCL22 (Treg-attractant) and CD8α (CTL marker) to FoxP3 (Treg
marker), in the treatment cohort, compared to patients receiving
standard care at our center (non-randomized control). The ran-
domized phase II portion of this clinical study is ongoing. Our
recently-implemented study UPCI 11–128 provides preliminary in-
dication of the feasibility and local effectiveness of intraperitoneal
modulation of tumor microenvironments in cisplatin-treated ovar-
ian cancer patients.
Conclusions
Our data provide early indications of the safety and feasibility of
using combinatorial adjuvants to selectively enhance intratumoral
CTL infiltration. Verification of these results in randomized phase II
portions of our trials may provide new means to enhance the clinical
effectiveness of checkpoint inhibitors, therapeutic vaccines and
adoptive T cell therapies (ACT) against “cold tumors”, enhancing the
scope of their applications.Acknowledgements
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Background
AGS003 is an immunotherapy consisting of autologous dendritic
cells (DCs) electroporated with amplified total tumor RNA plus
synthetic CD40L RNA and is currently being tested in combin-
ation with standard of care to extend survival of newly
diagnosed metastatic RCC patients in the phase III ADAPT clin-
ical trial. We set out to establish an animal model system to
more thoroughly study the AGS003 mechanism of action and
assess the functionality in combination with other therapeutic
agents.
Methods
Mouse DC precursors were processed in a similar manner to
how human monocytes are processed to manufacture AGS003.
Bone marrow cells from 7–10 week old Balb/c mice were incu-
bated with GMCSF and IL4 and matured with TNFa, IFNg and
PGE2. Mature DCs were electroporated with total tumor RNA
from RENCA tumor plus synthetic mCD40L RNA and injected i.p.
to treat syngeneic BALB/c mice in an orthotopic RCC model.
This model system was utilized to test the AGS003-like mouse
DCs as a single agent or in combination with the mPD-1 check-
point inhibitor.
Results
Here we report on successfully developing murine DCs with simi-
lar properties to AGS003, including phenotype (CD80, CD83,
CD86, MHCI, CCR7), secretion of IL12 induced by CD40L RNA and
induction of CD8 + CD28 + CD45RA- memory T cells in vivo. Re-
sults showed that, as a single agent, the DC therapy was superior
to PBS controls at increasing median survival, slowing tumor
growth and decreasing lung metastases. These effects were
dependent on inclusion of the amplified total RENCA cell RNA
based on comparison with irrelevant RNA controls. In addition,
the greatest control of tumor growth rate and median survival
occurred when combined with the PD-1 checkpoint inhibitor and
sunitinib.
Conclusions
These data demonstrate the importance of amplified total tumor
RNA in directing immune responses against the corresponding
tumor target and support the strategy of generating and/or aug-
menting preexisting antitumor immune responses with active im-
munotherapy to maximize clinical benefit when combined with
PD-1 checkpoint inhibition and sunitinib as the standard therapy
drug for renal cell carcinoma. This model system may be useful
to explore additional combination therapies with other thera-
peutic agents.
Fig. 17 (abstract P217). Survival curve of DC-based combination
therapy in RCC mouse model. DC monotherapy showed a 50% in-
crease in median OS compared to the PBS group (42 vs 28 days).
DC + Sutent combination therapy did not show increased OS com-
pared to monotherapy with DCs or Sutent (40 vs 42 or 43 days).
DC + aPD-1 combination therapy showed significantly increased
median OS compared to monotherapy with DCs or aPD-1 (67 vs 42
or 34.5 days). DC + Sutent + aPD-1 combination therapy showed
significantly increased media OS (>104 days) compared to all other
groups tested
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Background
Multiple cancer types resistant to immune checkpoint blockade (i.e.,
anti-PD-1, PD-L1, and/or CTLA-4) also demonstrate impaired antigen
presenting cell (APC) activation. We hypothesized that intratumoral
administration of agents designed to enforce APC activation would
convert a living tumor into a source of immunogenic APCs capable
of priming anti-tumor T cells.
Methods
Using a checkpoint-blockade resistant syngeneic B16 murine model
with established (0.5 - 1 cm) bilateral tumors, we screened and char-
acterized agents associated with APC activation for their ability to
overcome resistance to anti-PD-1 therapy. Such agents were adminis-
tered either systemically, or intratumorally to one of the two tumors,
allowing us to distinguish the effect at the injected tumor from that
at the contralateral tumor.
Results
In the setting of PD-1 blockade, we found that intratumoral treatment
with the TLR4 agonist monophosphoryl lipid A (MPL) and low-dose
CD40 agonist monoclonal antibody (mAb) induces an anti-tumor T cell
response. CD8+ T cells subsequently infiltrate and control noninjected
tumors at a distant site. Interestingly, locally injected tumors were heav-
ily infiltrated with neutrophils expressing costimulatory markers includ-
ing CD86 within 3 hours of treatment, and then rapidly regressed. In
addition, there was persistence of activated dendritic cells and mono-
cytes in the injected-tumor’s draining lymph node. Within 1 week, dis-
tant tumors were infiltrated with activated CD8+ T cells, and showed a
marked increase in the T effector to T regulatory ratio. The control of
distant tumors was abolished in RAG1-deficient animals lacking lym-
phocytes. Cured animals fully resisted tumor re-implantation at 90 days,
developing fur depigmentation at both the site of initial treatment andthe untreated tumor reimplantation site, but not elsewhere, suggesting
a highly specific anti-tumor response. Notably, systemic administration
of MPL and CD40 at 25-fold higher dose was less effective than intratu-
moral treatment.
Conclusions
In conclusion, low-dose intratumoral treatment with combined TLR4
and CD40 agonists induces anti-tumor T cells which in turn infiltrate
tumors at distant sites and provide durable immunity such that ani-
mals are resistant to tumor re-implantation. Given that this regimen
relies on agents that are FDA-approved for other indications, or in
clinical development, it can readily be translated into clinical trials
across a broad range of malignancies that are currently refractory to
immunotherapy.
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Background
Antibody-mediated immune checkpoint blockade has transformed
cancer therapy. However, the majority of patients fail to respond to
antibody therapies targeting single immune checkpoint pathways
and antibodies exhibit a long in vivo half-life which may contribute
to the emergence of immune-related adverse events. Additionally,
antibody therapies must be administered by intravenous infusion in
a hospital or clinic setting, which places additional burden on pa-
tients who may have mobility challenges. CA-170 is a small molecule,
orally bioavailable antagonist of the PD-L1, PD-L2 and VISTA/PD-1H
immune checkpoint pathways, currently undergoing phase I clinical
testing. CA-170 was developed through a rational design and a
screening strategy which identified small molecules that could
antagonize T cell suppression independently mediated by PD-L1, PD-
L2 and VISTA/PD-1H in functional assays.
Methods
CA-170 inhibition of the PD-1/PD-L1/2 or VISTA/PD-1H signaling has
been inferred though in vitro T cell effector function rescue studies
using human, monkey or mouse cells stimulated in the presence of
inhibitory PD-L1, PD-L2 or VISTA/PD-1H proteins. CA-170 selectivity
was tested against the related inhibitory immune checkpoint path-
ways CTLA-4, LAG-3, BTLA or the immune co-stimulatory B7/CD28
pathway in functional assays. CA-170 in vivo antitumor activity and
immune stimulatory activity was tested in multiple syngeneic mouse
tumor models. Definitive toxicology and pharmacokinetic profiling
studies were performed in mouse and cynomolgus monkey.
Results
CA-170 exhibits potent immune rescue activity, comparable to that of
blocking PD-1 or VISTA/PD-1H antibodies when tested in cell culture as-
says that measure the proliferation or IFN-γ secretion of T lymphocytes
stimulated in the presence of inhibitory PD-L1, PD-L2 or VISTA/PD-1H
proteins. CA-170 does not exhibit off target activity against CTLA-4,
LAG-3, BTLA pathways or the B7/CD28 pathway in functional assays. In
immune competent mice, orally administered CA-170 inhibits the
growth of syngeneic tumors, enhances peripheral T cell activation, and
promotes the immune activation of tumor infiltrating CD8+ T cells in a
dose dependent manner. In preclinical safety studies conducted in
rodents and non-human primates, orally administered CA-170 shows
no signs of toxicity when dosed up to 1000 mg/kg for 28 consecutive
days. CA-170 exhibits an oral bioavailability of approximately
40 % and <10 % in mouse and monkey, respectively, and the
plasma half-life ranges from approximately 0.5 hours for mouse
to approximately 3.25-4.0 hours for cynomolgus monkey.
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These non-clinical data provide a strong rationale for the contin-
ued clinical development of CA-170, the first oral, small molecule
immune checkpoint antagonist for the treatment of advanced
cancers.
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Background
Immune check point blockade therapy using antibodies to cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) benefits only a
limited number of cancer patients. Combination therapies are be-
ing pursued to augment the immune activation and drug effi-
cacy. SS1P and RG7787 are immunotoxins that consist of an anti-
mesothelin antibody fragment genetically fused to a portion of
Pseudomonas exotoxin A. We previously observed in patients
delayed onset of responses to SS1P treatment that persisted long
after discontinuation of the drug. This observation led us to
hypothesize that immunotoxins elicit anti-tumor immunity that
can be further potentiated by adding anti-CTLA-4 antibodies
(aCTLA-4).
Methods
To test our hypothesis, we constructed 66C14-M murine breast can-
cer cell line expressing human mesothelin on its cell surface. The
cells were grown in BALB/c mice transgenic for human mesothelin,
because they were rejected by wild type mice. RG7787 or SS1P were
injected directly into established tumors (average size >80 mm3) and
aCTLA-4 was administered IP.
Results
We found that the combination of aCTLA-4 with RG7787 or
SS1P induced complete remissions in 23 out of 38 mice treated
(60 %) providing a significant survival benefit compared to
mono-therapy (P < 0.001). No cures were obtained when aCTLA-
4, RG7787, or SS1P were given separately. In addition, we found
that responding mice treated with aCTLA-4 and SS1P had more
abundant tumor-infiltrating CD8+ T cells compared to mice
treated with aCTLA-4 or SS1P alone (P < 0.05) and that the re-
sponse was blocked when mice were treated with anti-CD8
antibodies. Furthermore, 22 out of the 23 surviving mice
rejected an additional tumor challenge with the same number
of 66C14-M or the parental cells (no human mesothelin) im-
planted 45 days after the mice were cured. These findings point
to immune mediated tumor regression. To explore the mechan-
ism responsible for the anti-tumor effect, we combined aCTLA-4
with a mutant RG7787 that is unable to kill 66C14-M cells and
found that the survival of mice was not significantly better than
that achieved with aCTLA-4 monotherapy. Some bacterial prod-
ucts activate the immune system by receptors that directly
recognize microbe associated molecular patterns (MAMPs). How-
ever, our result indicates that MAMP recognition does not ex-
plain our findings.
Conclusions
Combining intra-tumoral injection of immunotoxins with sys-
temic administration of aCTLA-4 induced a high rate of immune
mediated tumor regression. Our findings provide the first pre-
clinical evidence to support use of this combination in patients.P221
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Background
Adoptive immunotherapy utilizing anti-CD3 x anti-HER2 bispecific
antibody (HER2Bi)-armed T cells benefited both HER2+ patients
and patients with 1 or 2+ HER2 expression, ones that would be
considered “HER2-negative” by classical criteria. We have also
shown that the level of cancer stem cell (CSC) marker ALDH in
HER2+ breast cancer cells (ALDHhighHER2+) is much higher than
that in HER2− breast cancer cells (ALDHlowHER2−), and that in lu-
minal breast cancers that are considered HER2−, HER2 is actually
selectively expressed in the ALDHhigh CSC population. These ob-
servations might account for the surprising result that HER2Bi-
armed T cells, while intended to target HER2, seemed to benefit
HER2− patients after adoptive transfer.
Methods
We tested the “mouse HER2” (neu) expression on ALDHhigh vs.
ALDHlow 4 T1 cells (mouse TNBC). For mHER2 targeting in animal
models, we generated anti-mouse HER2-CD3 bispecific (mHER2Bi)
that binds to mouse HER2 and mouse CD3.
Results
HER2Bi-armed T cells used in the clinical trial killed ALDHhigh
human breast CSCs isolated from MCF7 (HER2−) tumor signifi-
cantly more than ALDHlow MCF7 cells in vitro, while the same
HER2Bi-armed T cells killed ALDHhigh human breast CSCs (ALDH-
highHER2+) isolated from BT474 (HER2+) tumor equally to ALDH-
low BT474 cells (ALDHlowHER2+). We also found that mHER2 was
selectively expressed in the ALDHhigh 4 T1 CSC population.
These results replicated our findings in human breast cancers
that HER2 is selectively expressed on CSCs, even in HER2− mur-
ine tumors, such as 4 T1. In vitro, the mHER2Bi-armed T cells
killed ALDHhigh 4 T1 CSCs significantly more than ALDHlow 4 T1
cells. In vivo, adoptive transfer of mHER2Bi-armed T cells for
HER2-targeted therapy showed antitumor effect in mHER2−
4 T1-bearing host. Administration of anti-mouse PD-L1 during
mHER2Bi-armed T cell adoptive transfer decreased metastases
significantly more than the use of either strategy alone.
Conclusions
These studies have generated evidence providing proof of principle
that due to the selective expression of HER2 on CSCs, HER2-targeted
T cell therapy could benefit HER2− hosts as well as HER2+ hosts via
immune destruction of HER2+ CSCs, and use of anti-PD-L1 could sig-
nificantly boost the efficacy of HER2-targeted T cell therapy.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause
of cancer in America with few efficacious therapeutic options other
than surgery. PDAC is characterized by dense and heterogeneous
stroma that secretes elevated levels of the proinflammatory cytokine
interleukin-6 (IL-6). Our laboratory has previously reported that
higher IL-6 in PDAC patients is strongly associated with poor overall
survival. Additionally, patients with pancreatic and gastrointestinal
cancers have the highest incidence of cachexia. This syndrome, char-
acterized by the loss of skeletal muscle and adipose tissue, cannot
be reversed by nutritional intervention and is mediated impart by IL-
6 signaling. Further, work completed by our group and others have
also shown that IL-6 and other factors can promote cross-talk be-
tween the STAT3 and MEK pathways. Thus, we hypothesized that IL-
6 blockade can be utilized to enhance the efficacy of novel immune
or targeted therapeutics (anti-PD-L1 and cobimetinib) in pancreatic
cancer.
Methods
In vivo efficacy studies were conducted with antibodies (Ab) blocking
IL-6, in combination with checkpoint immunotherapy (anti-PD-L1) or
MEK inhibition (cobimetinib). Experiments were conducted in mice
bearing subcutaneous KPC-derived MT5 tumors; orthotopically
injected KPC-luciferase expressing tumor cells in the pancreas; and
Colon26 tumor bearing CD2F1 mice to determine effects on cancer
cachexia.
Results
IL-6 blockade combined with anti-PD-L1 (p < 0.02) or cobimetinib
(p = 0.007) elicited anti-tumor efficacy in mice bearing subcutane-
ous KPC derived MT5 tumors, compared to vehicle controls. IL-6
blockade in combination with anti-PD-L1 antibodies limited tumor
growth of orthotopic KPC-luciferase expressing tumor cells com-
pared to isotype controls (p = 0.05). As a pancreatic cachexia
model is not currently available, we tested IL-6 blockade in combin-
ation with cobimetinib on a classically accepted tumor cachexia model
(CD2F1 mice bearing Colon26 tumors). Only mice treated with cobime-
tinib or the combination of IL-6 plus cobimetinib resulted in significant
tumor inhibition compared to IL-6 alone or vehicle controls (p <
0.0001). Furthermore, mice administered IL-6 alone or in combination
with cobimetinib prevented tumor-induced body weight loss (p <
0.005) and protected lean mass and hind limb muscles as compared to
vehicle-treated mice (p < 0.05).
Conclusions
These pre-clinical results indicate that inhibition of IL-6 may affect
the efficacy of novel targeted therapeutics on tumor progression, im-
munosuppression, and cachexia in pancreatic cancer.
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Background
Pharmacologic blockade of the CTLA-4 and PD-1 immune checkpoint
molecules is an effective approach for cancer immunotherapy espe-
cially in melanoma, but only a subset of patients respond. Trafficking
of immune regulatory cells into the tumor microenvironment creates
an immunosuppressive environment which dampens the anti-tumor
response. Thus, identifying the mechanisms involved in the traffick-
ing of effector and regulatory cells is critical for the development of
strategies that increase effectiveness of checkpoint blockade. We
aimed to determine which trafficking molecules are involved in anti-
tumor responses by studying both human and murine melanoma.Methods
RNA sequencing data were obtained from 475 melanoma patients
(The Cancer Genome Atlas database). Additionally, C57BL/6 mice
were subcutaneously injected with 100,000 B16-F10 cells in the flank
and sacrificed at day 14 for flow cytometry analysis. Anti-PD-1 + anti-
CTLA-4 blocking antibodies or PBS were injected intraperitoneally at
days 5, 8 and 11 after tumor inoculation.
Results
Analysis of RNA-seq data showed that inflammatory chemokines
(CCL2, CCL5, CXCL9, CXCL10) and their receptors (CCR2, CCR5,
CXCR3) were overexpressed in human melanoma tumors. Interest-
ingly, unsupervised clustering demonstrated that CCR2, CCR5 and
CCL2 were associated with CD68 and CD14 genes while CXCR3,
CCL5, CXCL9 and CXCL10 were associated with CD8A, CD8B and T-bet
genes. Moreover, immunophenotyping of tumor-infiltrating CD45+ cells
from B16-F10 tumor-bearing mice revealed higher levels of CCR2. Inter-
estingly, monocytic myeloid-derived suppressor cells (M-MDSCs) and
inflammatory dendritic cells had the highest expression of these recep-
tors. When B16-F10 tumor-bearing mice were treated with anti-PD-1/
anti-CTLA-4 antibodies, we observed a significant reduction of tumor
size and increased levels of CD45+ cells (p < 0.05), CD8+ T cells (p <
0.05) and increased CD8/Treg ratio (p < 0.01) in comparison to controls;
however, the numbers of M-MDSC were not reduced. More import-
antly, CCR2 and CCR5 were still high within total CD45+ cells (26-30 %)
and M-MDSCs (54-71 %) in both treated and control mice. Additionally,
dual checkpoint blockade significantly increased the expression of
CCR1 (p < 0.05) and CXCR3 (p < 0.05) in CD8+ T cells, without increasing
levels of CCR2 and CCR5.
Conclusions
Our data suggest that dual checkpoint blockade increases the traf-
ficking of CD8+ T cells into the tumor using the CXCL9/CXCL10-
CXCR3 axis but does not affect the CCL2-CCR2 and CCL5-CCR5 axis
that are critical for M-MDSCs trafficking into the melanoma micro-
environment. These results are important for the development of
novel immunotherapy combinations that harness trafficking mecha-
nisms to improve the efficacy of immunotherapies.
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Background
T cell activation and proliferation are metabolically demanding pro-
cesses that require essential nutrients such as glucose and glutamine.
Within the tumor microenvironment, competition between tumor
cells and immune cells for limited nutrients can lead to poor T cell
activation and suppression of an anti-tumor immune response. En-
gagement of immune checkpoints such as PD-1 further suppresses T
cell activation. While therapeutic blockade of immune checkpoints
may partially relieve T cell suppression, low nutrient availability in
the tumor microenvironment is expected to limit an optimal immune
response. CB-839 is a glutaminase inhibitor currently in phase I on-
cology trials. CB-839 blocks glutamine consumption by tumors lead-
ing to elevated glutamine levels in the tumor microenvironment.
Based on the high demand of T cells for glutamine, we hypothesized
that CB-839 might synergize with immune checkpoint inhibitors to
relieve immune suppression and lead to enhanced anti-tumor im-
mune responses.
Methods
Ex vivo T cell activation was performed with anti-CD3/CD28 on CD3+
cells isolated from human PBMCs. Changes in mRNA expression after
T cell activation was monitored by NanoString analysis. In vivo effi-
cacy studies were conducted in syngeneic CT-26 or B16 tumor
models.
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T cell activation in the absence of glutamine inhibited cell prolifera-
tion and the expression of cell surface activation markers. Analysis of
mRNA expression also showed suppression of normal activation
markers and induction of T cell exhaustion markers including PD-1,
CTLA-4 and BTLA, suggesting that T cell activation in the absence of
glutamine may be sufficient to induce an exhausted phenotype. Pre-
vious work showed that CB-839 blocks glutamine consumption in tu-
mors leading to reduced cell proliferation. Surprisingly, CB-839 had
only minimal impact on T cell proliferation, highlighting differences
in glutamine utilization pathways between tumor cells and T cells. In
mouse tumor models, administration of CB-839 elevated tumor glu-
tamine levels, consistent with inhibition of tumor glutaminase. Com-
bination of CB-839 with anti PD-1 or anti PD-L1 in the syngeneic CT-
26 colon model augmented tumor regressions relative to checkpoint
inhibition alone. CB-839 also enhanced the anti-tumor activity of
checkpoint inhibitors in the B16 melanoma model. Depletion of
CD8+ T cells from tumor-bearing animals reversed the anti-tumor
effects of the combination, confirming an immune-mediated
mechanism of action.
Conclusions
These data highlight a novel therapeutic approach to treat cancer by
selectively targeting tumor metabolism as a means of enhancing the
efficacy of checkpoint blockade. Our data provide a rationale for
combining CB-839 with immune checkpoint inhibitors in the clinic.
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Background
T cells and natural killer (NK) cells require L-arginine for proliferation.
Arginine depletion by arginase in the tumor microenvironment in-
duces immunosuppression and is associated with tumor immune
evasion. Arginase is expressed by myeloid-derived suppressor cells
(MDSCs) and polymorphonuclear cells (PMNs), and its pharmaco-
logical inhibition is expected to restore arginine levels and relieve
immunosuppression, leading to anti-tumor immune responses.
Methods
We developed CB-1158, a potent and selective small molecule inhibi-
tor of arginase (IC50 = 98 nM). The activity of CB-1158 was examined
ex vivo using immune cells isolated from healthy volunteers or cancer
patients, and in vivo using murine syngeneic tumor models. Arginase
abundance in cancer patient plasma and in tumor tissue microarrays
was also examined.
Results
In a co-culture system of T cells with PMNs or MDSCs, CB-1158 re-
verses PMN- or MDSC-mediated immunosuppression by blocking
arginine depletion, thereby allowing T cells to proliferate. T cells acti-
vated in the presence of PMN-conditioned media show suppressed
production of cytokines involved in Th1-type adaptive immunity, and
this effect is reversed by the addition of CB-1158. In vivo, CB-1158
has high oral bioavailability and is very well tolerated. In tumor-
bearing mice, twice daily dosing of CB-1158 causes dose-dependent
pharmacodynamic increases in plasma and tumor arginine levels as-
sociated with single agent anti-tumor efficacy in multiple syngeneic
models. The anti-tumor efficacy of CB-1158 is abrogated in immuno-
compromised mice or via depletion of either CD8+ T cells or NK cells,
confirming an immune-mediated mechanism of action. Moreover,
CB-1158 enhances CD8+ T cell infiltration into tumors and increases
expression of Th1 cytokines, T cell and NK cell activation markers,
and interferon-inducible genes in the tumor. The immunomodulatory
activity of CB-1158 supports the potential of its combination withother immunotherapies and/or standard-of-care therapies. CB-1158
enhances the anti-tumor efficacy of checkpoint inhibitors, including
anti-PD-L1 and epacadostat in the B16F10 model. Moreover, CB-1158
enhances the anti-tumor efficacy of standard-of-care therapies such
as chemotherapy. To assess the clinical potential of CB-1158, the
abundance of arginase in tumors and plasma from cancer patients
across multiple cancer histotypes was surveyed. Arginase-expressing
PMN infiltrates are abundant in multiple tumor types. Plasma argi-
nase levels are elevated in cancer patients compared to healthy con-
trols, and are associated with decreased plasma arginine.
Conclusions
These results support the clinical development of CB-1158, a first-in-
class arginase inhibitor, as a novel immunomodulatory agent antag-
onizing myeloid-mediated immunosuppression. A phase I clinical trial
testing the clinical activity of CB-1158 in cancer patients has been
initiated.
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Background
Blood cancers, with an estimated 160,000 new cases, account for
nearly 10 % of all cancer diagnoses and 9.4 % of all cancer deaths
this year in the United States. Unfortunately, despite therapeutic ad-
vances, the mortality rate still continues to rise. Thus, novel, mechan-
istically distinct therapies, such as immunotherapy, may have a
significant impact particularly in addressing aggressive lymphoma
subtypes such as those being modeled in our transplant-based ap-
proach. Two classes of immunotherapies that have had great success
in treating a wide array of cancers are: checkpoint blockade (e.g.,
anti-CTLA-4 antibody-based treatments and anti-PD-1 antibody-
based treatments) and adoptive T cell (e.g., TIL) transfer lymphocytes
into lymphodepleted hosts.
Methods
We have developed a novel therapy combining these approaches
into 'checkpoint-blockade-primed immunotransplant' comprised of:
treatment of tumor-bearing host with anti-CTLA-4 and/or anti-PD-1
antibodies, and splenocyte harvest and transfer to lymphodepleted
recipient.
Results
Our results show that this combined therapy results in superior
anti-tumor immunity compared to either individually as seen by
increased production of IFN γ positive T cells. Treatment of
both tumor-bearing donor and recipient with anti-PD-1 and
anti-CTLA-4 antibodies induces cure of the majority of recipi-
ents, in a CD8, NK, and IFNγ-dependent manner, despite the
finding that antibody therapy alone (without transplantation
and T cell transfer) induces minimal anti-tumor effect. Further-
more, we have demonstrated that T cells exposed to checkpoint
blockade and transfer into the lymphopenic hosts demonstrate:
greater in vivo serum levels of IL-15 and IL-7, higher ex vivo
levels of IL-15R and IL-7 -receptors expression on CD8s, in vitro
STAT5 phosphorylation in response to common γ-chain cyto-
kines, in vivo proliferation in response to exposure to cognate
tumor antigen, and in vitro production of IFNγ and TNF produc-
tion in response to exposure to cognate tumor antigen.
Conclusions
Ongoing studies will seek to assess the dependence of the above ob-
servations (cytokine production, proliferation, anti-tumor effect) on
specific common γ-chain cytokines, the role of the lymphopenia in
inducing T cell trafficking to tumor versus organs, and guide devel-
opment of the immunotransplant model to optimize the amplifica-
tion of anti-tumor immunity observed.
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Background
Pancreatic cancer remains a significant challenge with 5 year sur-
vival rates of less than 7 %. This devastating malignancy is ex-
pected to become the second leading cause of cancer death in
the United States by 2030. Although effective in other malignan-
cies, there has been a relative paucity of efficacy when immune
checkpoint blockade has been applied in pancreatic cancer. We
hypothesize this limited efficacy is due to local and systemic al-
terations in cytokine expression that shape the immune contex-
ture in these patients. Although dysregulated cytokines represent
attractive targets in pancreatic cancer, there are limited data to
help prioritize among them for future translation. Prior studies
from our group demonstrated that plasma interleukin-6 (IL-6),
interleukin-10 (IL-10) and circulating CD8 + CTLA-4+ cells were
correlated with overall survival in a population of n = 71 treat-
ment naïve metastatic pancreatic cancer patients. We hypothe-
sized that targeting IL-10 and IL-6 would augment the efficacy of
antibodies targeting CTLA-4.
Methods
In vivo efficacy of blocking antibodies against IL-6, IL-10, and
CTLA-4 were evaluated in C57BL/6 mice bearing syngeneic, sub-
cutaneous murine pancreatic tumor cells derived from LSL-
KrasG12D;LSL- p53R172H;Pdx1-Cr and in a highly aggressive genet-
ically engineered mouse model, harboring KrasG12D; p53R172H
and Brca2 mutation (KPC-BRCA2). Relevant immune biomarkers
were analyzed using flow cytometry or IHC, as appropriate.
Results
In vivo studies demonstrated that combined blockade of IL-6 and
CTLA-4 significantly decreased the rate of tumor growth in compari-
son to both isotype control (P = 0.0001) and anti-CTLA-4 alone (P =
0.0207). Treatment with antibody against IL-10, or IL-10 blockade in
combination with anti-CTLA-4 slowed tumor growth in comparison
to isotype control but were inferior to single agent anti-CTLA-4. FACS
analysis of splenocytes from these mice revealed that combined IL-6
and CTLA-4 blockade increased the proportion of circulating CD4+
central memory cells (CD62L + CD44+). Blockade of IL-6 and CTLA-4
in combination, and as single agents, resulted in an increase in circu-
lating Th1 cells while both isotype control and anti-IL-6 had signifi-
cantly more naïve systemic T cells (CD4+/CD8 + CD62L + CD44-). IHC
analysis revealed increased infiltrating CD3+ cells throughout the
tumor foci of the combination group in comparison to both single
agents and isotype control (all P’s < 0.01). Ongoing analysis will fur-
ther delineate the proportion and detailed phenotype of infiltrating
and systemic immune cells.
Conclusions
Antibodies targeting IL-6 but not IL-10 augment the efficacy of anti-
CTLA-4 in murine models of pancreatic cancer, modulate T cell infil-
tration and immune biomarkers to promote Th1 immune responses.
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Breaking tolerance mechanisms to mount a durable adaptive im-
mune response within tumors remains one of the preeminent
challenges of immuno-oncology. Immunosuppressive hurdles in-
clude: 1) suppression from immunoregulatory and tumor cells, 2)
insufficient intratumoral “immune space” and survival signals, and
3) exhaustion of tumor specific effector T cells (Teff). GITR, an acti-
vating receptor belonging to the tumor necrosis factor receptor
(TNFR) super family, is constitutively expressed on FoxP3+ regula-
tory T cells (Tregs) and to a lesser extent on quiescent Teff. Activa-
tion upregulates GITR on Teff and Tregs, which however remains
highest among Tregs. Thus, selectively targeting GITR can deliver
activating signals to Teff cells, while depleting high-GITR-
expressing Tregs, and may improve efficacy of a therapeutic can-
cer vaccine.
Methods
Recombinant poxviruses [modified vaccinia Ankara (rMVA-), fowl-
pox (rF-)] were engineered to express human CEA and murine
costimulatory molecules, B7.1, ICAM-1 and LFA-3 (TRICOM); termed
rMVA- or rF-CEA-TRICOM. A prime-boost strategy was utilized; the
priming vaccine utilized rMVA-CEA-TRICOM while rF-CEA-TRICOM
provided the boost. The diversified prime-boost vaccine regimen
can break tolerance in transgenic mice expressing human CEA.
GITR was targeted with a fusion protein (GITRL-FP) consisting of
the extracellular domain of murine GITR-ligand molecularly fused
to a trimerization domain and murine IgG2a-Fc. Murine colon
adenocarcinoma cells expressing human CEA (MC32A) were im-
planted subcutaneously in CEA. Tg mice and treated with control
IgG2a, GITRL-FP, rMVA/rF-CEA-TRICOM, or rMVA/rF-CEA-TRICOM +
GITRL-FP.
Results
Initial studies paired twice weekly dosing of GITRL-FP concur-
rent with MVA/rF-CEA-TRICOM and modest improvements in an-
titumor effects resulted. GITRL-FP targets GITR expressing cells,
delivering activating signals, while the IgG2a-Fc depletes via Fc-
mediated effector functions. Investigation into mechanism re-
vealed depletion of Tregs and Teff. To circumvent the problem of
depleting vaccine induced Teff, administration of GITRL-FP was
switched to a single dose given 2 days prior to vaccine. The
short half-life of the fusion protein allowed for temporal intratu-
moral depletion of both Tregs and Teff. Single dose GITRL-FP ab-
rogated the immunosuppressive constraints of Tregs and created
a lymphopenic intratumoral T cell compartment. These events
allowed for expansion of Teff in response to MVA-CEA-TRICOM
as shown by a 20 % increase of proliferating intratumoral CD4+
Teff compared to GITRL-FP monotherapy, and a 2-fold increase
in activated peripheral CD8+ Teff. Reduced tumor growth and
improved survival was observed comparing combination to
GITRL-FP monotherapy. Tumor-free mice were also protected
against tumor rechallenge.
Conclusions
These data demonstrate the increased efficacy of utilizing targeted
depletion of immunosuppression in combination with an immune
boosting cancer vaccine.P229
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Background
CD47 is a ubiquitous cell surface receptor that interacts with
the secreted protein thrombospondin-1 and its counter-receptor
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is highly expressed across many cancer types, hence, represent-
ing a potential target for therapeutic intervention. We recently
reported a direct role for thrombospondin-1/CD47 signaling on
cytotoxic T lymphocytes (CTL) to limit target tumor cell killing
[1]. Many tumors are not sufficiently immunogenic to induce
protective adaptive immunity. However, innate lymphoid cells
(ILCs) may also play functional roles in tumor regression [2].
Here we evaluated the role of CD47 in NK and other ILCs
homeostasis within the lymphoid organs as well as among
tumor infiltrating lymphocytes.
Methods
We analyzed tumor infiltration of NK and other ILCs following
antisense suppression of CD47 alone or in combination with
anti-CTLA-4 blockade. C57Bl/6 mice were injected with B16F10
melanoma in the hind limb, and once the tumors reached an
average of 100 mm3, mice were treated with CD47-morpholino,
anti-CTLA-4, or combined treatments.
Results
Treatment of mice with CD47-morpholino increased the frequen-
cies of splenic Lin−CD3−NK1.1+ and Lin−CD3−CD127+ populations.
Studies using CD47-null mice further validated this result. We ob-
served higher granzyme B and perforin mRNA expression in the
CD3−CD4−CD8− cells compared to the CD8+ cells from spleens of
CD47-null mice. Image cytometric analysis revealed that these are
mononuclear lymphocytes. These cells express higher eomes and
T-bet, but lower Gata3 and Rorγt as compared to their CD4+
counterparts, suggesting that they fall within the NK and ILC1 lin-
eages. Indeed, lineage-depleted splenocytes from CD47-null mice
showed higher frequencies of NK1.1+ and CD127+ cells compared
to wildtype littermate controls. These cells infiltrated into tumors
of B16F10-bearing mice, and their numbers further increased fol-
lowing treatment with a combination of CD47-morpholino and
anti-CTLA-4 antibody, which resulted in enhanced therapeutic
benefits.
Conclusions
Our data suggest that deficiency of CD47 in the tumor micro-
environment or therapeutic blockade increases subtypes of ILCs
with potent anti-tumor properties. The mechanism by which
CD47 controls the homeostatic balance of ILCs or their develop-
ment remains to be determined.
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Intratumoral accumulation of effector type-1 T cells (CTLs) is an inde-
pendent prognostic factor of survival of patients with many cancer
types and is required for the effectiveness of checkpoint blockade
therapies.
Methods
In this study, we have tested whether the enhancement of the num-
bers of tumor-infiltrating CTLs by DC vaccines together with com-
binatorial reprogramming of tumor-associated chemokines, can be
used to convert the nominally checkpoint-resistant “cold” tumors
into PD-1-sensitive ones.
Results
In colorectal and ovarian cancer (transplantable MC38 and ID8
models) bearing mice, we observed only marginal therapeutic
effect of PD-1 inhibition alone or combined with DC vaccine.
However, combinatorial reprogramming of tumor-associated
chemokines, using TLR3 ligand polyI:polyC12U, interferon-a and
COX2 blockers, resulted in a striking increase in the numbers of
tumor-infiltrating CTLs recognizing cancer-associated antigens
and allowed for the conversion of these immunotherapy-
resistant tumors into sensitive ones, resulting in high numbers
of long-term surviving animals.
Conclusions
This combinatorial DC-based vaccination approach may be used
to induce specific immune cells against different tumor-relevant
antigens and may be included as a component of anti-tumor
therapeutic approaches that, by themselves do not induce new
effector cells, nor promote their intratumoral accumulation.
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Background
IL-10 is regarded as an anti-inflammatory cytokine, but it is at
least equally important for the cytotoxicity and proliferation of
antigen activated CD8+ T cells. Activation of CD8+ T cells
through the T cell receptor elevates IL-10 receptors and PD-1 on
the cells. This provides the mechanistic rationale for combining
AM0010 and anti-PD-1 for the treatment of cancer patients. A
phase I clinical trial investigated the tolerability and anti-tumor
activity of AM0010 alone and in combination with anti-PD-1 im-
mune checkpoint inhibitors.
Methods
Patients with advanced RCC were treated with AM0010 (daily SC)
alone or in combination with pembrolizumab (q3wk IV) or nivolu-
mab (q2wk IV). Tumor responses were monitored following irRC.
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kines, and the activation and clonality of T cells in peripheral
blood mononuclear cells. Nineteen patients with RCC (15 evalu-
able), were treated with AMO010 alone (20 mg/kg). Eight patients
were treated in combination with pembrolizumab (2 mg/kg) and
15 patients with nivolumab (3 mg/kg).
Results
AM0010 alone or in combination with anti-PD-1 was tolerated well
(observation periods exceeding 16 months). All TrAEs were transient
and TrAEs leading to study discontinuation were not observed. There
was no colitis, pneumonitis, or endocrine disruptions. G3/4 TrAEs in
monotherapy included anemia (9), hypertriglyceridemia (3),
thrombocytopenia (2), ALT/AST increase (2) and fatigue (2). AM0010
combination with anti-PD-1 did not increase TrAEs. Objective re-
sponses (PR/CR) were observed in 4 of 15 evaluable RCC patients in
monotherapy (27 %), in 4 of 8 patients in AM0010/pembrolizumab
(50 %). Progression-free survival (PFS) was 3 and 9.4 months, respect-
ively. The AM0010/nivolumab cohort is currently in progress.
AM0010 alone and also in combination with anti-PD-1 increased Th1
cytokines (IL-18, IFNg, TNFa), CD8+ T cell associated effector mole-
cules such as FasL and LymphotoxinB as well as cytokines stimulat-
ing T cell proliferation (IL-4, IL-7). As a result, the number and
proliferation of activated, PD-1+/LAG-3+ CD8+ T cells in the blood of
patients were increased on AM0010. In contrast, the proliferation of
FoxP3+ Tregs and TGFb was decreased. AM0010 alone or with anti-
PD-1 induced oligoclonal expansion of T cell clones in the blood
without affecting total lymphocyte counts. In particular, selected T
cells clones previously not detected in the blood of patients before
treatment were strongly expanded (de novo amplification).
Conclusions
AM0010 alone or in combination with anti-PD-1 is well-tolerated. The
clinical activity and the observed CD8+ T cell activation encourages
the continued exploration of AM0010 in phase III studies.
Trial Registration
ClinicalTrials.gov identifier NCT02009449.Fig. 19 (abstract P231). See text for description
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Background
LAG-3 is a transmembrane receptor that negatively regulates T
cell activation. Signaling through LAG-3 and other T cell inhibi-
tory receptors, including programmed death-1 (PD-1), can lead to
T cell exhaustion and is a mechanism of immune escape for
tumors. Preclinical data suggest that simultaneous blockade of
LAG-3 and PD-1 may function synergistically to restore T cell acti-
vation and mediate tumor regressions. Here, we describe prelim-
inary first-in-human phase I/IIa data for BMS-986016, a fully
human IgG4 monoclonal antibody that targets LAG-3, alone and
in combination with nivolumab (anti-PD-1) in patients with ad-
vanced B cell malignancies or solid tumors.
Methods
Sequential cohorts received BMS-986016 ± nivolumab every 14 days
in 56-day cycles during dose escalation or expansion until disease
progression, completion of 12 cycles, or prohibitive toxicity. Primary
objectives included safety and tolerability.
Results
As of May 2016, 89 patients had received BMS-986016 alone
(20 mg [n = 8], 80 mg [n = 13], 240 mg [n = 24], or 800 mg [n =
15]) or with nivolumab (BMS-986016/nivolumab; 20/80 mg [n = 7],
20/240 mg [n = 9], 80/240 mg [n = 9], or 240/240 mg [n = 4]). The
pharmacokinetic characteristics of BMS-986016 were assessed
across dose levels in patients treated with monotherapy and
combination therapy. Anti-drug antibody assessments suggested
low immunogenicity. Increases in peripheral blood T cell LAG-3
receptor occupancy (RO; 74-99 %) were observed with escalating
BMS-986016 dose and exposure. The maximum tolerated dose
(MTD) was not reached with BMS-986016 monotherapy; evalua-
tions to determine the MTD for the combination are ongoing. In-
frequent and manageable treatment-related adverse events
(TRAEs) were observed across monotherapy doses (Fig. 20), and
included toxicities typically associated with immune checkpoint
blocking agents. DLTs among patients receiving combination
therapy included grade (G)3 mucositis, G4 ventricular fibrillation,
G4 elevated lipase, and G4 myocarditis. Most TRAEs were grade
1–2. TRAEs leading to discontinuation of therapy were reported
in 3 % (BMS-986016) and 14 % (BMS-986016 + nivolumab) of pa-
tients. There were no treatment-related deaths. Objective tumor
regression was observed with LAG-3 monotherapy, and with com-
bination therapy in PD-1-naive patients and in patients with dis-
ease progression on nivolumab monotherapy.
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BMS-986016 monotherapy was well tolerated at the dose levels
tested. Emerging data characterizing the safety of the combination
will be presented. BMS-986016 ± nivolumab demonstrated biological
activity as evidenced by toxicities characteristic of immune check-
point blockers and objective tumor regressions. These preliminary
data support the ongoing evaluation of this combination in patients
with solid tumors and hematologic malignancies.
Trial Registration
ClinicalTrials.gov identifier NCT02061761 and NCT01968109.Fig. 20 (abstract P232). TRAEs reported in > 2 patients or any TRAE ≥
grade 3 reported in patients treated with BMS-986016 ± nivolumabP233
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Background
While harnessing the power of the immune system to control cancer
is becoming established as an effective way of treating patients, it
has become increasingly clear that transformed cells exploit a num-
ber of mechanisms to escape such control. Hence, while the clinical
use of checkpoint inhibitors (CPI) has yielded significant success,
there is mounting evidence to suggest that combination treatment
of CPI with immunomodulating therapies may further benefit cancer
patients. Immodulon Therapeutics is developing IMM-101, an immu-
notherapeutic agent based on a heat-killed whole cell preparation of
Mycobacterium obuense (NCTC 13365), which modulates systemic im-
mune responses, as an adjunctive immunotherapy for cancer. Based
on exposure data in over 300 patients, alone and in combination,
IMM-101 is well-tolerated. Additionally, extended overall survival and
progression-free survival were observed in IMAGE-1, a randomized
open-label, phase II, first-line, proof of concept study (NCT01303172),
in combination with gemcitabine in advanced pancreatic ductal
adenocarcinoma.Methods
We found that in vitro exposure of IMM-101 primes in vitro generated
murine dendritic cells (DC) and human monocyte-derived DC in a
dose dependent manner and functionally affects DC by enhancing
their ability to process and present antigen. Moreover, IMM-101 acti-
vated DC promote T cell secretion of IFN-γ following re-stimulation
of draining lymph node cell preparations, 7 days after adoptive trans-
fer of IMM-101 primed DC into naïve recipient mice. We also investi-
gated whether the effects of IMM-101 on innate and adaptive
immune responses indeed improve on the therapeutic benefit of CPI
treatment (anti-CTLA-4 or anti-PD-1) in two murine xenograft models
using B16-F10, a mouse melanoma cell line, and EMT6, a mouse
breast cell line.
Results
We assessed effects on tumor burden and local and systemic im-
munological bias in treated mice. We report a significant benefit
from combination treatment of CPI and IMM-101 on tumor burden.
We also observed significant change to the CD8+/Treg ratio at the
tumor site. We performed in vitro stimulation (antigenic as well as
polyclonal) of immune cells present at the tumor site, in the draining
lymph nodes and in the spleen. We report results at different time
points over the course of the disease.
Conclusions
On the basis of these promising results, formal clinical evaluation of
IMM-101 in combination treatment with anti-PD-1 treatment is being
undertaken (EudraCT identifier 2016-001459-28).P234
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Background
Breast cancer brain metastases (BCBM) occur in up to 14.3 % of
patients with human epidermal growth factor receptor 2 positive
(HER2+) primary tumors [1]. Intravenous trastuzumab (anti-HER2
monoclonal antibody (mAb), Herceptin®) extends survival in patients
with HER2+ systemic disease but does not cross the blood brain bar-
rier (BBB) to treat HER2+ BCBM effectively [2]. Intrathecal (IT) trastu-
zumab can extend survival in patients with HER2+ BCBM [3] but
requires regular IT infusions which carry risks and can compromise
quality of life. Gene therapy offers a one-shot solution for mAb deliv-
ery across the BBB. Adeno-associated viral vectors, particularly sero-
type 9 (AAV9), can safely and efficiently deliver exogenous genes
(transgenes) to central nervous system tissues after a single IT admin-
istration, resulting in constitutive, long-term expression of the trans-
gene product [4].
Methods
We characterize a xenograft model of HER2+ BCBM using
BT474.M1 human ductal carcinoma cells injected stereotaxically
into the brain parenchyma of Rag1−/− mice. AAV9.trastuzumab
is delivered IT as tumor prophylaxis (at least 21 days before
tumor administration) or as tumor treatment (3 days post tumor
administration).
Results
Median survival (MS) of Rag1−/− mice receiving IT AAV9.trastuzumab
tumor prophylaxis (MS = 111 days, n = 7) is significantly greater
after tumor administration than mice receiving vehicle (MS =
48.5 days, n = 8, p = 0.0012*), AAV9 expressing an irrelevant anti-
body (MS = 54.5 days, n = 10, p = 0.0027*), or AAV9 without a
transgene (MS = 50 days, n = 4, p = 0.0069*). MS of mice bearing
tumors treated with IT AAV9.trastuzumab (MS = 82 days, n = 6) is
significantly greater than controls receiving vehicle (MS = 61 days,
n = 7, p = 0.002*). *Log-rank (Mantel-Cox) test.
Fig. 21 (abstract P235). Therapeutic effect of intratumoral TLR7 and
TLR9 agonist and anti-PD-1 in HPV negative HNC
Fig. 22 (abstract P235). Increased M1/M2 ratio by combination
therapy with TLR7 agonist and anti-PD-1 in HPV negative HNC
Fig. 23 (abstract P235). Increased IFNγ+ activated CD8+ T cell
population by combination therapy
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IT AAV9.trastuzumab as both tumor prophylaxis and treatment in-
creases survival in a murine xenograft model of HER2+ BCBM, thus
showing promise as HER2+ BCBM treatment and, more broadly, as a
prophylactic measure for patients with HER2+ primary disease to ex-
tend survival in the case of BCBM.
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Background
Head and neck squamous cell cancers (HNSCC) constitute the sixth
leading cancer by incidence worldwide. Though PD-1/PD-L1 block-
ade is effective in some patients, the majority do not benefit. We ex-
amined combination therapy with anti-PD-1 and synthetic agonists
of toll-like receptors (TLR)7 and TLR9 in mouse models representing
human papilloma virus (HPV)-positive and HPV-negative HNSCC, re-
spectively. We hypothesized that the intratumoral treatment with
TLR agonists could activate innate immune cells in the tumor micro-
environment and enhance tumor specific adaptive immunity. Fur-
thermore, this would be synergistic with checkpoint inhibitors that
release negative signals on tumor infiltrating CD8+ T cells.
Methods
Syngeneic tumor mouse models, SCC-7 cells (HPV-negative)/C3H
background and MEER cells (HPV-positive)/C57BL/6 background,
were used. Mice were implanted with tumor cells subcutaneously
into opposite flanks. Treatments were started with intratumoral
injections into only the right side with TLR7 or TLR9 agonists
with or without intraperitoneal injections of anti-PD-1 mAb. Lym-
phocytes were isolated from tumors and spleens on days 13 and
21 post tumor implantation, and were analyzed using flow cy-
tometry. The T cell receptor (TCR) repertoire of CD8+ T cells in
the tumor and the spleen was evaluated by unbiased high
throughput quantitative sequencing.
Results
In both HPV-negative and HPV-positive models, the combination
therapies of intratumoral TLR7 or TLR9 agonists with anti-PD-1 sup-
pressed tumor progression both at agonist-injected and uninjected
sites (abscopal-like effect) (Fig. 21). In the HPV-negative model, the
combination treatment with TLR7 agonists and anti-PD-1 increased
the M1/M2 ratio in CD11b+F4/80+ tumor infiltrating macrophages
(Fig. 22). Ex vivo treatment with TLR7 agonist upregulated the expres-
sion of costimulatory molecules CD40, CD80, and decreased the ex-
pression level of CD206 (M2-macrophage marker). The combination
therapy with TLR7 agonist increased the frequency of CD8+ T cells in
both sides of tumors and spleen. Elevated IFNγ+ activated T cellpopulation was observed in mice treated with the TLR7 ligand and
anti-PD-1 therapy (Fig. 23). TCR repertoire analysis showed anti-PD-1
increased clonal expansion of splenic CD8+ T cells (Fig. 24).
Conclusions
The combination therapy with TLR agonists and anti-PD-1 sup-
pressed progression of tumors in both injected and distant sites by
two different mechanisms of action; clonal expansion of low fre-
quency CD8+T cell population by anti-PD-1, and recruitment and acti-
vation of tumor specific T cells by intratumoral treatment with TLR
ligands.
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Fig. 24 (abstract P235). Anti-PD-1 increased clonal expansion of
splenic CD8+ T cells
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Background
Multiple mechanisms are involved in establishing an immunosuppres-
sive tumor microenvironment. Although blockade of the PD-1/L1 axis
alone has led to durable clinical responses in multiple malignancies,
the majority of patients do not receive or maintain clinical benefit from
monotherapy. Colony stimulating factor receptor 1 (CSF-1R) expressing
tumor associated macrophages (TAMs) have been implicated as a poor
prognostic factor in many cancers. TAMs and other suppressive mye-
loid cells may represent an additional suppressive axis present in many
malignancies where PD-1/L1 blockade has shown some or little activity.
CSF-1R has been implicated for maintaining TAM function and viability
in tumor tissues, making it an attractive target to modulate TAM and
possibly myeloid mediated suppression in cancer. As the CSF-1R Inhibi-
tor LY3022855 has recently entered clinical testing in combination with
PD-L1 blockade, it is important to understand how inhibiting two im-
mune suppressive mechanisms will alter immune function to help
guide rational clinical development.
Methods
To study and understand the immune modulating effects of CSF-1R
inhibition, we developed an anti-mouse CSF-1R surrogate antibody
CS7. CS7 blocks CSF-1 binding to CSF-1R and inhibits in vitro prolifer-
ation and differentiation of macrophages and depletes tissue resi-
dent macrophages in vivo.
Results
Monotherapy treatment with CS7 causes intra-tumor depletion of ~
50-60 % of F4/80+ TAMs leading to a modest delay in tumor growth.
This reduction was associated with an increased intra-tumor immune
inflammation signature and reduced inhibitory metabolites,
highlighting the role TAMs play suppressing the immune response
inside the tumor microenvironment. Combining CSF-1R blockade
with anti-PD-L1 enhances the control of tumor growth, displaying a
late combinatorial effect leading to complete regressions in the ma-
jority of mice (~60 %). Mice achieving complete regressions devel-
oped immunologic memory resisting rechallenge over 60 days after
cessation of therapy. Intra-tumor gene expression analysis demon-
strated a synergistic increase in T cell activation and reduction of im-
mune suppression late in the response, correlating with the time
point of increased efficacy. Effects of CS7 were dose-dependent,suggesting that while lower doses of CS7 are able to cause TAM
depletion, modulation of the microenvironment requires more
complete block of CSF-1R.
Conclusions
Our results demonstrate that combination of CSF-1R blockade with
PD-L1 checkpoint inhibition alters the tumor microenvironment in
favor of enhanced immune activation. In addition, our data imply
that the mechanism of CSF-1R blockade immunotherapy may extend
beyond reduction of intra-tumor macrophages.
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Background
Coxsackievirus A21 (CVA21, CAVATAK) is a naturally-occurring ICAM-1
targeted oncolytic immunotherapeutic virus. Pembrolizumab is a hu-
man programmed death receptor-1 (PD-1) blocking antibody that
has yielded significant solid tumor responses via reversal of tumor in-
duced T cell suppression. Preclinical studies in immune-competent
mouse models of non-small cell lung cancer (NSCLC) and melanoma
confirmed that combinations of i.v. CVA21 + anti-PD-1 mAbs medi-
ated significantly greater antitumor activity compared to use of ei-
ther agent alone. We postulate that the combination of CVA21 +
pembrolizumab may translate to a similar benefit in the clinic. We
describe a phase Ib study assessing safety and efficacy of IV CVA21 ±
pembrolizumab in advanced cancer patients (pts).
Methods
The phase I STORM (systemic treatment of resistant malignancies;
KEYNOTE 200) primary objectives are to assess dose-limiting toxicities
(DLT) of CVA21 ± pembrolizumab. Secondary objectives are to assess
ORR by irRECIST 1.1 criteria, PFS, and OS. Treatment Part A: pts were
infused with CVA21 in 100 mL saline in Cohort 1 (n = 3), at a dose of
1 x 108 TCID50, in Cohort 2 (n = 3) at a dose of 3 x 10
8 TCID50 and in
Cohort 3 (n = 10) at a dose of 1 x 109 TCID50 on study days 1, 3, 5, 22
and Q3W for 6 additional infusions. Part A enrollment is complete.
Treatment Part B: pts are infused with CVA21 in 100 mL saline +
pembrolizumab. In Cohort 1 (n = 3), CVA21 is administered at a dose
of 1 x 108 TCID50, in Cohort 2 (n = 3) at a dose of 3 x 10
8 TCID50 and
in Cohort 3 (n = ~80) at a dose of 1 x 109 TCID50 on study days 1, 3,
5, 8, 29, and Q3W for 6 additional infusions. Pembrolizumab is given
in all cohorts at 200 mg IV Q3W from Day 8 for up to 2 years. Treat-
ment with CVA21 ± pembrolizumab will continue until confirmed CR
or PD (whichever comes first) per irRECIST 1.1 or DLT. Part B, Cohort
1 enrollment is complete.
Results
IV delivery of CVA21 to all patients in Part A was generally well toler-
ated, with no Grade 3 or 4 product-related AE’s.
Conclusions
CVA21 tumor targeting in patients with melanoma, NSCLC, and blad-
der cancer patients in Part A Cohort 3 was confirmed by detection of
CVA21 viral RNA in tumor biopsies at study Day 8.
Trial Registration
ClinicalTrials.gov identifier NCT02043665.
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Background
p53 was reported to be an attractive immunotherapy target because
it is mutated in approximately half of human cancers, resulting in its
inactivation and often accumulation in tumor cells. Peptides derived
from p53 are presented by class I MHC molecules and may act as
tumor-associated epitopes which could be targeted by p53-specific T
cells. Interestingly, it was recently shown that there is a lack of sig-
nificant correlation between p53 expression levels in tumors and
their recognition by p53-TCR transduced T cells.
Methods
To better understand the influence of the mutational status of p53
on its presentation by the MHC system and on T cell anti-tumor re-
activity, we generated several mutant p53 constructs and expressed
them in HLA-A2+/p53- cells. Upon co-culture with p53-specific T
cells, we measured the specific recognition of p53-expressing target
cells by means of cytokine secretion, marker upregulation and cyto-
toxicity, and in parallel determined p53 expression levels by intracel-
lular staining. We also examined the impact of mutant p53
expression on cell cycle dynamics and on the expression levels of
the pro-apoptotic protein caspase-3.
Results
Our results show that selected p53 mutations altering protein stabil-
ity can modulate p53 presentation to T cells, leading to a differential
immune reactivity inversely correlated to measured p53 protein
levels.
Conclusions
Thus, p53 may behave differently than other classical tumor antigens
and its mutational status should therefore be taken into account
when elaborating immunotherapy treatments of cancer patients tar-
geting p53.
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Background
Immune checkpoint blockade therapies have been successfully
employed clinically to treat melanoma. Ipilimumab, which blocks in-
hibitory receptor CTLA-4 was one of the first checkpoint blockade
therapies to get FDA approval for treating melanoma patients. Des-
pite the effectiveness of these drugs, a significant number of cancer
patients do not respond, and durable responses are only observed in
a fraction of patients across tumor types. Therefore, combination
therapies including checkpoint blockade antibodies are being stud-
ied to improve the outcome from immunotherapy treatment. Pattern
recognition receptors like TLRs have been shown to have anti-tumor
effects in various tumor models, through their effect on innate
immunity.
Methods
In this study, we set out to combine the innate immune arm like TLR
ligand with the adaptive immune arm for treatment of melanoma in
a mouse model. We identified TLR1/2 ligand Pam3CSK4 as innate im-
mune system modulator to combine with anti-CTLA-4 antibody in
this combination therapy. Mice were injected intradermal (i.d.) on the
right flank with 3 × 105 B16/F10 and considered day 0. Initial B16/F10
challenge was doubled to 6 × 105 in experiments where mice wouldbe sacrificed on day 14. Mice were then treated with intraperitoneal
(i.p) injection of 100 μg anti-CTLA-4 antibody and intratumoral injec-
tion with TLR1/2 ligand on every third after initial tumor challenge till
day 12. The dose of anti-CTLA-4 antibody was doubled on day 3. In
experiments where mice would be sacrificed on day 14, only two
doses of anti-CTLA-4 antibody and TLR ligands were given on Day 9
and Day 12 after injection. These mice were either sacrificed on day
14 for obtaining lymphoid organs and tumors for phenotypic and
functional analysis or tumor growth was analyzed.
Results
Our studies show that combining TLR1/2 ligand Pam3CSK4 with anti-
CTLA-4 antibody decreases tumor burden and increases survival sig-
nificantly, compared to anti-CTLA-4 antibody treatment alone. In our
studies we found both CD4+ and CD8+ T cells to be important for
this combination treatment efficacy. Most interestingly, we found
that the mechanism of efficacy of combination treatment is due to
an increased depletion of regulatory T cells modulated by enhanced
FcγRIV expression on macrophages in combination therapy.
Conclusions
Our findings suggest that combining TLR1/2 ligand with anti-CTLA-4
antibody will be an interesting prospect for treatment of cancer and
it also suggest that TLR1/2 ligand modulate FcγRIV expression, which
can be used to modulate the efficacy of other antibody-based immu-
nomodulatory therapies.
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Background
Immune checkpoint targeted therapies against PD-1, PD-L1, and
CTLA-4 are currently revolutionizing cancer care. However, a minority
of patients generate objective tumor responses with these treat-
ments. Therefore, new therapeutic interventions are needed to in-
crease the immunogenicity of tumors in order to overcome the
resistance to immune checkpoint blockade therapy. Pattern recogni-
tion receptors (PRR) such as toll-like receptor agonists have been
shown to overcome resistance to immune checkpoint targeted ther-
apy in pre-clinical models. Besides their intrinsic ability to stimulate
PRR, the oncolytic properties of common viruses can be exploited
also for the priming of anti-tumor immune responses. Hypothesis:
Can anti-infectious vaccines be used as a source or PRR agonists
and/or oncolytic viruses?
Methods
We tested a TLR-Luc transgenic cell line for screening of the TLR
agonist activity of anti-infectious vaccines. Cytotoxic activity induced
by the vaccines was determined by SRB test and IncuCyte imaging.
Flow cytometry was performed to identify the type of cell death and
to characterize different population of infiltrated immunity cells in
the tumors. In vivo effect of immune checkpoints blockade were de-
termined in monotherapy and in combination with the vaccines on
tumor growth.
Results
We confirmed that commercially available anti-infectious vaccines do
have PRR agonist properties. Interestingly, we discovered that rota-
virus vaccines also have oncolytic properties. These attenuated vi-
ruses can directly kill cancer cells with features of immunogenic cell
death such as upregulation of calreticulin on dying cancer cells.
Moreover, they have pro-inflammatory properties and can activate
the NF-Kb pathway in a TLR and IRF3 independent manner. These
in vitro biological properties translate into in vivo anti-tumor activity.
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partly immune mediated as demonstrated by their activity in NSG
xenograft models of human tumors. Interestingly, in immunocompe-
tent syngeneic murine tumor models of neuroblastoma and lymph-
oma, intra-tumoral rotavirus therapy can overcome resistance and
synergize with immune checkpoint targeted therapy. This therapeutic
effect relied on specific modifications of tumor immune infiltrates
and immune activation pathways. Intratumoral rotavirus vaccines
was associated to an increase of leukocytes in the tumor microenvir-
onment and upregulation of activation markers such as OX40/CD137
and CD86 on T cells and APC, respectively.
Conclusions
Rotavirus vaccines are clinical grade products. Therefore, in situ
immunization strategies with intra-tumoral attenuated rotavirus can
be implemented quickly in the clinic. Intra-tumoral priming of the
anti-tumor immunity with oncolytic and immunostimulatory rotavirus
vaccines could be a feasible strategy to overcome resistance to anti-
PD-1/anti-CTLA-4 therapy in patients with cancer.
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Background
The success of immunotherapy for cervical cancer and HPV+ head
and neck cancer may be enhanced by a combination of immune
checkpoint blockade and tumor-selective vaccination. Axalimogene
filolisbac (AXAL or ADXS11-001) is an irreversibly attenuated Listeria
monocytogenes-listeriolysin O (Lm-LLO) immunotherapy bioengi-
neered to secrete an HPV E7 tLLO fusion protein that induces HPV-
specific cytotoxic T cells and reduces tumor-associated immune
tolerance. Durvalumab is a selective, high-affinity human IgG1 mAb
that blocks PD-L1 binding to PD-1 (IC50 0.1 nM) and CD80 (B7.1; IC50
0.04 nM). The PD-1/PD-L1 pathway is an important checkpoint used
by tumor cells to inhibit antitumor responses. Preclinical mouse
models demonstrate combination AXAL/anti–PD-1 treatment signifi-
cantly reduces tumor growth and prolongs survival.
Methods
This is a phase I/II study (NCT02291055) of AXAL + durvalumab in pa-
tients (≥18 years) with either recurrent/metastatic cervical cancer or
metastatic HPV+ SCCHN, who progressed on ≥1 platinum-based ther-
apy. The primary objectives of the phase I, Part A dose escalation are
to determine the safety/tolerability and establish the combination
recommended phase II dose (RP2D) of AXAL (1 × 109 colony-forming
units q4wk) and durvalumab (3 mg/kg or 10 mg/kg q2wk) following
a 3 + 3 design. Part A includes a SCCHN expansion cohort (N = 20) at
the RP2D to evaluate efficacy. Part B will evaluate tumor response
(RECIST and immune-related RECIST) of durvalumab monotherapy
and AXAL + durvalumab combination therapy at the RP2D in recur-
rent/metastatic cervical cancer. Preliminary results of phase I dose es-
calation are reported.
Results
To date, 11 patients are enrolled in phase I (AXAL + durvalumab
3 mg/kg: N = 5; AXAL + durvalumab 10 mg/kg: N = 6); 91 % had
ECOG performance status 0, 73 % had cervical cancer, of which 75 %
received prior bevacizumab. No dose-limiting toxicities have been
observed. The following adverse events (AEs) were reported (3 vs.
10 mg/kg): 100 % vs. 83 % of patients experienced AEs; 20 % vs.
50 % experienced SAEs; 60 % vs. 50 % experienced Grade 1 andGrade 2 treatment related AEs (TRAEs); Grade 3 TRAEs occurred in n = 1
(rigors) and n = 2 (rigors and neutropenia, respectively) patients. In the
AXAL + durvalumab 3 mg/kg cohort, 2 patients with cervical cancer ob-
tained an objective response; 1 CR that is ongoing (9 months follow-
up) and 1 PR with subsequent disease progression. Tumor assessments
from the AXAL + durvalumab 10 mg/kg cohort are not yet available.
The RP2D was declared at durvalumab 10 mg/kg q2wk+ AXAL 1 × 109
colony-forming units q4wk.
Conclusions
The combination of AXAL/durvalumab appears safe and tolerable.
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Background
Despite many therapeutic successes, cancer is the second-most fre-
quent cause of mortality in the United States. Strategies for cancer
therapy aim to overcome excessive proliferation and avoidance of
apoptosis. Therefore, methods of inducing apoptosis have become
an important approach in the design of effective cancer therapies.
Among these tumor necrosis factor-related apoptosis inducing ligand
(TRAIL) has shown considerable promise as a nontoxic apoptotic in-
ducer in cancer immunotherapy. However, many primary tumors are
inherently resistant to TRAIL-mediated apoptosis and require add-
itional sensitization. Therefore, there is an underlying interest in iden-
tifying agents that can be combined with TRAIL to improve its
efficacy. Recent studies have also described a role of TLR3 signaling
for initiating apoptosis in malignant cells and thus promote antican-
cer immune responses. We have previously shown that, withanolide
E (WE), a 17β-hydroxywithanolide (17-BHW) and a natural product
derived from the medicinal plant Physalis peruviana was capable of
sensitizing tumor cells to TRAIL-mediated apoptosis by reducing cel-
lular levels of the anti-apoptotic protein cFLIP.
Methods
Encouraged by this, we screened a small library of 17-BHWs and
have identified several that are more potent than WE for their ability
to promote death ligand-mediated cancer cell death.
Results
Among the 30 compounds tested, LG-02 was found to be 4–5 fold
more potent than WE in sensitizing tumor cells to apoptotic signaling
in response TRAIL as well as to the synthetic polynucleotide, poly(I:C),
which is known to mimic anti-viral responses by activating TLR (toll-
like receptor) signaling. Intra-tumor administration of LG-02 and
poly(I:C) in a xenograft M14 melanoma model provided therapeutic
benefit leading to complete tumor regression in 90 % of the mice as
compared to mice treated with vehicle or compounds alone. Molecu-
lar studies in melanoma cells demonstrated decreases not only in
the anti-apoptotic cFLIP proteins but also in a number of IAPs includ-
ing livin following LG-02 treatment. To date there are no withano-
lides reported to have this dual activity on reducing levels of
different anti-apoptotic proteins.
Conclusions
Thus, we hypothesized that 17-BHWs represent a unique NP scaffold,
structural modification of which would lead to potent non-toxic
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pathway similar to that of TNF death receptor signaling. Further
studies with 17-BHWs could lead to the identification of novel and
common therapeutic targets involved in apoptosis signaling in re-
sponse to both TNF death receptor family members as well as TLR
ligands.
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Background
Toll-like receptor (TLR) agonists, such as the TLR7 agonist imiquimod,
have been evaluated topically and systemically for cancer. Topical
administration has shown antitumor activity against various cancers,
such as melanoma, squamous cell carcinoma, and cutaneous breast
cancer. However, systemic administration of TLR agonists in cancer
patients has resulted in limited efficacy, in part due to cytokine-
induced systemic adverse effects, which limits the therapeutic
window. Therefore, a lipophilic imidazoquinoline, MEDI9197, was de-
signed to be retained within the tumor following injection with the
primary objective of directing immune activation to the tumor.
Methods
The antitumor effects of intratumoral (IT) administered MEDI9197 were
evaluated in 4 different mouse syngeneic subcutaneous implantation
tumor models. Tumor and serum drug levels were quantified following
IT administration. In addition, the tumor immune profile was assessed
by qPCR, histology, and flow cytometry. Lastly, the antitumor effects of
combination therapy using IT injected MEDI9197 in conjunction with
CTLA-4 or PD-L1 antibodies were evaluated.
Results
MEDI9197 is a human TLR7/8 agonist. Following IT administration,
pharmacokinetic analysis shows that the drug is retained in the
tumor, and very low levels of the drug are detected in the serum.
MEDI9197 mediates antitumor activity (tumor growth inhibition and
enhanced survival) in B16F10 luc, B16-OVA, 4 T1, and CT-26 mouse
tumor models. Administration of MEDI9197 by the IT route and by
the SC route away from the tumor demonstrates that the antitumor
effects of MEDI9197 require IT administration. IT dosed MEDI9197
modulates the local immune response characterized by an upregula-
tion of genes involved in innate and adaptive immunity. IT dosed
MEDI9197 induces tumor necrosis, leukocyte activation, and the for-
mation of lymphoid aggregates evident by 7 days postdose. IT
injected MEDI9197 increases the number of tumor infiltrating CD8+ T
cells, while concomitantly decreasing the number of tumor infiltrat-
ing CD4+ T cells. Moreover, MEDI9197 induces prolonged activation
of tumor T cells and NK cells. Additionally, combination of MEDI9197
with CTLA-4 and PD-L1 antibodies enhances the efficacy observed in
syngeneic mouse tumor models.
Conclusions
The data presented shows IT administration of the TLR7/8 agonist
MEDI9197 is retained in the tumor, modulates the tumor microenvir-
onment in a manner consistent with an antitumor signature, and
inhibits tumor growth in multiple mouse cancer models. Finally, the
antitumor effects of MEDI9197 are further enhanced by combination
therapy with checkpoint blockade therapies. MEDI9197 is currently
being evaluated for safety and efficacy in human clinical trials
(ClinicalTrials.gov Identifier: NCT02556463).P244
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Background
Cancer cells are subjected to evolutionary selection of clonal popula-
tions by changes in the microenvironment as well as their response
to drug treatment. We wished to evaluate how this heterogeneity
impacts efficacy of checkpoint inhibition.
Methods
To understand the contribution of clonal subpopulations to the ma-
lignant progression and to the response to drugs, we established a
model of tumor heterogeneity from six syngeneic, clonal primary
cancer cells isolated from a mutant Kras/P53 mouse pancreatic can-
cer (KPC). The clones were characterized molecularly and tumors
reconstituted from mixes of the clonal cell lines.
Results
These clonal cells formed invasive and metastatic lesions when
grafted into hosts. The original tumor and clonal cell lines harbored
common mutations in 99 genes suggesting their common ancestry.
Additional unique mutations in the clonal lines were used to identify
and quantitate clones in heterogeneous cell pools. The clones
showed different levels of MAP kinase signaling, unique morpholo-
gies, different growth rates in vitro and tumor growth rates in im-
mune competent mice. Moreover, the sensitivity to ~200 anticancer
drugs revealed an up to 25-fold varying in vitro sensitivity of the
clones to signal transduction inhibitors and cytotoxic drugs. To our
surprise, drug sensitivity of individual clones when included in a het-
erogeneous cell population was strikingly different from their drug
sensitivity when growing on their own. In particular, the sensitivity of
clones to MEK or PI3K inhibition was not predictive of their sensitivity
when grown in a pool with the other clones. Furthermore, the sensi-
tivity of clones to an anti-PD-1 checkpoint inhibitor was distinct
across the clonal cells growing in the heterogeneous mixture. Some
clones were resistant and others highly sensitive to the checkpoint
inhibition. We will discuss pathways and drivers of resistance in the
different subpopulations.
Conclusions
We conclude that malignant progression and selection of checkpoint
inhibitor sensitive cancer cell subpopulations is impacted by the
crosstalk between clonal cell populations present in heterogeneous
tumors and the host environment.
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Background
Tumors use tryptophan-catabolizing enzymes such as indoleamine
2–3 dioxygenase (IDO1) to induce an immunosuppressive
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and promotes immune tolerance, effector T cell anergy and en-
hanced Treg function. As such, IDO1 is a nexus for the induction of
key immunosuppressive mechanisms and represents an important
immunotherapeutic target in oncology.
Methods
We have identified and characterized a new, selective, orally bioavail-
able IDO1 inhibitor, PF-06840003.
Results
Key interactions of PF-06840003 with IDO1 will be presented, and ra-
tionalized using a novel X-ray crystal structure of PF-06840003 bound
to human IDO1. In addition, binding studies with ferrous and ferric
forms of human IDO1 have been performed. The results suggest that
PF-06840003 is a tryptophan non-competitive, non-heme binding
IDO1 inhibitor. Key in vitro and in vivo pharmacology data, including
combination studies with checkpoint inhibitors, and ADME data of
PF-06840003 will be discussed. PF-06840003 shows a very favorable
ADME profile (solubility, human hepatocyte stability, low in vivo
clearance in preclinical species, high permeability, and high fraction
absorbed in preclinical species) leading to favorable predicted hu-
man pharmacokinetic properties, including a predicted t1/2 of
19 hours.
Conclusions
PF-06840003 is a selective IDO1 inhibitor with very favorable
predicted human PK characteristics. Its prolonged projected human
half-life should allow QD administration. CNS penetration suggests
potential impact on brain metastases. Checkpoint antagonists against
PD-L1 cause enhanced IDO1 expression and enhanced in vivo anti-
tumor efficacy in combination with PF-06840003. These studies
highlight the potential of PF-06840003 as a clinical candidate in
Immuno-Oncology. A first in patient study for PF-06840003 in malig-
nant gliomas is described at ClinicalTrials.gov (NCT02764151).
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Background
Recent clinical studies have found that treatment with the immune
checkpoint inhibitors anti-PD-1 or PD-L1 induce durable anti-tumor
responses in some patients with advanced-stage cancers. However,
many patients do not benefit from treatment because the induction,
potency, and persistence of immune responses depend on a com-
plex interplay between different immune cell populations. Thus,
treatment with a combination of therapies that target distinct im-
mune pathways may be a promising strategy to improve anti-tumor
efficacy. NHS-IL-12 (MSB0010360N; M9241) is an investigational
immunocytokine designed to target tumor necrotic regions as a
method to deliver IL-12 into the tumor microenvironment. Avelu-
mab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 monoclonal
antibody designed to selectively bind to PD-L1 and competitively in-
hibit it from binding to PD-1, which has shown antitumor activity in
various malignancies in clinical trials.
Methods
In the pre-clinical studies described here, the anti-tumor efficacy of
combination treatment with avelumab and the surrogate NHS-muIL-
12 was investigated in an orthotopic EMT-6 breast cancer model’
Results
Treatment with NHS-muIL-12 and avelumab generated an enhanced
anti-tumor effect relative to either monotherapy. Most mice treated
with the combination therapy had complete tumor regression and
generated tumor-specific immune memory, as demonstrated by their
protection against rechallenge with EMT-6 tumor cells and thesignificant induction of effector and memory T cells. The combination
treatment dose-dependently stimulated cytotoxic NK and CD8+ T cell
proliferation. NHS-muIL-12 treatment induced CD8+ T cell infiltration
into the tumor microenvironment consistent with the induction of
chemoattractants. Also, avelumab monotherapy reversed T cell im-
munosuppression and restored the function of exhausted CD8+ T
cells in the tumor microenvironment.
Conclusions
These preclinical findings indicate that the combination therapy with
NHS-IL-12 and avelumab may provide a promising approach to treat
patients with solid tumors. Asterisk (*) indicates a proposed nonpro-
prietary name.
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Background
The mechanism underlying the improved anti-tumor activity of com-
bined CTLA-4 and PD-1 blockade is not yet well understood. We re-
ported that expansion of CD4+Foxp3− T cells expressing PD-1 (4PD-
1hi) was associated with limited therapeutic improvement when a
CTLA-4-blocking antibody was added to an anti-melanoma vaccine
in B16-melanoma bearing mice. We went on to define functions and
origin of 4PD-1hi to clarify the significance of their modulation by
checkpoint blockade in mouse tumor models and cancer patients.
Methods
4PD-1hi frequency was monitored by flow cytometry. Their function
was tested in standard in vitro suppression assays and 3D collagen-
fibrin gel killing assays. RNAseq gene expression analyses were per-
formed on a Proton sequencing system at the MSK Genomics Core
Facility.
Results
Circulating and intra-tumor 4PD-1hi frequencies positively correlated
and both increased as a function of tumor burden in anti-CTLA-4-
treated and naïve B16-bearing mice, suggesting a pro-tumor role of
4PD-1hi. Accordingly, the ratio between effector T cell (Teff) and 4PD-
1hi inversely correlated with tumor size. 4PD-1hi from spleens and tu-
mors of naïve and B16-bearing Foxp3-GFP-transgenic mice treated or
not with CTLA-4 blockade suppressed Teff functions. RNAseq gene
expression analysis revealed an enrichment of follicular helper T cell-
(Tfh)-associated genes in 4PD-1hi in comparison with regulatory T
cells (Tregs) and CD4+Foxp3−PD-1− T cells. We therefore immunized
Foxp3-GFP transgenic mice with sheep red blood cells (sRBC) to
boost development of Tfh and test their function in vitro. 4PD-1hi
from sRBC-treated animals inhibited Teff more efficiently than those
isolated from untreated mice. However, in contrast to Tregs and ac-
cording to their Tfh-like phenotype, 4PD-1hi promoted activation and
maturation of B cells in vitro. Moreover, concurrent PD-1 and CTLA-4
blockade, either alone or in combination with an anti-melanoma vac-
cine, prevented 4PD-1hi expansion and significantly improved anti-
tumor responses in mice. In cancer patients, ipilimumab increased,
whereas PD-1 blockade reduced, circulating 4PD-1hi. We took advan-
tage of differential CD25 expression in 4PD-1hi and Tregs to isolate
and compare these two cell subsets from healthy donors’ peripheral
blood as well as patients’ tumors. Human 4PD-1hi inhibited Teff func-
tions in vitro and expressed Tfh-associated markers, thus confirming
our observations in mice.
Conclusions
Our study describes T cell suppression functions of Tfh-like cells
expanded by CTLA-4 blockade. Importantly, we show that these
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 137 of 221cells exist in healthy individuals and expand in the presence of
tumor. We provide evidence that PD-1 blockade counteracts
anti-CTLA-4-mediated 4PD-1hi induction, thus underscoring one
of the mechanisms potentially responsible for the improved
therapeutic activity of combination checkpoint blockade.
Consent
Written informed consent was obtained from the patient for pub-
lication of this abstract and any accompanying images. A copy of
the written consent is available for review by the Editor of this
journal.
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Background
It has been well established that human T cells can recognize
and destroy tumor cells. In solid tumors, it has been shown that
peptide vaccine against tumor antigens can augment host anti-
tumor immune response and achieve tumor control in some
patients. WT1 is a defined leukemia-associated antigen, a tran-
scription factor that over-expressed in AML, CML, ALL, and other
tumors. WT1 is highly antigenic and is an attractive target for
immunotherapy. However, the optimal strategy for vaccination
to induce WT1-specific immune responses is not known.
Methods
In this pilot study, we randomized seven (4 males, 3 female
ages 39 to 73) HLA-A02+ patients with myeloid leukemia in the
minimal residual disease state to receive vaccination with WT1
126–134 peptide (RMFPNAPYL) in either Montanide or poly-ICLC
(TLR3 agonist). Four patients were randomized to receive WT1
in Montanide and three were randomized to receive WT1 in
poly-ICLC. The vaccine was administered every other week X 6
during the induction phase followed by monthly booster vacci-
nations X 6 months. Patients were monitored for disease and
toxicity. Blood was collected to monitor WT1 transcript levels,
antigen-specific CD8+ T cell responses, and TCR sequencing.
Results
After WT1 vaccination, three of four patients in the Montanide
arm had deceased WT1 levels in circulation detected by qRT-PCR,
and two of these demonstrated augmented WT1-specific CD8+ T
cell responses detected by IFN-γ ELISPOT assay. All three patients
had TCR clonal enrichment after WT1 vaccination suggested by
TCR alpha and beta CDR3 sequencing. In contrast, in the two pa-
tients on the poly-ICLC arm, no increase in WT1-specific CD8+ T
cell responses was detected by IFN-γ ELISPOT assay, and no
clonal enrichment was detected by TCR alpha/beta sequencing.
Interestingly, these two patients nonetheless demonstrated de-
creased WT1 transcript levels in circulation detected by qRT-PCR
and remained in remission 3 years after the initiation of WT1
vaccination.
Conclusions
Our results show that vaccination with WT1 peptide emulsified in
Montanide is a superior vaccine strategy based on increased WT1-
specific CD8+ T cell responses with TCR clonal and specific TCR
beta CDR3 enrichment and decreased WT1 transcripts as a measure
of minimal residual disease. The fact that vaccination with WT1
peptide in poly-ICLC nonetheless was associated with decreased
WT1 transcripts suggests that a distinct immune activation mechan-
ism might be occurring, for example an effect on dendritic cells of
poly-ICLC alone.P249
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Background
HPV can cause cervical, anal, vulvar, vaginal, penile, and oropharyngeal
cancers. AXAL is a genetically engineered Listeria monocytogenes-based
therapeutic cancer vaccine currently in clinical trials for cervical (phase III),
anal (phase II), and head and neck (phase I/II) cancers, either as mono-
therapy or in combination with checkpoint inhibitor (PD-1 or PD-L1) anti-
bodies. To identify potentially synergistic immunotherapies, we evaluated
AXAL ± antibodies for T cell co-inhibitory or co-stimulatory receptors
(checkpoint inhibitors: CTLA-4, PD-1, TIM-3, LAG-3; co-stimulators: CD137,
OX40, GITR, and CD40) in a mouse HPV-positive tumor model.
Methods
C57BL/6 female mice and TC1 cells (C57BL/6 mouse lung epithelial cells
co-transfected with HPV16 E6 and E7 and activated Ras) were obtained
from Jackson Laboratories and ATCC, respectively. All antibodies were
obtained from Bio X Cell. Mice were subcutaneously injected on the
hind-leg flank with TC1 cells. AXAL ± the respective antibodies was
injected intraperitoneally at 5 × 107 colony-forming units/mouse weekly
for 3 total doses. For combinations with superior performance, the
tumor microenvironment (TME) was further evaluated using flow cy-
tometry to immunophenotype the tumor-infiltrating lymphocytes (TILs),
spleen, and tumor-draining lymph node.
Results
Among 8 antibodies tested in combination with AXAL, CD137 and
CTLA-4 antibodies were the most effective for tumor growth inhibition,
tumor regression, and survival. Consistent with prior reports that
CD137 is expressed on natural killer, dendritic, and T cells, and can po-
tentiate antitumor responses by altering the cellular makeup of the
TME [1], immunophenotyping revealed increased TILs and CD8/Treg ra-
tio, and decreased levels of highly immunosuppressive CD103-positive
Tregs after CD137 + AXAL treatment versus treatment with either agent
alone. Additionally, increases were observed in PD-L1 expression on
tumor cells and PD-1 expression on CD8-positive T cells. Mice with
complete tumor regression after CD137 + AXAL treatment (n = 5) were
subsequently rechallenged with TC1 cells. Two mice remained tumor
free until study termination (an additional 6–7 weeks); the other 3 had
delayed or slower tumor growth versus controls. CTLA-4 + AXAL treat-
ment resulted in complete tumor regression in 3 mice evaluated. These
mice remained tumor free even after rechallenge.
Conclusions
AXAL demonstrated strong anticancer activity in this preclinical model of
HPV-positive cancer, especially in combination with CD137 and CTLA-4
antibodies. Moreover, these data suggest that addition of anti-PD-1 to
anti-CD137 +AXAL could be a potent triple combination therapy.
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A role for T cells in the antitumor effects of radiation therapy is be-
coming increasingly clear [1]. Since lymphocytes are considered to
be very sensitive to ionizing radiation (IR), and IR increases T cell infil-
tration of tumors, it is usually assumed that the newly infiltrating T
cells mediate the therapeutic effects of IR. However, there is no clear
data showing the contribution of tumor-resident vs. newly infiltrating
T cells to the therapeutic effects of IR.
Methods
Longitudinal in vivo imaging of tumors using window chambers was
performed as described [2]. “T cell reporter” mice were obtained by
crossing CD4-Cre or Lck-cre mice with R26-stop-EYFP mice (Jackson).
Results
Panc02SIYCerulean cancer cells were injected s.c. into EYFP+ T cell re-
porter mice bearing dorsal window chambers. When tumors were
established (around day 21), mice received 800 cGy of whole-body ir-
radiation (WBI) while their tumor was shielded. This procedure de-
pleted most peripheral T cells while preserving tumor-resident EYFP+
T cells. Following bone-marrow reconstitution with DsRed+Rag−/−
cells, EGFP+ 2C CD8+ T cells specific for the SIY antigen were adop-
tively transferred, to distinguish newly infiltrating T cells. 3–4 days
after 2C transfer, some mice received local IR as follows. 2 experi-
ments using (i) 5 doses of 1.8 Gy each, 24 hours apart (fractionated
IR model), and (ii) a single dose of 20 Gy (SBRT model) showed that
a significant proportion of tumor-resident EYFP+ T cells were still de-
tected in the tumor and kept their motility even after 20 Gy of IR, for
up to 2 weeks. 2C-EGFP+ T cells infiltrated IR-treated tumors with
some delay, but eventually reached high numbers in IR-treated and
untreated tumors. Treating MC38 tumor-bearing mice with increasing
doses of WBI (1–10 Gy) showed that tumor-resident T cells were
more resistant to IR than circulating T cells. Experiments treating
MC38-bearing animals with 20 Gy local IR and systemic sphingosine
1-phosphate receptor agonist FTY720, suggest that tumor-resident T
cells might suffice for the antitumoral effects of single high-dose IR.
Conclusions
Tumor-resident T cells show preferential survival to IR compared to
circulating T cells and can contribute to the therapeutic effects of
radiotherapy.
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Background
AGS-003, is an autologous dendritic cell (DC) immunotherapy consist-
ing of matured DCs co-electroporated with amplified autologous
tumor RNA and CD40L RNA. AGS-003, is being evaluated in the piv-
otal ADAPT phase III clinical trial for the treatment of metastatic renal
cell carcinoma (mRCC) in combination with standard-of-care, based
on a phase II clinical trial suggesting that response combination of
sunitinib + AGS-003 was greater than sunitinib alone. The standard-
of-care tyrosine kinase inhibitors including sunitinib, sorafinib,
axitinib, pazopanib, cabozantinib and tivozanib, and the mTOR inhibi-
tors, everolimus and temsirolimus, are anti-angiogenic therapeutics
targeting signaling pathways implicated in the progression of RCC.
However, these same signaling pathways are essential for the activa-
tion of antigen-specific T cell responses. Combining kinase inhibitortherapy with an active immunotherapeutic, such as AGS-003, may be
ineffective, if kinase inhibitor therapy impedes the induction of CTL
responses in vivo, which is the proposed mechanism of action (MOA)
of AGS-003. Therefore, it was of interest to test these combinations
in vitro with DCs representative of AGS-003 to observe the effects of
combination therapy on antigen-specific CTL proliferation and CTL
functional responses.
Methods
DCs derived from normal donor monocytes were co-electroporated
with MART-1 RNA and CD40L RNA to represent AGS-003 DC prod-
ucts. In vitro co-cultures were set up with autologous CD8+ T cells
and MART-1/CD40L-DCs in the presence of various concentrations of
the kinase inhibitors. Kinase inhibitor concentrations were chosen to
represent steady-state concentrations reported in patients receiving
active therapy. Subsequent expansion of MART-1 specific CTLs and
multi-functional responses were mapped using multi-color flow
cytometry.
Results
Our in vitro analysis demonstrated that sunitinib, axitinib, cabozanti-
nib, tivozanib, everolimus and temsirolimus did not impact the prim-
ing nor proliferation of MART-1-specific CTL responses. Furthermore,
these kinase inhibitors did not impact multi-functionality of CD28
+/CD45RA− effector/memory CTL. However, sorafenib, when present
in the CTL/DC co-cultures, did significantly impair anti-MART-1-spe-
cific CTL expansion and CTL multi-functionality.
Conclusions
Autologous DCs co-electroporated with MART-1 RNA/CD40L RNA ex-
hibit a similar MOA in vitro to AGS-003 administered in vivo, whereby
both DC preparations induce antigen-specific multi-functional CTLs.
Understanding the MOA of AGS-003 in vitro, allows for the testing of
a broad range of potential combination therapies to provide feasibil-
ity data to support clinical trials of combination therapy for mRCC.
Data provided show that most, but not all, kinase inhibitors are com-
patible with the MOA of AGS-003, the induction of effector/memory
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Background
We have previously reported that the immunotherapy with multiple
tumor antigens activated autologous T cells (MASCT) was a safe
treatment, which may improve the immunologic function and clinical
outcome of the patients with hepatocellular carcinoma (HCC). In this
study, we investigated the dynamics of MASCT-induced immune re-
sponses and demonstrated the mechanism and advantages of using
multiple tumor antigens.
Methods
13 patients with stage B stage (BCLC) were treated with MASCT for
three courses after tumor resection. During each course, the patients
received two subcutaneous injections of mature dendritic cells
(mDCs) pulsed with a peptide pool of multiple tumor antigens, and
three i.v. injections of autologous T cells activated by mDCs de-
scribed above. Each course lasted 14–15 weeks.
Results
After repeated treatment of MASCT, the frequency of regulatory T
cells in the patients’ PBMCs was significantly decreased, while
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production were significantly enhanced in the patients’ PBMCs.
Moreover, the specific immune responses of T cells against each kind
of tumor antigen peptide in the pool were also measured by IFNγ
ELISPOT assay. These specific immune responses could be detected
in 11 out of 13 patients’ PBMCs but with individual and dynamic pat-
terns during the treatments of MASCT. After 1 course of treatment,
the best patient has specific immune responses against 9 tumor anti-
gens out of 14 in the pool, and the worst patient has responses
against 2 tumor antigens. These numbers have increased to 11 and 3
after the second course. The most immunogenic tumor antigens are
survivin (7/13), cyclin D1 (CCND1, 6/13), carcinoembryonic antigen
(CEA, 5/13), and HBV DNA polymerase (5/13). There were 7 patients
left without progression 1 year after the immunotherapy initiation.
And, the specific immune responses detected in these patients’
PBMCs were significantly stronger than that in the patients with
progression.
Conclusions
Our study demonstrates that individual and dynamic tumor antigen-
specific T cell responses can be induced in HCC patients after
repeated treatments of MASCT, providing evidence to show the ad-
vantage of using multiple tumor antigens in immunotherapy instead
of single antigen. In addition, these specific immune responses may
correlate with the clinical outcomes.
P253
Live, attenuated, double-deleted Listeria monocytogenes
expressing mesothelin (CRS-207) with immuno-modulatory doses
of cyclophosphamide, combined with chemotherapy as treatment
for malignant pleural mesothelioma (MPM)
Raffit Hassan1, Thierry Jahan2, Scott J Antonia3, Hedy L Kindler4, Evan W
Alley5, Somayeh Honarmand6, Weiqun Liu6, Meredith L Leong6, Chan C
Whiting6, Nitya Nair6, Amanda Enstrom6, Edward E Lemmens6, Takahiro
Tsujikawa7, Sushil Kumar7, Lisa M Coussens7, Aimee L Murphy6, Dirk G
Brockstedt6
1Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda,
MD, USA; 2Department of Medicine, Division of Hematology Oncology,
UCSF, San Francisco, CA, USA; 3H. Lee Moffitt Cancer Center, Tampa, FL,
USA; 4Gastrointestinal Oncology and Mesothelioma Programs, Section of
Hematology/Oncology, University of Chicago, Chicago, IL, USA; 5Penn
Prebyterian Medical Center, University of Pennsylvania, Philadelphia, PA,
USA; 6Aduro Biotech, Inc., Berkeley, CA, USA; 7Oregon Health & Science
University, Portland, OR, USA
Correspondence: Somayeh Honarmand (shonarmand@aduro.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P253
Background
CRS-207 is live, attenuated, double-deleted Listeria monocytogenes
(LADD) engineered to express mesothelin, a tumor-associated
antigen over-expressed in several cancers, including MPM, an
aggressive treatment-refractory disease with poor prognosis. CRS-
207 activates innate and adaptive immunity and may act syner-
gistically with chemotherapy to increase the susceptibility of the
tumor microenvironment to immune-mediated killing. CRS-207 in
combination with standard of care (SOC) pemetrexed/cisplatin
demonstrated clinical activity in a phase Ib study. Low-dose
cyclophosphamide (Cy) has been shown to decrease regulatory T
cells and enhance vaccine-induced responses. Preclinical data
demonstrate CRS-207 with low-dose Cy improves survival in a
murine lung metastasis model.
Methods
60 patients were enrolled into 2 cohorts in this phase Ib study.
Eligibility required unresectable, untreated MPM, ECOG 0 or 1,
and adequate organ function. Patients in Cohort 1 received 2
CRS-207 2 weeks apart, 6 cycles pemetrexed/cisplatin 3 weeks
apart, followed by 2 CRS-207 3 weeks apart. Clinically stable pa-
tients continued CRS-207 every 8 weeks. Patients in Cohort 2 re-
ceived Cy (200 mg/m2) 1 day prior to each CRS-207. Safety,
immunogenicity, tumor responses, survival and tumor markers
were assessed.Results
22 patients were enrolled into the Cy/CRS-207 cohort of this study;
77 % male, median age 70. The most common Cy/CRS-207 related
adverse events (AEs) were grades 1/2 fever, chills, hypotension and
nausea/vomiting, with no treatment-related serious AEs or deaths. As
of August 2016, of 22 evaluable patients receiving Cy/CRS-207 +
chemotherapy, 86 % (19/22) had disease control with 11 (50 %)
whose best overall response was partial response (PR) and 8 (36 %)
had stable disease. Tumor shrinkage was observed in 8/22 (36 %)
patients including 3 PR after 2 doses of Cy/CRS-207 prior to
chemotherapy initiation. Comprehensive immune profiling includ-
ing multidimensional immunohistochemistry (IHC) analyses will be
presented.
Conclusions
Addition of immune-modulating doses of Cy to a regimen of CRS-
207 and SOC chemotherapy appears to be well-tolerated with no in-
crease in toxicity compared to those receiving CRS-207 alone with
chemotherapy. Preliminary results show signs of tumor activity fol-
lowing 2 doses of Cy/CRS-207 prior to chemotherapy (36 % tumor
shrinkage) and the combination with chemotherapy resulted in 86 %
disease control and 50 % response rate compared to published re-
sponse rates of 20-41 % with chemotherapy alone. Immune analyses
and further follow-up are warranted to evaluate the Cy/CRS-207 +
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Background
Preclinical studies demonstrated that local radiotherapy (RT) acts syn-
ergistically with RNActive® mRNA vaccines to enhance anti-tumor ef-
fects and increase tumor-infiltrating lymphocytes. BI1361849 is a
therapeutic vaccine comprising optimized mRNA constituents encod-
ing six NSCLC-associated antigens. Interim data of a phase Ib study,
employing local RT to increase the immune mediated tumor control
by BI1361849, have been previously published [1]. Here we report re-
sults of immune response analyses as well as updated safety and effi-
cacy data.
Methods
26 patients (pts) with stage IV NSCLC were enrolled in three cohorts
based on histological and molecular NSCLC subtypes (squamous and
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 140 of 221non-squamous cell with/without activating EGFR mutations). Pts re-
ceived two vaccinations with BI1361849 before local RT to a single
tumor lesion was administered in four consecutive daily fractions of
5 GY. Vaccination was continued until start of subsequent anti-cancer
therapy. Maintenance pemetrexed (mP) and EGFR-TKIs were
allowed where indicated. Cellular and humoral immune responses
were measured ex vivo by multifunctional intracellular cytokine
staining, IFN-g ELISpot, and ELISA in pre- and post-treatment
blood samples. The induction of humoral immune responses
against 27 lung cancer antigens not encoded by the vaccine was
measured by antibody array.
Results
26 pts were enrolled. 15 pts received mP, two received EGFR TKIs.
Most frequent AEs were mild to moderate injection-site reactions
and flu-like symptoms. No BI1361849-related SAEs were reported.
Based on preliminary data following up to 110 weeks of exposure,
one confirmed PR was observed in a pt on mP, 13 pts (52 %) experi-
enced SD (8 pts on mP, 2 pts on EGFR-TKI and 3 pts without con-
comitant maintenance treatment, associated with 15 % tumor
shrinkage outside the radiation field in one of them). 25 pts were
available for immune response analysis. Preliminary data indicate
that BI1361849 was capable of eliciting antigen-specific immune re-
sponses in of the majority of the patients including cellular and
humoral immune responses. Moreover all encoded antigens were im-
munogenic and responses against multiple antigens were observed.
Treatment induced immune responses against other lung cancer an-
tigens were detected in several patients.
Conclusions
BI1361849 can be safely combined with local RT and mP treatment.
Shrinkage of non-irradiated lesions and prolonged disease stabliza-
tion was observed in a subset of pts, mainly in combination with mP.
Data indicate immunogenicity of BI1361849. Analyses of cellular and
humoral immune responses will be updated, as well as updated clin-
ical data.
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Background
Receptor tyrosine kinase signals are altered in NSCLC and tyrosine
kinase inhibitors (TKIs) have been used to treat NSCLC harboring
driver mutations (e.g. ALK fusion and EGFR). Although TKIs are sensi-
tive to NSCLC with driver mutations, acquired resistance to TKIs is in-
evitable by various mechanisms including gatekeeper mutation and
alternative pathway activation. Considering immunotherapy is one of
the main strategies that override drug resistance and cancer stem-
ness, we evaluated an immunologic strategy to overcome acquired
resistance to TKIs using NK cells in NSCLC.
Methods
TKI-resistant NSCLC cell lines (H3122CR1, H3122LR1, H3122CR1LR1,
EBC-R1, EBC-R2, PC-9GR, and PC-9ER) were established from NCI-
H3122 (EML4-ALK fusion), EBC-1 (MET amplification), and PC-9 (EGFR
exon 19 deletion) after continuous exposure to crizotinib, ceritinib,
capmatinib, gefitinib, and erlotinib. NK cytotoxicity and antibody-
dependent cell-mediated cytotoxicity (ADCC) using anti-EGFR mono-
clonal antibody (mAb) cetuximab were measured using ‘off-the-shelf’
NK92-CD16 cell line as effectors and detected by 51chromium-release
assay. Expression of the ligands for NK cell receptors and total EGFR
were analyzed by flow cytometry.Results
Most of TKI-resistant NSCLC cell lines were more susceptible to
NK92-CD16 cells compared with their parental cell lines. The
percentage of cytotoxicity was determined to be 0.2 % in
H3122 and 13.4 %, 30.2 % and 39.1 % in TKI-resistant H3122
group with an effector:target ratio of 30:1. (PC-9: 18.2 % vs.
38.8 % vs. 24.8 %). The expression of ICAM-1, which is a ligand
for LFA-1 in NK cells, is higher in TKI-resistant NSCLC cells than
in parental cells. When we blocked ICAM1-CD11a interaction
during a cytotoxic assay, the cytotoxicity was decreased about
10 %. Cetuximab-mediated ADCC was higher in resistant cells
due to the increased expression level of total EGFR in resistant
cells.
Conclusions
TKI-resistant NSCLC cells are more sensitive to NK92 cell-mediated
cytotoxicity that is partially dependent on up-regulation of ICAM-1
via an immunological synapse. In addition, cetuximab, an EGFR-
targeting mAb, significantly increases NK cell cytotoxicity in TKI-
resistant NSCLC cells. Taken together, NK-cell based immunotherapy
with cetuximab might be feasible to treat NSCLC patients with ac-
quired resistance to TKIs.
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Background
Rose Bengal is a xanthene dye that has been utilized for liver func-
tion studies and is currently used topically in ophthalmology. Intrale-
sional (IL) Rose Bengal (PV-10) has been shown in murine models
and melanoma clinical trials to induce regression of treated melan-
oma lesions and uninjected bystander lesions. This study was under-
taken to measure whether IL PV-10 can induce systemic anti-tumor
effects alone or in combination with gemcitabine (Gem) therapy in a
murine model of pancreatic cancer.
Methods
C57BL/6 mice received Panc02 pancreatic tumor cells subcuta-
neously (SC) on one flank to establish a single tumor. On day 7,
tumor was treated with IL PV-10. Control mice received IL phos-
phate buffered saline (PBS). Tumor growth was measured.
Splenic T cells were collected and co-cultured with Panc02 or ir-
relevant B16 cells. Supernatants were collected to measure
Panc02-specific T cell responses by IFN-gamma ELISA. To meas-
ure the effect of IL PV-10 on the growth of an untreated, by-
stander tumor, mice received Panc02 cells in bilateral flanks.
The resulting right tumor was injected IL with PV-10 or PBS.
Tumor sizes were measured for both the right (treated) and left
(untreated/bystander) tumors. To determine the efficacy of com-
bination therapy with IL PV-10 and systemic Gem, mice bearing
a single or bilateral Panc02 tumors were treated with PV-10
alone or in combination with Gem. Mice received 60 mg/kg
Gem intraperitoneally (IP) twice per week.
Results
C57BL/6 mice bearing Panc02 tumors treated with IL PV-10 had sig-
nificantly smaller tumors than mice treated with PBS (p < 0.001). A
significant increase in the IFN-gamma production in response to
Panc02 was measured in the splenocytes of mice treated with PV-10
as compared to mice treated with PBS (p < 0.05). Mice with bilateral
tumors had a significant regression of tumors injected IL with PV-
10 and there was a reduction in the untreated (bystander) flank
Panc02 tumor (p < 0.01). Gem therapy in combination with IL PV-
10 injection led to enhanced tumor regression (p < 0.05) com-
pared to IL PV-10 or Gem alone in both a single tumor model
and a bilateral tumor model.
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 141 of 221Conclusions
Regression of untreated pancreatic tumors by IL injection of PV-
10 in concomitant tumor supports the induction of a systemic
anti-tumor response. Addition of Gem chemotherapy enhances
the effects of IL PV-10 therapy. Given that patients with meta-
static pancreatic cancer have a dismal prognosis, combination
therapy of IL PV-10 combined with Gem may benefit patients
with metastatic pancreatic cancer.
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Background
Preclinical models suggest radiation may synergize with im-
munotherapy; for instance, increased responses and prolonged
survival have been observed in mice treated with radiation and
either PD-1 inhibition or combined CTLA-4/PD-1 blockade. We
previously observed that radiation was associated with favorable
responses in melanoma patients treated with ipilimumab [1].
However, clinical data are lacking in regards to combining radi-
ation with PD-1 inhibitors with or without CTLA-4 blockade.
Methods
We conducted an IRB-approved retrospective multi-institution ana-
lysis of patients with metastatic melanoma, non-small cell lung can-
cer (NSCLC), and renal cell carcinoma (RCC) treated at 6 centers with
palliative radiation and PD-1 inhibitors, either before, after, or concur-
rent with radiation.
Results
137 patients (NSCLC, n = 79; melanoma, n = 48; RCC, n = 10) received
279 courses of radiation (median 2, range 1–6) and a median of 4 PD-1
inhibitor cycles (range 1–66). Sixteen patients received concurrent PD-
1/CTLA-4 blockade. Sites irradiated included the brain (n = 144), spine
(n = 40), lungs (n = 38), pelvis (n = 20), and other (n = 32); these sites,
and the use of WBRT/SRS were balanced before versus after the start of
PD-1 therapy. Median survival following start of anti-PD-1 therapy was
192, 394, and 121 days in patients with NSCLC, melanoma, and RCC, re-
spectively. On multivariate analyses adjusting for histology, targetable
mutations and concurrent PD-1/CTLA-4 inhibition, there was a signifi-
cant association between radiation administered following the start of
PD-1 directed treatment and improved survival (HR 0.59, p = 0.02).
There was a significant interaction between the impact of concurrent
PD-1/CTLA-4 checkpoint blockade and subsequent radiation on survival
(p = 0.03 for interaction, HR for radiation = 0.28). One-year survival was
71 % in patients treated with radiation following PD-1/CTLA-4 blockade,
and 4/8 of these patients continued to receive PD-1 therapy after radi-
ation. In all patients, median survival from first course of brain-directed
radiation was 634 days.
Conclusions
In this multi-institution retrospective analysis, targeted radiother-
apy administered following PD-1 blockade was associated with
increased survival. Although this finding is retrospective and
therefore subject to bias, particularly striking is survival observed
following brain-directed radiation and in patients treated with
concurrent CTLA-4/PD-1 blockade. These data suggest select use
of radiation in patients treated with anti-PD-1 therapy may allow
for continuation of effective systemic immunotherapy that could
augment long-term survival.References
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Background
Irradiation (IR) combined with chemotherapy is the post-surgical
standard of care treatment for melanoma, but metastasis still
results in high mortality rates. Recently, immune checkpoint in-
hibitors such as antibodies targeting cytotoxic T lymphocyte
antigen-4 (CTLA-4) have proven effective for immunotherapy of
melanoma. CTLA-4 is up-regulated post-T cell activation, and anti-
body blockade enhances tumor responses in immunocompetent
rodents and humans. Ongoing trials suggest that combinations of
immune checkpoint inhibitors are more efficacious than single
agents, but tumors in many patients remain resistant. Our labora-
tory is investigating CD47 blockade for the treatment of cancer
in several immune competent mouse models. CD47 expression is
frequently elevated in cancers and serves as an inhibitory recep-
tor for thrombospondin-1 on immune cells in the tumor stroma.
CD47 blockade on CD8+ T cells or tumor cells significantly en-
hances immune-targeted tumor cell killing post-irradiation com-
pared to irradiation alone. Here we explore the potential for
CD47 blockade to improve the response rates to anti-CTLA-4
therapy alone or in combination with irradiation using a syngen-
eic mouse melanoma model.
Methods
C57BL/6 mice were inoculated with 1x106 B16F10 melanoma cells
into the right hind limb and treated with local 10Gy irradiation com-
bined with CTLA-4 blocking antibody, CD47 translational blocking
morpholino, or the combination of CTLA-4 antibody and CD47 mor-
pholino. Subjects were humanely euthanized, and tumors were ana-
lyzed using qPCR to evaluate granzyme B and FOXP3 mRNA
expression. Tumors were sectioned and subjected to H&E and anti-
CD8 staining.
Results
In non-irradiated tumors, histology revealed minimal tumor ne-
crosis, while all irradiated groups showed increased necrosis.
Tumor IR in combination with CTLA-4 or CD47 increased im-
mune cell infiltration. However, the combination of irradiation
with CTLA-4 and CD47 showed widespread tumor necrosis
encompassing the entire field. All groups treated with the CD47
morpholino also exhibited focal hemorrhage, which was more
extensive when combined with CTLA-4. FOXP3 mRNA expression
showed a two-fold increase in CD47/CTLA-4-treated mice, which
further increased to 4-fold when administered with IR. Gran-
zyme B mRNA expression increased 3.5 fold with the CTLA-4/
CD47/IR combination. Overall survival in IR/CTLA-4 was ~50 %
while the combination of IR/CTLA-4/CD47 blockade was 75 % at
50 days.
Conclusions
The results described herein suggest that IR in combination
with CTLA-4 and CD47 checkpoint blockade can provide a sur-
vival benefit by activating beneficial adaptive immune signaling
pathways.
Fig. 25 (abstract P259). Treatment-related safety events
Fig. 26 (abstract P259). Efficacy of urelumab plus rituximab or
urelumab plus cetuximab
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Background
Urelumab, a fully human CD137 agonistic monoclonal antibody
(mAb) with single-agent pharmacodynamic and clinical activity in pa-
tients with lymphoma, has potential to enhance cytotoxic activity of
natural killer (NK) cells when combined with antibody-based targeted
therapies. The potential of urelumab to enhance ADCC/phagocytosis
and thus improve efficacy was evaluated in phase Ib studies of urelu-
mab combined with rituximab (anti-CD20 mAb) in patients with re-
fractory B cell non-Hodgkin lymphoma or cetuximab (anti-EGFR
mAb) in patients with refractory colorectal cancer (CRC) or squamous
cell carcinoma of the head and neck. Here we report safety/tolerabil-
ity, pharmacokinetics, pharmacodynamics, and preliminary clinical ef-
ficacy results from these trials.
Methods
During escalation in NCT01775631, patients with relapsed/refractory
B-NHL received urelumab at 0.1 or 0.3 mg/kg or a flat dose of 8 mg
(equivalent to 0.1 mg/kg in an 80-kg patient; initiated based on avail-
able pharmacokinetic and safety data) Q3W plus rituximab 375 mg/
m2 QW (4 doses); during expansion, patients with relapsed/refractory
diffuse large B cell lymphoma (DLBCL) or follicular lymphoma (FL)
were treated with urelumab 8 mg plus rituximab. The NCT02110082
study evaluated urelumab (0.1 mg/kg or 8 mg Q3W) plus cetuximab
(400 mg/m2 on week 1 and 250 mg/m2 Q1W thereafter) in patients
with metastatic CRC or SCCHN. Primary endpoints were safety/
tolerability.
Results
Treated patients included those with DLBCL (n = 29), FL (n = 17), CRC
(n = 47), and SCCHN (n = 19). Overall, 2–3 % of patients discontinued
due to treatment-related AEs, and one patient experienced a grade
3/4 ALT elevation (Fig. 25). One patient who received urelumab plus
rituximab experienced treatment-related sepsis and died. Apparent
increases in IFNγ-induced cytokines were observed, and activated/
proliferating CD8+ cells and cytotoxic NK cells appeared to increase
in the periphery after 1 week of treatment with either regimen; how-
ever, in most tumors, the increase in CD8+ and NK cells was not ob-
served. Overall response rates (ORRs) with urelumab plus rituximab
were 10 % (3/29) in DLBCL and 35 % (6/17) in FL (Fig. 26). There
were no confirmed responses with urelumab plus cetuximab in pa-
tients with CRC or SCCHN.
Conclusions
Urelumab is safe and well tolerated in combination with rituximab or
cetuximab at doses of 0.1 mg/kg or 8 mg, with minimal evidence of
liver toxicity. Although pharmacodynamic activity was observed in
peripheral blood samples, urelumab with rituximab or cetuximab did
not demonstrate substantial enhancement of clinical responses or
lead to intratumoral immune modulation in these tumor settings.Trial Registration
ClinicalTrials.gov identifier NCT01775631 and NCT02110082.P260
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Background
Activin A (actA) is a member of the transforming growth factor beta
(TGFβ) superfamily. Recent evidence suggests that actA may facilitate
tumorigenesis in part by suppressing immunity in the tumor
microenvironment [1]. Treatment-induced DNA double-strand breaks
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mutated (ATM) kinase is activated at DNA DSBs caused by genotoxic
agents such as radiotherapy (RT) and is critical for DNA repair. Here
we tested the hypothesis that induction of actA by RT limits RT-
induced activation of anti-tumor immunity.
Methods
To test this hypothesis, 4 T1 mammary carcinoma cells were engi-
neered to express a doxycycline (dox) inducible shRNA silencing
inhibin A (Inhba, gene encoding for actA) (4T1shInhba). 4T1shInhba or its
non-silencing control (4T1shNS) were exposed to ionizing radiations
to determine Inhba gene expression by RT-qPCR as well as secretion
of actA by ELISA. To determine if ATM controls the expression of
actA, derivatives with inducible knockdown of ATM were also gener-
ated (4T1shATM). 4T1shInhba, 4T1shATM and 4T1shNS were injected s.c. in
syngeneic BALB/c mice on day 0. Knockdown of ATM and Inhba
genes was induced by dox at day 8. Tumors were irradiated with
6 Gy repeated on days 13, 14, 15, 16 and 17. Mice were monitored
and euthanized at day 22 and day 28 for evaluation of immune cells
infiltration into the tumor.
Results
RT upregulated actA expression and secretion by 4 T1 cells. Secreted
actA promoted CD4+ T cells conversion into regulatory T (Tregs)
cells. In vitro, knockdown of ATM abolished both Inhba gene expres-
sion and actA secretion by tumor cells after RT. In vivo, this resulted
in reduced Tregs infiltration in irradiated tumors, and increased acti-
vation of intra-tumoral CD8+ T cells. 4T1shInhba and 4T1shATM tumors
showed an increased response to RT compared to 4T1shNS tumors.
Conclusions
These data suggest that ATM plays a critical role in RT-induced actA
secretion, which promotes an immunosuppressive environment in
the irradiated tumor. Inhibition of ATM may increase tumor radiosen-
sitivity and at the same time enhance in situ vaccination by radiation
by hindering Treg generation.
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Background
Preclinical data and clinical observations support the concept that
localized radiation therapy (RT) can be a powerful adjuvant to immu-
notherapeutic strategies by triggering de novo anti-tumor immune
responses to poorly immunogenic tumors. We have previously
shown that radiation induces the release of ATP in a dose-dependent
manner [1]. ATP enhances recruitment and activation of dendritic
cells (DCs), including CD103+ DCs recently identified as the key DC
subset responsible for cross-presentation of tumor-derived antigens
to CD8+ T cells. To determine whether rapid conversion of ATP to
immunosuppressive adenosine could contribute to the limited ability
of high dose RT to activate anti-tumor immunity we inhibited the
rate-limiting CD73 ectonucleotidase.
Methods
Wild type (WT) or BATF3−/− mice (ablated development of CD8a+/
CD103+ DCs) were inoculated s.c. with the poorly immunogenic
breast cancer cell line TSA on day 0 and assigned to treatment with:
(1) control Ab; (2) anti-CD73 (TY/23 Ab); (3) RT (20 Gy); (4) RT + TY/23.TY/23 (200 μg) was administered i.p. on day 11, 14, 17 and 20. RT
was given locally to the tumor as single 20 Gy dose on day 12. On
day 18, some tumors were harvested for flow cytometry analysis of
DCs and T cells. Mice were monitored for tumor progression by cali-
per measurements.
Results
In RT-treated mice, blockade of ADO generation by anti-CD73 re-
sulted in increased infiltration of CD103 + DCs (8.9 ± 2.6 % of DCs in
RT + TY/23 v. 3.5 ± 2.8 % of DCs in RT) expressing elevated levels of
activation markers CD40 and CD86 compared to mice treated with
RT alone. This change was associated with improved CD8 + T cell/
Tregs ratio (5 ± 2.8 in RT + TY/23 v. 0.8 ± 0.2 in RT). Importantly, CD73
blockade had no effect by itself but improved significantly radiation-
induced tumor control (tumor volume on day 57 post inoculation:
385 ± 525 mm3 in RT + TY/23 v. 1036 ± 727 mm3 in RT). Consistent
with the hypothesis that CD103+ DC are essential for anti-tumor re-
sponses, the therapeutic effect of RT + CD73 blockade was abrogated
in BATF3−/− mice.
Conclusions
Our data indicate a key role of adenosine generated in the irradiated
tumor in hindering development of anti-tumor immune responses
and identify, as a mechanism of this effect, the inhibition of CD103+
DCs. Blockade of adenosine generation is a promising strategy to en-
hance radiation-induced anti-tumor immunity.
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Background
Exercise immunology has become a growing field in the past
20 years, with an emphasis on understanding how different forms of
exercise affect immune function. Overexertion may lead to sup-
pressed immune function whereas moderate exercise may improve
immunity. The improvement of immune function through exercise
may benefit cancer patients receiving immunotherapy. To begin to
test this hypothesis, we investigated the effects of acute and endur-
ance exercise on the composition of peripheral blood leukocytes
over time in a healthy male population of varying fitness.
Methods
Fifteen males participated in two cycling bouts; a short incremental
exercise test to exhaustion on one visit and a 45 minute endurance
exercise test (cycling at 60 % maximum workload) on the second
visit. Lean body mass (LBM) and percent body fat (%BF) were calcu-
lated from DEXA (Dual-energy X-ray absorptiometry) scan on study
visit 1. Flow-volume curves (FVC) were also collected on visit 1 with
the average of 3 attempts within 150 mL of each other. Blood was
collected at pre-exercise, immediately post-exercise, 3 hours post-
exercise, and 24 hours post-exercise. Leukocytes were measured by
multi-parameter flow cytometry of more than 50 immunophenotypes
for each collection sample.
Results
We found a differential induction of leukocytosis dependent on exer-
cise intensity and duration. Cytotoxic natural killer cells demonstrated
the greatest increase (average of 5.6 fold) immediately post-maximal
exercise whereas CD15+ granulocytes demonstrated the largest
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intense endurance exercise resulted in an attenuated leukocytosis. In-
duction of leukocytosis did not differ in our limited study of active
(n = 10) and sedentary (n = 5) subjects to exercise although we found
that in baseline samples, sedentary individuals had elevated percent-
ages of CD45RO+ memory CD4+ T cells and elevated proportions of
CD4+ T cells expressing the negative immune regulator programmed
death-1 (PD-1). Finally, we identified several leukocytes whose pres-
ence correlated with obesity related fitness parameters.
Conclusions
Taken together, our data suggests pre-existing compositional differ-
ences of leukocytes based on fitness and rapid and specific accumu-
lation of leukocytes subsets into the blood dependent on the
intensity and duration of to exercise.
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Background
Radiation therapy has evolved into an effective treatment for many can-
cers because of its ability to kill tumor cells and stimulate anti-tumor im-
munity, but radioresistance remains a major obstacle in cancer
treatment. Recent studies indicate that norepinephrine (NE) released
from sympathetic nerves suppresses immune cells and promotes tumor
cell survival via β-adrenergic receptor (β-AR) activation. Work from our la-
boratory has shown that the cool housing temperature of laboratory
mice is a significant source of cold stress which stimulates NE release.
Moreover, we showed that β-AR signaling in mouse tumor models en-
hanced chemotherapeutic resistance, and treatment with β-AR antago-
nists (β-blockers) reversed this effect [1]. This finding led us to
hypothesize that β-AR signaling promotes radioresistance in tumor cells
but suppresses the anti-tumor immune response.
Methods
In vitro, we used Pan02 (abundant β-AR expression) and 4 T1 tumor
cells (no β-AR expression). We treated cells with the pan-β-agonist,
isoproterenol, and performed clonogenic assays examining survival
at various radiation doses (0–8 Gy). In vivo, we implanted CT26.CL25
tumor cells subcutaneously into the leg of immunodeficient SCID
mice and immune-competent BALB/c mice. When tumors became
palpable, mice were randomized to receive daily β-blocker or PBS in-
jections followed by radiation (6 Gy) 3 days later. Flow cytometry
was used to analyze immune cells within tumors.
Results
In vitro, isoproterenol treatment significantly increased the survival of
radiated Pan02 cells compared with controls but had no impact on
radiated 4 T1 tumor cells suggesting that β-AR signaling enhances
radioresistance. In vivo, radiation alone moderately slowed tumor
growth in SCID mice. However, combining β-blockade with radiation
significantly enhanced the effect of radiation, indicating that β-
blockade was sensitizing tumor cells to radiation. Lastly, we repeated
this experiment in immune-competent BALB/c mice and again ob-
served a significant reduction of tumor growth in mice receiving β-
blockade and radiation compared to radiation alone. To determine if
β-blockade was enhancing anti-tumor immunity in radiated mice, we
analyzed tumors using flow cytometry and observed a significant in-
crease in CD4+ and CD8+ T cells expressing IFN-g and granzyme B in
the group receiving β-blockade and radiation compared to thosereceiving radiation alone, indicating that β-blockade was also stimu-
lating anti-tumor immunity.
Conclusions
Taken together, this data suggests that β-AR blockade decreases
tumor cell radioresistance while simultaneously bolstering anti-tumor
immunity.
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Background
Lifestyle factors (e.g., body weight, physical activity) can impact
breast cancer risk and response to therapy. Changes in metabolic, in-
flammatory, and immune mediators are possible factors underlying
this relationship. Few studies have examined the effect of body
weight and activity on the efficacy of immunomodulatory or immu-
notherapeutic strategies. Thus, the goal of the current study was to
determine if preventing weight gain (via activity and diet) could
delay primary tumor growth and metastatic progression in tumor-
bearing mice and determine if there were any additive effects of
weight maintenance and the dual administration of an allogeneic
whole tumor cell vaccine and PD-1 checkpoint blockade on the
aforementioned outcomes.
Methods
Female BALB/c mice were randomized to sedentary, weight gain
(WG) or exercising, weight maintenance (WM) groups (n = 20-24/
group). After 8 weeks, all mice were orthotopically injected with
5x104 luciferase-transfected 4 T1.2 cells into the fourth mammary fat
pad and continued on their intervention for 35 days. After injection,
mice were further randomized into vaccination (n = 9-12/group) or
vehicle control (n = 11-12/group) groups and administered irradiated
4 T1.2 cells (VAX) or vehicle (VEH) control at day 7, 14, 21, and 28
post-tumor injection. Current studies are investigating if the dual ad-
ministration of VAX plus PD-1 checkpoint blockade (10 mg/kg/
mouse) is enhanced in WM tumor-bearing mice.
Results
All WM groups weighed significantly less than WG groups over the
course of the study (p < 0.0001). There was a significant effect of
both WM and VAX alone on primary tumor growth (p < 0.0001) and
splenic IFNγ production (p = 0.010) and an additive effect of WM +
VAX on primary tumor growth (p < 0.05), metastatic burden in lung
(p = 0.0267) and heart (p = 0.0492), and the accumulation of splenic
MDSCs (p = 0.021). A pilot study showed an additive effect of the
dual administration of VAX and anti-PD-1 in WG mice; however, ex-
periments investigating the dual administration of VAX and PD-1
checkpoint blockade in WM cohorts are currently underway.
Conclusions
These results demonstrate that activity-induced weight maintenance
in combination with an allogeneic whole tumor cell vaccine is highly
effective at delaying primary tumor growth and metastases, and re-
ducing splenic MDSC levels in this metastatic model. Interventions
that maintain body weight may yield significant additive benefit in
multimodal immunotherapy treatment strategies.
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Background
Reinvigorating exhausted T lymphocytes with immune checkpoint in-
hibitors has proved to be a particularly successful strategy for the
treatment of cancer. There remains however, a great deal of variabil-
ity in response and toxicity between patients. Our previous murine
studies revealed that obesity and age significantly enhanced toxicity
to stimulatory immunotherapy as a consequence of their resting pro-
inflammatory state. Here, we characterize the resting exhaustion
phenotype and functional characteristics of T lymphocytes in obese
and aged individuals, within a range of species, in order to under-
stand the differential impact checkpoint inhibition might have on
these populations.
Methods
Diet induced obese (DIO) mice within various age groups were fed a
high fat diet long-term prior to analysis of splenocytes. Peripheral
blood was collected from non-human primates (NHP) and laboratory
beagles stratified into lean and obese groups based on weight and
body condition score, respectively. Flow cytometry was used to
quantify relative expression of T cell exhaustion markers, in addition
to assessing T cell function as determined by intracellular cytokine
expression and Ki67 positivity.
Results
We observed elevated PD-1 expression in CD4+ and CD8+ T cells in ≥12-
month-old (mo) mice compared to 7mo mice. This coincided with altered
expression of TNF-α and IFN-γ expression, and decreased proliferation
following stimulation. Interestingly, PD-1 expression, proportions of
naïve and effector memory cells, cytokine expression levels and prolif-
erative responses of T cells from lean 13mo mice were similar to that of
7mo mice. Conversely, T cells from DIO 13mo mice appeared similar to
24mo mice in that they were phenotypically and functionally more
exhausted. In NHPs, while PD-1 expression did not differ between small
numbers of lean and obese animals, a trend towards decreased
proliferation in CD4+ memory T cells of obese animals was observed.
Similarly, decreased mitogen responses in T cells from obese dogs were
also noted.
Conclusions
Both aging and obesity appear to impact PD-1 expression and T cell
function. Data from dogs and NHPs suggest these findings may be
consistent across species. Ultimately, these data add to our under-
standing of T cell function in differing physiologic states, and may
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Background
Human arginase I (hArgI) is a Mn2+-dependent enzyme that displays
low activity and low stability in serum. Myeloid-derived suppressor
cells (MDSC) express human arginase I (hArgI) and nitric-oxide syn-
thase (NOS), which control the availability of L-arginine in the tumormicroenvironment and in turn regulate the function of T cells. Deple-
tion of L-arginine by MDSC has been correlated to impairment of T cell
anti-tumor function and tumor evasion of host immunity. Analysis of
the expression of enzymes of the L-arginine biosynthetic pathway in
peripheral blood mononuclear cells, bone marrow mononuclear cells
and CD34+ cells showed low levels of ornithine transcarbamylase (OTC)
and argininosuccinate synthase (ASS), suggestive of dependence of
these cells on exogenous/extracellular L-arginine for physiological func-
tion. As a result, long term depletion of L-arginine may negatively im-
pact the MDSC population and therefore enhance immune regulation
of tumor growth. This hypothesis was tested using a recombinant hArgI
(AEB1102), developed by replacement of the Mn2+ natural cofactor
with Co2+ which results in significantly improved catalytic activity and
serum stability as compared to endogenous hArgI.
Methods
Administration of AEB1102 results in chronic depletion of L-arginine
in serum to levels below 1 μM. The murine CT26 colon-cancer model
was dosed with AEB1102 alone and in combination with anti-PD-L1
and anti-PD-1 monoclonal antibodies (mAbs).
Results
In vivo treatment of CT26 mice with AEB1102 monotherapy resulted in
an increased life span (ILS) (46 %, p < 0.001) as compared to the
untreated control group, whereas standard monotherapy using immu-
nomodulatory antibodies that target PD-1 and PD-L1 resulted in a 0 %
(p = 0.5) and 29 % (p = 0.002) ILS respectively. Of significance, combin-
ation therapy of AEB1102 with anti-PD-1 (ILS 67 %, p < 0.001) or PD-L1
(ILS 67 %, p < 0.001) mAbs resulted in additive and synergistic anti-
tumor effect compared to AEB1102 alone and immunotherapy alone.
Conclusions
Collectively these results demonstrate that disrupting the L-arginine
physiological balance in the tumor microenvironment inhibits tumor
growth and further sensitizes the tumor to immunotherapy. AEB1102
is currently in phase I (monotherapy) clinical trials. These data open
the possibility of clinical combination of AEB1102 with anti-PD-1 and
anti-PD-L1 mAbs to further improve outcomes in cancer patients.
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Background
Tumors create a suppressive microenvironment that prevents antitu-
mor immunity through a number of mechanisms like recruitment of
regulatory T cells or through ligation of co-inhibitory molecules such as
PD-1. PD-1 blockade therapy has become a major success in cancer
treatment; however, most patients fail to respond to anti-PD-1 therapy.
It has become clear in recent years that the lack of nutrients and oxy-
gen in the tumor microenvironment may also play an immunosuppres-
sive role. Since T cell effector function is dependent on these nutrients
to produce the energy needed, we hypothesized that changing this en-
vironment would improve the efficacy of immunotherapy.
Methods
B16 and MC38 were injected into mice and were treated when tu-
mors were palpable with either 0.2 mg anti-PD-1 or hamster IgG iso-
type control, injected every 4 days intraperitoneally, and 50 mg/kg
metformin or PBS, injected every 2 days intraperitoneally. CD8+ T
cells were isolated from lymph nodes and tumors and tested for hyp-
oxia and cytokine production by flow cytometry and metabolic func-
tion with Seahorse XFe96 Bioanalyzer. Similar analysis was done
in vitro with B16, MC38, and SIINFEKL stimulated OT-1 cells harvested
from spleen and lymph nodes of mice.
Results
We show that B16, a melanoma resistant to PD-1 therapy, and MC38,
a colon adenocarcinoma partially sensitive to PD-1 blockade,
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tinct hypoxic environments in vivo. The amount of hypoxia in the
tumor microenvironment can be reduced by treating mice with met-
formin, a type II diabetes drug that inhibits mitochondrial complex I,
which we show acts directly on the tumor cells to inhibit their oxy-
gen consumption. As hypoxia can inhibit T cell responses in vivo, we
hypothesized that metformin-induced mitigation of tumor hypoxia
might improve immunotherapeutic responses. We also show that
pairing metformin with PD-1 blockade therapy results in substantially
improved antitumor immunity and tumor clearance, even in PD-1 in-
sensitive tumor models.
Conclusions
Our data suggest that the degree of tumor hypoxia, partially a result
of the degree of cancer cell metabolic deregulation, may determine
whether T cells have a permissive microenvironment for effective im-
munotherapy. More importantly, our results suggest that metabolic
remodeling of the tumor microenvironment may help patients better
respond to immunotherapy.
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Background
Previous studies have proposed an immune suppressive role for
alpha-fetoprotein (AFP), an oncofetal antigen expressed by over
50 % of hepatocellular carcinomas (HCC). AFP-L3 is the major isoform
present in the serum of HCC patients and is associated with poor pa-
tient prognosis. While tumor-derived AFP (tAFP) contains >80 % of
AFP-L3, cord blood serum-derived AFP (nAFP) contains less than 5 %
of AFP-L3. Our previous work shows that monocytes, cultured in the
presence of AFP (in particular tAFP), differentiated into dendritic cells
(DC), retained a monocyte-like morphology, had decreased expres-
sion of DC maturation markers, and exhibited limited production of
inflammatory cytokines and chemokines. Importantly, monocyte-
derived DC cultured in the presence of tAFP failed to stimulate
antigen-specific T cell responses. In this study, we examined the ef-
fect of AFP on DC cellular metabolism.
Methods
Monocytes were isolated from healthy donor peripheral blood mono-
nuclear cells and cultured for 5 days with IL-4 and GM-CSF in the pres-
ence or absence of 10 μg/mL ovalbumin (OVA), nAFP or tAFP (n = 3-5
HD per experiment). DC were collected and tested for 1) mitochondria
levels and function (flow cytometry), 2) metabolic function by seahorse
extracellular flux analyzer, and 3) expression of oxidative phosphoryl-
ation (OXPHOS)-related proteins, including electron transport chain pro-
teins, and PGC1α levels (western blot and flow cytometry).
Results
DC cultured in the presence of nAFP and tAFP, had reduced mito-
chondrial mass and mitochondrial activity compared to OVA-DC. This
was confirmed by a reduction in the basal oxygen consumption rate
(OCR) in nAFP-DC and a more severe reduction in basal OCR in tAFP-
DC. We also show that while mitochondrial metabolism is affected,
glycolysis of DCs was not affected. Our data suggest that the
changes observed in DC metabolism occur within 24 hours of AFP
exposure and that tAFP inhibition of mitochondrial metabolism leads
to a transient compensatory increase in glycolysis in the first 24–48
hours. We also show differences in the expression of mitochondrial
electron transport proteins responsible for OXPHOS in DC exposed to
nAFP and tAFP. Lastly, we show that there is reduced expression of a
key mitochondrial regulator, PGC1α, in nAFP and tAFP-DC.
Conclusions
Collectively, these data show profound negative effects of AFP, spe-
cifically tAFP on mitochondrial metabolism. These novel findingselucidate a key mechanism of immune suppression in HCC and may
lead to new therapeutic approaches to reverse tAFP effects.
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Background
The suppressive function of regulatory T (Treg) cells contributes signifi-
cantly to the failure of cytotoxic T cells to eliminate cancer cells in the
tumor microenvironment (TME). Within the TME, Treg cells retain their
metabolic capacity as well as proliferative and suppressive functions,
while conventional, effector T cells suffer reduced metabolic capacity in
the energy substrate dearth environment. Thus, in the metabolically dis-
tinct TME, Treg cells may be bioenergetically supported by factors distinct
from those that support conventional T cells. Lactic acid, a product of
tumor glycolytic metabolism that is abundant in the TME has long been
known to be immunosuppressive. We hypothesize that Treg cells in the
TME utilize alternative metabolic substrates, particularly lactic acid, that al-
lows them to maintain a significant level of suppression.
Methods
To test our hypothesis we employed lactic acid treatment of conventional
and regulatory T cells, as well as generating a mouse line in which
Slc16a1, encoding a lactate transporter, can be specifically deleted in Treg
cells, constitutively or in a tamoxifen-induced manner. We also employed
13C-labeled lactic acid coupled to mass spectrometric analysis.
Results
Intratumoral Treg cells are highly proliferative in the tumor micro-
environment. Lactic acid treatment of freshly isolated lymph node
Treg cells supports enhanced proliferation, in striking contrast to the
suppressive effects on conventional T cells. Intratumoral Treg cells
upregulate monocarboxylate transporters (MCT 1, encoded by
Slc16a1 and MCT2, encoded by Slc16a7) which actively transport
short chain carbons, including lactic acid, both into and out of cells.
We found that MCT1 null Treg cells have a diminished suppressive
capacity compared to MCT1 competent Treg cells. We also found
that the pharmacologic inhibition of lactate metabolism in tumor-
bearing animals results in dramatically decreased intratumoral Treg
cell proliferation. Our ongoing studies seek to determine specifically
how lactic acid is utilized by intratumoral Treg cells.
Conclusions
Our data strongly support a model in which tumor cells evade the
immune response, in part, by metabolically supporting immunosup-
pressive populations. Targeting MCT1 in Treg cells and diminishing
immune suppression may be an appealing target for therapeutic
intervention, especially while combining MCT1 inhibition with a ther-
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With the increasing use of immune checkpoint inhibitors (iCI), the
recognition and prompt effective treatment of immune related ad-
verse effects (irAEs), such as immune-mediated diarrhea (IMD) is cru-
cial. IMD is commonly managed with steroid treatment and in severe
cases, the TNF-alpha inhibitor infliximab (INF) however little is known
on the impact INF has on patient outcomes.
Methods
We retrospectively reviewed 46 patients treated with iCI (anti-CTLA-4,
anti-PD-1 or combination therapy) at Massachusetts General Hospital
between 2008 and 2015 who developed grade 3–4 IMD with 96 % of
cases confirmed on colonoscopy. The primary aim was to
characterize patients who received intravenous INF 5 mg/kg (up to 3
doses) compared to those who did not and evaluate for impact of
INF on outcomes. Kaplan-Meier and extended Cox regression were
used to calculate OS and PFS.
Results
Of the 46 patients who developed IMD, 60.9 % were treated with
CTLA-4 inhibitor monotherapy, 30.4 % with combination CTLA-4/PD-
1 inhibition and 8.7 % with anti-PD-1 therapy alone. Median follow-
up measured after the first dose of treatment causing diarrhea was
20.5 months (95 % CI: 13.0-25.1 months). Of the 46 patients, 2
(4.4 %) had neither steroids nor INF. Of the remaining 44, 17 (37 %)
had both steroids and INF and 27 (59 %) had steroids alone. Of the
27 patients treated with steroids alone, 26 improved to grade 1 or
better; median time of 25 days. For the 17 patients treated with ste-
roids followed by INF, the median time on steroids prior to INF was
24 days; median time from start of symptoms to grade-1 resolution
was 68 days. Of the 17 patients who received INF, 53 % required 1
dose, 35 % two doses, and 12 % three doses. When stratified by
ECOG PS and adjusted for comorbidities, INF therapy was a signifi-
cant predictor of PFS with a 76 % reduction compared with patients
who had not yet started or never received the drug (HR: 0.24, 95 %
CI: 0.1-0.8, p = 0.02). Treatment with INF was not a predictor of OS
(HR: 0.97, 95 % CI: 0.3-3.7, p = 0.97).
Conclusions
Development of IMD is a common ir-AEs. The lag between devel-
opment of IMD and the administration of INF in our study ren-
ders it difficult to determine if INF significantly shortens symptom
duration however our data demonstrate the significance of INF
use on PFS. Though this finding requires further validation in a
larger patient cohort it does bolster the hypothesis that severe ir-
AE, necessitating stronger immune suppression, may correlate
with treatment efficacy.
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Background
Autoimmune hepatitis is a well-documented rare but serious immune
related event known to occur with anti PD-1/L1 inhibition and may
mimic progression or tumor flare.
Methods
We evaluated three patients with liver metastasis who developed
transaminitis with anti-PD-1/L1 inhibitors using CTCAE ver4.0 and
RECIST ver1.1.
Results
Case 1: A 36 year old man with nasopharyngeal carcinoma with liver
metastasis developed grade 2 transaminitis and RUQ pain after 2
doses of nivolumab. Ultrasound revealed stable liver metastasis but
with hepatomegaly and new ascites. Nivolumab was discontinued
and switched to taxol. His hepatomegaly and ascites resolved. Case
2: A 35 year old woman with nasopharyngeal carcinoma with liver
metastasis developed grade 1 transaminitis after 3 doses ofnivolumab. Progression of liver metastasis was seen on CT scan. Case
3: A 69 year old man with oropharyngeal cancer with liver metastasis
was placed on a clinical trial utilizing tremelimumab and MEDI4736.
He had grade 1 transaminitis with stable disease on CT scan post
4 cycles. He continued on MEDI4736, developed grade 2 transamini-
tis and CT scan showed progression of liver metastasis. He was
switched to carboplatin/5FU with weekly cetuximab and his liver en-
zymes normalized soon after. These observations raise the issue of
the difficulties in distinguishing autoimmune hepatitis vs tumor pro-
gression vs tumor flare in patients with liver metastasis on PD-1/L1
inhibitors. Case 1 appears to have had autoimmune hepatitis,
whereas others had progression. Drug-related hepatitis is seen in
1 % to 2 % of patients on checkpoint inhibitors. Grade 3/4 transami-
nitis may require high-dose corticosteroids [1]. Toxicities with PD-1/
L1 antibodies may also vary with the histology. For example, in
NSCLC patients receiving nivolumab, pneumonitis was observed in
6 % [2] whereas only 1.9 % of melanoma patients had pneumonitis
[3]. Similarly, liver metastasis patients on PD-1/L1 therapy may be
more prone to autoimmune hepatitis.
Conclusions
Close monitoring of the liver enzymes as well as careful assessment
of liver are imperative while we await further “big data” on better
consensus to evaluate transaminitis following checkpoint inhibitors
in patients with liver metastasis.
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Background
Immune repertoire amplification of T cell receptors (TCR) coupled to
next-generation sequencing (NGS) provides detailed sequence-level
insight into the immune system. However, information related to the
cognate pairing of TCR alpha and beta chains is lost once RNA ex-
traction is performed on the bulk sample. We describe a sensitive
method that allows for the amplification of both human TCR alpha
and beta chains from single cells using amplicon-rescue-multiplex-
PCR in the same reaction tube.
Methods
During the first round of PCR, reverse transcription and PCR is per-
formed with nested, multiplex primers covering both the alpha and
beta locus with communal forward and reverse binding sites in-
cluded on the 5’ end of the inside primers. Included on the C-region
gene primer is an in-line 6 nucleotide barcode, which serves as a
plate identifier so that multiple 96-well (or 384-well) plates may be
multiplexed in the same sequencing flow cell. After RT-PCR1, the first
round PCR1 products are rescued using SPRI beads. A second PCR is
performed with dual-indexed primers that complete the sequencing
adaptors introduced during PCR1 and provide plate positional infor-
mation for the sequenced products. Libraries from multiple plates
may be pooled together on the same MiSeq flow cell and sequenced
directly using a 500 or 600 cycle kit (250 paired-end read). An iPair
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on the plate and to aid with identification of “interesting” pairs that
warrant further investigation.
Results
This method was utilized in the analysis of a breast cancer patient’s
peripheral CD4+ lymphocytes as part of a longitudinal study of the
immune repertoire pre- and post-treatment. Under optimal condi-
tions, the amplification success rate is greater than 90 %, with suc-
cessfully identified pairs as high as 60 % of those amplified. In the
described experiments, bulk sequencing of each chain was also per-
formed on RNA from remaining cells, and the observed single cell
alpha and beta chains are typically represented in the top 1 and 5 %
of the most frequent clones from the bulk sample, respectively.
Conclusions
We have developed an extremely sensitive method for the identifica-
tion of cognate pairs from single cells in the same reaction tube. Fu-
ture work involves the characterization of single cells for gene
products beyond the variable gene region of TCRs, allowing for a
more complete characterization of the cellular landscape. With the
rise of immunological-based treatments for cancer, this type of tech-
nology holds promise for uncovering TCR cognate pairs of thera-
peutic significance.
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Background
Recent success of immune checkpoint blockade solidifies the import-
ance of the immune system in the defense against cancer. The
clinical impact of the immune response is, however, very heteroge-
neous, with some patients achieving dramatic responses while others
fail to respond. Known genomic correlates of response to immuno-
therapy are not perfectly predictive of clinical outcome, supporting
the existence of unknown mechanisms of resistance. We hypothesize
somatic mutations account for heterogeneity in the spontaneous im-
mune response and response to immunotherapy. We have under-
taken a systematic in vivo screen to identify novel mechanisms of
resistance to tumor immunity in order to define a comprehensive set
of therapeutic targets and provide biomarkers of sensitivity to immu-
notherapeutic strategies.
Methods
Mouse tumor cell lines (MC38 colon carcinoma, B16 melanoma) were
engineered to express a library of barcoded open reading frames
(ORFs) mutagenized to encode cancer-associated somatic mutations
from the Pan-Cancer analysis within The Cancer Genome Atlas
(TCGA) [1]. These cell lines form tumors when implanted subcutane-
ously in immunocompetent animals. Tumor-bearing animals were
then subjected to immunotherapy with either therapeutic vaccin-
ation or anti-PD-1 checkpoint blockade. Barcode relative representa-
tion was measured by next generation sequencing at the time of
tumor implantation and at tumor harvest post-immunotherapy. Bar-
coded mutant ORFs that confer immune resistance increased in rep-
resentation under immune pressure in comparison to untreated or
immunodeficient animals.
Results
A mutation in Phospho-Inositol 3 Kinase (PI3K), PIK3CA c.3140A > G,
consistently increased in representation in both B16 and MC38
immunotherapy-treated tumors but not in immunodeficient animals.
This suggests that activity of this mutant allele conferred selective
growth advantage in the setting of tumor immunity. This mutation
encodes a constitutively active catalytic domain of PI3K, PIK3CA
H1047R. MC38 tumors homogenously expressing PIK3CA H1047R
and implanted into wild type mice failed to respond to anti-PD-1therapy, while tumors expressing a control gene regressed after
treatment with anti-PD-1. Pharmacologic PI3K inhibition resensitized
tumors to treatment with anti-PD-1. PD-1-treated PIK3CA H1047R tu-
mors had fewer infiltrating CD8+ T cells as measured by immunohis-
tochemistry and flow cytometry of tumor infiltrating lymphocytes.
Conclusions
PI3K has, in addition to its well-described oncogenic role, a role
in tumor immune evasion. As such, activating mutations in PI3K
may be useful as a predictor of poor response to immunother-
apy. Importantly, these findings also provide a rationale for thera-
peutic combination trials of immune checkpoint blockade and
PI3K inhibition.
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Background
Baseline tumor infiltration with CD8+ T cells and an associated che-
mokine/interferon gene signature are correlated with a favorable
clinical outcome to immunotherapies. Recent work has indicated that
differential presence of this phenotype can be influenced by specific
oncogene pathways activated within the tumor cells, and also by
host commensal microbiota. However, germline polymorphisms
among the patient population also could influence the degree of the
natural immune response against a tumor.
Methods
To investigate this possibility, TCGA RNAseq data were used to
analyze the degree of expression of a predetermined T cell gene
signature, and germline SNP data from the same patients were
utilized to perform a GWAS against the gene signature as a
phenotype. The top hit, a minor allele of SNP rs1483185, was sig-
nificantly associated with increased T cell gene expression in the
tumor (p = 8.812e−08). Interrogation using the GTEX database re-
vealed lower gene expression in association with this SNP, argu-
ing for a loss-of-function phenotype. To explore this concept
mechanistically, gene-targeted mice were utilized lacking this
gene. To focus gene deletion on hematopoietic cells, bone mar-
row (BM) chimeras were utilized.
Results
Mice reconstituted with knockout BM grew B16.SIY tumors more
slowly and had higher numbers of SIY+ CD8+ T cells in both the
tumor infiltrating lymphocyte fraction as well as the spleen com-
pared to WT engrafted mice. Additionally, 80 % of splenic SIY+ CD8+
T cells had an activated CD44+ CD62L− phenotype in knockout recipi-
ents versus 40 % in WT recipients. The TIL populations from KO re-
cipients also showed higher expression of surface molecules
indicating antigen experience, as well as expression of PD-1, Lag3,
and 4-1BB indicating antigen-specificity. Mechanistically, T cells from
KO mice showed no obvious increase in activation potential. How-
ever, a significant increase in CD11c+ CD8+ dendritic cells was ob-
served in KO BM recipients, suggesting a possible effect at the level
of APCs.
Conclusions
Together, our results have identified a functionally relevant SNP that
can lead to improved spontaneous anti-tumor immunity. The devel-
opment of pharmacologic approaches to phenocopy this loss of
function genetic phenotype may be attractive to pursue as a cancer
therapeutic.
Fig. 27 (abstract P275). Viability analysis with single cell mass
cytometry. The SPADE tree plot was constructed by using 17 cell-surface
antigens in treated and untreated healthy human PBMCs. The size of
each circle in the tree indicates relative frequency of cells that fall within
the 17-dimensional confines of the node boundaries. Node color is
scaled to the median intensity of marker expression of the cells within
each node, expressed as a percentage of the maximum value in the
data set (CIS is shown)
Fig. 28 (abstract P275). Microarray analysis. Top 5 first canonical
pathways ranking according to significance level [Fisher exact test es
log (p-value) reported in red] modulated by the GO and GONH2 in T
cell (Jurkat cell lines) and monocytes (THP1 cell lines) cell lines
identified using Ingenuity Pathway Analysis (IPA). The Z-score of
each pathway is expressed under each column
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Background
There is an enormous interest in exploring the potentialities of
novel nanomaterials such as graphene and its derivatives in
biomedical applications [1]. The understanding of the biomolec-
ular interactions of graphene nanomaterials with human cells is
critical for their implementation as diagnostic or therapeutic
agents [1]. In this context the immune modulation mediated by
graphene oxide (GO) or nanomaterials in general could be
interesting also in immunotherapy applications. Indeed nano-
technology can enhance the efficacy of immunostimulatory
small molecules and biologics by altering their co-localization,
biodistribution, and release kinetics [2]. The impact exerted by
graphene and GO exposure on the immune system is still
unknown.
Methods
Here, we propose an integrative analytical pipeline encompassing
molecular and cellular characterization of the impact of graphene
nanomaterials on immune cells. For the first time in the context
of nanotechnology, we employed single cell mass cytometry to
deconvolute the effect of GO flakes (between 1–2 graphene
layers) functionalized by us through the addition of 1,3 dipolar-
cycloaddition of amino groups (GONH2) on 15 immune cell popu-
lations looking at 30 markers at single-cell level. We then used
whole transcriptomic analysis for further functional molecular
characterization.
Results
Intriguingly functionalization is able to increase the biocompati-
bility of GO in all the sub-population analyzed (Fig. 27). GONH2
was found to be a potent immune-activator of monocytes and
dendritic cells. This effect was confirmed and explained by the
transcriptomic analysis. Notably, GO mainly modulated cell me-
tabolism. GONH2 instead did not have an impact on the cell
metabolism. Rather, they induce, in both monocytes and T cells,
the activation of immunomodulatory pathways mainly related
with innate and adaptive system and centered on interferon
(IFN) signaling (Fig. 28). Immune activations resulted in in-
creased expression of the T helper 1 chemokines (i.e., CXCR3
and CCR5 ligands), critical for the development of an effective
anti-tumor immune response [3].
Conclusions
These idiosyncratic immune-modulatory properties of GONH2 rep-
resent the proof of principle to develop new nanoscale platforms
in medicine as novel immunotherapeutic tools.
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Fig. 29 (abstract P276). Representation of breast cancer
transcriptome data by GXB. Example of CXCL9 gene expression
visualization either by annotated bar chart or box-plot
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Background
Sharing of -omics data has become the default modus operandi
in recent years, with many funding sources and journals requir-
ing authors to deposit their data in public repositories. This has
led to a wealth of available datasets for in silico analysis or val-
idation of new findings. To date, over 65,000 studies were de-
posited in the NCBI Gene Expression Omnibus (GEO) of which
more than 1200 relate to breast cancer. However, these reposi-
tories are accompanied with minimal analysis and/or limited
built-in visualization features in addition, offline analysis is rely-
ing on elevated bio-informatics skills. In order to make these
datasets more accessible and interactive, we developed a web
application called gene expression browser or GXB [1].
Methods
As a pilot project, we uploaded the GEO datasets we recently used
to validate breast cancer immune subtypes to the GXB application
and annotated the datasets collating data from the GEO database
entries, the matching publications and added our own immune gene
clustering assignments [2, 3].
Results
A total of 2178 samples were imported as part of 14 GEO data-
sets, 1728 of which were used in our validation set. One dataset
(GSE9151) was deposited in GEO in an incompatible format and
had to be reprocessed from the raw CELL files into a normal-
ized expression matrix. Adding group sets for clinical features,
immunological gene clusters and generating matching gene
rank lists will allow the users to quickly visualize differentially
expressed genes. The addition of extra overlay data will enable
the user to investigate correlations between phenotypic fea-
tures. An example of the visualizations available in this applica-
tion is demonstrated in Fig. 29.
Conclusions
The web application and the data set collection presented here
demonstrate how data that is now secluded from many scien-
tists can be made available in a more comprehensive and visu-
ally compelling environment. This approach will contribute to
more effective data sharing and increased reproducibility of
downstream bioinformatics pipelines.
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Background
Targeted therapies for breast cancers such as trastuzumab and
everolimus have durable clinical benefits for patients that express
the relevant biomarkers (HER2 and mTOR respectively). Triple nega-
tive breast cancer patients lack these biomarkers and are left with
few options. Recent advances in immunotherapy agents against PD-
1/CTLA-4 for patients with melanoma have yielded amazing clinical
benefits for a subset of patients and may have similar results in
breast cancer patients, but again the vast majority of patients still
undergo disease progression. We analyzed whole genome sequen-
cing and RNA sequencing data from The Cancer Genome Atlas
(TCGA) to identify neoepitopes across all cancer patients that could
be used to develop next-generation, patient-specific cancer immuno-
therapies. Neoepitopes are tumor-specific markers that arise from
mutations acquired from cancer and may represent a path to tar-
geted therapies.
Our in vitro studies on human tumors and in vivo murine studies
show that antagonism of the ER via tamoxifen
We analyzed 750 cancer patients from TCGA, containing a mixture of
23 different cancer classifications. These cancer patient samples were
selected by the availability of whole genome sequencing (WGS) data,
RNA-sequencing data as well as clinical outcome data.
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We identified an average of 680 potential neoepitopes per patient
based solely on WGS data. To further refine and select high quality
neoepitopes we restricted these neoepitopes based on gene expres-
sion yielding an average of 304 expressed neoepitopes per patient.
We predicted each patient’s HLA typing using only omics data, which
we then used to predict HLA-expressed neoepitope binding analysis
resulting in an average of 11 high-quality tumor specific neoepitopes
per patient. We identified few recurrent neoepitopes that were
bound and expressed, indicating the need for a personalized medi-
cine approach.
Conclusions
Within the TCGA dataset, the majority of neoepitopes among
patients with breast cancer were unique to each patient. Rarely
within subsets of breast cancers such as HER2+, do we identify
neoepitopes that are shared between patients. For cancer pa-
tients who do not respond to targeted therapies, high-
throughput identification of neoepitopes could serve as the
basis for the development of next-generation, patient-specific
immunotherapies.
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Background
In responding to immune selection pressure mediated by T cells,
somatic mutations can function in a bi-directional manner. On one
hand, somatic mutations give rise to neoantigens capable of eliciting
potent T cell responses. On the other hand, loss-of-function muta-
tions or downregulation of gene expression in the tumor cell can
also contribute to an immune evasion against T cells. Limited evi-
dence exists on which gene perturbations in human cancer can dir-
ectly or indirectly impair T cell mediated cytolysis.
Methods
To identify the genes essential in tumors to elicit a T cell-mediated
cytolytic response, we developed a ‘two cell-type’ (2CT) CRISPR assay
system consisting of human T cells as effectors and tumor cells as
targets. We combined CRISPR-Cas9 screen datasets with TCGA gene
expression datasets from >10,000 patient biopsies to study the pat-
terns of immune sensitivity in human cancers.
Results
Using the 2CT genome-scale perturbation screen in melanoma cells,
we identified and validated multiple genes whose loss impaired the
effector function of T cells. Moreover, we uncover a group of core
genes from these screens that correlates with cytolytic activity across
the majority of the cancer types, reflecting context independence of
these genes in the modulation of inherent T cell responses in mul-
tiple cancers. This dataset can be utilized to stratify patients for T cell
based immunotherapies, and also for studying emergence of novel
immune escape mechanisms.
Conclusions
This study demonstrates the broad applicability of 2CT CRISPR
screens to study the interaction of cancer cells with immune cells
and identify novel therapeutic targets for cellular therapies.
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Checkpoint inhibitors yield a significant clinical benefit for a subset
of cancer patients. Given the high cost of these therapies and the
time required to determine whether a therapy is efficacious, tests
that can identify patients who are most likely to benefit are urgently
needed. Supported by a strong biological rationale, tumor mutational
load has emerged as a robust determinant of clinical benefit for mul-
tiple checkpoint inhibitors in multiple cancer types. However, existing
approaches for assessment of tumor mutational load are expensive
and rely on tumor specimens that are not readily available or may
yield insufficient material for mutational load analyses.
Methods
We initiated the development of MutatorDetect, a plasma-based,
non-invasive, cost effective method that can accurately identify late
stage cancer patients whose tumors have high mutational load, re-
gardless of the availability of tumor specimens. Previously, we have
successfully developed an ultrasensitive platform for mutation detec-
tion using hybrid capture methodology and next generation sequen-
cing. The platform is able to interrogate large exonic regions and
detect cancer mutations from circulating cell free tumor DNA (ctDNA)
in plasma with high sensitivity and specificity.
Results
We are currently implementing MutatorDetect using this platform
and will present preliminary analytical and clinical validation data.
Conclusions
Further studies are warranted to examine MutatorDetect's perform-
ance in assessing tumor mutational load in large cohorts of late
stage cancer patients and identifying patients who are likely to re-
spond to checkpoint inhibitors.
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Background
The abscopal effect, or simultaneous tumor regression at multiple
sites, is believed to result from the migration of T cells activated at
the primary site to the distal sites. We have studied the case of a 1-
year-old boy with congenital fibrosarcoma (forearm) bearing a novel
EML4-NTRK3 fusion [1] who developed lung tumors 6 months after
resection of the initial tumor. He received fractionated radiation ther-
apy (RT) to the right lung only, but experienced complete regression
of both right and left lung tumors.
Methods
Using whole exome sequencing (WES), high-throughput sequencing
of peripheral and infiltrating T cell receptor repertoires (TCRseq), and
multiplex immunohistochemistry (mIHC) using MANTRA (for bio-
markers DAPI, CD3, CD4, CD8, CD68, HLA-DR, and Ki67), we investi-
gated the relationship between tumor progression and metastasis,
the pre- and post-treatment microenvironment, and the co-evolution
of the tumor-infiltrating immune cell populations in this patient.
Results
Comparative WES of the initial fibrosarcoma and subsequent lung
tumors identified the same EML4-NTRK3 fusion, validating their
metastatic relationship, as well as the evolution of additional
coding mutations upon recurrence. By both traditional and multi-
plex immunohistochemistry, the primary fibrosarcoma and pre-
radiotherapy lung tumor were infiltrated by a very low density of
CD4+ and CD8+ T cells. This infiltration was markedly increased
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the non-irradiated lung lesion, which is consistent with the model
that abscopal regression depends on infiltration by trans-acting
anti-tumor T cells. TCRseq of the TIL populations revealed little
similarity between those of the primary fibrosarcoma and the
lung lesions. However, the TCR repertoires of the irradiated and
non-irradiated sites following radiotherapy showed substantial
similarity, sharing a larger percentage of CDR3 sequences with
one another (6.7 % of combined total) than with the primary
tumor (≤0.6 % combined total) or the pre-radiotherapy lung
tumor (≤1.6 % combined total). Furthermore, the breadth of the
TIL repertoire and its binding-associated divergence from the per-
ipheral blood was greatest in the irradiated lung tumor following
radiotherapy, suggesting a direct link between the evolution of
trans-acting immunity and antigen-driven immunogenicity at that
site.
Conclusions
Our results, particularly anti-tumor T cell specificities shared inside
and outside of the radiation field, offer key insights into the mecha-
nisms underlying abscopal tumor regression, which may in turn be
targeted for enhancement through immunotherapy.
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Background
As our ability to detect cancer improves, there is an opportunity to
treat early tumors before they become invasive and metastatic. Most
cancers are known to exhibit a premalignant state, where an expanded
population of mutated cells disrupts normal tissue organization. This
premalignant state can exist for years and may remain, resolve, or pro-
gress into invasive cancer. Cancer screening programs, for example
those based around the Pap smear for cervical carcinoma, aim to iden-
tify these abnormal cells for intervention before further malignant
transformation. HPV+ tumors represent a large proportion of anal, vul-
var, vaginal, cervical, and head and neck carcinomas. Vaccination
against human papilloma virus (HPV) can prevent HPV infection and
thus prevent HPV-associated malignancies. However, once tumors de-
velop, vaccination against the virus does not impact tumor progression.
Current therapies for a positive pap smear include excision of the ab-
normal region, or ablation by freezing or lasers. Immunotherapies, in-
cluding interferon alpha and imiquimod have been added to excisional
therapies to decrease the rate of recurrence; however, in randomized
clinical trials it was found that neither approach impacts the rate of re-
currence of cervical dysplasia.
Methods
In the transgenic mouse model carrying the mutant tumor-driving
genes Kras(G12D) and p53(R172H) that are controlled by expression
of Cre under a pancreas-specific promoter, this results in progressive
carcinogenesis through pancreatic intraepithelial neoplasia to pan-
creatic ductal adenocarcinoma. In addition, due to leaky expression
of Cre, at variable penetrance these mice spontaneously develop
papilloma of the face and vulva. In these mice the normal skin
undergoes epidermal thickening that closely resembles HPV-associated papilloma in humans. Since innate immune molecules,
such as interferon alpha, and innate stimuli, such as imiquimod, have
shown efficacy but failed in randomized studies, there is a need for
novel approaches to treat premalignant disease and this mouse
model represents a novel model system to test new therapies.
Results
Recently, we and others have demonstrated that novel agents that
activate the STimulator of INterferon Genes (STING) are strong in-
ducers of type I IFN and TNFα and can cause rapid regression of a
range of advanced tumors. For these reasons, we tested the effect of
STING ligands on papilloma in mice.
Conclusions
We tested the effect of STING ligands on papilloma in mice. Treat-
ment with STING ligands causes rapid regression of spontaneous
murine papilloma, and may represent an advance in treatment of
virus-associated and premalignant diseases.
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Background
The CD47-SIRPα interaction serves as the critical self-recognition mech-
anism in macrophage phagocytosis toward self-cells through inhibitory
signaling via SIRPα cytoplasmic ITIMs and tyrosine phosphatase SHP-1/
2. This signaling axis, thus, prevents macrophage phagocytosis toward
cancer cells, which exploit this mechanism by upregulating expression
of CD47 to evade immunological eradication. Despite this mechanism
being suggestively imperative, deficiency of CD47-SIRPα does not mani-
fest enhanced macrophage phagocytosis toward self- or cancer cells.
Therefore, this phenomenon suggests that the CD47-SIRPα mechanism
alone provides little insight necessary to explain when macrophages
would target self- or cancer cells, which bear no ‘eat-me’ signal and
thus do not activate macrophage phagocytosis.
Methods
Establishment of SIRPα−/− mice. Ex vivo and in vivo determination of
macrophage phagocytosis toward self- and cancer cells (i.e., B16 mel-
anoma, MC38 colon cancer, LLC lung cancer and EL4 lymphoma).
Identification of signaling mechanisms that activate macrophage
phagocytosis toward self-cells.
Results
Mice depleted of SIRPα display activated macrophage phagocytosis
toward self-RBC or engrafted B16 and LLC tumors under inflamma-
tory conditions and/or treatment by LPS/IL-17. Ex vivo phagocytosis
assays demonstrate that macrophages from SIRPα−/− or CD47−/−, and
even WT mice, are generally incompetent to attack self-cells albeit
aggressive toward bacteria, fungi, apoptotic cells and immune com-
plexes. Treatment of macrophages with IL-17, LPS, IL-6, IL-1β or TNFα,
but not IFNɣ, markedly initiates potent phagocytosis toward self
which leads to macrophage-mediated eradication of B16, LLC, MC38,
and EL4 cancer cells, providing an absence of the CD47-SIRPα re-
straint. Capitalizing on cytokine/LPS-activated SIRPα−/− macrophages
targeting CD47-expressing cells, we enlist these macrophages against
B16 melanoma and demonstrate complete elimination of lung me-
tastases in SIRPα−/− mice and in WT mice into which SIRPα−/−
macrophage-induced cancer immunity has been adoptively trans-
ferred. Mechanistic studies suggest that a PKC-Syk-mediated signal-
ing pathway, to which IL-10 conversely inhibits, is required for
activating macrophages toward cancer cells.
Conclusions
These findings demonstrate for the first time that macrophage
phagocytosis toward cancer requires activation by inflammatory cy-
tokines/factors that stimulate the PKC-Syk pathway. The ramifications
to arise from the combination of both phagocytic activation and
perturbation of the CD47-SIRPα interaction would lead to the
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 153 of 221eradication of cancer, especially toward those which therapeutic
antibodies are yet unavailable. (The work is currently in press for pub-
lishing in PNAS.)
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Background
The Stimulator of Interferon Genes (STING) pathway has been
implicated as a major mechanism by which the host innate immune
system “senses” cancer. STING pathway activation leads to the pro-
duction of several downstream cytokines, most notably type I inter-
feron (IFN), which is essential for bridging innate and adaptive
immune responses against solid tumors. Administration of STING
agonists induces broad immunity against transplanted solid malig-
nancies in a type I IFN-dependent manner. We have recently demon-
strated potent efficacy of systemic STING agonist therapy in murine
AML models. Unlike the activity of STING agonists in solid tumor
models, we observed a major type I IFN-independent effect in mice
with AML, leading us to hypothesize that other cytokines may be im-
portant for the effectiveness of STING agonist therapy in mice with
systemic leukemia.
Methods
C1498 AML cells engineered to express the model SIY peptide anti-
gen (C1498.SIY) were inoculated intravenously into syngeneic C57BL/
6 or Ifnar−/− mice and mice were treated with the selective murine
STING agonist, DMXAA (5,6-dimethylxanthenone-4-acetic acid), or ve-
hicle control.
Results
Surprisingly, SIY/Kb pentamer and intracellular cytokine staining
followed by flow cytometric analysis revealed a similarly marked ex-
pansion of functional SIY-reactive CD8+ T cells in both wildtype and
Ifnar−/− mice. Survival following DMXAA treatment was significantly
prolonged in wild-type, and to a lesser extent, in Ifnar−/− mice, sug-
gesting that other downstream cytokines, such as TNF-a or IL-6 may
partially mediate STING-dependent immune effects in leukemia-
bearing hosts. For example, STING pathway activation led to signifi-
cantly increased TNF-a levels in both wildtype and Ifnar−/− mice (3-
fold and 6-fold, respectively). Based on the known inflammatory and
immune-activating properties of TNF-a, we speculate that it may also
be contributing to the positive effects of STING activation in
leukemia.
Conclusions
Collectively, our data demonstrate that STING-mediated enhance-
ment of anti-leukemia immunity are at least partially independent
of type I IFN. In addition to type I IFN, other cytokines/pathways
appear to be required to mediate the powerful immunotherapeu-
tic effect of STING agonists in AML.TNF-a is significantly increased
following STING activation and may be mediating these effects,
but further investigation is needed. Finally, these results imply
that the mechanisms by which STING activation mediates anti-
cancer effects may differ considerably between solid and
hematologic malignancies.
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Natural killer (NK) cells are lymphocytes that bridge innate and adap-
tive immune responses. The activity of NK cells is controlled by the
integration of activating and inhibitory signals. NK cells can be di-
vided into subsets termed licensed and unlicensed based on the ex-
pression of inhibitory receptors with varying affinity for MHC class I
molecules. In general, licensed NK cells have higher cytotoxic poten-
tial than unlicensed NK cells. Hematopoietic stem cell transplant
(HSCT) is a treatment for a number of hematological malignancies,
including acute myeloid leukemia (AML). Patients who are not
eligible to receive intensive cytoreductive therapy, are at risk for pri-
mary refractory disease, or are experiencing relapse, are all candi-
dates for HSCT. NK cells are the first lymphocytes to recover post-
HSCT and have been shown to be critical for an anti-leukemia re-
sponse. Here we investigate the contribution of NK cell subsets to
anti-leukemia responses in the context of a mouse model of HSCT.
Methods
C1498 acute myelogenous leukemia cells were administered to con-
trol mice and mice that received total body irradiation followed by
syngeneic HSCT. Monoclonal antibodies were used to deplete the li-
censed or unlicensed NK cell subsets (anti-Ly49C/I and anti-Ly49G2,
respectively). Survival was monitored continuously and immune re-
constitution was characterized by flow cytometry on days 17 and 24
post-C1498 administration.
Results
Control mice with intact immune systems survived with AML longer
than HSCT mice. In control mice, the depletion of licensed or
unlicensed NK cells did not significantly affect survival time. How-
ever, in HSCT mice, the depletion of the unlicensed NK cell subset re-
sulted in statistically significant prolonged survival when compared
to licensed-depleted and non-depleted controls, suggesting an an-
tagonistic role for unlicensed NK cells in combating AML post-HSCT.
Immune phenotyping showed that unlicensed depletion led to in-
creased numbers of the licensed population post-HSCT, without the
same reciprocal expansion of unlicensed NK cells with licensed
depletion.
Conclusions
Unlicensed NK cells limit the expansion of licensed NK cell post-
HSCT, which has a detrimental effect on survival after C1498 chal-
lenge. NK cell subsets have non-overlapping roles, with the licensed
playing the dominant anti-leukemia role post-HSCT, and the
unlicensed negatively regulating the response of the licensed. Modu-
lation of these opposing roles may be advantageous for clinical use
of HSCT and NK cell therapies.
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Background
The breast tumor environment is complex and includes both neo-
plastic and immune cells. The most abundant immune cell popula-
tion within breast tumors is tumor associated macrophages (TAMs).
Macrophages have the ability to polarize into either M1 cells, which
have potent anti-tumor capabilities, or M2 macrophages which pro-
mote tumor progression by stimulating tumor vasculature, invasion,
metastasis, and can enhance tumor resistance to chemotherapy.
Generally TAMs in breast tumors are considered M2 macrophages
and a high tumor density of TAMs clinically correlates to both overall
worse prognosis and increased metastasis. Several therapeutic
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 154 of 221strategies exist to modulate TAMs clinically, focusing on depleting or
inhibiting TAMs. However, macrophage are required for optimal
tumor regression in response to both chemotherapy and immuno-
therapy. Their embedded location and their untapped potential pro-
vide impetus to the discovery of strategies to turn them against
tumors and to harness for cancer therapy. Therefore here, we de-
scribe a novel method to polarize pro-tumor macrophages to an
anti-tumor phenotype.
Methods
We recently reported that a first in class selective class IIa HDAC in-
hibitor (TMP195) influenced human monocyte responses to colony
stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a
macrophage-dependent autochthonous mouse model of breast can-
cer to demonstrate that in vivo TMP195 treatment alters the tumor
microenvironment and reduces tumor burden and pulmonary metas-
tases through macrophage modulation.
Results
TMP195 induces recruitment and differentiation of highly phagocytic
and stimulatory macrophages within tumors. Furthermore, combining
TMP195 with chemotherapy regimens or T cell checkpoint blockade in
this model significantly enhances the durability of tumor reduction.
Conclusions
These data introduce class IIa HDAC inhibition as a novel means to
harness the anti-tumor potential of macrophages to enhance cancer
therapy.Fig. 30 (abstract P285). See text for descriptionP286
Interferon production and immunity elicited by a constitutively
active form of interferon-beta promoter stimulator-1 (IPS-1)
Richard S Kornbluth1, Sachin Gupta2, James Termini2, Elizabeth Guirado2,
Geoffrey W Stone2
1Receptome, LLC, La Jolla, CA, USA; 2Miller School of Medicine,
University of Miami, Miami, FL, USA
Correspondence: Richard S Kornbluth (rkornbluth@receptome.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P286
Background
Type I interferon (IFN) promotes the activity of anti-tumor CD8+ T
cells. IFN induced by intratumoral injections of stimulator of inter-
feron genes (STING) activators has shown remarkable efficacy as a
“gas pedal” when combined with PD-1/PD-L1 checkpoint blockade in
mouse models. Like STING, IPS-1 (also called MAVS, Cardif, or VISA)
can lead to strong IFN production. IPS-1 is normally activated by viral
RNAs bound to RIG-I which in turn modifies IPS-1 so that it clustersonto the surface of mitochondrial membranes. To circumvent the
need for RIG-I, this study fused IPS-1 with the membrane clustering,
N-terminal region of EBV latent membrane protein 1 (LMP1).
Methods
The N-terminus of the Epstein-Barr virus (EBV) LMP1 protein contains
6 transmembrane domains that self-associate and cluster in mem-
branes. Genetically fusing this N-terminal region to IPS-1 forms
LMP1-IPS-1 which is a constitutively activated form of IPS-1. The
resulting nucleic acid sequence was tested either as mRNA, plasmid
DNA, or by viral delivery using adenovirus 5 (Ad5) (Ad5-LMP1-IPS-1).
Results
Human dendritic cells transduced with Ad5-LMP1-IPS-1 upregu-
lated CD80 and CD86 and produced large amounts of IL-12 and
TNF. 293 cells transfected with LMP1-IPS-1 plasmid DNA pro-
duced high levels of IFN-α, IFN-β, and chemokines. By microarray
analysis, mRNAs for IFN-associated genes were strongly upregu-
lated. In vivo, mice vaccinated with Ad5-LMP1-IPS-1 plus Ad5 ex-
pressing HIV Gag were completely protected from vaccinia-Gag
challenge virus.
Conclusions
LMP1-IPS-1 shares similar activities with activated STING. Whereas
STING activators are small molecules, LMP1-IPS-1 is constitutively ac-
tive and its nucleic acid sequence can be used as mRNA, plasmid
DNA, part of a viral vector, or the payload of an “armed” oncolytic
virus.
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Background
HLA-G is a non-classical major histocompatibility complex (MHC)
molecule expressed at the fetal maternal interface and in tu-
mors, where it exerts immunomodulatory effects. These im-
munosuppressive effects are mediated through interactions of
HLA-G with its receptors, ILT2 and ILT4, which are expressed
primarily on cells of the myeloid lineage. To further understand
the effect of tumor HLA-G expression on myeloid immune sup-
pression, we investigated the effect of HLA-G on Fcγ receptor
signaling—a myeloid effector function which has important im-
plications in the immune response to tumors and the effect of
antibody-based therapeutics.
Methods
Using an inducible HLA-G-expressing tumor cell line and tumor-
specific antibody, we examined Fcγ receptor effector functions in a
human monocyte-like cell line as well as in primary human mono-
cytes and macrophages.
Results
We found that HLA-G inhibits signaling downstream of FcγR acti-
vation in a monocytic cell line and in primary monocytes. Fur-
thermore, HLA-G expression on tumor target cells results in
inhibition of antibody-dependent phagocytosis by macrophages
as well as decreased FcγR-induced production of inflammatory cy-
tokines. These effects were dependent on HLA-G interaction with
its receptors, ILT2 and ILT4.
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 155 of 221Conclusions
Our findings suggest a role for HLA-G in promoting tumor im-
mune escape, as well as a novel mechanism for HLA-G-
mediated inhibition of antibody-based tumor cell phagocytosis
by macrophages.
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Background
T cell-based immunotherapies have brought great progress for
cancer patients. However, very little is known about the cancer cell
response to cytotoxic T lymphocyte (CTL) attack.
Methods
We studied the dynamic T cell-cancer cell interplay. Low passage
melanoma cell lines were cultured with MelanA/MART1-specific
CD8+ T cells and characterized using differential gene expression
analysis and flow cytometry. Specific gene products were investi-
gated by immunohistochemistry and results were interpreted
based on the literature including single cell data from melanoma
patients.
Results
As expected, significant fractions of melanoma cells died in pres-
ence of melanoma-specific CD8+ T cells. However, still many mel-
anoma cells persisted for up to three days of co-culture.
Characterization of the surviving melanoma cells revealed in-
creased mRNA levels of genes associated with an antimicrobial
immune response: DDX58, TLR3, AIM2, MyD88, NFKB, IFITM3, and
ISG15 after co-culture. Upregulation of these genes is known to
enhance innate immune responses. DDX58 (also RIG-I) and TLR3
sense intracellular viral RNA, and AIM2 recognizes cytosolic
double-stranded DNA. MyD88 acts as an adaptor downstream of
TLRs and signals to NFκB. IFITM3, a transmembrane protein, in-
hibits viral entry into its host and ISG15 has multiple anti-viral
roles including induction of NK cell proliferation. These and
further gene and protein expression changes were dependent on
antigen-specific interaction of CTLs with melanoma cells and
were mediated by IFNγ and TNFα, two cytokines secreted by
CTLs upon antigen recognition.
Conclusions
So far, mainly immunosuppressive mechanisms of cancer cells
upon exposure to CTLs have been described, such as increased
expression of IDO1 and the inhibitory receptor ligand PD-L1. Here
we show that in addition to these immunosuppressive mecha-
nisms, melanoma cells respond to melanoma-specific CTLs with a
cytokine-driven upregulation of genes involved in the innate im-
mune response, likely also supporting the T cell responses. More-
over, melanoma cells upregulate further immune genes which we
will discuss at the congress. Our findings may play a role in im-
munotherapy, and might explain why immune reactions in cancer
patients are often promoting both pro- and anti-tumor immune
mechanisms.
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Background
Identifying T cell receptors (TCRs) targeting self-antigens may provide
opportunities for effective cancer therapy employing adoptive T cell
therapy. However, the enormous diversity of TCRs and low abun-
dance of antigen-specific clones make identification of individual
TCRs difficult. Moreover, tolerance further limits self-reactive TCR
abundance and affinity.
Methods
Here, we define a process to identify TCRs from CD4+ T cells recog-
nizing the intestinal self-antigen GUCY2C, an emerging target in colo-
rectal cancer immunotherapy. GUCY2C-specific CD4+ T cells were
identified and purified from GUCY2C-immunized mice. Next-
generation sequencing of TCR transcripts quantified individual TCRs,
permitting synthesis and assembly of TCR constructs that were engi-
neered into CD4+ T cells.
Results
GUCY2C recognition by engineered CD4+ T cells in vitro confirmed
TCR specificity and activity. Further, TCR constructs were engineered
into purified mouse hematopoietic stem cells (HSCs) ex vivo, which
were adoptively transferred to HSC-depleted recipient mice. These
engineered HSCs gave rise to naïve T cells expressing GUCY2C-
specific TCR transgenes, allowing us to validate our in vitro findings
of GUCY2C recognition following GUCY2C vaccination.
Conclusions
This transgenic TCR model system can be employed to define toler-
ance mechanisms restricting GUCY2C-specific immunotherapy, facili-
tating 2nd-generation GUCY2C vaccine design. Moreover, this
approach to identify and validate self-antigen specific TCRs may be
employed for cancer immunotherapies, accelerating therapeutic
discovery.
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Background
Gastric neoplasms constitute some of the most commonly occurring
and heterogenic tumors, which are associated with a high percent-
age of mortality among affected individuals. While the most common
is gastric cancer, within the gastric tissue, several other types of ma-
lignancy may arise, including lymphomas, gastrointestinal stromal
Fig. 31 (abstract P291). E:T Ratio dependent cytotoxicity
fluorescent images. The calcein AM fluorescent images are the K562
Target cells at t = 4 hours, showing decrease in calcein AM positive
Target cells as E:T ratio increased. The IMR32 images were similar
Fig. 32 (abstract P291). Time course and dose dependent
cytotoxicity results. The time course results showed increase in %
lysis from 1 to 4 hours. The dose response graphs showed
increasing % lysis as E:T ratio increased
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vorable prognosis. Recently there has been an increased interest in
the potential role of bone marrow-derived stem cells (BMSCs) in the
development/progression of malignancies in humans. However, cur-
rently very little is known about BMSC homeostasis in patients with
different types of gastric neoplasms. Therefore, in this study, we
wanted to comprehensively examine and compare the peripheral
trafficking of different populations of BMSCs in these patients, as well
as to (at least preliminarily) elucidate the immune-related substances
that might be associated with this phenomenon.
Methods
Using FACS analysis supported by ImageStream technique verifi-
cation, various populations of BMSCs, such as Lin-CD45-CD133 +
CXCR4+ very small embryonic/epiblast-like stem cells (VSELs),
CD45-STRO-1 + CD105+ mesenchymal stem cells (MSCs), Lin-
CD45 + CD133+ hematopoietic stem/progenitor cells (HSPCs),
and CD34+/KDR+/CD31+/CD45- endothelial progenitor cells
(EPCs), were enumerated and sorted from the peripheral blood
samples collected from patients with gastric cancer (n = 25)
other gastric tumors (GISTs, NENs, lymphomas; n = 15) and con-
trol individuals (n = 20). Plasma levels of stromal-derived factor-1
(SDF-1), complement-derived anaphylatoxins/molecules (C3a,
C5a, C5b-9), cytokines (IL-1, IL-6, IL-8, IL-10, IL-17, IL-23, TNFα),
growth factors (HGF, FGF, IGF-1) and immunomodulatory bio-
active lipids (sphingosine-1-phosphate–S1P and lipoxin A4) were
measured using ELISA.
Results
Significantly lower numbers of circulating HSPCs and intensified per-
ipheral trafficking of both VSELs and MSCs was observed in patients
with gastric cancer but not in those with other types of gastric tu-
mors. The abnormal balance in the peripheral trafficking of BMSCs in
patients with gastric cancer was neither associated with the clinical
stage of the disease nor with the systemic levels of SDF-1, which
were comparable between all analyzed groups. In patients with gas-
tric cancer, significantly increased levels of C5b-9, interleukins (IL-6,
IL-8, IL-23), HGF and bioactive lipids (S1P, lipoxin A4) were strongly
associated with observed phenomenon of intensified circulation of
VSELs and MSCs.
Conclusions
Abnormal peripheral trafficking of BMSCs occurs in patients with gas-
tric cancer and is specific only for this group of patients suffering
from gastric tumors. Selected interleukins, complement cascade-
derived molecules, growth factors and bioactive lipids, but not SDF-
1, seem to be significant players associated with this phenomenon in
humans.
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Background
Cytotoxicity assays play a central role in studying the function of im-
mune effector cells such as cytotoxic T lymphocytes (CTL) and nat-
ural killer (NK) cells. Traditionally, cytotoxicity assays have been
performed using 51chromium (51Cr) and calcein release assays. The
assays involve labeling tumor cells (target) with radioisotope or fluor-
escent dyes, when the target cells are subjected to cytolysis by CTLs
or NK cells (effector), they releases the entrapped labels into the
media upon lysis. The amount of labels in the media is measured to
determine the level of cytotoxicity the effectors have induced. These
traditional methods may generate inconsistent results due to lowsensitivity caused by poor loading efficiency and high spontaneous
release of the reagents.
Methods
In this work, we demonstrate a novel cytotoxicity assay using the
Celigo imaging cytometry method. Utilizing imaging cytometry, dir-
ect cell counting of live fluorescent target cells can be performed,
which is a direct method for assessment of cytotoxicity. Human NK
cells from one healthy donor were used as effectors, and K562 (sus-
pension) and IMR32 (adherent) were used as the target cells. Both
target cells were first stained with calcein AM, and seeded at 10,000
cells/well in a standard 96-well microplate. The donor NK cells were
then added to each well at effector-to-target (E:T) ratios 10:1, 5:1,
2.5:1, 1.25:1, 0.625:1, and 0.3125:1. The 96 well plate was then
scanned and analyzed using Celigo imaging cytometer at t = 1, 2, 3,
and 4 h to measure the % lysis of target cells.
Results
The results showed increasing % lysis as incubation time and E:T ra-
tio increased. For the E:T ratios at 10:1, 5:1, 2.5:1, 1.25:1, 0.625:1, and
0.3125:1, the % lysis were 99, 93, 75, 52, 30, and 7 %, respectively for
IMR32. The K562 cells showed similar % lysis results. In addition, the
change in % lysis over time was monitored for both cell types, show-
ing increasing % lysis from 1 to 4 hours.
Conclusions
The proposed Celigo imaging cytometry is an accurate and simple
method for direct quantification of NK cell-mediated cytotoxicity,
which can be an attractive method for both academic and clinical re-
search. In addition, plate-based image cytometry enables high-
throughput screening platform for more efficient identification of po-
tential antibody drug candidates.P292
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Hepatocellular carcinoma (HCC) is the sixth most common cancer
with a growing incidence and mortality. Since HCC is believed to
be immunogenic, immunotherapy is considered a promising new
treatment modality. The identification of novel and specific
tumor-associated antigens provides the basis for the development
of an efficient immunotherapy. However, only very few HCC-
specific tumor antigens have been characterized so far and post-
translational modified peptides have been completely overlooked
in the past. Dysregulation of signaling pathways in cancers leads
to aberrant and augmented protein phosphorylation and in such
way modified proteins can be degraded to generate cancer-
specific phosphopeptides. These are presented by MHC class I
molecules and recognized by T cells. The aim of this study was
to identify HCC-associated, MHC class I-bound phosphopeptides
(MHC-I-pP) and to assess immunity against this novel class of an-
tigens in patients with chronic liver disease and HCC.
Methods
For identification, tissues were lysed and MHC class-I complexes affin-
ity purified. The bound phosphopeptides were eluted, enriched and
characterized using mass spectrometry. We compared MHC class I-
bound phosphopeptides (MHC-I-pP) found on healthy, cirrhotic liver
tissue and HCC from patients undergoing liver transplantation. To as-
sess immunity PBMCs, intrahepatic lymphocytes (IHLs) and tumor-
infiltrating lymphocytes (TILs) were extracted from healthy donors,
patients with chronic liver disease and HCC, and analyzed using mul-
tiplexed intracellular cytokine staining. Additionally, MHC-I-pP-specific
CD8+ T cells from IHLs and TILs were expanded in a large scale using
a rapid expansion protocol with anti-CD3, IL-2 and irradiated feeder
cells.
Results
So far we have identified over 300 HCC-associated MHC-I-pP pre-
sented by various HLA molecules. Many of the novel identified MHC-
I-pP were derived from proteins, which can be directly linked to im-
portant cancer-associated signaling-pathways. More MHC-I-pP were
displayed in a greater diversity during the course of liver disease
from non-cirrhotic liver to precancerous liver cirrhosis and up to HCC.
CD8+ T cell responses were found regularly in patients with early
chronic liver disease and were much rarer in patients with end-stage
liver cirrhosis and after HCC formation.
Conclusions
Immune responses against these novel tumor-antigens were compar-
able in quantity and quality to those seen against viral control epi-
topes. Our results therefore suggest that MHC-I-pP may be the target
of cancer immune surveillance in liver disease. Furthermore, a di-
rected expansion of MHC-I-pP-specific CD8+ T cells was possible in a
large scale for a possible application in adoptive T cell therapy.
Therefore, MHC class-I bound phosphopeptides represent an attract-
ive novel target for future cancer immunotherapies.
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Background
Cancer testis antigens (CTA) represent one type of tumor antigen
that can elicit strong immune responses thanks to their restricted ex-
pression in normal germ cells and tumor cells. Upregulated expres-
sion has been observed in various cancer types including melanoma,
bladder, lung, ovarian, and hepatocellular carcinomas. NY-ESO-1 has
emerged as a promising target as it is highly immunogenic and asso-
ciated with poor clinical outcome [1, 2]. Reports on CTA expression
in breast cancer are inconclusive and sparse data is available on
triple negative breast cancer (TNBC).Methods
Using a bioinformatics approach, we investigated the expression of
CTAs that are transcriptionally silent in normal non-germline tissues
[3] in both human TNBC cell lines and specimens. Gene and protein
analyses were performed in vitro to evaluate our in silico findings,
and functional assays were conducted for 3 CTAs.
Results
We mined the TCGA and NCBI GEO repositories for CTA expres-
sion in TNBC and found a consensus moderate expression of
DKKL1, LDHC, MAGE-A3, PIWIL2, PLAC1, PRAME, PRSS50 and
TSGA10 in cell lines and tumor specimens. Interestingly, NY-ESO-1
expression was not found to be upregulated in triple negative
breast cancer. Expression profiling of 9 human TNBC cell lines,
encompassing all 6 TNBC subtypes, confirmed LDHC, MAGE-A3
and PRAME to be good candidate targets. Their cellular
localization, determined by immunocytochemistry, indicates that
redirected, rather than chimeric antigen receptor (CAR)-modified
T cells, should be developed as tools for adoptive T cell therapy.
We are currently identifying the immunogenic peptides to be
used for T cell engineering. Furthermore, we are conducting func-
tional assays to determine the role of LDHC, PRAME and MAGE-A3
in TNBC development and progression, in particular in cell metab-
olism, proliferation, apoptosis, migration and invasion.
Conclusions
We found a number of cancer testis antigens to be expressed at
moderate to high levels in triple negative breast cancer. Our prelim-
inary findings suggest that LHDC, MAGE-A3 and PRAME could be
good targets for adoptive T cell therapy of TNBC.
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Background
High dose IL-2 (HD IL-2) can provide durable responses in patients
with metastatic melanoma (mM) and metastatic renal cell carcinoma
(mRCC). PROCLAIMSM [http://www.proclaimregistry.com] is an IL-2
registry that captures real-world patient population survival and out-
comes. Herein, we report on patient experience sequencing HD IL-2
with immune checkpoint blockade (ICB) and/or targeted therapy (TT)
in mM and mRCC.
Methods
Patients were prospectively enrolled into the registry as of 2011
and must have received at least one dose of HD IL-2. Statistics
and survival analysis were performed on datasets as of December
17, 2015.
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The mOS for mM patients (n = 337) was 19.4 months, with a median
follow-up (mFU) of 22 months. The overall response rate (ORR) for
323 patients with available data was 13.9 %. The mOS for those with
complete response (CR, n = 10) and partial response (PR, n = 35) was
not reached (NR). The mOS for patients experiencing stable disease
(SD, n = 92) and progressive disease (PD, n = 186) was 29.3 and
12.2 months, respectively. The mOS for all mRCC patients (n = 412)
was NR, with a mFU of 21 months. The ORR for the 382 patients with
available data was 17.8 %. For patients with CR (n = 14), PR (n = 53),
or SD (n = 146) mOS was NR while in patients with PD (n = 169), mOS
was 17 months. In mM, two groups were further analyzed; HD IL-2
followed by ipilimumab alone (IL-2 then IPI), and HD IL-2 followed by
PD-1/PD-L1 inhibitors with or without ipilimumab (IL-2 then aPD-1 ±
IPI, Table 2). In mRCC, survival based on TT or ICB after HD IL-2 was
analyzed (Table 3). Survival of patients receiving HD IL-2 as first line
with no post therapy was also determined (Table 3).
Conclusions
This analysis of the national IL-2 registry suggests that HD IL-2 con-
tinues to be a valuable treatment option for eligible mM and mRCC
patients. Attainment of SD is clinically relevant and contributes to HD
IL-2’s survival benefit. Support for investigation of HD IL-2 in combin-
ation or sequence with ICB is warranted.
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76, 65, 65 82, 72, 72 Fig. 33 (abstract P295). THU-Dec directly cytoreduced lung cancer
in vivo by p53-independent mechanisms while preserving immune-
effectors and increasing antigen presentation. C57/BL6 mice were
inoculated via tail vein with LL3 lung cancer cells. a Survival time; b
Protein expression in tumor; c Absolute numbers of CD4/8 T cells in
peripheral blood after 2 weeks of treatment; d Absolute numbers of
MDSC in blood after 2 weeks of treatment; e Cancer testis antigen
expression in tumor; f Intracellular IFNγ expression in tumor. Data
were expression as mean ±SD. *p < 0.05, **p < 0.01 vs PBS group
Table 2 (abstract P294). See text for description
Metastatic Melanoma
Groups based on therapies after IL-2 IL-2 then IPI IL-2 then aPD-1±IPI
N 81 56
mOS (months) 15.8 28.7
1-,2-,3-year survival (%) 64, 28, 18 96, 66, 35P295
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Background
Even if a cancer is immune recognized, it may evade immune attack
using immune checkpoint. Such immune-recognized cancers are vulner-
able to immune checkpoint inhibitors (e.g., anti-PD-1). Unfortunately, the
response rate of non-small cell lung cancer to nivolumab is only ~20 %.
One important approach to improve immune checkpoint blockade is to
increase the rate at which NSCLC is immune-recognized in the first place.
A major way in which cancers escape immune recognition is by epigen-
etic silencing of neo-antigens. A central epigenetic protein mediating
such silencing is DNA methyl-transferase 1 (DNMT1), and DNMT1 has
been validated as a molecular target to increase NSCLC immune-
recognition. Moreover, DNMT1-depletion cytoreduces cancers directly byincreasing expression of epithelial-differentiation genes that directly
antagonize MYC, to produce p53-independent cell cycle exits that spare
immune-effectors. Decitabine (Dec) depletes DNMT1 and can potentially
translate this science; however, Dec has a very brief plasma t1/2 in vivo.
Therefore, we combined an inhibitor of CDA, tetrahydrouridine (THU),
with reduced doses of Dec, with the objective that depletes DNMT1
while avoiding a high Cmax that causes off-target cytotoxicity.
Methods
C57/BL6 mice were inoculated with LL3 cells by tail vein. Mice (n =
15) randomized into 3 groups were treated with PBS, Dec (0.2 mg/
kg s.c. 3X/wk), or THU-Dec (10/0.1 mg/kg s.c. 3X/wk). Peripheral
blood was collected to detect MDSC and T lymphocytes. Survival
time was recorded. At sacrifice, tumor samples were examined by
flow cytometry, H&E staining, Western blot and QRT-PCR.
Results
Survival time significantly increased with THU-Dec (62) > Dec (50) > ve-
hicle (37) (median survival days) (Fig. 33a). Tumor DNMT1 and MYC pro-
tein decreased to a substantially greater extent with THU-Dec than with
Dec alone, concurrent with substantial increase in p27 (Fig. 33b). THU-
Dec preserved peripheral blood counts including absolute lymphocyte
counts (Fig. 33c), while substantially decreasing the numbers of MDSC
(Fig. 33d). THU-Dec also significantly increased expression of immuno-
therapy antigenic targets MAGE-A1 and MAGE-A3 to a greater extent
than Dec (p < 0.01) (Fig. 33e). THU-Dec treatment also decreased regula-
tory T cells in blood and tumor, and increased the release of INFγ and ex-
pression of PD-L1 in tumor cells, compared to Dec alone or PBS (Fig. 33f).
Conclusions
Addition of THU to Dec, to address pharmacologic limitations of Dec
alone, improved immune-priming and induced p53-independent cell
cycle exits in NSCLC in vivo. There is scientific and pharmacologic ra-
tionale to combine THU-Dec with nivolumab in the clinical trial
NCT02664181.P296
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Background
The liver is the principal metabolizing site of the body, which is com-
monly prone to damage through various toxicants. Diethylnitrosamine
Fig. 34 (abstract P297). HLA-A2.1+ donor-derived CTLs specifically
recognize HLA-A2.1+ K27M+ glioma cells in an HLA-class I-dependent
manner. Peripheral blood mononuclear cells from an HLA-A2.1+ donor
were stimulated in vitro with the H3.3.K27M peptide and evaluated for
their reactivity against: a HLA-A2.1/H3.3.K27M-specific tetramer and anti-
CD8 mAb, and (b) T2 cells pulsed with the mutant or non-mutated H3.3
peptide by IFN-γ ELISA. In (a), among the CD8+tetramer+ population
(64.1% of total lymphocyte-gated cells), there is a tetramerhigh subpopula-
tion (2.4% of total lymphocyte-gated cells), some of which were used as
CTL clones (Aim 2). In (b), the Cap1-6D peptide (tested at 5mcg/ml only)
is a high avidity HLA-A2.1-binding epitope derived from CEA1 used as an
irrelevant negative control. c The CTL line was evaluated for cytotoxicity
against glioma cell lines T98 (HLA-A2.1+but K27M-negative), HSJD-DIPG-
07 (HLA-A2.1-negative but K27M+), and HSJD-DIPG-13 (HLA-A2.1+ and
K27M+) lines. CFSE-labeled target cells (10e4/well) were incubated with
CTLs at the E/T ratio of 25 for 4 hours. To block the CTL cytotoxicity, anti-
HLA-ABC 10μg/ml was added to one group. At the end of incubation, 7-
AAD was added into each well and incubated for 10 minutes on ice. The
samples were analyzed by flow cytometry, and the killed target cells
were identified as CFSE+ and 7-AAD+ cells. The cytotoxicity was calcu-
lated as the percentage of CFSE+ and 7-ADD+ cells in total HLA-A2+
CFSE+ cells (*p<0.05 by Wilcoxon rank-sum tests)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 159 of 221(DEN) is a potent hepatocarcinogen and hepatotoxin, which is well
known for modulating the inflammatory cytokines and oxidative stress in
the liver. The plants are the rich source of umbelliferone, which are the
secondary metabolites widely distributed in various species of fruits, veg-
etables, tea, spices and widely consumed by humans worldwide. The aim
of the current investigation was to exemplify the effect of umbelliferon-
α-D-glucopyranosyl-(2I→ 1II)-α-D-glucopyranoside (UFD) on tissue pro-
tection, chronic hepatic inflammation and oxidative stress induced by
DEN.
Methods
The rats were subjected to hepatic carcinogenesis by treating with a
single intraperitoneally injection of DEN (200 mg/kg). The rats were eu-
thanized at the end of the experiment and livers were microscopically
scrutinizing. Biomarker of oxidative stress (lipid peroxides, reduced
glutathione and conjugated dienes), liver enzyme parameters and
nonenzyme liver parameters were also examined. The liver tissue was
also invested for the existence of proinflammatory cytokines, including
IL-1β, IL-6 and TNF-α.
Results
The results clearly demonstrated the UFD dose-dependently inhibited
those as mentioned earlier elevated oxidative stress parameters, liver
and non-liver parameters dose dependently. Our result revealed the es-
sential repression of the inflammation cascade through modulation of
nuclear factor-kappa B (NF-κB) signaling pathway may characterize a
novel mechanism of action hepatic tumor inhibitory effect of UFD
against experimental toxicant-induced hepatocarcinogenesis.
Conclusions
It is evident from the present study that UFD inhibits the DEN-
initiated hepatocarcinogenesis in rats through proinflammatory cyto-
kines via the anti-inflammatory mechanism.
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Background
Brain tumors are the leading cause of cancer-related mortality and
morbidity in children. Recent genetic studies have revealed that ma-
lignant gliomas in children and young adults often show shared mis-
sense mutations in the gene encoding the replication-independent
histone 3 variant H3.3 [1]. Approximately 70 % of midline gliomas,
such as DIPG, harbor the amino-acid substitution from lysine (K) to
methionine (M) at the position 27 of H3.3 (the H3.3 K27M mutation
hereafter). The K27M mutation in DIPG is universally associated with
shorter survival compared with patients with non-mutated H3.3.Methods
We evaluated whether the H3.3 K27M mutation can induce spe-
cific cytotoxic T lymphocyte (CTL) responses in human leukocyte
antigen (HLA)-A2+ CD8+ T cells as a neoantigen epitope. Com-
petitive binding inhibition assays were performed for evaluation
of affinity of synthetic peptides to HLA-A2. α- and β-chain cDNAs
from a high-affinity T cell receptor (TCR) were cloned by amplifi-
cation of cDNA Ends–PCR (RACE-PCR).
Results
In vitro stimulation of HLA-A2+ donor-derived CD8+ T cells with a syn-
thetic peptide encompassing the H3.3 K27M mutation (the H3.3.K27M
epitope hereafter) induced CTL lines which recognized not only the
synthetic H3.3.K27M epitope peptide loaded on T2 cells but also lysed
HLA-A2+ DIPG cell lines which endogenously harbor the H3.3.K27M
mutation. On the other hand, CTL lines did not react to HLA-A2+, H3.3
K27M mutation-negative cells or HLA-A2-negative, H3.3 K27M muta-
tion + cells. The H3.3.K27M epitope peptide, but not the non-mutant
counterpart, indicated an excellent affinity (Kd 151 nM) to HLA-A2. Fur-
thermore, CTL clones with high and specific affinities to HLA-A2-
H3.3.K27M-tetramer were successfully obtained, and both retroviral and
lentiviral vectors have been created to encode α- and β-chain cDNAs
from a high-affinity TCR. Human T cells transduced with the lentiviral or
retroviral TCR demonstrated antigen-specific reactivity. Furthermore,
critically important for safety of clinical application, alanine scanning
demonstrated that the key amino-acid sequence motif in the epitope
for the TCR reactivity is not shared by any known human protein.
Conclusions
These data provide us with a strong basis for developing peptide-
based vaccines as well as adoptive transfer therapy using autologous
T cells transduced with the TCR.
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Fig. 36 (abstract P297). Efficient expression of transgene TCR
on human PBMC-derived T cells. Human PBMC-derived T cells
were transduced with serially diluted preparation of the
retroviral vector encoding H3.3.K27M-specific TCR and evaluated
by HLA-A2-H3.3.K27M-specific tetramer and anti-CD8
monoclonal antibody
Fig. 37 (abstract P297). Alanine scanning to determine the key
immunogenic AA residues of the H3.3.K27M epitope. a Relative HLA-
A*0201-binding affinity of each peptide to that of H3.3.K27M (26–35)
was determined by cell-free binding assay. b J.RT3-T3.5 cells were
transduced with lentiviral vector encoding the H3.3.K27M-specific
TCR and evaluated for the recognition of each peptide loaded on
T2 cells by production of IL-2. Each group was assayed as tripli-
cate *<0.05 by Student-t compared with the mutant H.3.3. In addition
to 10 synthetic peptides each containing the substitution with alanine
(A1-A10), we also evaluated synthetic peptides designed for citrulli-
nated H3.3. K27M epitope (Cit H3.3; i.e., the first AA of the H3.3.K27M
epitope is replaced by citrulline)
Fig. 35 (abstract P297). Evaluation of H3.3.K27M-specific TCR. a
J.RT-T3.5 cells were transduced with lentiviral vector encoding
the TCR α- or β-chains derived from H3.3.K27M-specific CTL
clone IH5 (J.RT-T3.5-TCR). The J.RT-T3.5-TCR or control non-
transduced J.RT-T3.5 cells were evaluated for the surface
TCR expression using PE-labeled HLA-A*0201/H3.3.K27M tetra-
mer (upper panel) or PE-labeled anti-CD3 mAb (lower panel)
and FITC-labeled anti-human CD8 mAb (upper and lower
panels). Since J.RT3-T3.5 cells are CD4+ and CD8-negative,
tetramer+ CD8-negative cells are ones expressing the
transgene-derived TCR. CD3-upregulation indicates activation of
cells. b J.RT-T3.5-TCR, but not control J.RT-T3.5 cells, upregulate
CD69 expression upon recognition of the H3.3 K27M peptide
loaded on T2 cells. c DIPG 13 cells [HLA-A*0201+ (albeit dim),
K27M mutation+] were incubated with J.RT-T3.5-TCR or control
J.RT-T3.5 cells. IL-2 secretion in the culture media was assayed
by specific ELISA
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Background
2-Fluorofucose (2FF) is a small molecule inhibitor of glycoprotein fuco-
sylation. 2FF-mediated afucosylation of cancer cells results in reduced
adhesive properties. Furthermore, T cells treated with 2FF during ex-
pansion show increased T cell receptor (TCR) signaling, enhanced mat-
uration of autologous dendritic cells (DCs), and reduced regulatory T
cell numbers, demonstrating modulation of immune activity [1]. 2FF
has shown promising in vivo anti-tumor activity, both alone and in
combination with a cancer vaccine, which appears to be dependent on
immune cell activity. Specifically, 2FF elicits growth delay in the gener-
ally refractory 4 T1 murine breast cancer model, whereas this effect is
lost when the 4 T1 model is run in immunodeficient NSG mice.
Methods
To further understand the immune modulatory activity of 2FF, tumor
infiltrating immune cells in 4 T1 tumors were counted and profiled
using multi-color flow cytometry. Additionally, antigen recall function
of CMV reactive T cells expanded with 2FF was assessed by culturing
T cells and autologous DCs with CMV peptides and monitoring IFNγ
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 161 of 221and IL-12p70 production. We also used this model to investigate the
combinatorial activity of 2FF treated T cells with anti-PD-1 antibodies.
Results
2FF treatment in the 4 T1 murine model reduced the number of regula-
tory T cells and increased activated DCs. These DCs showed a mild in-
crease in the maturation markers CD83, CD86, and MHCII. The effects
observed in vivo recapitulate our in vitro observations with human T
cells and T cell/DC co-cultures, and demonstrate the translation of 2FF
immune modulatory activity from in vitro to in vivo. Since 2FF reduces
the regulatory T cell population, an effect seen with anti-CTLA-4 anti-
bodies, we postulated that PD-1 checkpoint blockade antibodies would
enhance 2FF-treated T cell function. T cells treated with 2FF during ex-
pansion showed increased CMV antigen specific response, while co-
cultures that contained both 2FF-treated T cells and anti-PD-1 antibody
showed increased levels of production of IFNγ and IL-12p70 above
those seen with either single agent alone. These data suggest that co-
treatment with 2FF and anti-PD-1 antibody can lead to increased anti-
gen specific T cell activation in vitro.
Conclusions
Overall, we conclude that 2FF may promote a more active tumor im-
mune microenvironment, providing a better opportunity for an ef-
fective host anti-tumor immune response alone or in combination
with checkpoint blockade. A first-in-human phase I clinical trial evalu-
ating 2FF in advanced solid tumors is planned.
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Background
There is a pressing need for novel immunotherapeutic targets in
colorectal cancer (CRC). Memory CD8+ T cell infiltration is now well
established as a key prognostic indicator in CRC, and it is known that
these tumor infiltrating lymphocytes (TILs) are specifically targeting
and killing tumor cells. However, the antigens that these TILs target
have not previously been determined. This has limited the use of im-
munotherapies in CRC, despite their efficacy in other cancer types.
Recently, phosphopeptides have emerged as strong candidates for
tumor-specific antigens, since dysregulation of signaling in cancers
leads to aberrant protein phosphorylation. Here, we identify CRC-
associated phosphopeptides and assess the tumor-resident immunity
against these novel posttranslationally modified tumor antigens.
Methods
We compared tumor and healthy tissue from CRC patients, to iden-
tify tumor-specific MHC class I associated phosphopeptides. Phos-
phopeptides were enriched using immobilized metal affinity
chromatography, and characterized using mass spectrometry. TILs,
from the same tumors, were extracted and expanded, and their re-
sponses to the phosphopeptides assessed using multiplexed intracel-
lular cytokine staining. Cytolytic activity was observed by staining for
surface mobilization of CD107a. Healthy donor responses were quan-
tified using interferon-γ ELISpot and functionality assessed using a
europium release killing assay.
Results
We have identified 133 tumor-associated MHC class I phosphopep-
tides from CRC, with different HLA-restrictions. There were, on aver-
age, 3.1 times more different phosphopeptides identified on primary
cancers than healthy tissues, at 6.9-fold higher levels. 35 % of thesecan be attributed to signaling events in well-defined cancer path-
ways and are therefore markers of malignancy. Through analysis of
TIL’s cytokine responses to these phosphopeptides, we have estab-
lished that they are playing a key role in tumor-resident immunity.
There were multifunctional TILs present in primary and metastatic tu-
mors that recognized and killed in response to these phosphopep-
tides. Up to 0.7 % of expanded TILs targeted each phosphopeptide,
comparable with responses seen to viral epitopes. Immunity to these
tumor-associated phosphopeptides represents a biological strategy
for distinguishing tumor from healthy tissue. Furthermore, we have
shown that healthy donors have pre-existing, memory T cell re-
sponses to many (58 %) of these CRC-associated phosphopeptides.
These phosphopeptide-specific T cells are readily expanded ex vivo
and kill CRC cell lines. Thus, MHC class I associated phosphopeptides
are ideal immunotherapeutic targets, as immunity must spare
healthy tissue.
Conclusions
The identification of this novel class of MHC class I antigens in CRC
offers new hope for the future of immunotherapy in this malignancy.
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Background
Metastatic UC is usually fatal causing significant morbidity. Atezo-
lizumab, an anti-PD-L1 checkpoint inhibitor, is FDA-approved for
locally advanced or metastatic UC after progression on/after
platinum-containing chemotherapy based on results of the IMvi-
gor 210 trial.
Methods
We present a trial patient with unique sloughing of tumor tissue, out-
standing treatment response and tolerance.
Results
A 76 year old man was diagnosed with high grade muscle-invasive
UC of the bladder in April 2013. Patient completed 3 cycles of ‘neo-
adjuvant’ gemcitabine/cisplatin but had progression, he then re-
ceived 6 cycles of docetaxel & investigational agent with progression,
followed by 2 cycles of a targeted therapy on a phase I trial also with
progression. Patient was then screened for the cohort 2 of the IMVi-
gor210 trial evaluating the use of atezolizumab, 1200 mg every
21 days, in platinum-pretreated advanced UC. Screening CT showed
the bladder lumen replaced by multiple masses and a left peri-aortic
node 1.1 cm without other clear evidence of metastasis. Patient was
experiencing fatigue, and hourly urgent urination with detrimental
effect on his sleep, and overall quality of life (ECOG PS 1, normal
GFR, Hgb 10.2 on Cycle 1 Day 1(C1D1). Tumor tissue analysis showed
high PD-L1 expression in both tumor-infiltrating immune cells (IC2)
and tumor cells (TC2), TCGA subtype IV (Basal), and a high mutational
load of 18.02 Mut/MB (compared to IMvigor210, Cohort 2 median of
8.11 Mut/MB). At C2D1 visit, he already had major clinical benefit
with symptomatic improvement and sloughing of tumor tissue that
passed through the urethra; the latter underwent pathology review
and showed necrotic debris with highly atypical cells suspicious for
carcinoma. Ten days later he presented to the ED due to difficulty
voiding; cystoscopy was performed to remove necrotic tissue passing
through urethra. Scans at C3D1 demonstrated great response with
83 % tumor reduction, he continued to have very good quality of life.
Scans at C10D1 showed that the bladder mass was no longer meas-
urable and the lymph node was stable. Patient continues on trial
without notable adverse events (has asymptomatic atrial fibrillation
that was deemed possibly related to therapy) and has received 35 cy-
cles. Patient remains very active, riding his bike most days of the
week, denies urinary issues, has ECOG PS 0, with durable complete
response on scans.
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Atezolizumab can produce rapid and durable responses in advanced
platinum-resistant urothelial cancer and represents a new treatment
option. Several clinical trials are ongoing.
Trial Registration
ClinicalTrials.gov identifier NCT02108652.Fig. 40 (abstract P300). Bladder CT - 9 Months of Therapy.
Complete Response
Fig. 39 (abstract P300). Bladder CT - 9 Weeks of Therapy.
83% Reduction
Fig. 38 (abstract P300). Bladder CT - BaselineP301
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Background
TLR9 agonists have shown anti-tumor effects, modulating the immune
system via cellular and humoral responses. Two different families of
DNA molecules containing non-methylated CG-motifs for TLR9 activa-
tion have been established so far: i) Dumbbell-shaped dSLIM® mole-
cules protected against exonucleolytic degradation by their covalently-
closed, natural phosphodiester (PO) backbone and ii) single-stranded,
oligodeoxynucleotides (CpG-ODN) in most cases chemically-stabilized
by phosphorothioates (PTO) in their phosphate moieties. However, PTO
modifications produce off-target effects in immune cell populations
and result in unfavorable risk-to-benefit ratios.
Methods
A novel family of TLR9 agonists avoids the off-target effects of PTO-
modified CpG-ODN: linear single-stranded ODN synthesized using L-
deoxyribonucleotides (natural enantiomers of D-deoxyribonucleotides)
at their 3’-ends - EnanDIM®. The vast majority of deoxyribose in organ-
isms consists of D-deoxyribose, thus co-evolved nucleases are blind for
L-deoxyribose - thereby leaving L-protected ODN intact. We selected
nucleotide sequences of EnanDIM® using high secretion of IFN-alpha
and IP-10 from human peripheral blood mononuclear cells as marker.
We employed a maximum feasible dose (MFD) approach: Mice received
subcutaneous injection of single doses of 10 to 50 mg EnanDIM® to
evaluate their acute toxicity and immunomodulatory properties. A pilot
study was used to investigate the anti-tumor effect of EnanDIM® in a
CT26 tumor model.
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EnanDIM581 and EnanDIM532 were selected due to their pro-
nounced activation of immune cells (e.g. monocytes, NK cells and
pDC) and their prominent induction of IFN-alpha and IP-10 secretion
in vitro. EnanDIM744, an EnanDIM581 variant with additional 5’-end
L-nucleotide protection, was also used for MFD studies. Safety assess-
ments throughout the study revealed no signs of toxicity despite the
extremely high doses (300 to 1700 mg/kg). A gross necropsy consist-
ing of a macroscopic organ evaluation at day 15 also revealed no ab-
normalities. Dose-dependent increase of IP-10 levels in serum was
observed between 6 and 24 hours after injection but none after
15 days, confirming that L-nucleotides in EnanDIM® do not alter the
kinetic profile known from other TLR9 agonists. First data from the
CT26 tumor model showed that EnanDIM532 reduces tumor growth
and prolongs survival of mice.
Conclusions
EnanDIM®, a new family of TLR9 agonists, broadly activates the im-
mune system. Even maximal feasible doses of EnanDIM® resulted in
no signs of toxicity, whereas a reduction of tumor growth was ob-
served in a murine CT26 tumor model. Therefore EnanDIM® com-
pounds have the potential for clinical development as immune
surveillance reactivators in the treatment of cancer.
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Background
In the past, antigen-armed antibodies have been used in cancer immuno-
therapy. Recently, Yu et al.[1] efficiently delivered Epstein-Barr virus (EBV)
antigens to lymphoma cells by targeting B cell surface receptors. How-
ever, they only obtained CD4+ T cell activation, as externally introduced
proteins enter the MHC class II antigen processing pathway. Here, we
generated antibody-targeted pathogen-derived peptides (ATPPs), which
deliver and release mature, virus-derived MHC class I peptides in an
endosomal compartment where MHC is loaded with peptide, thereby
triggering CD8+ T cell activation and tumor cell killing.
Methods
We generated antigen-armed antibodies called ATPPs, by coupling
virus-derived MHC class I peptides to tumor-associated antigen-
specific antibodies. Fluorescence resonance energy transfer (FRET)
was performed to demonstrate the supposed mode of action. T cell
activation and tumor cell killing was assessed by quantification of
interferon-gamma or lactate dehydrogenase (LDH) release. Human
PBMCs or expanded peptide-specific T cells were used as effector
cells for in vitro functionality assays and in vivo efficacy in MDA-
MB231 breast cancer subcutaneous xenograft model.
Results
FRET Imaging revealed that after ATPP binding to the antigen and
subsequent internalization, the peptides are released in an early
endosomal compartment and loaded onto recycling MHC class I
complexes. MHC-peptide complexes are subsequently presented on
the tumor cell surface and mediate activation of peptide-specific
CD8+ T cells. Treatment of various tumor types resulted in efficient ac-
tivation of peptide-specific CD8+ memory T cells and subsequent lysis
of target cells in vitro. Similar results were obtained when targeting dif-
ferent tumor antigens or using various peptides with differing HLA-
restrictions. Intriguingly, a 7200-fold higher amount of free peptide ver-
sus ATPP was required for comparable T cell activation. Using an elon-
gated peptide that would require antigen processing for MHC class I
binding revealed that the MHC class I antigen processing machinery is
not involved. Importantly, PBMCs, where only 0.5 % of CD8+ T cells
were antigen specific, mediated significant tumor cell lysis at an E:T cell
ratio of 1:10. ATPP activated peptide specific CD8+ T cells induced
tumor growth inhibition in vivo.Conclusions
Our results demonstrate potent ATPP-mediated anti-tumor efficacy,
independently of the MHC class I antigen processing machinery, by
loading tumor cells with viral peptide antigens and redirecting virus-
specific cytotoxic T cells against cancer.
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Background
Mirvetuximab soravtansine (IMGN853) is an ADC, comprising a hu-
manized FRα-binding M9346A antibody linked to the tubulin-
disrupting maytansinoid, DM4. IMGN853 binds to FRα on cancer cells
and is internalized; DM4 is released through enzymatic degradation
of the antibody and linker cleavage, resulting in disruption of cell
division and cell death. IMGN853 shows promising single-agent activ-
ity and a favorable safety profile in FRα-positive ovarian cancer pa-
tients in a phase I study. IMGN853 is entering FORWARD I, a phase III
monotherapy study and is also being evaluated in combination with
other agents including pembrolizumab in a phase Ib/II study, FOR-
WARD II. Here we have explored potential mechanism(s) whereby
IMGN853 can show enhanced activity in combination with a check-
point inhibitor. Specifically, we report pre-clinical studies that exam-
ine the impact of IMGN853 treatment of tumor cells on human
monocytes in vitro.
Methods
Peripheral blood mononuclear cells (PBMC) from normal donors were
incubated with FRα-expressing KB tumor cells in the presence of test
articles for two days. PMBC were then analyzed for activation marker
expression by flow cytometry. The level of immunogenic cell death
markers were evaluated by flow cytometry or ELISA to examine the
direct impact of IMGN853 on KB cells.
Results
IMGN853 treatment of PBMC did not affect monocytes. Incuba-
tion of PBMC with KB cells decreased the CD86+ monocytes
from ~30 % to ~10 %, and addition of DM4, the free payload
of IMGN853, reversed the CD86 expression to basal levels. Intri-
guingly, addition of IMGN853, but not non-targeting ADC, in-
creased the activated monocytes to ~80 %. Similar results were
obtained with isolated CD14+ monocytes, indicating that the
monocyte activation is independent of other types of peripheral
blood cells. Additionally, comparable increases in monocyte acti-
vation were observed in co-cultures of monocytes and KB cells
treated with a mixture of M9346A and DM4, and not with
M9346A or DM4 alone, suggesting both components of the
ADC are necessary. Furthermore, a variant of IMGN853 with a
point mutation that abrogates the FcγR binding only produced
the same degree of monocyte activation as DM4 treatment,
suggesting the significance of Fc/FcγR interaction. Finally, treat-
ment of KB cells with IMGN853 increased calreticulin, ATP and
HMGB1, three immunogenic cell death markers which can acti-
vate monocytes.
Conclusions
Treatment of FRα-expressing KB cells with IMGN853 induces activa-
tion of co-cultured monocytes through Fc/FcγR interaction and up-
regulation of immunogenic cell death markers. These data provides a
rationale for the clinical evaluation of IMGN853 and a checkpoint
inhibitor.
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Background
Monoclonal antibodies coupled to highly toxic agents or ADC
(antibody-drug conjugate) are becoming a significant component
of anticancer treatment. Currently approved immunoconjugates
are heterogeneous in terms of degree of substitution, which is
suboptimal both in terms of antitumor efficacy and risk of tox-
icity. The aim of this project is to bring the in vivo proof of con-
cept of a novel immunoconjugate technology using a unique
enzymatic coupling of the payload on a substrate for an enzyme
site inserted in the antibody core. These enzyme substrates are
small unnatural and innovative peptide (patent pending). The
major advantage of this method named CovIsoLink™ is to obtain
a homogenous immunoconjugate with uniform stoichiometry by
controlling: (a) the location of coupling sites on the antibody
without affecting its immunoreactivity and (b) the number of
molecules coupled per molecule of antibody by controlling the
coupling drug antibody ratio (DAR) and consequently the toxicity
and efficacy of therapeutic molecules.
Methods
Using an in house peptide library, and the transglutaminase col-
orometric assay, we identified selected tag peptides that were
recognized as glutamine donor substrates with improved affinity
compared with the known peptides (such as ZQG, LLQG, etc.). As
a proof-of-concept, we compare our CovIsolink immunoconju-
gates with Kadcyla® (targeting HER2) recently approved.
Results
We developed and characterized different recombinant anti Her2
IgG1 mAb carrying optimized enzymatic substrate (tag) by gen-
etic insertion in the coding sequence of mAb. We then evaluate
the best linkers and conformation to incorporate different com-
pounds through bacterial transglutaminase (mTG) enzymatic reac-
tion. We set up experimental conditions, production, purification,
HPLC/MS analysis and control of the immunoreactivity of CovIso-
Link™ Her2-ADC. Using mTG, we obtained site specific conjuga-
tion of different modified drugs with optimized linker on the
antiHer2 IgG1 antibody. By HIC analysis, we validated a specific
and reproducible DAR reaching DAR2 depending on drugs and
experimental conditions. In vitro and In vivo characterization and
dose response studies of CovIsolink-ADC specificity and reactivity
are currently performed in Her2 positive models by comparison
with Kadcyla (T-DM1).
Conclusions
This technology is potentially applicable to a large variety of anti-
tumor (or anti-stromal) antibodies since it is neither limited by
the specificity of antigen targeted by the antibody nor by drugs
that can be engrafted. Site specific conjugation will allow to re-
move barriers for the use of molecules that are too toxic in sys-
temic injection or to enhance the efficacy of antibodies with low
anti-tumor activity.
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Background
Hepatocellular carcinoma (HCC), a hypervascular tumor, one of the
most cancers worldwide, it causes the cancer related mortality. Hep-
atic inflammation and oxidative stress plays an important role in the
development of HCC, which occur due to viral infections, environ-
mental carcinogens, dietary carcinogens as well as alcohol abuses.
We have found that gallic acid, a dietary flavonoids present in vari-
ous plants avoid diethyl nitrosamine (DENA) induced hepatic carcin-
oma in experimental rats through inhibit the oxidative stress and
repression of inflammation. The aim of the present study to investi-
gate the chemoprotective effect of gallic acid on hepatic cytokines in
the DENA induced carcinogenesis rats.
Methods
DENA (200 mg/kg) used for the induction of HCC in the Wistar rats.
The DENA treated rats were divided into different groups and re-
ceived the doses of gallic acid (25, 50 and 100 mg/kg) for 22 weeks
different biochemical alpha feto-protein (AFP), serum glutamate oxa-
loacetate transaminase (SGOT), serum glutamate pyruvate transamin-
ase (SGPT), alkaline phosphatase (ALP); hematological parameters
viz., red blood cells (RBC), white blood cells (WBC), hemoglobin (Hb),
erythrocytes sedimentation rate (ESR); antioxidant markers viz., lipid
peroxidation (LPO), superoxide dismutase (SOD), catalase (CAT), re-
duced glutathione (GSH); inflammatory mediators viz., tumor necrosis
factor-α (TNF–α), interlukin-6 (IL-6) and interlukin-1α (IL-1α) were
estimated.
Results
DENA induced rats received the different doses of the gallic acid at
dose dependent manner until 22 weeks. The hepatic serum, antioxi-
dant markers and hematological parameters significantly (P < 0.001)
altered at effective dose dependent manner. The level of proinflam-
matory cytokines viz., TNF-α, IL-6 and IL-1α significantly altered by
the gallic acid at dose dependent manner. The histopathology study
showed from the test group exhibited almost normal architecture as
compared to HCC control rats.
Conclusions
It can be concluded that gallic acid mediated chemoprotective effect
of DENA induced hepatocarcinogenesis is related to alteration of oxi-
dative stress as well as proinflammatory cytokines.
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Talimogene laherparepevec (T-VEC) is an engineered oncolytic her-
pes simplex virus, type 1 (HSV-1) encoding GM-CSF that has been ap-
proved for treating melanoma. Oncolytic viruses may preferentially
replicate in cancer cells due to defects in oncogenic signaling path-
ways that promote cell survival and allow time for more complete
viral replication and assembly by suppressing apoptotic machinery
including double-stranded RNA-dependent protein kinase (PKR). It is
thought that the MAPK pathway interacts with PKR, but the mechan-
ism is poorly understood. Since the MAPK pathway is frequently mu-
tated in melanoma cells, we sought to determine if mutations in
BRAF or NRAS might enhance T-VEC-mediated oncolysis. We further
sought to determine if BRAF or MEK inhibition might influence the
oncolytic potential of the virus.
Methods
Melanoma cell lines were selected for BRAF, NRAS, and other mu-
tations for evaluation. The cells were plated in 96 well plates (104
cells/well) and treated with a range of T-VEC doses (MOI of 1–
0.001). Cell viability was assessed by the AlamarBlue assay. After
establishing baseline viability results, cells were concurrently
treated with T-VEC and MEK inhibitors (trametinib or PD0325901
at doses 100nM-1nM) or BRAF inhibitor (vemurafenib, 100nM-
1nM) and cell viability determined by AlamarBlue assay. For
in vivo viral propagation, NSG mice were challenged with SK-
MEL-28 (5x106) at day 0. Mice were treated with T-VEC (3x106
PFU) and/or trametinib (0.3 mg/kg) on day 10 and day 12. Tu-
mors were harvested (day 17) and viral load was determined by
immunoblotting for HSV-1 glycoprotein D. Statistical comparisons
between treatment groups were determined using the Student’s t
test with P < 0.05 being considered statistically significant.
Results
All cell lines were highly susceptible to lysis by T-VEC although this
effect was reduced when the MOI was decreased to 0.001 for most
cells. There was no correlation between BRAF or NRAS mutation sta-
tus and cell viability at tested doses. There was also no effect of
vemurafenib on cell viability following T-VEC infection. However,
treatment with the combination of T-VEC and trametinib significantly
increased cancer cell death (P < 0.01). A similar effect was seen with
a second MEK inhibitor (PD0325901; P < 0.001).
Conclusions
The combination of T-VEC with MEK inhibition resulted in enhanced
in vitro tumor cell killing and viral propagation. Combining MEK in-
hibitors with T-VEC represents an attractive therapeutic option and
further studies are needed to understand if oncolytic viruses in vivo
might limit resistance to MEK inhibition.
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Background
The first oncolytic virus using an attenuated oncolytic herpes simplex
virus, type 1 (HSV-1) encoding GM-CSF, called talimogene laherpare-
pevec (T-VEC) has been approved for the treatment of accessible and
unresectable melanoma. T-VEC enters tumor cells through Nectin cell
surface receptors and results in cell lysis and induction of anti-tumor
immunity. We previously identified MART-1-specific CD8+ effector T
cells within the tumor microenvironment of T-VEC-treated lesions but
the contribution of viral-specific T cell responses to the anti-tumor
activity following T-VEC treatment has not been reported. To deter-
mine if there might be a role for HSV-1-specific T cells, we developed
a murine-adapted model in which the complete T-VEC backbone was
used with the substitution of murine GM-CSF (mTVEC) in place of thehuman gene. We hypothesized that anti-viral T cell responses might
contribute to the anti-tumor activity.
Methods
C57/BL6 mice were challenged with B16-nectin (105) tumor cells on
the right and left flank (day 0). mTVEC (3*106 PFU) was injected into
the right flank tumor (day 7). Tumor growth was monitored every 2–
3 days by caliper measurement. Tumors were harvested at various
times and analyzed by flow cytometry for NK cells, antigen-
presenting cells, T cells, and activation markers. Antigen specificity
was determined using gp100 and HSV-1 glycoprotein B tetramers.
Statistics were determined using the Student’s t test with P < 0.05 be-
ing considered statistically significant.
Results
mTVEC resulted in significant regression of injected, right flank tu-
mors with minimal effects on the growth of un-injected, left flank tu-
mors (P < 0.0001). We observed a significant increase in tumor
immune infiltration into the injected lesion, with a lower number of
immune cells in the un-injected sites (P < 0.01). The pattern and the
timing of immune infiltration mimicked that of acute viral infection
with an initial infiltration of NK cells and antigen-presenting cells
followed by infiltration of HSV-1 gB-specific CD8+ T cells that peaked
at day 7 post injection. Additionally, we observed that HSV-1-specific
CD8+ T cells trafficked to un-injected lesions. In this model, gp100 T
cell responses were not detected.
Conclusions
Our data indicate that oncolytic HSV-1-GM-CSF mediates anti-tumor
therapeutic responses in a mouse model of melanoma, treatment in-
duces a typical anti-viral innate and adaptive immune response, and
HSV-1-specific T cells can be generated and traffic to both injected
and un-injected tumors. These data suggest that anti-viral T cell re-
sponses may contribute to the anti-tumor effects of HSV-1-based
oncolytic virus immunotherapy.
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Background
Oncolytic vaccinia viruses (VV) have shown antitumor activity in early
phase clinical studies but few patients have been cured, likely due to
the inability of VVs to kill all tumor cells. Tumor-associated macro-
phages (TAMs) are key in creating an immunosuppressive tumor
microenvironment. However, recent studies have shown that the
phagocytic capacity of TAMs can be harnessed to induce antitumor
responses by blocking CD47 and providing a phagocytosis signal
using a chimeric molecule composed of the high-affinity ectodomain
of SIRPα fused to IgG4 Fc (SIRPα-Fc). We propose to adapt this ap-
proach to oncolytic VVs and hypothesize that an oncolytic VV genet-
ically modified to express SIRPα-Fc (SIRPα-Fc-VV) has enhanced
antitumor activity.
Methods
To initially evaluate our strategy we genetically modified CD47+
tumor cells (OV10.315, MC38, Raji) with lentiviral vectors encoding
SIRPα or SIRPα-Fc.
Results
In vitro, OV10.315.SIRPα-Fc cells were readily phagocytosed by
M1 and M2 macrophages in comparison to OV10.315.SIRPα and
non-transduced (NT) OV10.315 cells (p < 0.05). In vivo, Raji.SIRPα-
Fc cells had decreased tumorigenicity in comparison to Raji.-
SIRPα and NT Raji cells post IV injection in NSG mice resulting
in a significant survival advantage (p < 0.05). 4/5 C57BL/6 mice
rejected MC38.SIRPα and MC38.SIRPα-Fc cells post SC injection
in contrast to 0/4 NT MC38 cells (p < 0.05). Having established
that SIRPα-Fc expression in tumor cells has the desired thera-
peutic effect, we generated VVs encoding either SIRPα or SIRPα-
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Fc-VV had similar oncolytic activity compared to parental VV
(VSC20). The expression and secretion of SIRPα and SIRPα-Fc
was confirmed by FACS analysis. In co-culture assays, only
SIRPα-Fc-VV was able to induce M1 and M2 macrophage killing.
Based on our encouraging in vitro experiments, we have initi-
ated in vivo studies to test the safety and efficacy of SIRPα-Fc-
VV in the MC38 C57BL/6 model.
Conclusions
We demonstrate here that tumor cells secreting SIRPα-Fc are
readily phagocytosed by M1 and M2 macrophages and have re-
duced tumorigenicity in xenograft and immune competent animal
models. In addition, SIRPα-Fc-VVs readily infect tumor cells and
induce phagocytosis by macrophages. Thus, arming oncolytic vi-
ruses such as VVs with SIRPα-Fc has the potential to improve
their antitumor activity.
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Background
Oncolytic viruses (OVs) are characterized by their ability to select-
ively infect and kill tumor cells. More recently they have been
exploited for their capacity to be encoded with, and locally de-
liver, a variety of payloads including immunotherapeutic trans-
genes to enhance immune responses against the tumor. Viral
properties of OVs may also be able to engage the innate im-
mune system and thus influence the suppressive nature of the
tumor microenvironment. A better understanding of these inter-
actions may help guide both the rational design of ‘armed’ vi-
ruses as well as the design of strategies for combining with
other immunotherapies. Enadenotucirev (EnAd) is a chimeric
Ad11/Ad3 group B oncolytic adenovirus under development for
the systemic treatment of metastatic carcinomas. Unlike the
group C virus Ad5, EnAd does not bind to cells via the CAR re-
ceptor but instead uses CD46 which is expressed by innate im-
mune cells.
Methods
We have been evaluating the effect of EnAd on innate immune re-
sponses using in vitro immature human monocyte-derived dendritic
cells (DC) as a model suppressive phenotype APC.
Results
EnAd induced up-regulation of surface activation markers and
induced the production of pro-inflammatory cytokines. Further
mechanistic experiments, comparing the effects of EnAd to
those of Ad5 indicated that the activation was selective for
EnAd, was particle-mediated and dependent on CD46 binding.
In order to understand the functional implications downstream
of these interactions, T cell activation and phenotype was
assessed using an allogeneic mixed lymphocyte reaction ap-
proach. EnAd-treated DCs selectively stimulated stronger T cell
responses, including enhanced IFNg production. The data sup-
ports EnAd as a good candidate OV for steering the response
of T cells activated within the tumor towards a Th1 phenotype
for enhanced effector responses.
Conclusions
Thus, as well as its potent oncolytic properties, EnAd particles
may also function in the tumor microenvironment to help drive
functional adaptive immune responses by inducing pro-
inflammatory phenotype APCs, which should also synergize ef-
fectively with other immunotherapy strategies.P310
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Background
CD40-CD40L signaling is a powerful pathway that can be used in
cancer immunotherapy. CD40 stimulation of immune cells drives a
Th1 anti-tumor response but CD40 stimulation on tumor cells can
lead to enhanced tumor cell apoptosis. This is due to the up-
regulation of FASL, tumor necrosis factor alpha (TNFα), and TNF-
related apoptosis-inducting ligand (TRAIL) on tumor cells after CD40-
CD40L interaction. Also, CD40 signaling in tumor cells can induce ac-
tivation of caspases through the binding of TRAF 2. LOAd viruses are
oncolytic adenoviruses that encode a trimerized form of CD40L
(TMZ-CD40L) alone (LOAd700) or in combination with 4-1BBL
(LOAd703). In the current study, the role of CD40L on CD40+ tumor
cells has been elucidated.
Methods
The cell viability post virus infection of CD40+ T24 tumor cells was in-
vestigated in vitro by MTS assay. To further investigate the cell death in-
duced by CD40L signaling apart from oncolysis due to LOAd virus
infection, monocyte-derived dendritic cells were infected with LOAd(−)
and LOAd700 and then co-cultured with T24 cells. Apoptosis induction
was investigated at 48 hours post co-culture initiation by flow cytome-
try for Annexin V and 7-AAD. In a T24 xenograft model using Nu/Nu im-
munodeficient mice, LOAd viruses expressing human TMZ-CD40L that
does not cross-react to murine CD40 was used (6x) to evaluate in vivo
efficacy. LOAd(−) was used as a control of growth control by oncolysis
and PBS-treated controls determined normal growth rate.
Results
The LOAd viruses induced oncolysis of the CD40+ urinary bladder
cancer T24 cell line independently of transgene expression. However,
infected T24 showed a significant decrease in cell viability after infec-
tion with TMZ-CD40L-expressing LOAd700 compared to LOAd(−). Co-
culture of LOAd-infected dendritic cells expressing TMZ-CD40L or not
with T24 led to an increased induction of apoptosis when co-
cultured with dendritic cells expressing TMZ-CD40L. In vivo, both
LOAd(−) and LOAd703 treatment led to a decreased tumor growth
compared to PBS-treated animals. When TMZ-CD40L was expressed
(e.g. LOAd703), tumor control was faster and at end point, only 1/5
animals had tumor growth compared to 3/5 in the LOAd(−)-treated
group, demonstrating the additional growth control by CD40-
induced tumor cell death. Models with CD40- tumor cells (Panc01,
H727, SKOV3) responded similarly to control virus and virus express-
ing TMZ-CD40L.
Conclusions
Oncolytic viruses encoding TMZ-CD40L have an increased killing cap-
acity via CD40L-mediated killing of CD40+ tumor cells.
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Immunotherapies aim to break the tolerance of immune cells seen in
cancer patients and redirect the response from a pro-tumor to an
anti-tumor response. There are many ways to achieve anti-tumor im-
munity, for example by stimulation of immunostimulatory pathways.
CD40L interactions with its receptor CD40 on dendritic cells leads to
maturation of these cells and polarization towards a Th1 response.
CD40L can also reduce the level of myeloid suppressor cells and M2
macrophages as well as induce apoptosis in CD40 positive tumor
cells. 4-1BB ligand (4-1BBL) interactions with its receptor 4-1BB on T
cells leads to activation and survival of the cells and can expand
memory T cells. Herein, we present an oncolytic adenovirus with a
CMV-driven transgene cassette containing the human transgenes for
a trimerized, membrane-bound CD40 ligand (TMZ-CD40L) and the
full length 4-1BBL.
Methods
Pancreatic cell lines and exocrine cells from healthy donors were in-
fected with LOAd703 and analyzed for cell death 48 and 72 hours
post-infection with MTS-assay. Immunodeficient mice with estab-
lished human Panc01 tumors were treated twice a week for three
weeks and evaluated for tumor size. Both the in vitro and in vivo ex-
periments were repeated in combination with gemcitabine. Dendritic
cells were infected with the virus and evaluated by flow cytometry
and ProSeek. The dendritic cells were also pulsed with CMV peptides
and co-cultured with autologous CD14- cells to investigate the ex-
pansion of CMV+ T cells by flow cytometry.
Results
LOAd703 decreased the viability of pancreatic tumor cells at both
48 hours and 72 hours as compared to cells infected with a non-
replication competent virus but spared healthy exocrine cells. Mice
treated with LOAd703 had a decreased tumor burden compared to
PBS treated animals. LOAd703 could be successfully combined with
gemcitabine without any negative effects on oncolysis both in vitro
and in vivo. Dendritic cells infected with LOAd703 showed a mature
phenotype with expression of CD83, CD86, and secretion of cyto-
kines, chemokines including IL12p70 and IFNγ. The dendritic cells
were also functional and could expand antigen-specific CMV+ T cells
and NK cells.
Conclusions
In conclusion, LOAd703 is a novel oncolytic virus that targets both
the tumor with oncolysis and the immune system with Th1 type re-
sponse from dendritic cells and an expansion of antigen-specific T
cells. The next step is to bring the virus from the lab bench to the
bedside in a clinical trial to elucidate its effect in pancreatic cancer
(NCT02705196).
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Background
The tumor microenvironment supports the tumor cells. In pancreatic
cancer, stellate cells, immune cells and extracellular matrix compose
the majority of the lesions and create a condition referred to as des-
moplasia. IL6 drives STAT3 activation leading to transforming growth
factor (TGF) beta and collagen type 1 production. TGF beta also pro-
motes immunosuppression by inhibition of T cells and expansion of
T regulatory cells (Tregs). Hence, IL6, which is overexpressed in pan-
creatic cancer, is one of the regulators of desmoplasia. Further, IL6 is
associated to poor prognosis of pancreatic cancer. In order to target
both IL6 and induce immune activation, the oncolytic adenovirus
LOAd713 was developed. It is double-armed with an anti-IL6 receptor
antibody single chain fragment (aIL6R scFv) aiming to disrupt IL6signaling and a trimerized membrane-bound CD40 ligand (TMZ-
CD40L) that drives Th1 immunity.
Methods
LOAd713 is an Ad5/35 virus that replicates only in cells with a dys-
functional retinoblastoma pathway (E1Adelta24). Further, the sero-
type 5 fiber was changed to a serotype 35 fiber to target CD46
expressed by most tumors. A CMV-driven transgene cassette with
the transgenes for TMZ-CD40L and aIL6R scFv was added into the
genome. The activity of LOAd713 was evaluated by 1) infecting pan-
creatic tumor cell lines and evaluating their viability in a MTS cyto-
toxicity assays (oncolysis), 2) by infecting human dendritic cells (DC)
and performing phenotypic assays by flow cytometry, cytokine arrays
and lymphocyte stimulation assays (immune activation), and 3) by in-
fecting pancreatic stellate cells and investigating biological changes
in a proteomic analysis (ProSeek).
Results
LOAd713 had oncolytic capacity in a panel of pancreatic cancer cell
lines as shown by the viability analysis post infection while pancre-
atic stellate cells infected with LOAd713 did not lose viability. How-
ever, LOAd713 significantly decreased the expression of hepatocyte
growth factor (HGF), TGF beta, fibroblast growth factor-5 (FGF-5) and
collagen type I, all connected to stellate cell function and desmopla-
sia. Nevertheless, LOAd713-infected stellate cells increased their ex-
pression of IL1 alpha, IL6, IL8, CXCL10 and CCL20, which may both
promote angiogenesis and attract lymphocytes. LOAd713-infected
DCs showed an increased level of maturation markers such as CD83
and IL12 as shown by flow cytometry and luminex methodology,
and such DCs could expand antigen-specific T cells.
Conclusions
LOAd713 is an oncolytic adenovirus aiming to interrupt the IL6/IL6R
pathway resulting in reduced factors that drive desmoplasia. Further,
via TMZ-CD40L, LOAd713 can activate DCs to drive lymphocyte
responses.
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Background
The oncolytic herpes virus talimogene laherparepvec (T-VEC), engi-
neered to express GM-CSF, is the first oncolytic virus approved for
treatment of cancer in the US. T-VEC treatment increases median
overall survival (OS) in patients with locally advanced and metastatic
melanoma; however, a majority of treated patients still progress on
this therapy. Radiation therapy (RT) in combination with immuno-
therapies has been shown to improve response rates in melanoma
(compared to either modality alone) and may exhibit different cyto-
toxic and immunoloregulatory effects on tumors than T-VEC. There-
fore, we hypothesized that combination RT and T-VEC may represent
a potentially synergistic therapeutic approach and investigated the
effect of this combination.
Methods
Human melanoma cell lines cultured in 96-well plates (7x103 cells
per well) were treated in triplicate with RT (0, 4, or 8 Gy) delivered
via the Gammacell 40 exactor. Twelve hours later the cells were fur-
ther treated with T-VEC (0, 0.01, 0.1, and 1 MOI) for 60 hours. The ef-
fects of RT and T-VEC were determined by AlamarBlue cell viability
assay performed 72 hours after initial treatment. A P value < 0.05 ob-
tained using the Student’s t test was considered to denote a statisti-
cally significant difference between groups.
Results
Treatment of UACC62 melanoma cells with T-VEC (1 MOI) alone re-
sulted in a 12 % decrease in cell viability compared to no treatment
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 168 of 221(P < 0.013), while treatment with RT (8 Gy) did not result in a signifi-
cant decrease (2.1 %, P = 0.42). However, combination RT (8 Gy) and
TVEC (1 MOI) resulted in a significant decrease in cell viability (21 %,
P < 0.001) compared with no treatment. This likewise represented a
significant decrease compared to RT alone (p = 0.0028) or T-VEC
alone (p = 0.0389). Similar findings were noted in experiments utiliz-
ing other melanoma cell lines.
Conclusions
Treatment with combination RT and T-VEC results in an in vitro de-
crease in melanoma cell viability. Further studies are needed to
understand the mechanism underlying the reported synergy, the ef-
fect of radiation on viral propagation, the effect of viral replication
on radiation sensitivity, and whether this approach can be used in
patients resistant to either modality alone or to other single and
combination immunotherapies. Studies assessing this combination
therapy in other solid tumors and in pre-clinical in vivo immune-
competent autologous double-humanized mouse models are cur-
rently underway.
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Background
CAVATAKä is a novel bio-selected oncolytic, immunotherapeutic Cox-
sackievirus A21 (CVA21) strain. Intratumoral (i.t.) CAVATAKä injection
can induce selective tumor-cell infection, immune-cell infiltration, g-
INF response gene up-regulation, increased PD-L1 expression, tumor
cell lysis and systemic immune responses. Preclinical studies in an
immune-competent mouse model of melanoma have revealed that
combinations of i.t. CVA21 and anti-PD-1 blockade mediate signifi-
cantly greater antitumor activity compared to use of either agent
alone. The presented clinical trial evaluates combination CAVATAKä
and pembrolizumab based on increased expression of PD-L1 follow-
ing virus administration and higher response rates of pembrolizumab
in patients with increased tumor PD-L1.
Methods
This is a phase I trial of i.t. CVA21 and pembrolizumab for treated or
untreated unresectable Stage IIIC-IVM1c melanoma. Patients receive
up to 3 x 108 TCID50 CVA21 i.t. on days 1,3,5,8 and 22, and then
every 3w for up to 19 injections. Patients also receive pembrolizu-
mab (2 mg/kg) i.v. every 3w starting day 8. The primary endpoint is
safety/tolerability by incidence of dose-limiting toxicity. Secondary
endpoints include response rate, immune-related progression-free
survival at 12 m, PFS hazard ratio, 1y and overall survival. In addition,
quality-of-life, time to initial response, durable response rate, changes
in melanoma-specific T cells, PD-L1 expression and Th1/Th2 gene ex-
pression profiles, will be determined. Safety will be assessed using NCI
CTCAE. Response will utilize Simon's two-stage design. In the first stage,
12 subjects will be accrued. If 2 or fewer responses occur within 12 m
of starting treatment, the study will be stopped due to futility of treat-
ment. Otherwise, 18 additional subjects will be accrued.
Results
To-date, 10 subjects have been enrolled with one patient leaving the
study with PD and another patient with a non-treatment-related
adverse event. Overall, adverse events have generally been low-
grade constitutional symptoms related to CVA21 and standard
pembrolizumab-related side effects. Preliminary observations have
revealed reduction in a number of injected and non-injected lesions,
with a number of patients displaying evidence of post-injection sys-
temic exposure to CVA21.Conclusions
At present combination CVA21 and pembrolizumab appears to be
generally safe and well-tolerated in an interim analysis of patients
with advanced melanoma. Early analysis identified reductions in a
number of injected and non-injected lesions and we look forward to
evaluating a more mature overall response data set. Combination
CVA21 and pembrolizumab may represent a new approach for the
treatment of advanced melanoma.
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Background
Toca 511 (vocimagene amiretrorepvec) is a gene therapy which
utilizes a gamma retroviral replicating vector encoding cytosine de-
aminase to selectively infect cancer cells. When used in combination
with the prodrug, 5-fluorocytosine (5-FC), Toca 511 and 5-FC kill
tumor cells by local production of 5-fluorouracil (5-FU), and induce a
local immunotherapeutic effect that results in long-term survival after
cessation of 5-FC treatment. The work described herein identifies the
immune cell populations that change over time following administra-
tion of 5-FC as well as the role of T cells in long-term anti-tumor im-
mune memory.
Methods
A mouse glioma cell line, Tu-2449SC (2 % pretransduced with
Toca 511) was injected subcutaneously in B6C3F1 mice. 5-FC
(500 mg/kg, IP, SID) or PBS treatment was initiated once tumors
were palpable, for 5 consecutive days followed by 2 days off
drug. This treatment cycle was continued for the duration of the
study. At 3, 6, 9, and 14 days after 5-FC start, tumors were har-
vested for immunophenotyping.
Results
Tumor burden was significantly reduced within 14 days of treatment
in mice that received 5-FC vs. PBS control. By day 6 post 5-FC treat-
ment initiation, tumor associated macrophages (TAM), myeloid de-
rived suppressor cells (MDSC), and monocyte populations were
significantly reduced in treated tumors compared to PBS controls.
This myeloid cell depletion effect correlates with previous work by
others [1] using systemic 5-FU but was complemented by an attract-
ive pharmacokinetic profile with high levels of 5-FU in tumor tissue
and undetectable levels of 5-FU in the plasma, thus avoiding
systemic myelotoxicity. At 14 days post 5-FC treatment start, TAM
and MDSC remained reduced in tumors of treated animals, and both
CD4+ and CD8+ T cells were significantly increased. Additionally we
noted that treatment with 5-FC induced high expression of IFNγ in
CD8+ T cells and polarized CD4+ T helper cells away from Th2 and
Th17 differentiation pathways. Tumors were completely cleared from
greater than 50 % of animals treated with 5-FC and such animals
resisted subsequent rechallenge at a distant site with the virus-free
parental cell line. Further, adoptive transfer of splenocytes from these
cured and now immunized animals led to clearance of established,
orthotopic Tu-2449 tumors in recipient naïve animals as long as the
donor cell transfer contained T cells.
Conclusions
Toca 511 + 5-FC treatment results in reduced tumor burden and cre-
ates a tumor microenvironment that is more permissive to immune
activation and ultimately establishment of anti-tumor immune
response.
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Background
The immune system is both friend and foe to oncolytic viruses (OV). It
is a friend because OV rely on anti-tumor cytotoxic T lymphocytes (CTL)
for a major component of their clinical efficacy. It is a foe because CTL
that recognize viral antigens can kill infected cells. This blocks viral
spread by terminating in situ viral progeny production. In this way, anti-
viral CTL limit the number of virally killed cancer cells and blunt induc-
tion of tumor neo-antigen CTL necessary for achieving durable patient
responses. BeneVir’s T-Stealth™ OV arming technology blocks display of
viral antigens on the surface of infected cells. This promotes viral
spread and persistence in the tumor microenvironment because it ren-
ders infected tumor cells invisible to anti-viral CTL. By evading anti-viral
CTL, T-Stealth™ armed OV kill more cancer cells in the context of an in-
flamed tumor microenvironment resulting in enhanced induction of
anti-tumor CTL. T-Stealth™ armed OV are designed to combine espe-
cially well with immune checkpoint inhibitors (ICI). This is because ICI
facilitate both anti-tumor as well as anti-viral CTL effector function in
the tumor microenvironment and exacerbate the friend vs. foe dy-
namic between OV and the immune system.
Methods
We generated an attenuated, replication competent HSV-1 OV encod-
ing T-Stealth™ technology as well as viruses that do not encode T-
Stealth™ technology or encode murine GM-CSF. These viruses were
tested for their ability to control the growth of both virally infected as
well as uninfected tumors in multiple syngeneic murine tumor models.
Results
Compared to control viruses that do not encode T-Stealth™ technol-
ogy or express murine GM-CSF, the T-Stealth™ armed OV persisted
longer in the tumor microenvironment and enhanced the generation
of anti-tumor CTL. Simultaneous treatment of mice with the T-
Stealth™ armed HSV-1 and ICI against PD-1 and CTLA-4 yielded syn-
ergistic results in an aggressive bi-lateral murine tumor model. De-
tailed analysis of lymphocytes in untreated distant tumors revealed
that the T-Stealth™ armed HSV-1 induces greater infiltration of CD8+
CTL and significantly increases TCR diversity.
Conclusions
T-Stealth™ technology allows OV to resist premature clearance by anti-
viral CTL. Because ICI enhance the ability of anti-viral CTL to clear OV
from the tumor microenvironment, T-Stealth™ armed OV hold great
promise for synergism with ICI in simultaneous combination regimens.
The first T-Stealth™ armed OV is currently undergoing cGMP manufac-
turing and a phase I trial in solid tumors will commence in late 2017.
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Several strategies are being evaluated to activate the anti-tumor
immunity for combinations with checkpoint blockade. Among
these agents, viruses are promising for their natural immunogen-
icity and the interferon gamma response they induce. Many
different viruses are being tested in the clinic as tumor vaccina-
tions, and preliminary clinical data suggests that a local virus vac-
cination can induce a cellular anti-tumor response. However,
virus-induced anti-tumor responses seem to be a rare exception,
likely due to the initial host response to the virus overwhelming
the initiation of any meaningful responses directed against tumor.
Means to divert the immune response from virus towards tumor
are needed to fully exploit the potential of viruses to activate
clinically relevant anti-tumor immunity.
Methods
PeptiCRAd is an oncolytic adenovirus vaccine platform where
MHC I-restricted immunogenic tumor peptides, that have been
modified to become positively charged, are adsorbed onto the
negatively charged viral capsid via electrostatic interactions. We
used the classical proof-of-concept SIINFEKL peptide (the chicken
ovalbumin model) as well as clinically relevant human melanoma
peptides complexed with an oncolytic adenovirus, and analyzed
the characteristics and efficacy of our approach in different
in vitro and immunocompetent in vivo models of murine and hu-
man melanoma.
Results
Our results clearly show that PeptiCRAd is superior to oncolytic
virus or peptide vaccinations. Importantly, the adsorption of pep-
tides to the virus capsid is crucial, as virus in combination with
non-complexed peptides was significantly less effective than
PeptiCRAd. Treatment with PeptiCRAd resulted in clear growth re-
duction both in treated and distant tumors in aggressive im-
munocompetent melanoma tumor model. With PeptiCRAd
approach the peptides were efficiently cross-presented in an
MHC I restricted manner and both the frequency of dendritic
cells cross-presenting the PeptiCRAd peptides and the frequency
of peptide-specific CD8+ T cells were clearly elevated in Pepti-
CRAd treated animals compared to virus alone or virus with non-
complexed peptide.
Conclusions
PeptiCRAd is a novel oncolytic vaccine platform which innovatively
combines adjuvant (virus) and tumor epitopes to enable a robust
anti-tumor immune response. This simple strategy rapidly and cost-
efficiently adapts to different tumors and antigens without the need
to manipulate the viral backbone. A phase I/II clinical trial is currently
under preparation.P318
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HF10, an attenuated, replication-competent mutant strain of herpes
simplex virus type 1 (HSV1), is a promising new oncolytic viral im-
munotherapy. HF10 (intratumoral injection) shows activity in injected
lesions and uninjected metastatic lesions. An ongoing phase II study
in melanoma patients (pts) is assessing whether the combination of
HF10 and the immune checkpoint inhibitor ipilimumab (ipi) en-
hances the antitumor effect of HF10.
Methods
Ipi naïve pts with stage IIIB, IIIC or IV unresectable melanoma were
enrolled. HF10 was administered intratumorally into single or mul-
tiple tumors (1x107 TCID50/mL, up to 5 mL/dose); 4 injections qwk;
then up to 15 injections q3wk. Ipi was administered intravenously
(3 mg/kg), q3wk for 4 doses. Tumor responses (irRC) were assessed
at 12, 18, 24, 36, and 48wks. Best Overall Response Rate (BORR) was
determined at 24wks. Serial peripheral blood and tumor biopsies
were obtained and analyzed for changes in cytokines, immune pro-
file and tumor microenvironment. Herein we present the safety, effi-
cacy, and preliminary correlative study results.
Results
In total, 46 pts were enrolled, of which 20 % were stage IIIB, 43 %
stage IIIC, and 37 % stage IV melanoma. Most HF10-related adverse
events (AEs) were ≤ G2, similar to HF10 monotherapy. No DLTs were
reported; 3 G4 AEs reported, all not treatment related. 30.4 % had G3
AEs. HF10-related G3 AEs (n = 3) were left groin pain, thrombo-
embolic event, lymphedema, hypoglycemia, and diarrhea. Of 44 effi-
cacy evaluable pts, preliminary BORR at 24 wks was 42 % and overall
study BORR including those after 24 wks was 50 % (20 % CR, 30 %
PR) with a disease control rate of 68 %. Of 15 evaluable stage IV pts,
8 (53 %) pts were responders. In 24 treatment naïve pts BORR was
58 % (21 % CR, 37 % PR) and in 20 pts who had failed ≥1 therapies,
BORR was 40 % (20 % CR, 20 % PR). Preliminary serial peripheral
blood analyses demonstrated in 75 % of responders a sustained ≥2
fold induction of the Th1 cytokines IFN-gamma and/or TNF-alpha
compared to baseline at day 0. In contrast, 12 % of non-responders
demonstrated similar induction. Future efforts will focus on compre-
hensive statistical analysis of T cell cytokine induction in response to
treatment, correlated to disease outcome.
Conclusions
Combination HF10 and ipi treatment is safe and well tolerated, with
promising responses in both treatment naïve and treatment failure
pts. Peripheral blood Th1 cytokine upregulation may be a potential
marker for response in HF10 + ipi treatment.
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Background
CAVATAK™, an oncolytic immunotherapy, is a bio-selected strain of
Coxsackievirus A21. Intratumoral (IT) injection of CAVATAK can in-
duce preferential tumor cell infection, cell lysis and enhancement of
a systemic anti-tumor immune response. The phase II CALM study
investigated the efficacy and safety of IT CAVATAK in 57 patients
(pts) with advanced melanoma resulting in a confirmed ORR of
28.1 % and DRR (>6 mths) of 21.1 %. Presented is an extension study
aimed at understanding the impact of CAVATAK on immune cell
infiltrates and immune checkpoint molecules within the tumor-microenvironment (TME) of treated lesions from advanced melanoma
pts referenced to tumor response.
Methods
In the CALM extension study a cohort of 13 advanced melanoma pts
received up to 3 x 108 TCID50 CAVATAK IT on study days 1, 3, 5, and
8 and then every three weeks for a further 6 injections. Sequential
tumor biopsies of injected lesions (study days 1 and 8) from 9 pts
were monitored for evidence of viral-induced changes to immune
cell infiltrates and checkpoint molecules being referenced to tumor
response.
Results
Of the 9 pts evaluable for tissue response assessment in this study,
CAVATAK-treated lesions from 6 pts displayed disease control (CR, PR
or SD), while injected lesions from 3 pts exhibited disease progres-
sion. Multi-spectral immunohistochemistry imaging revealed elevated
levels of immune cell infiltrates within the TME of lesions displaying
disease control (DC) compared to progressing lesions, in particular el-
evated levels of CD8+ cells and PD-L1+ cells. NanoString® RNA ana-
lysis of pre- and post-treatment biopsy samples identified significant
increases in the levels of immune checkpoint molecules, including
PD-L1, CTLA-4, IDO, TIM-3 and LAG-3 in lesions exhibiting DC com-
pared to progressing lesions. A similar differential pattern was ob-
served with respect to a number of immune modulation elements,
including interferon-induced and viral RNA response genes. Of not-
able interest was the preferential up-regulation in DC lesions of
CD122 (a component of the IL-2 receptor complex), which is postu-
lated to be a potential prognostic marker for anti-tumor activity by
anti-CTLA-4 blockade strategies. In addition, CAVATAK treatment initi-
ated the reconstitution of immune cell infiltrates in a number of le-
sions from pts failing previous immune-checkpoint blockade or other
immunotherapies.
Conclusions
The changes in TME induced by CAVATAK support combination ther-
apy with T cell checkpoints, especially anti-CTLA-4. There is an on-
going phase Ib study of CAVATAK + ipilimumab showing higher ORR
than anticipated with either agent alone supporting the continued
study of the combination.
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Background
Dendritic cell (DC) therapy is currently considered as a promising
cancer immunotherapy. Dendritic cells are considered as principal
initiators of the immune system. However, tumor induced immuno-
suppression impairs the biological function of DCs. Therefore, clinical
outcomes with DC therapy have often been disappointing. Interest-
ingly, oncolytic adenoviruses have good safety profile in humans.
They have been shown to activate immune responses by triggering
danger signals at the tumor site and enhancing the release of tumor-
specific antigens.
Methods
To achieve optimal activation of the transferred dendritic cells, we
armed adenoviruses with CD40 ligand (CD40L), best known for its
capacity to initiate multifaceted signals in dendritic cells, leading to
the activation of cytotoxic T cells. Therefore, we constructed a novel
virus Ad3-hTERT-CMV-hCD40L which features Ad3 for enhanced
tumor transduction, human telomerase reverse transcriptase (hTERT)
promoter for enhancing tumor selectivity and CD40L, a potent stimu-
lator of dendritic cells and to increase antitumor efficacy. The viral
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phate method. Then, HeLa cells were infected with the cell lysate
containing Ad3-GFP virus for further virus propagation. The function-
ality of the viruses is studied by infecting different cell lines with dif-
ferent amount of viral particles and measuring the proportion of
surviving cells with MTS assay. To deeply dissect if CD40L encoding
adenovirus can modulate the tumor microenvironment, we gener-
ated a murine version of the virus (Ad5/3-CMV-mCD40L).
Results
The major obstacle with oncolytic adenoviruses is suboptimal sys-
temic delivery, which is circumvented by using a fully Ad3 platform.
As human [1] and our animal data have shown, the ability of Ad3 to
successfully reach tumors is through the intravenous route. In syn-
geneic studies in immunocompetent model, DC therapy in combin-
ation with Ad5/3-CMV-mCD40L showed potent antitumor activity
and triggered significant antitumor immune responses. The improved
therapeutic effect by the adenovirus expressing CD40L and DCs com-
bination treatment correlated with increased numbers of tumor
infiltrating lymphocytes, induction of the T helper type 1 cytokines
IFN-gamma, RANTES, and TNF-alpha and the reduction of immuno-
suppression in the tumor stroma.
Conclusions
Our findings support the development of clinical trials where den-
dritic cell therapy is enhanced with oncolytic adenovirus.
References
1. Hemminki O, Diaconu I, Cerullo V, et al.: Ad3-hTERT-E1A, a Fully
Serotype 3 oncolytic adenovirus, in patients with chemotherapy
refractory cancer. Mol Ther 2012, 20:1821–1830.
Promoting and Measuring Anti-Tumor Immunity
P321
A multi-color natural killer-cell mediated cytotoxicity detection
using fluorescence and direct cell imaging
Tameem Ansari, Srividya Sundararaman, Diana Roen, Paul Lehmann
Cellular Technology Ltd, Shaker Hts, OH, USA
Correspondence: Tameem Ansari (tameem.ansari@immunospot.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P321
Background
The most essential role of effector immune cells such as CD8+ cells and
natural killer (NK) cells is to identify and lyse target cells. NK cell - and
antibody dependent cell cytotoxicity (ADCC) - has traditionally been
assessed by the release of radioactive chromium from target cells fol-
lowing lysis. These assays are laborious and require substantial quan-
tities of patient blood to detect minor changes in cell lysis. We have
previously developed an assay that can visualize individual target cells
to detect cytolytic activity within a high signal to noise range, without
involving radioactivity, via high-throughput imaging. In order to further
reduce the amount of cell material required and detect the effect of NK
cells on different target cell lines, we have now developed a multi-color
cytotoxicity detection assay.
Methods
The assay we developed images individual fluorescence-labeled target
cells. K562, A549 and T2 tumor cells were used as targets, and periph-
eral blood mononuclear cells (PBMC) as effector cells. When performing
the assay in 96 well format, the PBMC were plated in serial dilution be-
tween 500,000 and 7,500 cells per well with 5,000 target cells per well.
Four hours later, the number of viable tumor cells was quantitated
using a fluorescence capable ImmunoSpot® Analyzer or the radioactiv-
ity released was measured. For multi-color analysis, we stained three
different cancer cell lines (one of which had intact MHC receptors) with
three different dyes and incubated them in the same well with effector
to target ratios that match one cell line per well.
Results
The target cell visualization and chromium release assay in a 96-well
format required the same number of cells and the results were compar-
able to each other. While, expectedly, percentage of killing for different
donors was highly variable, the assay was highly reproducible for cryo-
preserved samples between multiple days and when performed bymultiple researchers. The results obtained via multi-color assessment
show that we can simultaneously detect the cytolytic effect of NK cells
on three different target cell types using only a third of the effector
cells as previously required. Also, the data show that control target cells
with MHC receptors are not susceptible to NK killing.
Conclusions
We have demonstrated the feasibility of assessing NK function in a
non-radioactive, high-throughput capable system which will benefit
clinical immune monitoring. The multi-color analysis should be of
particular value when access to PBMC is limited, such as in pediatric,
geriatric, and immune deficient populations.
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Background
Standard care for many types of cancer involves systemic administra-
tion of cytotoxic agents. This may result in low drug concentration at
tumor sites, which limits cell killing. More recently it has been shown
that cytotoxic formulations designed for intratumoral delivery improve
drug efficacy presumably by increasing drug concentration at the
tumor site. Furthermore, it has been revealed that the mechanisms of
anticancer agents extend beyond direct tumor cell lysis. One major as-
pect is that cell death often induces an immune response. Different
types of cell death such as necrosis and autophagy induced by cyto-
toxic agents trigger immune responses with varying degrees of inflam-
mation and involving different types of immune cells. The ideal
immune responses that may give maximum benefit to patients would
be strong and long lasting anti-tumor T cell responses.
Methods
In this study, a novel tissue and cell diffusive cytotoxic formulation,
INT230-6, was administered intratumorally over 5 sequential days
into subcutaneous 300 mm3 murine Colon26 tumors.
Results
Treatment resulted in regression from baseline of 100 % of the tumors
and up to 80 % complete response (CR). We then sought to analyze the
T cell responses in the protection induced by INT230-6. Mice with CR
were protected from re-challenge either by subcutaneous or intravenous
re-inoculation of the Colon26. The protection was abrogated by CD4/CD8
double depletion prior to the re-challenge, indicating that immunological
memory was induced. Colon26 tumors express the endogenous retroviral
protein gp70 containing the AH-1 CTL epitope. AH-1-specific CD8+ T cells
were detected ex vivo in systemic organs such as spleens and peripheral
blood of a subset of mice with CR, confirming induction of CD8+ T cell
specific responses to tumor cells upon INT230-6 treatment.
Conclusions
Hence, INT230-6 given locally to treat tumors induces tumor specific
protective T cell immunity.
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Background
Glioblastoma multiforme (GBM) is the most common brain cancer for
which classical treatment options remain limited. Recent advances in
Fig. 42 (abstract P323). Biodistribution quantification of fixed tissue
samples by 19F NMR at 2 days and 7 days post treatment. 19F NMR
measurements of organ biodistribution of the PFC-labeled CAR-T cells
and untransduced T cells show strong liver, lungs, lymph node, and tail
signal but modest signal in the spleen and tumors in both groups. Data
is presented as the average fluorine atom content per organ (top) and
the corresponding apparent cell number (bottom). These measurements
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of GBM. To uncover the mechanisms of such therapies, it is critical to de-
velop tools to quantitatively assay T cell biodistribution and survival after
delivery to correlate with putative therapeutic effects. In this study, we
used a new probe technology to quantify T cell therapy distribution in in-
tact tissue samples and correlated the results to tumor growth.
Methods
Human PBMC-isolated T cells were transduced with a chimeric
antigen receptor (CAR) lentiviral vector to express a surface anti-
body against EGFRvIII, a common receptor in GBM. We compared
CAR T cells efficacy and biodistribution to those of naïve T cells.
CAR-T cells and naïve T cells were intracellularly labeled with a
perfluorocarbon (PFC) emulsion ex vivo and injected intravenously
in SCID mice bearing bilateral subcutaneous human U87 tumors
engineered to express EGFRvIII. Tumor growth was monitored
over 7 days with bioluminescence imaging and caliper measure-
ments. Intact organs were then harvested for fluorine-19 NMR
measurements to quantify the fluorine content and apparent cell
count, followed by processing for histological validation.
Results
Longitudinal bioluminescence acquisitions and tumor measurements
showed considerable tumor regression 7 days after CAR treatment with
a radiance average of 5.02 × 1010 photons/sec/cm2/sr, which was twice
lower than the luminescence measured for both naïve T cell treated
and untreated groups (p = 0.0001, Fig. 41). NMR measurements in
whole organs at days 2 and 7 showed strong signal in the liver, lungs,
lymph nodes and tail (injection site) but modest signal in the spleen
and tumors in both groups (Fig. 42). We were able to detect as low as
20,000 CAR T cells homing to the tumors but did not find any naïve T
cells in the tumors. On average, the liver in naïve T cell recipients had
twice the fluorine signal compared to CAR T cells. The liver signals likely
represent the dead T cell fraction. We were also able to visualize failure
of therapy delivery in a few animals where most of the cells remained
in the lungs days after therapy injection.
Conclusions
To conclude, 19F NMR analysis, in conjunction with bioluminescence im-
aging, may accelerate the timeline to evaluate new immunotherapeutic
cell candidates by providing a rapid and straight-forward method to de-
termine therapy efficacy, cell biodistribution and fate in preclinical stud-
ies. We are currently performing in vivo 19F MRI studies using the PFC
technology.do not account for cell division, thus referred to as “apparent cell num-
ber”. The tail signal represents mis-injection
Fig. 41 (abstract P323). Immunotherapy impact on tumor growth
in vivo. a Representative BLI images at day 1, 3 and 7 after
immunotherapy for all 3 groups. Signals are expressed in radiance (p/
sec/cm2/sr) b Time course of bioluminescence intensity in treated and
untreated groups. CAR-T cell treated animals display a radiance half as
high as untransduced-T cell treated animals or untreated animals. C. Cor-
responding tumor volumes show 50% reduction in tumor growth for
the CAR-T cell treated group (p=0.0001) and no significant difference
between untransduced T cell treated and untreated groups (p=0.38)P324
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Background
Anti-tumor antibodies can contribute to effective patient immune re-
sponses to cancer, yet we do not fully understand their characteris-
tics or mechanisms of action. To better elucidate the nature and
significance of such antibodies we sequenced over 2500 blood plas-
mablasts (activated B cells) of a patient (DID-08291) with stage IV
melanoma during a period of stable disease and characterized activ-
ities of resultant monoclonal antibodies.
Methods
Patient plasmablasts were collected and antibody sequences ob-
tained from single cells using Atreca’s Immune Repertoire Capture™
(IRC™) technology. IRC™ incorporates complex DNA barcodes with
Table 4 (abstract P325). Elevation in intracellular cytokine levels
CD4 T cell CD8 T cell
Wk 6 Mo 6 Wk 6 Mo 6
PA2024 IL-2 p < 0.001 p < 0.001 p < 0.05 p < 0.01
IFN-γ p < 0.001 p < 0.05 p < 0.10 p < 0.05
PAP IL-2 p < 0.001 ns p < 0.05 ns
IFN-γ p < 0.05 ns p<0.05 ns
ns = not significant
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nearly error-free, full-length variable regions of natively paired im-
munoglobulin heavy and light chain genes. Sequences obtained
through IRC™ can subsequently be used to synthesize and express
recombinant antibodies for in vitro and in vivo testing.
Results
The IRC™ analysis of two sequential samples, collected 3 months
apart while the patient was undergoing ipilumumab therapy, re-
vealed extensive diversity of germline gene usage, CDR lengths, and
levels of somatic hypermutation (SHM) across individual B cells. Over
1400 putative clonal antibody families were identified by grouping
sequences based on immunoglobulin gene usage and other se-
quence features. Of these families, over 400 showed evidence of
clonal expansion and/or were observed at both blood collection time
points. Full length natively paired variable regions were subsequently
expressed from IRC™ sequences representing both large and small
putative families to generate recombinant antibodies. Multiple anti-
bodies were found to exhibit binding to the surface of cancer cells
and were further characterized for their ability to mediate in vitro
cancer cell killing through various mechanisms including ADCC, ADC,
and/or ADCP. Protein arrays are being used to identify the targets of
these antibodies, while tumor growth inhibition/regression studies in
syngeneic mouse models are underway to better understand the
antibodies therapeutic capabilities when delivered alone or in com-
bination with other immunotherapies.
Conclusions
These results illustrate that naturally occurring patient antibodies
have anti-tumor activity and support their further development as
novel immunotherapeutics.
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Background
Sipuleucel-T is an autologous cellular immunotherapy approved by
the FDA for treatment of asymptomatic or minimally symptomatic
metastatic castration-resistant prostate cancer (mCRPC)[1]; it is manu-
factured from autologous peripheral blood mononuclear cells
(PBMCs) cultured with the immunogen PA2024, a fusion of prostatic
acid phosphatase (PAP) conjugated to granulocyte macrophage col-
ony-stimulating factor. Antibody and T cell responses to PA2024 and/
or PAP correlate with improved overall survival in sipuleucel-T–
treated mCRPC patients [2]. To better understand sipuleucel-T–in-
duced T cell responses, we assessed CD4+ and CD8+ T cells for pro-
liferation, intracellular cytokine production, and cytokine release after
PA2024 or PAP stimulation.
Methods
PBMCs were obtained from sipuleucel-T–treated mCRPC patients
(STRIDE) and nonmetastatic, biochemically recurrent, hormone-sensi-
tive PC patients (STAND). Samples were collected at baseline through
month 6 post–sipuleucel-T. PBMCs were cultured in vitro and stimu-
lated with either PA2024 or PAP. CD4+ and CD8+ T cells were
assessed (n=19) for proliferation and for intracellular IL-2 and IFN-γ.
The cytokine profile was confirmed in supernatant with a meso scale
discovery assay. p < 0.10 was statistically significant.
Results
Compared with baseline, PA2024-specific proliferating CD4+ and
CD8+ T cells had increased intracellular IL-2 and IFN-γ at week 6 andmonth 6 with a similar trend for PAP-specific proliferating T cells
(Table 4). Compared with unstimulated controls, a significant >2-fold
increase in PA2024-stimulated IL-2 and IFN-γ in supernatant was ob-
served at wk 6 and mo 6 over baseline (p < 0.001). PAP-stimulated IL-
2 and IFN-γ supernatant levels increased over baseline and was sig-
nificantly elevated for IFN-γ at wk 6 (p < 0.10).
Conclusions
Sipuleucel-T therapy generated a de novo PA2024-specific T cell re-
sponse, as indicated by the cytokine release profile. The PAP-stimu-
lated cytokine profile suggests that pre-existing immunity with
terminally differentiated T cells are expanded. Thus, sipuleucel-T reac-
tivated an anti-PAP response in memory T cells, thereby overcoming
immunosuppressive mechanisms in PC.
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Background
Interleukin-15 has been identified as a promising candidate for use
as an immuno-oncology therapeutic, but the native cytokine has
poor drug-like properties. NKTR-255 is a novel immunotherapeutic
agent consisting of polymer-engineered IL-15 designed to optimally
engage the IL-15 receptor complex and provide durable pathway ac-
tivation in vivo. Here we show that NKTR-255 has greatly improved
plasma and tumor exposure relative to IL-15, induces NK and CD8+ T
cell activation and proliferation, and has single-agent efficacy in syn-
geneic tumor models.
Methods
Binding kinetics and affinity of NKTR-255 for IL-15Rα were measured
by surface plasmon resonance using immobilized IL-15Rα. Cell-based
potency was determined by treating CTLL-2 cells with NKTR-255 at a
range of concentrations and measuring phosphorylation of STAT5 in
cell lysate by immunoassay. Pharmacokinetic analysis was performed
following single-dose intra-venous administration of IL-15 and NKTR-
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CT-26 tumors, with analytes quantified in tumor and plasma by
ELISA. Immunophenotyping studies were performed by flow
cytometry on lymphocytes from peripheral blood of NKTR-255-
treated and IL-15-treated normal mice and from spleen, tumor and
draining lymph node of treated mice carrying sub-cutaneous TRAMP-
C2 tumors. Efficacy was determined by measuring tumor volume of
sub-cutaneous TRAMP-C2 and CT-26, with q5dx3 treatment with
NKTR-255.
Results
NKTR-255 binds to IL-15Rα, and induces STAT5 phosphorylation
in CTLL-2 cells with sub-nanomolar EC50. Following intravenous
administration, NKTR-255 demonstrates a greatly reduced clear-
ance rate compared to IL-15, with plasma t1/2 of 22-26 h versus
<1 h for IL-15. Tumor exposure of NKTR-255 was 50-fold greater
than IL-15 in B16F10-bearing C57/Bl6 mice and 110-fold greater
in CT-26-bearing Balb/c mice. Immunophenotyping studies in nor-
mal mice showed an induction of Ki-67 and CD122 expression in
NK cells, indicating proliferation and activation. In tumor-bearing
mice, NKTR-255 treatment resulted in an increased CD8:CD4 and
CD8:Treg ratio in tumor and spleen, and an increased frequency
of CD8+TNF+IFNγ+ T cells. Tumor growth inhibition was observed
in both CT-26 and TRAMP-C2 models.
Conclusions
NKTR-255 treatment results in sustained IL-15 activity which induces
CD8+ T cell and NK cell activation and proliferation, and produces
long-lived immunophenotypic changes in tumor-bearing mice. The
design of NKTR-255 enables a potential drug-like therapeutic strategy
for accessing IL-15-based immunotherapy.
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Background
NKTR-214 is a novel agonist of the IL-2 pathway that provides a sus-
tained and biased activation signal to the heterodimeric IL-2R complex
(IL-2Rbg). Here we examine its biological activity, pharmacodynamic ef-
fects and mechanism of action in a murine tumor model.
Methods
To determine efficacy, mice bearing established subcutaneous B16F10
melanoma tumors were treated with NKTR-214 (q9dx3) or aldesleukin
(qdx5, two cycles). For mechanistic studies, mice were treated once
with NKTR-214 or with five daily administrations of aldesleukin. Splenic
or tumor-infiltrating lymphocytes (TIL) were assessed by flow cytometry
and gene expression analysis was conducted by RNA-Seq 5, 7, and
10 days after treatment initiation. To assess the relative contribution of
tumor-resident or migrating lymphocytes to efficacy, the sphingosine-
1-phosphate receptor modulator FTY720 was administered daily alone
or in combination with NKTR-214.
Results
In the aggressive B16F10 model, vehicle-treated tumors grew to the vol-
ume endpoint 8 days after initiation, with a tumor volume quadrupling
time (TVQT) of 5 days. NKTR-214 showed better efficacy than aldesleukin
(TVQT 16.7 versus 10 days). FTY720 significantly decreased blood lympho-
cytes and when added to treatment, efficacy with NKTR-214 was reduced
by 39 % but not completely abrogated. Analysis of TIL demonstrated that
both NKTR-214 and aldesleukin led to an increase in activated NK cells.
However, NKTR-214 administration led to significant and sustained in-
creases in total and memory CD8+ T cells, while the effects from aldesleu-
kin were transient. NKTR-214 also reduced the percentage of intratumoralTregs at every time point, while aldesleukin had little effect on this par-
ameter. Consequently, NKTR-214 increased the average CD8+ T cell/Treg
ratio to >400, which surpassed that achieved by aldesleukin. Immune cell
changes in the spleen followed a similar pattern, however with a lesser
magnitude. In addition to changes in cell number, NKTR-214 treatment
also induced modulation of immune gene expression networks directly
in the tumor microenvironment.
Conclusions
Efficacy generated by the sustained and biased signaling of the
IL-2 pathway with NKTR-214 cannot be achieved even with
multiple daily administrations of aldesleukin. Furthermore, the
profound changes in tumor-infiltrating lymphocytes associated
with the anti-tumor activity of NKTR-214 arise from T cells
stimulated in both the tumor microenvironment and the lymph-
oid tissues. NKTR-214 is currently being evaluated in a in an on-
going single-agent phase I/II clinical trial to assess safety,
efficacy, pharmacokinetics and immune changes in the tumor
microenvironment.
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Background
Nano-Pulse Electro-Signaling (NPES) is a non-thermal, localized
application of ultrashort electrical pulses in the nanosecond range
that can trigger immunogenic cell death in treated tumors. We
have demonstrated previously that the application of 2000 pulses
100 ns long and, 30 kV/cm in amplitude completely ablates the
treated tumor within 3 weeks via apoptosis and initiates an im-
mune response that inhibits secondary tumor growth [1]. We
wanted to determine if this primary tumor treatment also inhibits
metastasis by injecting live tumor cells into the tail vein and
counting the number of lung metastases 3 weeks later.
Methods
14 female B6/J albino mice were given intradermal injections of
500,000 B16-GFP cells in 15uL HBSS. Upon reaching 5 mm in
their largest dimension as visualized by epifluorescence, 6 mice
had their tumors resected surgically, and the tumors in 8 mice
were treated with 2000 pulses of 100 ns and 53 kV/cm. Four
weeks after resection or NPES treatment, both the six surgically
resected mice and four NPES-treated mice were injected with
200,000 B16-GFP cells into the lateral tail vein. 4 NPES treated
mice were not challenged as negative controls. Lung metastases
were counted 3 weeks later by epifluorescence imaging.
Results
Three weeks after intravenous injection with 200,000 B16-GFP melanoma
cells, mice with surgical resection of the primary tumor averaged 17 lung
metastases/mouse. Mice with NPES ablation of the primary tumor aver-
aged 3.3 lung metastases/mouse from intravenous challenge. Mice with
NPES ablation of the primary tumor and no challenge exhibited no lung
metastases.
Conclusions
Immunogenic cell death caused by NPES treatment of primary tu-
mors stimulates anti-tumor immunity to a subsequent challenge with
intravenous B16-GFP cells, extending the vaccination effect beyond
solid secondary malignancies to circulating cancer cells.
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Fig. 44 (abstract P329). Ecto-Calreticulin 24 h. Ecto-calreticulin on
NPES-treated cells 24 h after treatment
Fig. 43 (abstract P328). NPES treatment of primary tumor inhibits
lung metastases. B16-GFP cell metastasis is greatly inhibited in mice
whose primary tumor was treated with NPES
Fig. 45 (abstract P329). ATP secreted at 24 h. ATP concentration
outside cells 24 h after treatment
Fig. 46 (abstract P329). HMGB1 secretion 24 h after treatment.
HMGB1 is secreted 24 h post treatment at all energies
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Background
Nano-Pulse Electro-Signaling (NPES) is a non-thermal, localized
application of ultrashort electrical pulses in the nanosecond range
that can trigger immunogenic cell death in treated tumors. We
have demonstrated previously that the application of 400 pulses
100 ns long and, 30 kV/cm in amplitude completely ablates
treated orthotopic rat liver tumors within 2 weeks via apoptosis
and initiates an immune response that inhibits secondary tumor
growth in a CD8-dependent manner [1]. Here we determine if
NPES treatment results in the expression of three damage-
associated molecular patterns (DAMPs) that play significant roles
in immune signaling.
Methods
We treated three separate cancer cell lines (MCA205, McA-RH7777,
Jurkat E6-1) with NPES. One million cells were suspended in 800 μl
media and treated in a 4 mm electroporation cuvette. Five total
treatments were delivered ranging in energy from 5–50 J/mL. The
pulse parameters were fixed (15 kV/cm, 100 ns, 2 pps) and energy
delivery was controlled by varying the pulse number. 500,000 cells
from each treatment group and untreated cells were seeded into a
24-well plate and incubated at 37 °C for 24-hours. Cell culture super-
natants were collected to measure levels of HMGB1 and ATP. Cells
were also harvested and the expression levels of cell surface calreti-
culin were determined using flow cytometry.
Results
NPES induced all three markers of ICD in an energy-dependent man-
ner. HMGB1 release and calreticulin expression increased with treat-
ment energy in all three cell lines. Extracellular ATP followed a
different pattern, showing a bell-shaped response that peaked at
15 J/mL followed by a drop off at 25 J/mL in both the MCA-205 and
McA-RH7777 cell lines. ATP levels in the Jurkat cells remained low
across all conditions.
Conclusions
We have demonstrated that three key markers of ICD can be induced
by treating tumor cells with NPES. This can explain why we see a
vaccine-like effect after in vivo NPES treatment, inhibiting secondary
tumor growth after subsequent challenges with tumor cells.References
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Background
The development of novel immunotherapeutic approaches need to
consider two critical aspects of anti-tumor immunity: generation of
high-magnitude effector and memory T cell responses (i.e. cytotoxic
CD8+ T, CTLs) and the means to facilitate effective infiltration of CTLs
into the tumor microenvironment.
Methods
Here we use a novel protocol of evaluating the changing numbers of
tumor-specific T cells within tumors of mice receiving different forms
of immunotherapy, and strategies to increase numbers of specific
CTLs in murine tumors.
Results
We report separate requirements for the induction of tumor-specific
T cells in the spleen and lymph nodes versus the tumor tissues in
the course of combinatorial immunotherapies involving a specialized
dendritic cell (DC) vaccine, with augmented ability to enhance sys-
temic numbers of tumor-specific effector CTLs, and the combinatorial
strategy to promote the homing of the vaccination-induced CTLs to
tumors.
Conclusions
In contrast to commonly used tumor models involving highly-
immunogenic model antigens, our approach allows for the
assessment of local immune responses to more clinically
relevant, weakly-immunogenic non-manipulated cancers, facili-
tating the development and preclinical evaluation of new
immunotherapies.
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Background
The immunosuppressive tumor microenvironment disturbs im-
mune regulatory networks and takes over host antitumor immune
responses. We have previously reported that tumor interferes
with host hematopoietic Notch system, which could result in the
inadequate induction of antitumor immunity. Interestingly, we
found that tumor-induced decrease in immune Notch could be
restored by the FDA-approved proteasome inhibitor bortezomib,
which also sensitizes tumors to death signals. We are also eluci-
dating components of microRNA regulation affecting NICD–NFκB
crosstalk.
Methods
WT Balb/c mice (Harlan) will be used in four different groups
with 3 mice per group. The treatment groups are as follows: sa-
line alone, bortezomib alone, tumor (4 T1 breast tumor cells
2x106) alone, or tumor + bortezomib administration. Tumor-
bearing mice will be injected sub-cutaneously with the tumor
cells. We will then allow for the solid tumor to establish in the
mice, which takes approximately 14 days. The tumors should beapproximately 125 mm3. After the establishment of tumor, the
mice will be injected with 1 mg/kg body weight of bortezomib
intra-veneously. After 4 hours, the mice will be sacrificed and the
spleen and lymph nodes will be harvested and CD8+ T cells will
be purified. Analysis of T cell activation markers, Notch signaling
markers, T cell effector molecules and miR-155 expression will be
analyzed by flow cytometry and RT-qPCR.
Results
Bortezomib administration modulates Notch system in CD8+ T
cells isolated from tumor-bearing mice. Bortezomib improves
cytolytic T lymphocyte function. Bortezomib abrogates the nega-
tive effect of g-secretase inhibitor (GSI) on T cell effector mole-
cules. Bortezomib abrogates GSI effect and stimulates Notch
genes via NICD cleavage and/or NFkB activation. Bortezomib in-
tersects with both canonical (NICD) and non-canonical (NFkB)
pathway. Bortezomib upregulates miR-155 expression in the pres-
ence of tumor. miR-155 expression is suppressed in T cells when
Notch signaling is inhibited by GSI. Notch target gene expression
is suppressed when miR-155 is inhibited.
Conclusions
Bortezomib modulates Notch signaling at both the Notch recep-
tor and target gene level, thereby improving the expression of T
cell effector molecules in tumor-bearing mice. Bortezomib pre-
sents the opportunity to sensitize tumors to cell death, while sim-
ultaneously improving CD8+ T cell function via NICD and NFkB
activation leading to effective antitumor immune function. Borte-
zomib has the ability to increase miR-155 expression even when
Notch signaling is blocked by GSI, suggesting an interplay be-
tween Notch and miR-155 affecting expression of T cell effector
molecules.
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Background
Tumor-induced immune suppression is a hallmark feature of tumor
growth, which is responsible for the blockade of host antitumor im-
munity and poor efficacy of anti-cancer immunotherapy. Therefore,
restoration of the antitumor immune response is a cornerstone of
therapeutic interventions aimed to control tumor growth. The thera-
peutic proteasome inhibitor bortezomib sensitizes solid tumors to
apoptosis in response to TNF-family death ligands.
Methods
We investigated the effects of bortezomib on T cell responses in im-
munotherapy models involving low-avidity antigens. We also investi-
gated the potential of bortezomib in modulating the antitumor
immune response in solid tumor mouse models.
Results
Bortezomib did not decrease MHC class I/II-associated antigen pres-
entation to cognate T cells. Rather, bortezomib stabilized the expres-
sion of T cell receptor CD3ζ and IL2 receptor-α, while maintaining
IFNγ secretion to improve FasL-mediated tumor lysis. Notably, borte-
zomib increased tumor cell surface expression of Fas in mice as well
as human melanoma tissue from a responsive patient. In renal
tumor-bearing immunodeficient Rag2−/− mice, bortezomib treatment
after adoptive T cell immunotherapy reduced lung metastases and
enhanced host survival. We observed that bortezomib treatment also
resulted in increased CD8+ T lymphocyte IFNγ secretion and expres-
sion of effector molecules, perforin and granzyme B, as well as the T-
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over, bortezomib promoted CD8+ T cell nuclear factor-κB (NFκB) ac-
tivity by increasing the total and phosphorylated levels of the IκB
kinase and IκBα as well as the cytoplasmic and nuclear levels of
phosphorylated p65. In addition, Bzb treatment increased the levels
of immunostimulatory interleukins IL-2, IL-12, IL-15, and increased
prosphorylation of STAT3/5. Along with these immunostimulatory ef-
fects, bortezomib administration reduced number of pulmonary
tumor nodules in 4 T1.2HA tumor-bearing mice.
Conclusions
These findings provide novel insights on using bortezomib not only
as an agent to sensitize tumors to cell death but also to enhance an-
titumor T cell function, provide lymphocyte-stimulatory effects, and
help in modulating lymphocyte-stimulatory cytokine signaling,
thereby overcoming immunosuppressive actions of tumor on antitu-
mor T cell functions.
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Background
While oligonucleotide therapeutics (ONTs) allow for targeting of cur-
rently undruggable molecular targets, such as oncogenic/tolerogenic
STAT3, their delivery to target cells remains major obstacle limiting
clinical application. We previously developed a strategy for delivery
of STAT3 siRNA, decoy DNA or antisense ONTs to certain immune
and cancer cells as conjugates with TLR9 ligand, CpG oligonucleotide.
The CpG-STAT3 inhibitors (CSIs) proved effective in systemic adminis-
tration against mouse models of leukemia. To further improve conju-
gate nuclease resistance, circulatory half-life and thereby penetration
to distant organs or solid tumors, we developed a method for encap-
sulation of CSIs in extracellular vesicles (EVs).
Methods
We tested several types of immune and cancer cells, such as human
and mouse macrophages (RAW264.7), leukemia (MV4-11) and pros-
tate cancer cells (DU145, PC3, TRAMP-C2), for their ability to spontan-
eously encapsulate CSIs into EVs following the ONT uptake. The
loaded EVs were then isolated by a standard ultracentrifugation and
characterized as for the vesicle size, concentration (Nanosight) as
well as loading efficiency (fluorescent assay/FACS). The biodistribu-
tion of EV-encapsulated and fluorescently labeled CpG-siRNACy3 was
assessed after intravenous injections into mice.
Results
Cells were incubated with various concentrations of CSIs in EV-free
medium for 72 h resulting in the near complete penetration of target
cells. The EVs were isolated from supernatants collected from donor
cells and further characterized. We found that ~20-40 % isolated EVs
were loaded with CSIs. The EVs had an average diameter of 100-
150 nm depending on donor cell type. For majority of tested cells,
concentration of EVs increased following treatment using CSIs which
suggests a potential positive effect of TLR9 signaling on EV secretion.
The EV/CSIs were internalized mainly through scavenger receptor-
mediated endocytosis and not by a fusion with target cell membrane
as verified using confocal microscopy. Importantly, the encapsulation
of CpG-STAT3siRNA did not prevent target gene silencing or TLR-
dependent NF-kB activation. Systemic injection of EV-encapsulated
CpG-STAT3siRNA into mice improved the biodistribution of oligonu-
cleotides especially to myeloid cells in bone marrow and other
organs.Conclusions
We demonstrate the feasibility of using EV-encapsulated CSIs for improv-
ing systemic delivery of immunostimulatory ONTs to TLR9+ immune and
cancer cells. Our further studies will verify whether EV/CSIs will allow for
improved penetration of solid tumors and their distant metastases.
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Background
Checkpoint blockade is able to elicit durable responses in a fraction
of cancer patients. However, what factors define responsiveness to
checkpoint blockade therapy remain to be elucidated [1, 2]. Tumor
cell intrinsic properties and the host immune response co-define re-
sponsiveness to checkpoint blockade. We sought to identify facets of
the host immune response that are regulated by and functionally im-
portant for the efficacy of checkpoint blockade.
Methods
To accomplish this we utilized mass cytometry to comprehensively profile
changes in tumor immune infiltrates following checkpoint blockade. This
approach allows for the interrogation of greater than 40 analytes at single
cell resolution [3]. We subsequently analyzed mass cytometry data using
clustering and dimension reduction algorithms to identify and visualize
infiltrating immune populations in an unsupervised manner.
Results
Using this approach we analyzed B16BL6 murine melanoma tumors
in mice treated with anti-CTLA-4, anti-PD-1, or control antibody. More
than 20 distinct tumor infiltrating immune cell populations were
identified. Notably, multiple sub-populations within canonical im-
mune compartments were identified as individual clusters. This sug-
gests that this approach can capture, to an extent, the complexity of
tumor immune infiltrates. Using these clusters to categorize immune
infiltrates, we identified cell types responsive to checkpoint blockade.
Of particular interest, we were able to survey the diversity within the
T cell compartment and assess the influence of checkpoint blockade
on the frequencies of distinct T cell populations. Broadly, both check-
point blockade responsive and non-responsive immune clusters were
identified, including those that expanded and contracted following
treatment (n = 6 to 7 per group; p < 0.05).
Conclusions
These results indicate that deep profiling of tumor immune infiltrates
using mass cytometry can identify biologically relevant populations
in a comprehensive and unsupervised manner. These data support
our understanding that CTLA-4 and PD-1 regulate T cell activity
through distinct mechanisms. Further investigation into the identity
and functional requirement of the identified subsets is required and
will help to further elucidate the mechanism of action of individual
checkpoint blockade therapies.
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Background
Neutrophils can have immunosuppressive effects, and the neutrophil-
to-lymphocyte ratio (NLR) is a negative prognostic marker in some can-
cers. We analyzed whether immune cells can predict outcome in pa-
tients enrolled in an ongoing clinical trial of radiation plus ipilimumab
(NCT 02239900). We hypothesized that patients with greater absolute
lymphocyte counts (ALC) or decreased neutrophil counts (NC) will have
increased survival.
Methods
Data were available from 74 patients. Blood samples for NC and
ALC were collected at baseline, at the end of treatment, and
immediately before every cycle of ipilimumab. Tumor size was
measured by CT scan at baseline, between cycles 2 and 3 of
ipilimumab, and every 1–3 months thereafter and response was
classified by the immune response criteria (ir-RC). Information on
body weight was extracted starting 6 months before treatment
through the end of treatment. Continuous and discrete variables
were analyzed with Spearman correlations and Fisher’s exact
test. Overall survival was compared via log-rank test and
hazard ratios obtained by Cox proportional analysis. Commonly
reported cut-points used were 5 for NLR and 5x109/L for NC.
Associations were considered significant at p < 0.05; all tests were
two-sided.
Results
Baseline NC correlated with tumor growth (rho = 0.312, p =
0.0069). High baseline NC (>5 x 109/L) was a significant risk factor
for progressive disease (odds ratio = 4.83, p = 0.0034); 9 out of 28
patients with high baseline NC had a best response of stable dis-
ease or partial response versus 32 out of the 46 patients with
low baseline NC. Baseline NC predicted survival (HR = 3.108, p =
0.0006), as did baseline NLR (HR = 2.570, p = 0.0049). NC at the
time of the second ipilimumab administration predicted survival
more strongly than did NC at baseline (HR = 4.598, p < 0.0001).
Both end-of-treatment NC and NLR were associated with survival
(NC: HR = 4.881, p < 0.0001; NLR: HR = 5.055, p < 0.0001). Weight
loss correlated with an increase in tumor growth (rho = 0.26, p =
0.025), a decrease in ALC (rho = −0.34, p = 0.0031), and an in-
crease in NC (rho = 0.394 p = 0.0022).
Conclusions
Our findings suggest that having high NC or NLR is a strong negative
prognostic indicator in cancer patients receiving radiation with im-
munotherapy. These outcomes may reflect neutrophils antagonizing
the effects of ipilimumab by suppressing lymphocyte proliferation or
exacerbating cachexia.
Trial Registration
ClinicalTrials.gov identifier NCT02239900.Therapeutic Cancer Vaccines
P336
Heterologous boosts with an adenoviral vector following a
dendritic cell-tropic ZVex® prime generates robust antigen-specific
T cell responses and enhanced anti-tumor protection
Tina C. Albershardt, Andrea J Parsons, Jardin Leleux, Rebecca S Reeves,
Jan ter Meulen, Peter Berglund
Immune Design, Seattle, WA, USA
Correspondence: Tina C Albershardt
(tina.albershardt@immunedesign.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P336
Background
Effective immunization regimens generally require more than one
administration, often in the form of prime-boosts. ZVex is an
integration-deficient lentiviral vector platform, pseudotyped with a
modified Sindbis virus envelope protein to deliver tumor-associated
antigens (TAAs) to human dendritic cells (DCs) for optimal priming of
TAA-specific CD8+ T cells. We have previously reported that mice im-
munized once or repeatedly with ZVex/TAA developed strong, dose-
dependent, multifunctional, and TAA-specific cytotoxic T cells that
critically controlled tumor growth. Here, we show that priming with
ZVex/TAA and boosting with adenoviral vector (Ad5) encoding the
same antigen strongly increased frequency of TAA-specific T cells
and improved anti-tumor efficacy.
Methods
To evaluate immunogenicity of ZVex and Ad5 expressing human NY-
ESO-1 and murine TRP-1, BALB/c or C57BL/6 female mice were im-
munized with ZVex/TAA or Ad5/TAA twice, 21 days apart. Splenic T
cell responses were assessed 14 days post-last immunization via
intracellular cytokine staining. To evaluate therapeutic efficacy of
immunization regimens, two murine tumor models were used: 1) a
B16 melanoma model, where tumor cells were inoculated in the
flank and measured 2–3 per week; and 2) a metastatic CT26 colon
carcinoma model expressing human NY-ESO-1, where tumor cells
were inoculated intravenously, and lung nodules were enumerated
17–19 days post-tumor inoculation.
Fig. 50 (abstract P337). TNFα, IL-2, IFNɣ secretion after in vitro T
cells NP restimulation
Fig. 49 (abstract P337). Cytotoxic T Lymphocytes response
following vaccination based on Montanide™ ISA 51 VG
Fig. 48 (abstract P337). W/O emulsion structure and mechanism of
immune stimulation
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Repeated ZVex/TAA administration (homologous prime-boost) in mice
maintained the frequency of TAA-specific CD8+ T cells at peak levels.
While repeat-dose compared to single-dose regimen did not improve
anti-tumor control in the CT26 lung metastasis model, it delayed tumor
growth in the B16 tumor model, suggesting that homologous prime-
boost can be efficacious against selected tumor types. Compared to mice
immunized repeatedly with ZVex/TAA, mice primed with ZVex/TAA and
boosted with Ad5/TAA (heterologous prime-boost) generated 10-fold in-
crease in frequency of TAA-specific CD8+ T cells capable of producing
IFNg, TNF, and/or IL-2. Tumor-bearing mice that received heterologous
prime-boost regimen exhibited slower tumor growth or developed fewer
metastatic lung nodules than animals that received a homologous regi-
men. These results demonstrate that a heterologous prime-boost strategy
can be used to generate more TAA-specific T cells, leading to more effica-
cious anti-tumor control.
Conclusions
ZVex is a DC-tropic vector platform that efficiently primes robust antigen-
specific CD8+ T cell responses that alone can effectively control tumor
growth. Heterologous prime-boost regimens, where adenoviral vectors or
other modalities are used as booster immunizations, provide exciting op-
portunities to further enhance this unique DC-tropic gene delivery plat-
form, by further increasing T cell effectors and anti-tumor efficacy.
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Background
Therapeutic cancer vaccines are an interesting alternative to treat cancer
by active immunotherapy. The use of small, highly defined antigens or
over-expressed self-antigens is generally linked with weak and too brief
immune responses. In order to improve the immune response induced,
antigens may be associated with enhancers such as adjuvants. Water-in-
oil (W/O) emulsions represent an interesting option for immunotherapy
vaccines where potent adjuvants are required. These emulsions, based
on Montanide™ ISA 51VG adjuvant, have been successfully used to in-
crease the biological efficacy and immunogenicity of human therapeutic
peptides vaccines. Some of the mechanisms of action that allow this po-
tent and prolonged stimulation are brought forward.
Methods
Cellular activation mechanisms: 5 C57BL/6 mice per group were vacci-
nated subcutaneously with 25 μg of nucleoprotein (NP) alone or with
the Montanide™ ISA 51 VG at weeks 0 and 3. At week 5, splenocytes
are sampled. T cells are put in culture for 48 h and restimulated with
NP antigen. IFNɣ response is followed by ELISpot. Cytokine secretions
into the medium (supernatant) (TNFα, IL-2, IFNɣ) were measured by
ELISA. Distinct populations of memory CD8+ T cells were evaluated by
flow cytometric analysis.
Results
Mice immunized with NP associated with the Montanide™ ISA 51 VG elic-
ited an increase in anti-NP T cells, CD4+ and CD8+ T cell responses. We
observe a significant increase of IFNɣ response in the group vaccinated
with adjuvant. Response from total splenocytes is increased 6 times, 5
times for CD4+ population and more than 4 times for CD8+ T cell popu-
lation. Mice immunized with the NP associated to the Montanide™ ISA 51
VG showed an increase in TNFα, IL-2, and IFNɣ cytokine secretion. Mice
immunized with NP antigen associated with the Montanide™ ISA 51 VG
elicited a higher amount of effector memory T lymphocytes and central
memory T lymphocytes. The higher amount of CD44+ CD62L+ (TCM sub-
population) in mice immunized with NP associated to Montanide™ ISA
51 VG showed an increased engraftment and persistence of T cells.Conclusions
Vaccines based on Montanide™ ISA 51 VG are strong inducers of
danger signals through an enhancement of interaction between anti-
gen and dendritic cells. They induce an important IFNɣ TH1 polarized
response, and potent CD8+ T cell response. Montanide™ ISA 51 VG is
an interesting candidate in therapeutic cancer vaccines. Moreover it
has been safely administered to almost 20,000 patients in 258 clinical
trials, some of them being included in vaccination schedules involv-
ing repeated doses over several years.
Fig. 51 (abstract P337). TCM (CD44+ CD62L+) sub-population of
CD8+ cells in mice vaccinated with or without Montanide™ ISA 51 VG
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Background
Recent advances have highlighted the importance of the immune re-
sponse in the fight against cancers. In many cancers, these responses
are thought to target mutated peptides; however, leukemia has been
shown to have a lower mutational load than many cancers, despite be-
ing highly immunogenic. Thus, leukemia-specific antigens may derive
from the posttranslational modifications (PTMs) associated with aberrant
signaling. Previously, phosphorylated peptides have been identified as
potent cancer antigens; here, we identity several peptides with O-linked
β-N-acetylglucosamine (O-GlcNAc) modifications, with some that also
contain methylated arginine residues. O-GlcNAc is a PTM that modulates
cellular functions through extensive cross-talk with the signaling cas-
cades also regulated by phosphorylation. Thus, O-GlcNAcylated peptides
may represent cancer-specific neoantigens.
Methods
We eluted MHC class-I associated peptides from leukemia patient samples
to identify O-GlcNAcylated antigens, using enrichment coupled with high-
resolution mass spectrometry. Healthy donor immune responses were
assessed using IFNγ ELISpot and multiplexed intracellular cytokine staining.
Functionality was assessed using a europium-release killing assay.
Results
We have identified 36 MHC class I associated O-GlcNAc neoantigens from
primary leukemia samples, the first tumor antigens containing this PTM.
A subset of these neoantigens is linked to key cancer pathways, including
the mitogen activated protein kinase (MAPK) and retinoblastoma (RB1)
pathways, and these peptides were shared across all of the patient sam-
ples tested. 71 % (5/7) of the HLA-B*0702 O-GlcNAcylated neoantigens
tested were immunogenic, with 100 % (5/5) of healthy donors having
multifunctional memory CD8+ T cell responses to them. Cells targeting
these neoantigens were shown to degranulate. This multifuntionality and
degranulation in response to antigen indicated that O-GlcNAc-specific Tcells may kill. Indeed, an O-GlcNAc-specific T cell line was grown and
these cells specifically killed autologous cells pulsed with the modified
peptide, but not the equivalent unmodified peptide (p = 0.015). T cell re-
sponses were also identified that specifically targeted the methylated ar-
ginine in the peptide with the O-GlcNAc modification.
Conclusions
O-GlcNAcylated neoantigens derive from aberrations in key cancer
pathways, are shared across patients and are immunogenic. CD8+ T
cells targeting these O-GlcNAcylated neoantigens specifically recognize
and kill only the PTM antigen. Therefore, these O-GlcNAcylated neoanti-
gens provide logical targets for cancer immunotherapy.
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Background
Modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia strain
that is an important vaccine vector for infectious diseases and cancers.
MVA has a 31-kb deletion of the parental vaccinia genome and was
shown to be safe for human use during smallpox vaccination. The investi-
gation of MVA as cancer therapeutics has so far been limited to its use as
a vaccine vector to express tumor antigens. We hypothesize that intratu-
moral delivery of recombinant MVAΔE3L (with deletion of vaccinia viru-
lence factor E3) expressing human flt3L (Fms-like tyrosine kinase 3 ligand)
would provide in situ therapeutic vaccine effects. Flt3L plays a critical role
in the development of DC subsets, including CD103+/CD8α+ DCs, which
are critical for cross-presentation of tumor antigens.
Methods
We compared the immune responses of B16-F10 murine melanoma cells
and MC38 murine colon adenocarcinoma cells as well as dendritic cells to
either MVA or MVAΔE3L infection. We compared the efficacy of intratu-
moral delivery of MVA vs. MVAΔE3L in two syngeneic bilateral tumor im-
plantation models. We also generated recombinant MVAΔE3L-TK−-hFlt3L
through homologous recombination at the thymidine kinase (TK) locus.
We compared the efficacies of intratumoral delivery of MVAΔE3L-TK
−-hFlt3L vs. MVAΔE3L in bilateral tumor implantation models.
Results
We found that MVAΔE3L infection of B16-F10 and MC38 induces higher
levels of IFN-β, IL-6, CCL4 and CCL5 than MVA. MVAΔE3L-induction of type
I IFN in cDCs is mainly dependent on the cGAS/STING pathway. Intratu-
moral injection of MVAΔE3L is more efficacious than MVA in tumor eradi-
cation and extension of survival in bilateral tumor implantation models,
which correlates with stronger induction of activated CD8+ and CD4+ ef-
fector T cells in both injected and non-injected tumors from MVAΔE3L-
treated mice compared with MVA-treated mice. Furthermore, intra-
tumoral injection of MVAΔE3L-TK−-hFlt3L exerts stronger anti-tumor
effects than MVAΔE3L in a murine melanoma bilateral implantation
model. B16-F10-tumor bearing mice successfully treated with
MVAΔE3L-TK−-hFlt3L also rejected a lethal dose of MC38 challenge.
Conclusions
Our results show that intratumoral injection of MVA or MVAΔE3L
leads to alteration of tumor immune suppressive microenvironment,
which facilitates tumor antigen presentation, recruitment and
activation of anti-tumor CD8+ and CD4+ T cells. MVAΔE3L is a
stronger immune activator than MVA. Intratumoral delivery of
MVAΔE3L-TK−-hFlt3L is more efficacious than MVAΔE3L. Current
studies focuses on tumor infiltrating immune cells including
CD103+ DCs and CD8+ cytotoxic T cells in MVAΔE3L-TK−-hFlt3L
vs. MVAΔE3L-treated mice.
Fig. 53 (abstract P339). MVAΔE3L infection of MC38 cells induces
higher levels of IFN and proinflammatory cytokines and chemokines
than MVA. MC38 colon cancer cells (1 x 10e6) were infected with
MVA, and MVAΔE3L viruses at a MOI of 10. Supernatants were
collected at 22 h post infection. The levels of cytokines were
determined by ELISA
Fig. 52 (abstract P339). MVAΔE3L infection of B16-F10 cells induces
higher levels of Ifnb, Il6, Ccl4 and Ccl5 than MVA. B16-F10 melanoma
cells (1 x 10e6) were infected with MVA, and MVAΔE3L viruses at a
MOI of 10. Cells were collected at 6 h post infection. Real-time PCR
was performed to analyze gene expression
Fig. 54 (abstract P339). Innate immune sensing of MVAΔE3L virus
in cDCs. Shown here is a series of bar graphs showing that cGAS is
required for the induction of type I IFN by MVAΔE3L in cDCs. a Bar
graphs showing mRNA levels of IFNA4 and IFNB in cGAS+/+ and
cGAS−/− cDCs infected with MVAΔE3L. b Bar graphs showing
IFN-α and IFN-β secretion levels in cGAS+/+ and cGAS−/− cDCs
infected with MVAΔE3L or treated with cGAMP, an agonist for
STING. c A scanned image of an immunoblot showing protein
levels of p-IRF3 and GAPDH in cGAS+/+ and cGAS−/− cDCs
infected with MVAΔE3L
Fig. 55 (abstract P339). Intratumoral injection of MVAΔE3L or
MVA is effective in a B16-F10 bilateral implantation model. B16-
F10 bilateral tumor implantation model was used to assess the
anti-tumor efficacy of MVAΔE3L vs MVA. Briefly, B16-F10 melan-
oma cells were implanted intradermally to the left and right
flanks of C57B/6 mice (5 x 10e5 to the right flank and 1 x 10e5 to
the left flank). 8 days after tumor implantation, the larger tumors
on the right flank were intratumorally injected with 2 x 10e7 pfu
of MVA or an equivalent amount of MVAΔE3L. The tumor sizes were
measured and the tumors were re-injected twice a week. The
survival of mice was monitored. Graphs of injected (a, c, e) and
non-injected (b, d, f) tumor volume plotted against time (days)
after PBS, MVA, or MVAΔE3L injection respectively. g is a Kaplan-
Meier survival curve of tumor-bearing mice (B16-F10 cells) injected with
PBS (filled circles), MVA (filled squares), or MVAΔE3L (filled triangles).
****, p < 0.0001 (MVAΔE3L vs. PBS group); ***, p < 0.001 (MVA vs.
PBS group)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 181 of 221
Fig. 57 (abstract P339). MVAΔE3L-hFlt3L is more efficacious than
MVAΔE3L. Shown here are tumor volumes of injected (a, c and e) and
non-injected tumors (b, d, and f). (g) A Kaplan-Meier survival curve of
tumor-bearing mice (B16-F10 cells) injected with PBS (filled circles),
MVAΔE3L (filled squares), or MVAΔE3L-hFlt3L (filled triangles). **, p < 0.01
(MVAΔE3L vs. PBS group); **, p < 0.01 (MVAΔE3L-hFlt3L vs. MVAΔE3L
group). (H) A Kaplan-Meier survival curve of tumor-bearing mice (B16-F10
cells) successfully treated with MVAΔE3L-hFlt3L vs naive mice challenged
with a lethal dose of MC38 cells intradermally (1 x 10e5)
Fig. 56 (abstract P339). Intratumoral injection of MVAΔE3L and
MVA induces activating TILs in injected and non-injected tumors.
B16-F10 melanoma cells were implanted intradermally to the left
and right flanks of C57B/6 mice (5 x 10e5 to the right flank and 2.5 x
10e5 to the left flank). 7 days after tumor implantation, the larger
tumors on the right flank were intratumorally injected with 2 x 10e7
pfu of MVA or an equivalent amount of MVAΔE3L, repeated three
days later. Both injected and non-injected tumors were harvested at
3 days post the second injection, and TILs were analyzed by FACS.
Shown here is a series of graphical representations of data showing
that intratumoral injection of MVA or MVAΔE3L induces activated
effector CD8+ and CD4+ T cells in both injected and non-injected
tumors in a murine B16-F10 melanoma bilateral implantation model.
(A) Dot-plots of flow cytometric analysis of CD8+ cells expressing
granzyme B+. (B) %CD8+ granzyme B+ T cells in both injected and
non-injected tumors treated with PBS, MVA or MVAΔE3L. (C) Dot-plots
of flow cytometric analysis of CD4+ cells expressing granzyme B+. (D)
%CD4+ granzyme B+ T cells in both injected and non-injected tumors
treated with PBS, MVA or MVAΔE3L. (*, p < 0.05; **, p < 0.01; ***, p <
0.001; ****, p < 0.0001). (E) Histogram of CD8+ granzyme B+ and CD4+
granzyme B+ TILs in both injected and non-injected tumors treated
with PBS, MVA or MVAΔE3L
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Background
Breast cancer remains a leading cause of cancer death worldwide. Ef-
fective adjuvant therapy exists, but there is evidence that immunother-
apy may play a significant role in the eradication of residual disease.
Peptide vaccines require adjuvants to achieve durable immune mem-
ory. Toll-like receptor agonists and help peptides are two recently opti-
mized adjuvants which are investigated in this trial.
Methods
A vaccine consisting of nine-class I MHC-restricted breast cancer-
associated peptides was combined with a TLR3, poly-ICLC) along
with a helper peptide from tetanus toxoid. The peptides used in the
study are encoded by the genes: MAGE-A1, −A3, −A10, CEA, NY-ESO-1,
and HER2. The peptides lack tumor-specific mutations. The vaccine was
given on days 1, 8, 15, 36, 57, 78 and response was assessed by both
direct and stimulated ELISpot. Eleven patients with breast cancer were
treated. Five of the patients had estrogen receptor positive disease.
None were HER2 amplified.
Results
The vaccine was well tolerated with no grade 3 nor dose limiting
toxicities. Mild injection site reactions and flu-like symptoms were
reported in most patients. The most common toxicities were in-
jection site reaction/induration and fatigue, which were experi-
enced by 100 % and 91 % of participants, respectively. The
stimulated ELISpot detected T cell responses in four out of eleven
patients. None were detectable in a direct ELISpot assay. Another
two patients had borderline immune responses and four had im-
mune response extending 30 days beyond the end of the vaccin-
ation series. No difference in immune response was observed
between patients receiving endocrine therapy and those not re-
ceiving endocrine therapy. The peptides from CEA and MAGE-A1
were immunogenic.
Conclusions
The administration of a peptide vaccine in the adjuvant breast cancer
setting was safe and feasible. An adjuvant poly-IC plus helper peptide
mixture provided modest immune stimulation and should be further
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IL-2 has been used as effective immunotherapy in metastatic renal
cell carcinoma and melanoma, and may synergize with other cancer
immunotherapies. However, toxicities associated with high dose IL-2
treatment limited its further use in anti-cancer therapies. NKTR-214,
which is an engineered IL-2 cytokine, was designed to provide a
non-toxic, stable and more efficient alternative to IL-2. NKTR-214
provides sustained activation of the IL-2 pathway through controlled
release of active CD122-biased (IL-2Rβɣ) cytokines. Prior preclinical
studies demonstrated that NKTR-214 can expand tumor-infiltrating
lymphocyte populations resulting in marked tumor growth suppression
as single-agent and in combination with checkpoint inhibitors. In this
pre-clinical study, we investigated whether NKTR-214 can promote ex-
pansion and function of vaccination-induced, tumor specific effector
CD8+ T cells using the murine B16 melanoma model. We also studied
how NKTR-214 impacts the localization of effector CD8+ T cells and
Tregs to tumor and spleen.
Methods
To understand the effect of NKTR-214 on antigen-specific CD8+ T cells,
we adoptively transferred naïve gp100-specific TCR transgenic pmel-1
CD8+ T cells into mice bearing established subcutaneous B16 tumors,
followed by vaccination (gp100 peptide + anti-CD40 mAb + TLR-7 agon-
ist) alone or in combination with NKTR-214 or IL-2. Mice then received
NKTR-214 or IL-2 every 8 days. Tumor growth, survival and T cell re-
sponse in blood was monitored, and localization of effector pmel-1
CD8+ T cells and CD4+ Foxp3+ Tregs in tumor and spleen were
analyzed.
Results
NKTR-214 efficiently synergized with vaccination, potently suppressing
tumor growth and improving survival of mice compared to vaccination
with IL-2. NKTR-214 enhanced pmel-1 CD8+ T cell numbers and de-
creased numbers of immune-suppressive Tregs in tumor. NKTR-214
was able to stably maintain a high ratio of pmel-1 CD8+ T cells over
Tregs in tumor for >30 days. Despite the induction of very strong
CD8+ T cell responses and anti-tumor activity, no gross toxicity was
observed.
Conclusions
NKTR-214 synergizes with vaccination by supporting the survival,
maintenance and tumor infiltration of effector CD8+ T cells without
promoting the intratumoral accumulation of immune-suppressive
Tregs. These preclinical results establish that NKTR-214 is highly ef-
fective in increasing CD8+ effector T cell responses with potent anti-
tumor activity.
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Background
Mitochondria provide energy for cells via oxidative phosphorylation.
Reactive oxygen species, a byproduct of this mitochondrial respiration,
can damage mitochondrial DNA (mtDNA), and somatic mtDNA muta-
tions have been found in all colorectal, ovarian, breast, urinary bladder,
kidney, lung, and pancreatic tumors studied. The resulting altered mito-
chondrial proteins or tumor-associated mitochondrial antigens (TAMAs)
are potentially immunogenic, suggesting that they may be targetable
antigens for cancer immunotherapy.
Methods
We generated a cellular tumor vaccine by pulsing dendritic cells with
enriched mitochondrial proteins from RENCA cells.
Results
Our dendritic cell-based RENCA mitochondrial lysate vaccine elicited a
cytotoxic T cell response in vivo and conferred durable protection against
challenge with RENCA cells when used in a prophylactic or therapeuticsetting. By sequencing mtDNA from RENCA cells, we identified two mu-
tated molecules: COX1 and ND5. Peptide vaccines generated from
mitochondrial-encoded COX1 but not from ND5 had therapeutic
properties similar to RENCA mitochondrial protein preparation.
Conclusions
Our results demonstrated that TAMAs can elicit effective antitumor
immune responses, potentially providing a new immunotherapeutic
strategy to treat cancer.
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Background
Checkpoint blockade therapy has therapeutic benefit in several human
cancers [1], but in many patients, checkpoint blockade-induced T cells do
not infiltrate tumors [2,3], preventing clinical benefit. One mechanism of
intratumoral T cell accumulation is through the activity of the integrins
very late antigen-4 (VLA-4) and lymphocyte function-associated antigen-1
(LFA-1) on activated T cells. We evaluated the effect of an integrin agon-
ist, 7HP349, on promoting intratumoral T cell accumulation to potentiate
CTLA-4 checkpoint blockade-induced anti-tumor activity.
Methods
To evaluate the effect of 7HP349 in promoting checkpoint blockade-induced
anti-tumor immunity, we combined it with anti-CTLA-4 therapy in the stand-
ard treatmentmodel of established subcutaneous B16melanoma [4].
Results
CTLA-4 checkpoint blockade enhanced vascular cell adhesion molecule-1
(VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) expression
on tumor vasculature consequently resulting in increased intratumoral
accumulation of CD8loCD11ahiCD44hi effector T cells (Teff) and inflamma-
tory monocytes (iMO) and granulocytes (Gran). ICAM-1 antibody block-
ade or genetic ablation caused reduced accumulation of Teff and tumor
control. Intratumoral administration of 7HP349 enhanced CD8+ T cell ac-
cumulation and tumor control compared to mice treated with anti-CTLA-
4 monotherapy or with vehicle control (P < 0.01). Mice treated with anti-
CTLA-4 and 7HP349 showed increased depigmentation (vitiligo) suggest-
ing immunity to melanocyte differentiation antigens. Therapeutic efficacy
was also observed after systemic administration of 7HP349 in combin-
ation with anti-CTLA-4 therapy, resulting in (80 %) tumor-free survival
compared to anti-CTLA-4 monotherapy (33 %) (P < 0.01).
Conclusions
Activation of integrin cell adhesion molecules with 7HP349 is a
promising approach to enhance the anti-cancer activity of check-
point blockade therapy with antibodies against CTLA-4, and possibly
other checkpoint molecules such as PD-1 and PD-L1.
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Background
Monoclonal antibodies (mAbs) are taking the field of cancer immunother-
apy by storm. Despite their growing use, a broader accessibility and
implementation is hampered by dismal pharmaco-economics, the practi-
calities and patient discomfort associated with frequent and long-term
high-dose mAb administration, and the often limited therapeutic effect as
single agent. To address these issues, the laboratory focuses on the devel-
opment of a therapeutic DNA platform for non-viral antibody gene trans-
fer. After administration of vectors that carry the encoding mAb
sequences, this approach enables the site of delivery (e.g., muscle or
tumor) to produce mAbs in vivo followed by secretion into circulation for
a prolonged period of time. In vivo mAb expression presents a labor- and
cost-effective alternative to the conventional production, purification and
parenteral delivery of mAb proteins. The less frequent administrations
and gradual in vivo mAb production and buildup are anticipated to im-
prove patient comfort and safety. Also, by making mAb therapy more af-
fordable, more effective combinations could be implemented more easily.
Methods
This study aims to demonstrate the feasibility of intramuscular mAb gene
electrotransfer in mice using the well-characterized trastuzumab or its mur-
ine precursor 4D5 encoded in plasmid DNA (pDNA). Following intramuscu-
lar pDNA injection and electroporation, mAb plasma levels were measured
with ELISA using HER2-coated plates. In vivo therapeutic efficacy of mAb
gene transfer was evaluated in a BT474 breast cancer mouse model.
Results
Following intramuscular electrotransfer of the encoding pDNA in BALB/c
mice, trastuzumab was found at microgram per milliliter concentrations
in plasma. In this immune competent strain, however, detection was lost
10 days after pDNA delivery, because of an immune response against
the humanized trastuzumab. This was overcome by delivery of trastuzu-
mab pDNA in immune compromised mice (RAG2−/−gammaC−/− and
athymic nude mice) or by delivery of 4D5 pDNA, thus matching the
mAb sequence with the host species. Both approaches resulted in con-
tinued mAb expression at microgram per milliliter concentrations for at
least 6 months, the duration of the follow-up. mAb plasma concentra-
tion could be adjusted by adapting the pDNA dose or administering
additional pDNA doses. In a BT474 xenograft mouse model, intramuscu-
lar electrotransfer of 4D5 pDNA induced significant anti-tumor responses
compared to the untreated control group.
Conclusions
This study achieved proof of concept for prolonged and therapeutic-
ally relevant in vivo mAb expression in mice using anti-HER2 mAbs as
demonstrator. Ongoing work focuses on expanding the DNA plat-
form to immunomodulatory mAb combinations and bridging the
gap towards clinical application.
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Background
Antigen presentation by MHC is central to the development of adaptive
immunity. While traditional modeling approaches yield large numbers
of candidates and high attrition rates, direct identification of naturally-
processed peptides by mass spectrometry can significantly streamline
the neo-epitope identification.Methods
To demonstrate the feasibility and advantages of this approach, a pilot
study was conducted in clear cell renal cell carcinoma. MHC I-peptide
complexes were isolated from tumor and matched adjacent normal tis-
sue from treatment-naïve patients with the same tumor grade but het-
erogeneous HLA haplotypes. Peptides were eluted from the complexes
using mild acid and were analyzed by mass spectrometry and their ex-
pression was compared to matched adjacent tissue.
Results
Results demonstrated effective enrichment and detection of MHC- associ-
ated peptides, with identification of an average of over 6800 peptides
per sample and characteristics appropriate for peptides presented by
MHC I. Differential expression analysis indicated that approximately 13 %
of identified peptides were substantially overexpressed (>3-fold) in the
tumor tissue, with approximately 3.5 % uniquely presented in tumors. In
many cases multiple HLA allele-specific peptides derived from the same
tumor-presented protein were identified, thereby increasing coverage
across different haplotypes. A relatively small number of modified pep-
tides presented only by the tumor were identified, consistent with the
low mutational load of clear cell renal cell carcinoma. Most of these pep-
tides appeared to be derived from protein fusions (37 %), single amino
acid substitutions (25 %) and frameshift mutations (19 %), with a lower
contribution from splicing variants (6 %) and post-translational modifica-
tions (9 %). Pathway analysis showed significant over-representation of
proteins associated with hypoxia and angiogenesis, two processes previ-
ously reported to change in clear cell renal carcinoma.
Conclusions
Thus tumor-associated antigen presentation reflected protein ex-
pression changes previously reported in renal cell carcinoma, and
identified multiple novel candidates. Direct identification of natur-
ally processed peptides generated a small but high quality list of
candidates for further investigation.
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Background
Accumulating pre-clinical data indicate that the efficient induction of
antigen-specific cytotoxic T cells characterizing viral infections is caused
by cross-priming where initially infected DCs act as a pure adjuvant, not
as antigen presenting cells, producing inflammatory factors that recruit
and activate non-infected "bystander" DCs. Accordingly, we have devel-
oped a cellular adjuvant consisting of pro-inflammatory monocyte-
derived allogeneic DCs producing high levels of DC-recruiting and
DC-maturating factors in a sustained fashion.
Methods
Eleven patients with advanced hepatocellular carcinoma (HCC) where
included in a phase I/II study. Vaccine cells (INTUVAX) were produced
from a leukapheresis-product collected from one healthy blood
donor and subsequently deep-frozen. Three doses of vaccine cells
(10–20 million cells/dose) were injected intratumorally. Using mixes
of overlapping peptides for alpha fetoprotein (AFP) and human tel-
omerase reverse transcriptase (hTERT) spanning the entire protein se-
quence, CD8+ T cell responses could be evaluated, regardless of the
patient's HLA-type.
Results
Nine out of 11 patients received all 3 vaccine doses. Six of these 9 pa-
tients had received prior first-line systemic treatment with sorafenib
while 3 patients were naive to systemic treatment. INTUVAX was gener-
ally well tolerated but two severe adverse events, both fever episodes,
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 185 of 221were reported as drug-related. Among the 9 fully treated patients, 6 pa-
tients exhibited an increase of AFP and/or hTERT specific and IFN-
gamma producing CD8+ T cells 1 week after the third vaccine dose as
compared to pre-vaccination levels. Median overall survival (mOS) for
the fully treated patient subgroup given INTUVAX as second-line sys-
temic treatment (n = 6) is still not reached but is currently (8AUG2016)
8.2 months while mOS for the three patients receiving INTUVAX as
first-line systemic treatment was 11.7 months. These data compare fa-
vorably with historical data. Notably, two out of three patients who did
not respond with an increase in tumor-specific T cells died within
5 months after the first INTUVAX dose.
Conclusions
Our findings indicate that intratumoral administration of proinflam-
matory allogeneic DCs induces a CTL-mediated systemic anti-tumor
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Background
With the rapid development of next-generation DNA/RNA sequen-
cing technology, patient-specific tumor neo-antigens can now be
identified, potentially ushering in the new era of personalized cancer
vaccines. Peptide vaccines, known for ease of manufacturing, quality
control and human safety, can be easily applied for neo-antigen-based
immunotherapy. However, peptide-based cancer vaccines have shown
limited therapeutic efficacy in humans, partially due to inefficient
co-delivery of antigen (Ag) and adjuvants to lymphoid tissues as
well as T cell dysfunction and deletion.
Methods
Here we report that synthetic high density lipoprotein (sHDL) nano-
discs, with an established clinical manufacturing procedure and excel-
lent safety profiles in humans, can be simply mixed with Ag peptides
and adjuvants, producing homogeneous, stable, and ultrasmall
(~10 nm in diameter) nanodiscs in less than 2 hrs for personalized
neo-antigen vaccination.
Results
Nanodiscs efficiently co-delivered Ag and CpG, a Toll-like receptor-9
agonist, to draining lymph nodes and promoted strong and durable Ag
presentation on antigen-presenting cells. Strikingly, nanodiscs elicited
up to 47-fold greater frequency of tumor neoantigen-specific CD8+ T
lymphocytes (CTLs) than soluble vaccines and even 31-fold greater
than arguably the strongest CTL adjuvant in clinical trials (i.e., CpG in
Montanide). Moreover, in mice bearing MC-38 colon tumors, thera-
peutic sHDL vaccination led to significantly enhanced IFN-γ+TNF-α+ Ag-
specific CTL responses that substantially inhibited tumor growth and
extended animal survival, compared with soluble vaccines (p < 0.01).
When nanodisc vaccination was combined with the immune check-
point inhibitor, anti-PD-1 (α-PD-1), ~88 % of MC-38 tumor-bearing mice
were cured, whereas the soluble peptide + CpG vaccine combined with
α-PD-1 therapy cured only 25 % mice. Those cured mice were com-
pletely protected against MC-38 cell re-challenge administered on day
70, indicating resistance to tumor relapse. To treat a more aggressive
B16F10 melanoma model, multiple MHC class I and class II epitopes
were loaded in nanodiscs. Vaccination with multi-epitope nanodiscs
generated ~30 % tumor antigen-specific, IFN-γ+ CD8+ and CD4+ T cells
in peripheral blood, whereas only ~2 % response was observed for the
soluble vaccine or Ag + CpG +Montanide group. More strikingly, when
multi-epitope nanodisc vaccination was combined with α-PD-1/α-CTLA-
4 therapy, ~90 % B16F10 tumor-bearing mice were cured, whereasonly ~38 % rate of tumor regression was observed in animals treated
with the soluble peptide vaccine plus α-PD-1/α-CTLA-4 therapy.
Conclusions
Overall, our approach offers a powerful and convenient platform
technology for patient-tailored cancer vaccines, which in combination
with the immune checkpoint inhibitor can efficiently eliminate estab-
lished tumors and prevent relapse.
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Background
Clinical success of checkpoint inhibitors, dendritic cell-based therap-
ies and adoptive T cell transfer studies highlight the importance of
tumor-specific neoantigens as critical targets for effective immuno-
therapy [1, 2]. Advances in genome sequencing and predictive epi-
tope binding algorithms provide an unprecedented opportunity to
develop highly personalized immunotherapeutics [3]. Aduro is devel-
oping personalized therapy (pLADD) based on the live, attenuated
double-deleted Listeria monocytogenes (LADD) platform which has
been administered to over 300 cancer patients with an acceptable
safety profile.
Methods
Tumor-bearing C57BL/6 mice were treated with pLADD-MC38 and
anti-PD-1. MC38 mutated epitopes [4] were expressed as a synthetic
neoantigen protein from the Listeria chromosome. Tumor growth
was monitored; immune responses measured by IFNg ELISpot.
Results
We constructed a pLADD strain expressing tumor-specific neoepitopes
from murine MC38 tumor cells (pLADD-MC38). Administration of
pLADD-MC38 in mice induces cellular immune responses against
encoded neoepitopes but not against native sequences. Moreover, we
also showed synergistic anti-tumor efficacy of pLADD-MC38 and anti-
PD-1. To effectively translate pLADD into the clinic, we have established
an accelerated, small-scale LADD manufacturing process.
Conclusions
pLADD is an attractive immunotherapy approach to target mul-
tiple tumor-specific neoantigens using the LADD platform to take
advantage of rapid construction, manufacture, and release, an
established clinical safety profile with repeated administration,
and induction of innate and adaptive immunity and favorable
tumor microenvironment changes. The FDA has cleared an IND
for a phase I trial to evaluate safety and immunogenicity of
pLADD in subjects with advanced gastrointestinal cancers, and its
progress will be discussed.
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Background
We have previously reported the development of a strategy to target
the cancer stem cell (CSC) populations in melanoma and squamous cell
carcinoma using CSC lysate-pulsed dendritic cells (DCs). Using mouse
models we demonstrated that DCs pulsed with CSCs enriched by virtue
of their expression of the CSC marker ALDH (termed CSC-DC) signifi-
cantly inhibited tumor growth. However, CSC-DC vaccine therapy alone
may not be sufficient to overcome the immunosuppressive compo-
nents of the tumor microenvironment. CSC-mediated suppression of T
cells has been reported in a process involving the PD-L1/PD-1 axis. Im-
munologically targeting CSCs while simultaneously blocking PD-L1/PD-
1-mediated immune suppression may significantly enhance the out-
come of current immunotherapies of cancer.
Methods
To test this hypothesis, we investigated the effect of using anti-PD-L1 to
block immunosuppression during the CSC-DC vaccination to augment the
therapeutic efficacy of using each regimen alone. We used the 4 T1 cell
line, a mammary carcinoma syngeneic to BALB/c mice, and found that
4 T1 tumors contain approx. 6-10 % ALDEFLUOR+/ALDHhigh cells, and that
these cells are enriched for tumor initiating capacity compared to bulk or
ALDEFLUOR−/ALDHlow cells. Inoculating 4 T1 cells into the mammary fat
pad induces the development of spontaneous pulmonary metastases.
Results
ALDHhigh 4 T1 CSCs expressed PD-L1. 4 T1 ALDHhigh CSC-DC vac-
cine + anti-PD-L1 administration significantly reduced pulmonary
metastases and prolonged survival compared with 4 T1 ALDHhigh
CSC-DC vaccine or anti-PD-L1 administration alone. Anti-PD-L1 ad-
ministration increased systemic anti-4 T1 CSC immunity induced
by CSC-DC vaccine. This is evident by the increased production
of total IgG in the serum samples collected from the 4 T1-bear-
ing animals subjected to 4 T1 CSC-DC vaccination with anti-PD-L1
administration. The CSC-reactivity/specificity of the immune sera
was demonstrated by their specific binging to the ALDHhigh vs.
ALDHlow 4 T1 cells in flow cytometry. Importantly, the immunological
consequence of such binding was Ab-mediated ALDHhigh 4 T1 CSC lysis
via complement dependent cytotoxicity. In addition, CTLs generated
from the splenocytes harvested from the hosts subjected to 4 T1 CSC-
DC vaccination with anti-PD-L1 administration killed ALDHhigh 4 T1
CSCs significantly more than ALDHlow 4 T1 cells.
Conclusions
These results are supportive of the conclusion that administration of
anti-PD-L1 could significantly boost the therapeutic efficacy of the
CSC-DC vaccine, and that this effect was due to both antibody and T
cell-mediated anti-CSC immunity.P350
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Background
We have previously reported interim results of safety and immunogenicity of
the INO-3112 in subjects with HPV-associated HNSCCa. INO-3112 was shown
to be safe and immunogenic, inducing HPV-specific CD8+ T cell responses [1].
Methods
Subjects were enrolled into two cohorts. Cohort 1 received INO-3112
pre- and post-surgery. Cohort 2 received INO-3112 after completion
of cisplatin based chemoradiation. Here, we report immune re-
sponses post immunotherapy in peripheral blood and tumor tissue
obtained from surgery for Cohort 1 subjects. Tumor samples were
stained with immunohistochemistry techniques for CD8 and FoxP3.
In addition, ELISpot analysis was used to determine the number of
cells capable of secreting IFN-γ in response to HPV antigen
stimulation.
Results
As of August 1 2016, accrual has been completed with 22 enrolled subjects.
Cohort 1: n= 6, Cohort 2: n= 16, 20 males, median age 57.5 years; base of
tongue cancer = 10, tonsil cancer =12; never smoker =10. Six subjects in Co-
hort 1 received at least one dose of INO-3112 on average 14 days (range 7
to 28 days) prior to definitive surgery. Paired pre- and post-INO-3112 therapy
tumor samples were available for five of the 6 subjects. CD8 positive T cell
counts increased in tumor tissue in 2 subjects, average 160.6 % increase
(range 61.7 % to 259.4 %) from baseline. FoxP3 positive cell counts de-
creased in tumor tissue in 3 subjects, average 48 % decrease (range 44 % to
53 %). Four of the 5 subjects showed increased CD8:FoxP3 ratio post INO-
3112, average 60.3 % increase (range 1.4 % to 209.3 %). Five of 6 subjects
had peripheral blood available for analysis of peripheral HPV-
specific T cell responses by IFN-γ ELISpot. Four subjects exhibited
an increase in ELISpot response magnitude post INO-3112 com-
pared to baseline (range 30.00 to 158.33 SFU). Two subjects with
increase in CD8 positive cells in tumor tissue demonstrated the
highest increase in ELISpot response (108.33 and 158.33 SFU, re-
spectively). Four of 6 subjects remain progression-free; median
PFS of 17 months (range 12 to 23 months) to date. One subject
withdrew consent after surgery. One subject demonstrated only
marginal increases in ELISpot response magnitude to HPV 16
(3.33 to 16.67 SFU) and no increase in CD8/FoxP3 ratio (0.95 to
0.60) in tumor tissue post INO-3112 developed progressive dis-
ease (11 months post INO-3112).
Conclusions
These results demonstrate that INO-3112 DNA-based immunotherapy
can induce detectable immune responses in peripheral blood and




1. J Immunother Cancer 2015, 3(Suppl 2):426.
Fig. 58 (abstract P352). See text for description
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 187 of 221P351
DNA vaccine with pembrolizumab elicits anti-tumor responses in
patients with metastatic, castration-resistant prostate cancer (mCRPC)
Douglas G McNeel1, Jens Eickhoff2, Robert Jeraj2, Mary Jane Staab1, Jane
Straus1, Brian Rekoske2, Glenn Liu1
1University of Wisconsin Carbone Cancer Center, Madison, WI, USA;
2University of Wisconsin, Madison, WI, USA
Correspondence: Douglas G McNeel (dm3@medicine.wisc.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P351
Background
In our evaluation of anti-tumor DNA vaccines as treatments for prostate can-
cer, we have recently shown in murine models that, depending on the dur-
ation of antigen expression encoded by the DNA and the strength of
MHC:TCRaffinity of CD8+T cells elicitedwith vaccination, these T cells express
higher levels of PD-1 or LAG-3 [1]. Blockade of these regulatory mechanisms
at the time of T cell activation with vaccine produced anti-tumor responses
in vivo. Similarly, we have recently found that patients with prostate cancer
previously immunizedwith a DNA vaccine develop PD-1-regulated T cells [2].
These findings suggested that combined PD-1 blockade with vaccination
should elicit superior anti-tumor responses in patientswith prostate cancer.
Methods
A clinical trial was designed to evaluate the immunological and clin-
ical efficacy of a DNA vaccine encoding PAP (pTVG-HP) when deliv-
ered in combination or in sequence with pembrolizumab, in patients
with mCRPC. Serial biopsies, blood draws, and exploratory FLT PET/
CT imaging are being conducted for correlative analyses.
Results
While trial accrual continues, 1 of 14 subjects has experienced a grade 3
adverse event. There have been no grade 4 events. 4 of 6 patients
treated with the combination have experienced serum PSA declines, and
3 of 6 have experienced decreases in tumor volume by radiographic im-
aging at 12 weeks, including one partial response. Expansion of PAP-
specific Th1-biased T cells has been detected in peripheral blood samples.
Exploratory FLT PET/CT imaging has demonstrated proliferative responses
in metastatic lesions and in vaccine-draining lymph nodes.
Conclusions
PD-1 pathway inhibitors have demonstrated little clinical activity to date
whenused as single agents for treatingprostate cancer. Our findings suggest
that combining this blockadewith tumor-targeted T cell activation by a DNA
vaccine is safe and can augment tumor-specific T cells, detectable within the
peripheral blood and by imaging, and result in objective changes. We are
currently exploring expansion of this trial to treat over an extended period of
time and in an earlier stage of disease.
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Adjuvants for cancer vaccines have not been optimized. In a murine
model, vaccines with IFA may deplete circulating T cells, but vaccination
with TLR agonists plus CD40 antibody induces strong, durable CD8 re-
sponses. An alternate approach to ligating CD40 is to activate CD4+ T
cells, to upregulate CD40L. The present study tests safety and immuno-
genicity of vaccination with 12 Class I MHC-restricted melanoma peptides
(12MP) to activate CD8+ T cells and a tetanus toxoid peptide (Tet) to acti-
vate CD4+ T cells, plus either of two TLR agonists, with or without IFA.
We hypothesized that vaccines with TLR3 agonist polyICLC or TLR4 agon-
ist lipopolysaccharide (LPS) would be safe and would induce stronger
and more durable T cell responses than when IFA was included.
Methods
Participants with resected stage IIB-IV melanoma were randomly assigned 2:1
to cohort 1 (LPS dose-escalation, n=33) or cohort 2 (polyICLC 1 mg, n=18).
Each cohort included 3 subgroups (a-c), receiving 12MP+Tet + TLR agonist (a)
without IFA, (b) plus IFA in the first vaccine only (V1), or (c) plus IFA in all six vac-
cines (V6). Toxicitieswere recorded (CTCAEv4). T cell responsesweremeasured
with IFNγ ELISpot either ex vivo, or 14 days after in vitro stimulation (IVS).
Results
There were no DLTs in Cohort 1 (LPS) but two in cohort 2 (1 of 6, sub-
groups 2b and 2c). CD8+ T cell responses to 12MP were detected
ex vivo in 43 %, 67 %, 50 %, and 29 % of patients in Cohort 1 with 25,
100, 400, and 1600 EU LPS, respectively, and in 56 % of patients in Co-
hort 2. Responses to 12MP were detected ex vivo in 18 %, 50 %, and
78 % for subgroups (a)-(c), respectively (Fig. 58). Responses were more
durable and of highest magnitude for IFA V6. IVS CD8 responses and
ex vivo CD4 responses were also improved with addition of IFA.
Conclusions
LPS is a safe and effective vaccine adjuvantwhen combinedwith IFA; the op-
timal biologic dose may be 100–400 EU. All regimens were deemed safe.
Despite recent concerns about IFA, this study demonstrates that in humans,
IFA enhanced magnitude and durability of T cell responses to peptide vac-
cines when added to TLR agonists. Thus, combination strategies with IFA
and LPS and/or pICLC offer promise for next generation vaccines.
Trial Registration
ClinicalTrials.gov identifier NCT0158535.P353
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Background
EWS is an aggressive, rare (10 cases per million 10–19 year old chil-
dren) pediatric cancer of bone and, less frequently, extraskeletal
sites. Although first-line intensive chemotherapy has been effective
in localized disease, it is less so in metastatic disease and poorly ef-
fective in patients with progressive or recurrent disease. Patients re-
lapsing within 2 years of diagnosis, which occurs in 72 % of the
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 188 of 221patients, have a 2-year survival of 7 %. The outcome for refractory
and third-line patients is even worse.
Methods
We recently completed a 3-year follow-up of a prospective, non-
randomized study of Vigil vaccine (1x10e6 - 1x10e7 cells/ID injection
1x/mo) in recurrent/refractory EWS patients (n = 16) and compared
results to a contemporaneous group (n = 14) not treated with Vigil
(Table 5).
Results
Results suggest survival benefit without evidence of Vigil related
toxicity (no ≥ grade 3). Specifically, we observed 1-year actual sur-
vival of 73 % for Vigil treated patients compared to 23 % in those
not treated and a 17.2 month improvement in overall survival
(Fig. 59).
Conclusions
In conclusion, Vigil appears to confer a survival advantage and en-
hanced therapeutic index in advanced EWS. A randomized multi-site
study comparing Vigil vs. gemcitabine/Taxotere in third-line metastatic
EWS has been initiated to see if these exploratory data can be con-
firmed (n = 62, HR 0.387).Table 5 (abstract P353). Ewing’s Sarcoma Phase I Demographics
Vigil® Matched Comparator (MC)a
Tum or Location Harvest (Lung/Soft
Tissue/Other)
13/0/3 11/2/1
Sex (M/F) 12/4 7/7
Age median (range) 19 (59–12) 17 (30–12)
Performance (ECOG 0, 1) 16 14
Ethnicity (Caucasian/Other) 13/3 12/2
Prior Systemic Tx (Frontline/2nd/=3rd) 1/5/10 3/4/7
General Surgery Harvest (Yes/No) 16/0 14/0
a3 insufficient viable tumor cells, 6 contaminants, 5 sought other management
Fig. 59 (abstract P353). See text for descriptionP354
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Survival of patients with advanced prostate cancer is significantly
less than patients with early stage. Immunotherapy is a promising
approach for the treatment of patients in advanced stage. In the
current study, we have evaluated the clinical and immunological
responses in patients with advanced or relapsed prostate cancer
who received Wilms’ tumor 1 (WT1) peptide-pulsed dendritic cell
(DC) vaccination in combination with a toll-like receptor (TLR) 4
agonist, OK432.
Methods
Twelve patients aged 57–82 years were enrolled in the present
study. Autologous DCs were generated by culturing adherent
mononuclear cells with interleukin-4 and granulocyte-
macrophage colony stimulating factor. DCs were then loaded
with synthetic peptides derived from WT1 following maturation
by prostaglandin E2 and OK432. DCs and OK432 were adminis-
tered intradermally every 2 weeks for 7 times. Induction of
vaccine-induced T cell responses was evaluated using a HLA-
tetramer assay, an intracellular cytokine staining assay and a
flow cytometry analysis.
Results
The treatment was well tolerated and none of the patients ex-
perienced more than grade 2 adverse events. Of 12 patients, 7
had stable disease (SD) and 5 had disease progression after one
course of vaccination. Survival of patients achieving SD after DC
vaccination (responder) was longer than those who did not re-
spond to the treatment (non-responder) (median duration of
survival; 48 vs 10 months). Increase in positivity of WT1-specific
CD8+ T cells was observed in both responders and non-
responders after one course of vaccination. However, increment
in positivity was marked in responders in comparison with non-
responders; 53.5 and 2.1 fold in responders and non-responders,
respectively. Similarly, intracellular IFNɤ staining assay showed
that marked increase in WT1 specific IFNɤ-producing CD8+ T
cells in responders compared with non-responders (68.2 vs 3.9
fold increase). Decrease in the absolute number of regulatory T
cells (Tregs) or myeloid-derived suppressor cells (MDSCs) was ob-
served in responders after vaccination. While the reduction in the
absolute number of Tregs and monocytic MDSCs was moderate
(9.0 % and 13.5 %, respectively), marked reduction in the absolute
number of granulocytic MDSCs (61.0 %) was observed, indicating
that DC vaccination may contribute to the reversal of immunosup-
pression by these cells.
Conclusions
DC vaccine-based immunotherapy combined with a TLR agonist was
demonstrated to be safe and elicit both innate and acquired cellular
immune responses correlated with clinical effects. These results sug-
gest that DC vaccination might be a promising novel strategy for the
treatment of patients with advanced or relapsed prostate cancer.
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Background
Folate binding protein (FBP) is over-expressed in multiple cancers. An
immunogenic peptide (E39) and an attenuated version (J65) have
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and destroy FBP-expressing cancer cells. In addition, previous trials
have shown that boosting vaccinations helps maintain long-lasting
immunity, though attenuated peptides may be a better choice for
boosting due to antigen-induced cell death (AICD) of CTLs after over-
stimulation. Here, we report peptide-specific immune response to
E39 and J65 after different combinations of vaccination and
boosting.
Methods
This is a prospective, randomized, non-blinded, single-center
phase Ib trial. Patients with breast or ovarian cancer rendered
disease-free after standard-of-care therapy were enrolled. HLA-A2+
patients were stratified (breast versus ovarian), and for the primary vac-
cine series (PVS) received either six inoculations with E39, three E39,
then three J65 or three J65, then three E39. Ex vivo immunologic
recognition of E39 was assessed by clonal expansion of cytotoxic
T lymphocytes (CTL) and in vivo response by delayed-type hyper-
sensitivity (DTH). The 6-month post-PVS immunologic data was
used to assess patients for significant residual immunity (SRI), de-
fined as ≥2-fold increase from pre-PVS in E39-specific CD8 + T
cells. Patients were sorted into two groups: with SRI (SRI) and
without (nSRI). Patients within each group were randomized to
one booster of either J65/E39 resulting in four groups: SRI receiving
E39 (SRI-E39), SRI receiving J65 (SRI-J65), nSRI receiving E39 (nSRI-E39),
nSRI receiving J65 (nSRI-J65). Immunologic data was gathered at 1- and
6-months post-booster. This immunologic data was then analyzed.
Results
28 patients were randomized to booster arms (SRI-E39:n = 9; SRI-
J65:n = 7; nSRI-E39:n = 7; nSRI-J65:n = 5). There were no clinico-
pathologic differences between groups. All related adverse
events were grade 1–2. When comparing DTH pre-booster and
at 1 and 6-months post-booster there were no significant differ-
ences between SRI vs nSRI (p = 0.350, p = 0.276, p = 0.133, re-
spectively), E39 vs. J65 (p = 0.270, p = 0.329, p = 0.228), nor
between all four groups (p = 0.394, p = 0.555, p = 0.191). Com-
paring delta-CTL from pre- and 6-months post-booster, regard-
less of SRI, patients boosted with J65 had increased CTL (+0.02)
while those boosted with E39 had decreased CTL (−0.07, p =
0.077). There was no difference comparing delta-DTH between
groups (p = 0.927).
Conclusions
Both E39 and J65 are safe, well tolerated boosters. Though numbers
were small, patients boosted with the attenuated peptide did appear
to have increased CTL response to boosting regardless of SRI after the
PVS. This is consistent with the theoretical advantage of boosting with
an attenuated peptide, which has a maintained E39 specific immunity.
Trial Registration
ClinicalTrials.gov identifier NCT02019524.P356
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Despite the unprecedented efficacy of checkpoint inhibitor (CPI) ther-
apy in treating some cancers, the majority of patients fail to respond.
Several lines of evidence support that the mutational burden of the
tumor influences the outcome of CPI therapies. Capitalizing on
neoantigens derived from non-synonymous somatic mutations may
be a good strategy for therapeutic immunization. Current approaches
to neoantigen prioritization involve mutanome sequencing, in silico
epitope prediction algorithms, and experimental validation of cancer
neoepitopes. We sought to circumvent some of the limitations of
prediction algorithms by prioritizing neoantigens empirically using
ATLAS™, a technology developed to screen T cell responses from any
subject against their entire complement of potential neoantigens.
Methods
Exome sequences were obtained from peripheral blood mononuclear
cells (PBMC) and tumor biopsies from a non-small cell lung cancer
patient who had been successfully treated with pembrolizumab. The
tumor exome was sequenced and somatic mutations identified. Indi-
vidual DNA sequences (399 nucleotides) spanning each mutation site
were built, cloned and expressed in E. coli co-expressing listeriolysin
O. Polypeptide expression was validated using a surrogate T cell
assay or by Western blotting. Frozen PBMCs, collected pre- and post-
therapy, were used to derive dendritic cells (MDDC), and CD8+ T cells
were enriched and expanded using microbeads. The E. coli clones
were pulsed onto MDDC in an ordered array, then co-cultured with
CD8+ T cells overnight. T cell activation was detected by analyzing
cytokines in supernatants. Antigens were identified as clones that in-
duced a cytokine response that exceeded 3 standard deviations of
the mean of ten negative controls, then their identities compared
with T cell epitopes predicted using previously described algorithms.
Results
Peripheral CD8+ T cells, screened against 100 mutated polypeptides
derived from the patient’s tumor, were responsive to five neoanti-
gens prior to CPI intervention and seven post-treatment. One was
identified as a T cell target both pre- and post-CPI therapy. Five
neoantigens did not contain epitopes predicted by in silico methods.
Conclusions
These data represent evidence that multiple patient-specific neoanti-
gens can be identified through functional evidence of T cell response
from peripheral blood without epitope prediction. By profiling nat-
ural and CPI-enhanced immunity to neoantigens, a broad catalog of
T cell targets can be identified for development of immunotherapies
that engage T cells against cancer to improve outcomes for patients
for whom current therapies are insufficient.
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Background
Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248)
is a protein found on tumor vasculature and in tumor stroma.
Methods
Here, we tested whether TEM1 has potential as a therapeutic
target for cancer immunotherapy by immunizing immunocompe-
tent mice with Tem1 cDNA fused to the minimal domain of the
C fragment of tetanus toxoid (referred to herein as Tem1-TT
vaccine).
Results
Fig. 60 (abstract P358). HfO2 nanoparticles: same mode of action
than radiotherapy, but amplified
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against immunodominant TEM1 protein sequences. Prophylactic
immunization of animals with Tem1-TT prevented or delayed
tumor formation in several murine tumor models. Therapeutic
vaccination of tumor-bearing mice reduced tumor vascularity, in-
creased infiltration of CD3+ T cells into the tumor, and controlled
progression of established tumors. Tem1-TT vaccination also elic-
ited CD8+ cytotoxic T cell responses against murine tumor-
specific antigens. Effective Tem1-TT vaccination did not affect
angiogenesis-dependent physiological processes, including wound
healing and reproduction.
Conclusions
Based on these data and the widespread expression of TEM1 on the
vasculature of different tumor types, we conclude that targeting TEM1
has therapeutic potential in cancer immunotherapy.
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Background
Effective immunotherapy requires optimal combination of immu-
notherapeutic agents to build a robust immune response against
cancer. In this framework, radiotherapy has proven its ability to
induce immunogenic cell death (ICD), showing a promising po-
tential for successful combination. Hafnium oxide (HfO2) nanopar-
ticles, undergoing clinical trials for enhancing radiotherapy, was
designed as high electron density material at the nanoscale to
enhance the absorption of radiation delivered within tumors. The
nanoparticles are taken up by cancer cells and, when exposed to
radiotherapy, locally increase the radiation dose deposit, trigger-
ing more cancer cells death when compared to radiotherapy
alone (Fig. 60).
Methods
Generation of ICD components – namely calreticulin (CALR) surface
exposure, release of high mobility group box 1 (HMGB1) protein and
liberation of adenosine-5’-triphosphate (ATP) – were examined on
human cancer cell lines across human cancer types, 24- to 96-hrs
post-treatment with HfO2 nanoparticles and exposure to irradiation
(from 4Gy to 15 Gy). CT 26 (murine colorectal cancer cells) treated
with or without HfO2 nanoparticles were exposed to irradiation
(6Gy). Irradiated cells (1.106) were inoculated subcutaneously into the
flank of BALB/c mice (vaccination phase). Seven days after, mice were
challenged with live CT 26 tumor cells (3.105) (challenge phase). The
host immune response against these cells was evaluated by the ap-
parition of at least one tumor (vaccination or challenge site).
Results
In vitro, human cancer cell lines treated with HfO2 nanoparticles
exposed to irradiation enhanced the quantity of ICD (more than
25 %) when compared to irradiation alone. Interestingly, in tested
human cell lines HCT116 (radiosensitive colorectal cancer) and
42MGBA (radioresistant glioblastoma), the generation of HMGB1
from cells treated with HfO2 nanoparticles and exposed to 4Gy
and 10Gy respectively, was superior to the generation of ICD
from cells treated with 6Gy and 15Gy alone respectively. In vivo,the percentage of mice protected against live CT 26 challenge
was markedly increased for mice vaccinated with cells treated
with HfO2 nanoparticles exposed to 6Gy versus 6Gy alone (66 %
vs 33 % respectively).
Conclusions
HfO2 nanoparticles exposed to irradiation enhanced cancer cells
destruction and ICD compared to irradiation alone, suggesting a
strong potential for transforming tumor into an effective in situ
vaccine. They may contribute to transform “cold” tumor into
“hot” tumor and effectively be combined with most of the immu-
notherapeutic agents across oncology.P359
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Background
Prostate cancer is the cancer type for which the first therapeutic vaccine
was approved by the FDA. Sipuleucel-T is a personalized cell based im-
munotherapy that costs $93,000 per patient and prolongs life for
4.1 months. Another most clinically advanced prostate cancer vaccine,
ProstVac-VF, is based on the two replication competent viral vectors, vac-
cinia and fowlpox. A global phase III trial of this vaccine has completed
enrollment and the results are eagerly awaited by the scientific commu-
nity. Both Sipuleucel-T and ProstVac-VF were shown to induce cellular im-
mune responses but the responses were of relatively low magnitude,
which could be an underlying cause of the modest clinical benefit.
Methods
We set out to evaluate an alternative viral based vaccination approach
as a novel prostate cancer immunotherapy. The scientific rationale for
this endeavor has been underpinned by numerous studies conducted
at the Jenner Institute research laboratories over the past decade. They
have demonstrated that a prime boost vaccination regime based on
Fig. 61 (abstract P360). The combination of BiVaxwith IL-2cx induced a
robust amount of endogenous TR-CTLs. aC57BL/6micewere immunized
with BiVax on day 0 and 12. IL-2 complexCD122 or IL-2 complexCD25was
administered on day 12, 14, and 16 in the indicated group. The percentage
of (TAPDNLGYM) Trp1-tetramer+ cells in blood CD8+ T cells was examined
on day 19 (boost). Images of the representative results on day 19
are shown. b On day 19, the number of Trp1-tetramer+ cells in
spleen was examined. c Purified CD8+ T cells from vaccinated
mice were used in ELISpot assay. T cells were cultured with
B16F10 melanoma cells for overnight. Results are presented as
mean ± SD. (*p<0.05, n.s.: not significant)
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vaccinia Ankara virus, MVA, is the most potent strategy for induction of
strong, poly-functional, durable and protective cellular immune re-
sponses in infectious disease setting. To test this vaccination platform
in cancer settings, simian adenovirus, ChAdOx1, and MVA were engi-
neered to express 5 T4 - the tumor-associated antigen that has been
previously targeted clinically by homologous vaccinations in a number
of tumor types including colorectal, renal and prostate cancer.
Results
Following ChAdOx1.5 T4-MVA.5 T4 vaccination, the mice mounted
strong T cell responses against 5 T4 and were completely protected
against subsequent tumor challenge with the syngeneic B16 melanoma
cell line expressing 5 T4. The vaccine was also protective in therapeutic
settings delaying progression of already established tumors in vacci-
nated mice. The ChAd-MVA vaccination platform significantly outper-
formed 5 T4 targeting homologous vaccinations previously tested by
other researchers in terms of both immunogenicity and efficacy. Strik-
ingly, a combination of ChAd-MVA vaccine with anti-PD-1 mAb resulted
in 80 % of mice remaining tumor-free while all the control animals suc-
cumbed to tumors in this highly aggressive cancer model.
Conclusions
Our preclinical data have supported further clinical development of the
novel prostate cancer vaccine. Recruitment is currently underway in the UK
to test ChAdOx1.5 T4-MVA.5 T4 vaccination regime in a first-in-human
“window” trial in low and intermediate risk prostate cancer patients. Prelim-
inary immunogenicity and efficacy data are expected later on this year.
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Background
Cancer vaccines, that generate tumor-reactive cytotoxic T lympho-
cyte (TR-CTL) responses are promising approach in cancer treatment.
Unfortunately, most cancer vaccines induce suboptimal CTL re-
sponses (both in the quality and quantity), which are not sufficient to
eradicate established tumors. In contrast, CTL adoptive cell therapy
(ACT) has shown in many instances great therapeutic success but this
therapy is not cost effective and remains technically challenging. We
hypothesize that expansion of high quality endogenous TR-CTLs
using peptide vaccines will circumvent the technical difficulties of
ACT and boost the antitumor efficacy in a cost effective manner.
Methods
Our lab developed a novel vaccination strategy using peptides from
tumor-associated antigens and poly-IC (BiVax), which showed promis-
ing antitumor effects [1]. Mice were injected with BiVax (120 μg of pep-
tide and 50 μg of Poly-IC) on day 0 and 12. Mouse IL-2cxCD25, IL-
2cxCD122, or IL-2Fc (20 μg/mouse) was injected intraperitoneally on day
12, 14, and 16. In some mice, cytokines were injected on day 1 to 4.Results
In this study, we further improved the efficacy of BiVax by utilizing IL-2/
anti-IL-2 antibody complexes (IL-2cx). The combination of BiVax with IL-
2cx (BiVaxIL-2cx) induced a robust amount of endogenous TR-CTLs (~40
million TR-CTLs/spleen) in a peptide dose-dependent manner. These
cells were able to recognize tumor in vitro as shown by ELISPOT assay.
Moreover, BiVaxIL-2cx-expanded TR-CTLs were able to significantly delay
B16F10 melanoma growth, enhance the survival of the tumor bearing
mice, and eradicate tumors in 20 % of mice. The timing for IL-2cx ad-
ministration was critical, thus the activation of T cells by peptide vac-
cines before cytokine administration was crucial to expand the TR-CTLs.
Conclusions
In conclusion, our data showed that peptide vaccines have the ability
to expand huge number of TR-CTLs with good quality that able to con-
trol and in some instances eradicate aggressive tumors. Moreover, the
adjuvant and its timing of administration are critical in expanding the
TR-CTLs by peptide vaccines. Finally, our findings may pave the way for
the development of promising immunologic approach for cancer treat-
ment, which may circumvent lymphodepletion in ACT therapy and en-
hance the checkpoint blockade inhibitors treatment.
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Fig. 63 (abstract P360). The antitumor effects of BiVax correlate with
the percentage of Trp1-tetramer positive CD8+ T cells. C57BL/6 mice were
inoculated with B16F10 melanoma cells (5 x 105 cells/mouse). After 7 days,
mice received BiVax twice on day 7 and 12 and IL-2 complexCD122 or IL-2
complexCD25 was administered on day 12, 14, and 16. a The percentage
survival of Trp1-BiVax-received mice. b The Pearson correlation analysis of
the tumor size (day 22) and the percentage of Trp1-tetramer+ cells in
PBMC. c The Pearson correlation analysis of the tumor size (day 22) and
the percentage of PD-1+ cells in PBMC. d The Pearson correlation analysis
of the percentage of Trp1-tetramer+ cells and the percentage of PD-1+
cells in PBMC. e The sizes of individual tumor are demonstrated
Fig. 64 (abstract P360). Proper timing of IL-2 complex administration
is necessary to induce CD8+ T cell responses. a C57BL/6 mice were
injected with BiVax on day 0 combined with IL-2 complexCD122 (day
1, 2, and 3), IL-2 complexCD25 (day 1, 2, and 3) or IL-2Fc (day 1 to 4).
The percentage of tetramer+ cells in CD8+ T cell or (b) CD44+ T cells
in Trp1-tetramer- CD8+ T cells was examined in blood on day 7. c
C57BL/6 mice received IL-2 complexCD122 on day 0, 2, and 4 and the
number of CD44+ or CD122+ cells in spleen was examined on day 7.
The picture of spleen after the treatment is shown. d C57BL/6 mice
received TgTR1 cells (2000 cells/mouse) and BiVax. After 7 days, the
expression of blood CD62L, CD44, and CD122 on activated TgTR1 cells
were compared to naïve TgTR1 cells. b C57BL/6 mice were injected
with BiVax on day 0 and 5. IL-2 complexCD122 or IL-2 complexCD25
was administered on day 5, 7, and 9. The percentages of tetramer+
cells in blood CD8+ T cells and (f) the numbers of tetramer+ cells in
spleen on day 12 are shown. Results are presented as mean ± SD.
(*p<0.05, n.s.: not significant)
Fig. 62 (abstract P360). The therapeutic effects of IL-2 complex with
peptide vaccine. a-e C57BL/6 mice were inoculated with B16F10 melanoma
cells (5 x 105 cells/mouse). After 7 days, mice received BiVax twice (day 7
and 12). IL-2 complexCD122 or IL-2 complexCD25 was administered on day
12, 14, and 16. a The mean sizes of tumor and (b) the overall survival of
tumor-bearing mice are depicted. c The percentage of Trp1-tetramer+ cells
in CD8+ T cells was examined on day 18 and 31. d The representative
image of vitiligo at the tumor-inoculated lesion in the mouse, which
received BiVax and IL-2 complexCD25 (day 30). e The expression of PD-1 on
Trp1-tetramer+ CD8+ T cells was assessed on day 31. Results are
presented as mean ± SD. (*p<0.05, n.s.: not significant)
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Background
Human papillomavirus (HPV) type 16 is associated with the etiology
of cervical cancer, head and neck squamous cell carcinoma (HNSCC),
and many other HPV-associated tumors. Current HPV-16 vaccines
utilize viral coat proteins or virus-like particles with HPV-16 late gene
products. Many HNSCC express early E6/E7 rather than late viral genes
such as the viral coat proteins. Thus, vaccines that use late viral proteins
may not be effective in treating established tumors. E6/E7, the early
proteins of HPV-16, have a transforming capacity. They interfere with
cell-cycle control of infected cells and are essential for maintaining the
transformed state. An immune-based therapeutic vaccine that targets
E6/E7 may prove more effective than a late viral protein vaccine. Identi-
fying and characterizing MHC class I-restricted immunogenic pep-
tides derived from E6/E7 proteins is essential for designing and
developing vaccines to treat HPV-16-induced carcinomas, and for
monitoring clinical trials and immunotherapeutic approaches for
the treatment of these tumors.
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We report here the development of immunogenic HLA-A*0201-restricted
9-mer epitopes and agonist epitopes of E6 and E7. We selected two
E6- and one E7-derived peptide epitope and the corresponding
agonist epitopes with high affinities for HLA-A*0201 molecules. The
immunogenicity of these six peptides was evaluated by their ability
to activate T cell lines generated from human dendritic cells in-
fected with the Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector and normal human
peripheral blood mononuclear cells (PBMC). The Ad5 [E1-, E2b-]–E6
Δ/E7Δ vector contains mutations that render E6/E7 nononcogenic,
while preserving antigenicity.
Results
Our results show that these peptide-pulsed dendritic cells, as well as
Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector-infected dendritic cells, can activate
T cell lines generated from human dendritic cells infected with the
Ad5 [E1-, E2b-]–E6 Δ/E7Δ vector. Compared to native peptides, the
agonist peptides more efficiently (1) enhanced the production of
IFN-γ by peptide-activated human T cells and (2) lysed human tumor
cells expressing HPV in an MHC-restricted manner. These agonist
peptides are highly immunogenic.
Conclusions
These studies provide a rationale for the incorporation of these agon-
ist epitopes into therapeutic vaccine platforms and for the ex vivo
generation of HPV-specific human T cells.
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Background
Challenging the notion that chemotherapy negatively modulates
the immune system of tumor-bearing hosts, recent evidence on
the contrary indicates that some cytotoxic drugs control tumor
growth in part by facilitating an anti-tumor immune response. The
precise mechanism(s) that controls this phenomenon have not
been elucidated. Chemotherapy, especially at low doses, may
modify the host’s immune system by either augmenting antigen-
specific effector cells by rendering tumor cells immunogenic or
eliminating immune-suppressive cell populations that limit the
anti-tumor immune effect. Doxil (pegylated liposomal doxorubicin)
possesses specific immunomodulatory properties such as inducing
immunogenic tumor cell apoptosis.
Methods
Mice were injected intraperitoneally (i.p.) with 5 x106 ID8 cells. For che-
motherapeutic treatment, mice received a single i.p. injection of either
50 mg/m2 of Doxil (doxorubicin HCl liposome injection) or 50 mg/m2 of
doxorubicin. DNA immunization (mTERT-LTB) was performed according
to commonly used protocols: 50 micrograms of plasmid DNA was
injected into mice quadriceps and then electroporation was carried out
with a BTX electroporator intramuscularly at the injection site. For nat-
ural killer (NK) cell depletion, tumor-free and ID8 tumor-bearing mice
were treated with anti-asialo GM1.
Results
Here, we characterize how Doxil treatment is able to improve both the
tumor-free and tumor-bearing host immune system by expanding NK cell
populations after 5 days from the time of drug administration. Moreover,
NK cells isolated from Doxil-treated mice produce greater amounts of
interferon (IFN)-γ compared to isolated NK cells from untreated mice, pro-
moting selective Th-1 polarization of naïve CD4+ T cells. These immune
modifications mediated by chemotherapy ameliorates the capability of a
DNA-vaccine to select and expand an antigen-specific CD8 + T cell popu-
lation. This synergistic effect between chemotherapy and vaccination was
completely mediated by NK cell expansion; in fact, the in vivo depletion
of this cell subset totally abrogated the Doxil immune adjuvant activity.We combined Doxil with a DNA-vaccine encoding mouse telomerase re-
verse transcriptase (TERT).
Conclusions
TERT is an attractive target antigen for cancer vaccine because its
expression is reactivated in tumors of different histology such as
ovarian cancer. We verified different vaccination schedules in ID8
ovarian tumor-bearing mice and only combinations that resulted in
significant tumor growth inhibition were related to a specific anti-
TERT CD8+ T cell response. This data demonstrates “chemo-im-
mune adjuvancy” of a conventional drug and highlights the import-
ance to define the precise time window between treatments to
improve their therapeutic synergism.
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Background
Recently, a lot of tumor antigen peptides are examined for clin-
ical applications. The treatment strategy using multiple peptides
is expected to achieve better outcomes than single peptide treat-
ment in terms of HLA restriction. In addition, many advantages
administering the synthetic long peptides (SLPs) are reported.
Based on this information, and aiming for improvement of popu-
larity coverage, we planned to design SLP vaccines containing
multiple cytotoxic T lymphocyte (CTL) epitopes which are re-
stricted HLA-A2, A24, A3 supertype, respectively. However, there
are few screening strategies to confirm whether designed SLP
vaccines could induce all epitopes specific-CTLs in humans except
confirmations using human PBMCs or expensive HLA-expressing
mice. In order to improve this issue, we performed the following
screening procedures.
Methods
Murine-immunoproteasome digestion assay was conducted as follows.
Briefly, SLPs were dissolved with buffer and incubated with murine i20s
immunoproteasome for 1 h, 2 h and 4 h. Then, digested peptides were
separated using an UPLC system, and the eluent was analyzed by mass
spectrometry. The sequences of the digested peptides were assigned
based on the results of their m/z. Finally, the “digestion maps” were
drawn by rearranging digested peptides fragments from N-terminal. In
order to compare the digestion maps to the peptide specific CTL induc-
tion, the SLPs were administered to HLA-A knock-in mice and the CTL
induction was analyzed using IFN-γ ELISPOT assay.
Results
We applied 4 SLPs to the murine-immunoproteasome digestion assay.
Immunoproteasomal degradations were observed in all SLPs and they
were time-dependent. In this study, we focused on the generations of in-
tact epitopes, Arg added epitopes, and Arg-Arg added epitopes to the N-
terminus at any time points because proteasomal digestion of exact C-
terminus of CTL epitope is known to be an essential process for the anti-
gen presentation. Regarding this criteria, 8 epitopes were determined as
a “living epitope,” which would be able to induce specific CTLs, but 4 epi-
topes were determined as a “dead epitope”. Compared with the IFN-γ
ELISPOT assay, the results of murine-immunoproteasome digestion assay
were substantially matched the results of CTL induction (11 of 12 epi-
topes: 91.7 %).
Conclusions
Murine-immunoproteasome digestion assay could predict the CTL
induction with a high degree of accuracy. We concluded that
murine-immunoproteasome digestion assay strategy could be a prog-
nostic approach for IFN-γ ELISPOT assay using an HLA-expressing mice
model. In addition, our results suggested that the positions of each epi-
tope peptide are important for the design of SLP vaccines. Murine-
immunoproteasome digestion assay is very useful to develop “suitable”
multi-valent SLP vaccines.
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Background
Head and neck cancer (HNC), including TC, is the 6th most common
group of cancers worldwide. Survival rates with conventional treat-
ments are unsatisfactory and treatment-associated side effects
marked, necessitating development of novel therapeutic approaches.
Arguably, DC-mediated immunotherapy is one such option, owing
to the outstanding potential of DCs to elicit tumor-specific immune
responses. Our work presents frequency as well as transcriptional
and phenotypical assessments of myeloid and plasmacytoid DC
subsets in TC and benign tonsils to fulfill a descriptive need of DC
characterization in DC-mediated immunotherapy context.
Methods
From biopsies of TC tissue (n = 4) and benign tonsils (n = 4), DC subsets
were identified and sorted through an 8-color flow cytometry Ab panel.
Sorted cells were run on a human transcriptome array and gene ex-
pression profiles of the subsets in TC were compared to their peers
with benign tonsils. Two fold upregulated subset-specific gene signa-
tures were determined by the intersection derived from separate two-
group comparison tests against other subsets. They were then analyzed
and candidate genes were extracted based on association with cross-
presentation, endocytosis, and signaling activities. A set of selected
candidate markers was investigated at the protein level through
flow cytometry (approximately 15 benign and 10 TC samples).
Results
DCs were more frequent among CD45+ leukocytes in TC compared
to benign tonsils and showed an elevated myeloid CD11c+/plasmacy-
toid CD123+ ratio. In agreement, some statistically significant
changes were observed in different subsets where CD123+ DCs were
less frequent in TC compared to benign tonsils while CD1c− CD141−
DCs were more frequent. In contrast, no significant differences were
detected in DC subsets’ gene expression profiles between TC and be-
nign tonsils. Lists of subset-specific candidate genes were generated
and some of them were confirmed at protein level, e.g., CD206 and
CD207 on the CD1c+ DCs in TC and benign tonsils.
Conclusions
DCs are present in TC and benign tonsil tissue with somewhat different
subset ratios but similar transcriptional and phenotypic profiles. Surpris-
ingly, DCs may therefore not be markedly affected by the microenvir-
onment in TC (as may be the case for many other cancers).
Accordingly, our work suggests a maintained DC functionality and po-
tentially a unique possibility of tailored DC-mediated immunotherapy
for TC. This is now facilitated by our present description of subset-
selective target molecules for induction of favored cell-mediated anti-
tumor responses. Further functional studies are warranted and whether
our findings extend to other HNCs remains to be examined.
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Our recent results demonstrate that the ovarian tumor environment
is characterized by local T cell exhaustion and high levels of immuno-
suppressive cytokines, including interleukin (IL)-10 [1]. We hypothe-
sized that IL-10 blockade would synergize with immune checkpoint
antibodies to promote tumor clearance in ovarian cancer.
Methods
Dendritic cells (DC) in mice treated with 300ug of an IL-10 receptor
antibody (IL-10Rab) were analyzed in two murine tumor models [2,
3]. In the implantable ID8ova model, mice were treated 7 and 14 days
after tumor challenge; MISIIRTag mice were treated at 14 weeks of
age. Immune checkpoint antibody treatment was evaluated in wild-
type or IL10-knockout (IL10KO) mice treated with 500ug of anti-PD-1
antibody on days 17 and 21 after ID8ova tumor challenge (n = 5/
group). Survival was measured from tumor challenge until mice
reached 30 g due to ascites accumulation.
Results
In both models, IL-10Rab treatment increased stimulatory CD103+ DC
(18 % to 30 % in ID8ova; 5 % to 45 % in MISIIRTag), and decreased sup-
pressive Lair1+ DC in the peritoneal tumor environment and in primary
ovarian tumors [1]. This was associated with an increase in CD8+ T cells
and a decrease in regulatory FoxP3+ CD4+ T cells (45 % to 30 %). The
proportion of CD4+ and CD8+ T cells producing interferon-gamma also
increased (12 % to 28 %). Long-term survival was observed in 100 % of
IL10KO mice treated with PD-1 antibody but treatment did not improve
survival in wild-type controls.
Conclusions
These results demonstrate an enrichment of stimulatory CD103+ DC
in the tumor microenvironment with IL-10R blockade, associated
with evidence of increased T cell effector capacity and a reduction in
suppressive Treg. This was associated with a significant survival
benefit in IL10KO mice receiving anti-PD-1 antibody. These data sup-
port combining IL-10Rab with immune checkpoint antibodies for the
treatment of ovarian cancer.
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Background
Hypofractionated high dose ionizing radiation (RT) can enhance antitu-
mor immune responses in many cancers. In some cases the combination
of RT and checkpoint immunotherapy suppress adaptive resistance
leading to a greater immunologic effect. However, many tumors are
unresponsive to the combination making it important to understand
factors that render tumors immunologically inactive. We previously de-
scribed immunologically responsive (Py117) and unresponsive (Py8119)
syngeneic tumors from the PyMT mammary carcinoma model and
used these tumors to determine new targets to reverse T cell exclusion.
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A reverse phase protein array was used to study differences between
the Py117 and Py8119 tumors. The CRISPR/Cas9 technology was used
to knockout Axl, a TAM family tyrosine kinase. We confirmed signal
abrogation with the loss of Axl through western blot, measured the
intrinsic radiosensitivity by clonogenic survival, determined cellular
proliferation, evaluated growth in 3D tissue culture, implanted tumors
to determine radiosensitivity in mice, and evaluated the response in im-
munodeficient mice. Given the presence of an immunologic phenotype
we measured the impact of Axl on antigen presentation and cytokine
production. Lastly, we defined the antitumor immune response by dis-
sociating tumors then immunophenotyping infiltrates, evaluating T cell
function, and tumor cell responses. Lastly, we combined radiation,
PD-1, and CTLA-4 therapy to demonstrate that loss of Axl sensitizes
tumors to immunotherapy.
Results
Through a RPPA, we identified differences in Axl expression a protein
associated with the epithelial to mesenchymal transition (EMT). Then
we knocked out Axl, which revealed no changes in proliferation or
intrinsic radiosenstivity but altered the EMT phenotype, resulted in
greater tumor latency and enhanced radiosensitivity after 20 Gy in
mice. Key features of the Axl knockouts were enhanced MHCI expres-
sion and decreased myeloid promoting cytokines and chemokines.
The radiation response was decreased in mice carrying Axl knockout
tumors suggesting the importance of the immune response. Profiling
the tumor microenvironment revealed greater immune infiltrates in
Axl knockout tumors and greater CD8+ T cells at baseline. Ten days
after radiation there was increased CD8 and CD4+ T cells and decreased
macrophages. T cells remained functional but adaptive immune resist-
ance was supported by increased PD-L1 and FoxP3+ T regs in Axl defi-
cient tumors. We hypothesized and confirmed that a greater radiation
response was obtained with PD-1 and CTLA-4 inhibition in Axl deficient
tumors.
Conclusions
These data suggest that Axl may not only mediate invasion and me-
tastasis but can influence immunosurveillance and response to ther-
apy by suppressing an antitumor immune response.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause
of cancer death in the United States [1]. PDAC is characterized by
oncogenic KRAS mutations and resistance to chemotherapy and im-
munotherapy [2]. Epidermal growth factor receptor (EGFR) is required
for KRAS-induced pancreatic tumorigenesis [3]. Although EGFR net-
work activation represents a possible therapy target in PDAC, the
anti-EGFR small molecule erlotinib has minimal therapeutic activity
[4]. Accumulating evidence suggests that the immune system plays
an important but complex role in the development and progression
of PDAC [2]. Accordingly, we explored the effect of immune selection
pressure on EGFR and related signaling pathways using syngeneic
Panc02 pancreatic cancer models.
Methods
1 X106 Panc02 cells were injected subcutaneously in immunocompetent
B6.CB17 (WT) and immunodeficient B6.CB17-Prkdcscid/SzJ (SCID) mice
(16mice/group). One cm3 tumors were harvested and processed for
reverse phase protein array (RPPA) of 125 proteins (18 total proteins,
107 phosphorylated species) to evaluate protein signaling networks.
Due to tumor invasiveness it was not possible to perform laser cap-
ture microdissection on the specimens. Statistical analysis included
Wilcoxon test, Student’s t-test and principal component analysis(PCA) to identify significant hits. Pathways Studio was then used to
identify selectively activated signaling pathways.
Results
As expected, Panc02 tumors grow more slowly in immunocompetent
as opposed to syngeneic immunodeficient mice. Interestingly, PCA of
the RPPA data demonstrated a significant difference in cellular pro-
tein activity between Panc02 tumors engrafted in the two groups of
mice. 32.8 % (41/125) of proteins tested by RPPA were statistically
significantly activated in immunocompetent mice as opposed to im-
munodeficient mice. Pathway analysis of these activated hits re-
vealed selective activation of EGFR, ERK/MAPK, JAK/STAT, AMPK and
TGFβ/Smad signaling pathways in immunocompetent mice.
Conclusions
Immune selection pressure in syngeneic Panc02 pancreatic cancer
models selectively activates multiple, related signaling pathways.
These observations lay important groundwork for understanding and
therapeutically exploiting the interplay of host immunity and tumor
cell signaling.
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Background
The presence of T cells in the tumor microenvironment and their po-
tential impact on prognosis has been investigated over many years.
One implication has been that the presence of CD8 (cytotoxic T cell
marker), as well as a high CD8/FoxP3 ratio, indicates a positive effect
on patient survival. The forkhead box p3 (FoxP3) regulatory T cell
(Tregs) marker has been utilized to investigate how Tregs function in
suppressing immune response, in particular their influence on other T
cells [1]. Therefore, understanding suppressive mechanisms and inter-
actions between T cell subsets, by exploring spatial interactions, will in-
evitably provide evidence in support of the development of drugs for
effective control of immune responses via Tregs. Using recent develop-
ments in histology image analysis techniques, we aimed to quantify
CD8 and FoxP3 immune cell relationships in terms of cell infiltrations
and cell-cell proximities within the tumor tissue microenvironment.
Methods
Tumor tissue was immunohistochemically (IHC) dual labelled for FoxP3
(brown nuclear chromogen) and CD8 (red membrane chromogen).
Image analysis was performed within manually annotated regions of
interest (ROI) using Indica Labs Halo™ software. Cellular analysis settings
and thresholds were established to identify and count FoxP3, CD8, and
dual labelled cells. 50 μm margin bands were generated around inter-
face ROI into the active stroma region and out to tumor regions. Appli-
cation of spatial analysis was performed using cytonuclear analyzed
object data outputs to quantify infiltration analysis (number of cells per
50 μm margin band around defined interfaces) and proximity analysis
(measure distances between defined cell populations within <50 μm
range, using 5 μm bins).
Results
Tumor/stroma interface quantification indicated higher FoxP3 to CD8
ratios 100 μm inside the tumor boundary when compared to adjacent
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 196 of 221active stromal regions, 100 μm outside the tumor. This difference in cell
number was also reflected in cell proximity values with shorter FoxP3
to CD8 cell distances in the stroma compared to tumor.
Conclusions
These example data highlight the benefits of utilizing tissue-based
whole slide image analysis to characterize therapeutic activity using
spatial correlations within the tumor microenvironment, which pro-
vides distinct advantages over flow cytometry-based approaches
where critical information on spatial cellular context is lost.
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Background
Abundance and functional quality of tumor-infiltrating lymphocytes
are positively linked with tumor response and improved survival
with checkpoint inhibitors. NKTR-214 provides sustained activation
of the IL-2 pathway through controlled release of active CD122-
biased (IL-2Rβɣ) cytokines. Preclinical models demonstrated NKTR-
214 preferentially expands effector CD8 + T cells and NK cells within
the tumor resulting in marked tumor growth suppression as single-
agent and in combination with checkpoint inhibitors. A phase I/II
trial was initiated to evaluate NKTR-214 safety and efficacy and to
assess immune changes in the tumor microenvironment.
Methods
This is an ongoing dose-escalation and dose-expansion study of
NKTR-214 in patients with locally advanced or metastatic solid tu-
mors with a standard 3 + 3 design. Extensive blood and tumor tissue
samples have been collected to measure immune activation using
immunophenotyping including flow cytometry, immunohistochemis-
try (IHC), T cell clonality and gene expression analyses. Safety,
pharmacokinetics and preliminary anti-tumor activity of NKTR-214
are being evaluated. NKTR-214 is administered IV q2-q3 weeks in an
outpatient setting with initial dosing at 0.003 mg/kg.
Results
As of August 2, 2016, 18 patients who received prior standard of care
were enrolled (RCC [n = 12], MEL [n = 4], CRC [n = 1]; UBC [n = 1]). 7/
12 (58 %) patients had stable disease at initial 6 or 8-week scan with
9 patients still on treatment. Outpatient treatment with NKTR-214
was well tolerated and the MTD has not been reached. One patient
experienced DLTs (Grade 3 syncope and hypotension) at 0.012 mg/
kg. No immune-related AEs or capillary leak syndrome were observed
at any dose. No drug-related AEs led to study discontinuation. 9/18
patients had serial tumor biopsies (pre and post-dose) evaluable. In
6/9 patients, flow cytometry enumeration and/or IHC revealed an up
to 10-fold increase from baseline in CD8 + T cells and NK cells in the
tumor microenvironment, with minimal changes to Tregs. Most of
the infiltrating CD8 + T cells were newly proliferative (Ki67+) and cell-
surface PD-1 expression was increased up to 2-fold. Analyses of
blood samples showed concordant increases in Ki67+ immune cells,
PD-1+ CD8 + T cells, and NK cells 8 days after a single dose of NKTR-
214. The study continues to enroll patients.Conclusions
NKTR-214 results in substantial increases in both CD8 + T cells and
NK cells in the tumor microenvironment with a favorable outpatient
safety profile. These data support continued evaluation of NKTR-214
and the potential advantages of combining NKTR-214 with a variety
of immunotherapeutic agents including checkpoint inhibitors. Up-
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Background
Glioblastoma multiforme (GBM) brain tumors are nearly uniformly fatal.
The GBM microenvironment includes abundant tumor-associated mac-
rophages (TAMs) that predominantly assume a pro-tumor “M2” pheno-
type rather than a pro-inflammatory “M1” phenotype. The inhibitory
p50 subunit of the NF-kB transcription factor exhibits markedly in-
creased nuclear expression in TAMs and M2-polarized macrophages,
and p50 knockdown/deletion suppresses expression of M2-associated
factors [1, 2]. We hypothesize that absence of p50 will convert TAMs to
an M1 phenotype that will reduce glioma growth and prolong survival.
Methods
GL261-Luc cells were intracranially implanted into mice. Tumor
growth was monitored by IVIS imaging. Brains were removed 13–16
days after implantation for flow cytometry (FC) or RT-qPCR analysis.
Depleting antibodies were administered by i.p. injection; clodronate
by tail vein injection. Naïve T cells were enriched from spleens,
skewed in vitro with cytokines and blocking antibodies, expanded in
IL-2, then stimulated with PMA/ionomycin. Cells were assessed for Th
or Tc1 skewing by FC or ELISA.
Results
p50(−/−) mice exhibit significantly slower GL261-Luc tumor growth
and prolonged survival. p50(−/−) tumor CD11b +myeloid cells ex-
press increased M1-associated and decreased M2-associated mRNAs
relative to WT mice. FC indicates glioma-bearing p50(−/−) brains con-
tain fewer TAMs expressing the M2 marker CD206/MRC1, as well as
fewer Tregs, increased IFNg-producing CD4+ T cells, and increased
granzyme B+ CD8+ T cells. Transplant of p50(−/−) bone marrow into
lethally-irradiated WT recipients confers a significant survival advan-
tage upon tumor inoculation. Clodronate-mediated macrophage de-
pletion decreases survival of tumor-bearing p50(−/−) mice but has
no effect on WT mice. Depletion of CD4+ T cells markedly reduces
survival in tumor-bearing p50(−/−) mice whereas depletion of CD8+
T cells has no effect. We observe no intrinsic defect in the ability of
p50(−/−) naïve splenic CD4+ T cells to differentiate into Tregs, Th1,
Th17, or Th2 subsets; however, p50(−/−) naïve splenic CD8+ T cells
exhibit enhanced ability to produce IFNg, TNFa, and granzyme B.
Conclusions
NF-kB p50 is an important modulator of the suppressive immune pheno-
type in GBM. Both TAM and T cells are more activated and less tumor-
permissive when p50 is absent. Targeted deletion of p50 from TAMs
and/or T cells may serve as a viable therapeutic for patients with GBM.
References
1. Saccani A, et al.: p50 nuclear factor-κB overexpression in tumor-
associated macrophages inhibits M1 inflammatory responses and
antitumor resistance. Cancer Res 2006, 66(23):11432–11440.
2. Porta C, et al.: Tolerance and M2 (alternative) macrophage polarization
are related processes orchestrated by p50 nuclear factor κB. Proc Natl
Acad Sci 2009, 106(35):14978–14983.
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 197 of 221P371
The differentiation of Th17-into-Treg cells in the tumor
microenvironment reveals novel targets in cancer immunotherapy
Sara Berkey1, Stephanie Downs-Canner1, Greg M Delgoffe2, Robert P
Edwards2, Tyler Curiel3, Kunle Odunsi4, David Bartlett1, Nataša Obermajer1
1Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA;
2University of Pittsburgh, Pittsburgh, PA, USA; 3University of Texas Health
Science Center at San Antonio, San Antonio, TX, USA; 4Roswell Park
Cancer Institute, Buffalo, NY, USA
Correspondence: Sara Berkey (berkeyse@upmc.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P371
Background
Th17 and regulatory T (Treg) cells are integral in maintaining immune
homeostasis and the Th17-Treg balance is associated with the inflam-
matory immunosuppression observed in cancer. Expansion of Treg
cells within the tumor is a known barrier to successful cancer im-
munotherapy. Because of this, Treg cell regulation has become a
popular interest for new therapeutic modalities. However, current ap-
proaches designed to deplete Treg cells are only variably effective
and urge for novel strategies to specifically target the suppressive
function of intratumoral Treg cells.
Methods
We have used IL17 (Il17aCreRosa26eYFP) and Treg (B6.129(Cg)-
Foxp3tm3(DTR/GFP)Ayr) reporter mice to study Th17 cell plasticity and
Th17-into-Treg cell transdifferentiation as a novel tumor-associated
phenomenon supporting immunosuppressive microenvironment in
tumor-bearing mice.
Results
We demonstrate that in addition to natural (n)Treg and induced (i)Treg
cells developed from naïve precursors, Th17 cells are a novel source
of tumor-induced forkhead box P3 (Foxp3+) cells by progressive direct
conversion into immunosuppressive IL17A+Foxp3+ and ex-Th17 Foxp3+
cells. Transcriptome analysis of the Th17-Treg plastic subsets reveals
upregulation of 119 genes in the IL17A+Foxp3+ cells compared to
IL17A+ Foxp3neg Th17 cells (Th17-Treg plasticity markers). Seven of
these plasticity markers identified by transcriptome analysis were
confirmed by flow cytometry of plastic IL17+Foxp3+ cells. The
immunometabolism of the plastic IL17A+Foxp3+ subset revealed an
additional level of complexity in controlling the immune function
of CD4+ T cells and to modulate (trans) differentiation of Th cells,
which thereby control their ultimate function and role in diverse
environments.
Conclusions
Tumor-associated Th17-into-Foxp3+ T cell transdifferentiation helps
to reconcile the contradictory observations about the role of Th17
cells in tumor immune surveillance, and demonstrates an alternative
source for IL17+Foxp3+ and IL17negFoxp3+ T cells in tumors. Further,
this newly identified tumor-associated phenomenon warrants strat-
egies to manipulate the Th17-Treg cell plasticity in cancer and identi-
fies novel IL17/Treg- associated targets that might be amenable for
therapeutic interventions to enhance antitumor immunity.
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Despite improvements in surgical techniques and combined chemo-
and immunotherapies, the 5-year survival rate for all stages of non-small
cell lung cancer (NSCLC) is only 18 %. The focus of immunotherapy has
been on subsets of CD8+ and CD4+ tumor infiltrating lymphocytes
(TILs). However, tumor infiltrating B cells (TIL-Bs) have been reported in
tertiary lymphoid structures (TLS) with CD4+ TILs, both positively correl-
ating with patient survival. TIL-B function in the tumor microenviron-
ment (TME) has been understudied with no focus on their role as
antigen presenting cells (APCs). We hypothesized that TIL-Bs help gener-
ate potent, long-term immune responses against cancer by presenting
tumor antigens to CD4+ TILs.
Methods
All studies were completed on freshly collected, un-manipulated pri-
mary human B cells from tumor and tumor adjacent lung tissue. We
analyzed the number and phenotype of TIL-Bs via flow cytometery
and immunofluorescence. We generated a specific antigen presenta-
tion assay in vitro to assay APC function.
Results
We observed that the total number of B cells at the site of the tumor
versus the tumor-adjacent tissue was increased compared to other
immune subsets. Further, we found three types of CD4+ TIL responses
when TIL-Bs presented autologous tumor antigens. There were activated
responder CD4+ TILs that proliferated when combined with TIL-Bs alone,
which indicates stimulation with endogenous tumor antigens. There
were antigen-associated responders that required exogenous autolo-
gous tumor lysate to elicit a CD4+ TIL response, and there were patient
CD4+ TILs that did not respond to antigen presentation by TIL-Bs. Within
the activated and antigen-associated responders, the TIL-B phenotype
associated with the CD4+ TIL phenotype; if the TIL-Bs were activated
(CD69 + CD27 + CD21+), the CD4+ TILs were T helper (anti-tumor) CD4+
T cells and if the TIL-Bs were exhausted (CD69-CD27-CD21-), the CD4+
TILs were T regulatory cells (pro-tumor). These data suggest that TIL-Bs
affect the phenotype and function of CD4+ TILs in NSCLC patient
tumors.
Conclusions
In conclusion, TIL-Bs are increased in NSCLC primary tumors and they
can present antigen to and associate with CD4+ TILs in the tumor
microenvironment. Determining if TIL-Bs are activated or exhausted
in NSCLC patients will determine the extent of their anti-tumor func-
tion. Ultimately, results from this study will help predict how to tar-
get TIL-B functions in future immunotherapies for NSCLC patients.
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Background
The success of cancer immunotherapy is often limited by multiple
mechanisms of tumor-induced immunosuppression; M2-like TAMs be-
ing one of the critical mediators of immunosuppression. Imprime PGG
(Imprime), an intravenously administered soluble yeast β-1,3/1,6 glucan
is being clinically developed in combination with tumor-targeting anti-
bodies, anti-angiogenics, and checkpoint inhibitors. Imprime has shown
promising results in two randomized phase II studies in non-small cell
lung cancer (NSCLC). Imprime acts mechanistically as a PAMP enlisting
innate immune functions including cytotoxic effector mechanisms,
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mune system. With respect to immunosuppression, Imprime has
been shown to repolarize M2 macrophages to an anti-tumor M1-
like orientation in human ex vivo studies [1]. The objective of this
study was to expand on this finding in an in vivo setting.
Methods
Imprime’s M1-polarization effect was evaluated in tumor-free mice, and
xenograft and syngeneic tumor models. Bone marrow-derived macro-
phages (BMDM) prepared from Imprime- or vehicle-treated tumor-free
mice were evaluated by qRT-PCR. Imprime was tested in combination with
an anti-angiogenic agent, DC101 (α-VEGFR2 Mab) in H441 NSCLC xenograft
model in athymic nude mice, and in combination with anti-TRP1 tumor-
targeting antibody TA-99 in B16 experimental lung metastases model. Im-
munohistochemistry of FFPE tumor tissue or lung tissue were evaluated.
Results
qRT-PCR analyses of Imprime-treated BMDM from tumor-free mice re-
vealed an increase in M1 markers (iNOS, PD-L1, IL-12b, TNF-a, CXCL9,
CXCL10, and CXCL11) with a coincident decrease in M2 markers
(CD206, YM-1, Fizz1, and CCL17). Imprime’s M1-polarization effect was
also observed in H441 NSCLC tumor model where Imprime treatment
alone upregulated M1-like genes in TAMs as well as significantly
suppressed tumor growth when combined with DC101, an agent
that also modulates tumor microenvironment. Imprime-mediated
M1-polarization was also observed in the B16 experimental lung
metastasis model where the combination of Imprime with TA-99
significantly reduced both the number and size of B16 lung metas-
tases. Immunohistochemistry analysis showed an increase in the
number of tumor-infiltrating CD11b + cells with an M1 phenotype
evidenced by increase in iNOS expression.
Conclusions
Collectively, these data indicate that Imprime, by reorienting the M2
macrophages to an M1-like polarization state can remold the sup-
pressive tumor microenvironment to be more sensitive to other im-
munotherapeutic modalities.
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Background
The somatic mutation burden, together with the immunoregulatory
processes active in the tumor microenvironment, can provide power-
ful predictive biomarkers to facilitate the clinical translation of check-
point control modulators and therapeutic vaccines. The molecular
determinants of a productive anti-tumor immune response is multi-
factorial, shows significant intersubject variability and is influenced
by host genetic and environmental factors. To investigate this com-
plex interaction between the epithelial, stromal and the immune
compartments, an unbiased NGS approach is a powerful method that
can complement other conventional techniques, such as immunohis-
tochemistry and cell sorting.
Methods
In this study, we have used our proprietary integrated NGS-based
immuno-genomics platform OncoPept™, to analyze the TCGA som-
atic mutation and gene expression data and produced novel bio-
logical insights of therapeutic relevance. The combined expression of
genes present in a signature was used to calculate an expression
score that captured the relative abundance of specific cell types
within the tumor. We also analyzed 9345 tumors from 33 cancers forT cell neo-epitope burden using our proprietary neo-epitope
prioritization pipeline and combined the abundance of T cell neo-
epitopes with the infiltration of specific immune cell types present in
the tumor microenvironment to examine potential relationship be-
tween these two separate biological events.
Results
Our signature-based analysis of immune cell abundance identified
core signaling pathways associated with high CD8+ T cell infiltra-
tion. These core pathways are enriched across many different can-
cers. Components from these core pathways can be combined with
other immune cell markers to create a comprehensive response sig-
nature to select patients for treatment with checkpoint control
modulators. Several recent studies have highlighted the signifi-
cance of T cell neo-epitopes in enhancing the therapeutic benefit
of cancer immunotherapy drugs, specifically in tumors with low
mutation burden. We assessed the T cell neo-epitope burden using
our neo-epitope prioritization pipeline and observed that in some
cancers the neo-epitope load is associated with higher inflamma-
tion, higher CD8+ T cell infiltration, IFN-g signaling and high PD-1
and PD-L1 level providing a basis for superior clinical response.
Conclusions
In conclusion, our analysis supports the idea that application of NGS
in a clinical setting has the potential to generate deep biological in-
sights of the tumor and its microenvironment to enable cancer im-
munotherapy treatment effective and personalized.
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Background
Previous data has shown that a positive response to immunotherapy usu-
ally relies on active interactions between tumor cells and immunomodu-
lators inside the tumor microenvironment (TME). The aim of this study
was to classify gastric cancer subsets based on the TME immune status
according to the expression of PD-L1 and infiltration of CD8+ T cells.
Methods
186 gastric cancer patients with a curative D2 gastrectomy were en-
rolled (Table 6). PD-L1 and CD8+ T cell status were evaluated with
immunohistochemistry using specific antibodies (SP142, SP16). The
samples were classified into four TME immune types and associated
with different clinicopathological features and outcomes.
Results
Among 186 samples, there was positive PD-L1 expression (TC1/2/
3 or IC1/2/3) in 60.3 % (112/186) of patients (Fig. 65a). A signifi-
cant correlation between the PD-L1 expression and the intensity
of CD8+ T cell infiltration (p = 0.000, Fig. 65b) was found. Accord-
ing to the immune-related classification, the TME was divided into
both PD-L1+ and CD8+ T cell positive (type I), both PD-L1 and
CD8+ T cell negative (type II), PD-L1 positive but CD8+ T cell
negative (type III), and PD-L1 negative but CD8+ T cell positive
(type IV). Types I, II, III, IV were 60.3 %, 11.8 %, 0 %, and 27.9 %, re-
spectively (Fig. 65c, Fig. 66, Table 7). The expression of STAT3, and
pSTAT3, rather than STAT1 and pSTAT1, was significantly corre-
lated with the CD8+ T cell infiltration, and PD-L1 status (Fig. 67,
Fig. 68). CD8+ T cell infiltration was significantly associated with
disease-free survival (DFS) and overall survival (OS) (p = 0.003 and
p = 0.001, Table 8, Table 9, Fig. 69a). The DFS and OS of patients
with immune type II tumors was significantly worse compared to
immune types I and IV; there was no significant difference in DFS
and OS between type I and IV (type I vs. type II, p = 0.015, p =
0.003; type IV vs. type II, p = 0.017, p = 0.005; type I vs. type IV, p =
0.806, p = 0.808; Fig. 69c). The hazard ratios of DFS and OS numerically
favored type I and type IV compared with type II across most sub-
groups (Fig. 70).
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This is the first reported stratification of TME based on PD-L1 expres-
sion and CD8+ T cell infiltration in gastric cancer. The PD-L1 expres-
sion was significantly correlated with the CD8+ T cell infiltration.
Immune type III was absent, and type II patients have a worst prog-
nosis compared with type I and IV patients. Our results may be useful
for the development of clinical treatments for the blockade of im-
mune checkpoints.Table 7 (abstract P375). Correlation of Tumor-infiltrating CD8+ T cells,
PD-L1 status, and TME Immune Types with Clinicopathologic Features in
186 patients
































Sex Male 16 45 54 13 0.874 52 76 0.728 76 16 36 0.901
Female 6 21 23 8 22 36 36 6 16
Age <65 17 42 55 13 0.527 51 76 0.879 76 17 34 0.597
≥65 5 24 22 8 23 36 36 5 18
Histological
grade
G1-G2 9 35 29 5 0.080 35 43 0.228 43 9 26 0.372
G3-G4 13 31 48 16 39 69 69 13 26
Stage I 2 6 6 4 0.637 6 12 0.395 12 2 4 0.671
II 3 15 21 4 14 29 29 3 11
III 17 45 50 13 54 71 71 17 37
Tumor
location
EGJ 6 29 29 6 0.414 29 41 0.722 41 6 23 0.364
Gastric 16 37 48 15 45 71 71 16 29
Fig. 66 (abstract P375). Representative images of
immunohistochemistry (IHC) staining for tumor-infiltrating CD8+ T cells
and PD-L1 status from the 186 patients with gastric cancer. a Type I,
adaptive immune resistance. More than 50% of the tumor cells (TC=3)
demonstrated cell membrane PD-L1 expression with a “severe” grade
of CD8+ T cell infiltration. b Type I, adaptive immune resistance. About
1-3% of the tumor cells (TC=1) and 3-5% tumor-infiltrating immune
cells (IC=1) in the invasive tumor margin demonstrated cell membrane
PD-L1 expression with a “moderate” grade of CD8+ T cell infiltration.
c Type II, immune ignorance. PD-L1 negative (TC=0 and IC=0) with
no CD8+ T cell infiltration. d Type IV, other suppressor. PD-L1 negative
(TC=0 and IC=0) with a “severe” grade of CD8+ T cell infiltration
Fig. 65 (abstract P375). a Distribution (%) of 186 patients with
gastric cancer according to the expression of PD-L1 on tumor cells
(TC) and tumor-infiltrating immune cells (IC). b PD-L1 expression by
tumor cells (TC) and tumor-infiltrating immune cells (IC) is reduced
with fewer infiltrating CD8+ T cells. c Distribution (%) of tumor
microenvironment immune type based on the presence of tumor-
infiltrating CD8+ T cells and PD-L1 status. Tumor-infiltrating CD8+ T
cell IHC score=1-3 were considered positive. PD-L1 in tumor samples
by TC1/2/3 or IC1/2/3 was considered positive





Sex Male 128 (68.8%)
Female 58 (31.2%)
Histological grade G1-G2 78 (41.9%)
G3-G4 108 (58.1%)
Stage I 18 (9.7%)
II 43 (23.1%)
III 125 (67.2%)
Tumor location Esophagogastric junction 70 (37.6%)
Gastric 116 (62.4%)
Fig. 67 (abstract P375). Representative images of IHC staining for
STAT3, pSTAT3, STAT1, and pSTAT1 from the 186 patients with gastric
cancer. a pSTAT3 positive cells with nuclear staining in the invasive
tumor margin, IHC score=3. b STAT3 positive cells with cytoplasmic
staining in tumor foci and in the invasive tumor margin, IHC score=4.
c pSTAT1 positive nuclear staining in tumor cells and partly in stroma
lymphocyte, IHC score=6. d STAT1 positive cytoplasmic staining in
tumor cells and partly in stroma lymphocyte, IHC score=7
Table 9 (abstract P375). Multivariate analysis of prognostic factors for




95% CI P value Hazard ratio 95% CI
CD8+ T-cells 0.006 0.779 0.652-0.930 0.013 0.747 0.593-0.941
Stage 0.033 1.289 1.020-1.628 0.042 1.277 1.009-1.616
TME Immune
Types
0.095 0.853 0.707-1.028 0.108 0.859 0.714-1.034
PD-L1 0.420 0.896 0.686-1.170 0.452 0.903 0.692-1.178
Table 8 (abstract P375). Univariate analysis of clinicopathologic
prognostic factors for survival in 186 patients
Variable n m DFS p-value m OS p-value
Sex Male 127 53.0 0.335 54 0.225
Female 59 57.0 63.0
Age <65 128 55.0 0.196 56.0 0.259
≥65 58 43.0 54.0
Histological guide G1-G2 78 55.0 0.375 57.0 0.452
G3-G4 108 53.0 55.0
Stage I 18 72.0 0.024 72.0 0.040
II 43 55.0 64.0
III 125 34.0 54.0
Tumor location EGJ 70 43.0 0.123 54.0 0.136
Gastric 116 56.0 57.0
CD8+ T-cells IHC=0 22 22.0 0.003 36.0 0.001
IHC=1 66 53.0 55.0
IHC=2 77 54.0 56.0
IHC=3 21 60.0 65.0
PD-P1 status TC=0 and IC=0 74 53.0 0.333 55.0 0.276
TC=1 or IC=1 45 47.0 55.0
TC=2 or IC=2 44 54.0 56.0
TC=3 or IC=3 23 56.0 57.0
Fig. 68 (abstract P375). Relation between immunohistochemical
staining for STAT3 (a), pSTAT3 (b), STAT1 (c), and pSTAT1 (d) in 186
tumor specimens and tumor-infiltrating CD8+ T cell, PD-L1 status
and TME immune type
Fig. 69 (abstract P375). Kaplan-Meier survival curves for Disease-
Free-Survival (DFS) and Overall Survival (OS) in 186 patients according
to tumor-infiltrating CD8+ T cells, PD-L1 status and TME immune type.
a DFS and OS associations with four grades of tumor-infiltrating CD8+
T cells. b DFS and OS associations with PD-L1 expression by the TC
and IC. c DFS and OS associations with TME immune type
Fig. 70 (abstract P375). Prespecified subgroup analysis of Disease-
Free-Survival and Overall Survival, according to the TME immune type
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Background
Human carcinomas consist of a complex mixture of neoplastic epithelial
cells, endothelial cells, fibroblasts, myofibroblasts, and immune cells,
which collectively form the tumor stroma. The presence of stromal cell
types within carcinomas is a powerful component of the biology of a
tumor through its ability to have profound influences on cancer pro-
gression, metastasis, and drug resistance. Correspondingly, the clinical
importance of tumor immune infiltrates is now recognized as an emer-
ging area of triple-negative breast cancer (TNBC) research, where in-
creased immune infiltrate predicts both responses to chemotherapy and
improved survival. Quantitative molecular profiles of tumor-associated
normal cells may provide valuable insights into tumor biology and facili-
tate the discovery of new biomarkers and therapeutic targets.
Methods
To this end, we have developed GeneNet™, a genome-wide targeted
RNA expression assay that profiles ~19,000 genes using multiplex RT-
PCR followed by NGS. The GeneNet 19 K assay provides comprehen-
sive cellular composition analysis of tumor stroma and allows human
hematopoietic cell phenotypes, including naïve and memory B cells,
seven T cell types, dendritic cells, plasma cells, natural killer (NK) cells
and myeloid subsets to be distinguished. The developed targeted
RNA expression platform profiles in 10^5-fold dynamic range the
complete set of genes involved in checkpoint blockade and immunother-
apy biomarkers, immune cell activation, and canonical immune pathway
genes for both innate adaptive and humoral immune responses.
Results
Proof-of-principle studies demonstrate the assay's unparalleled speci-
ficity and sensitivity resulting in unique detection of low abundance
mRNA transcripts as well as an improved cost-effectiveness for high-
throughput clinical applications.
Conclusions
In this study, we present a molecular assay that unambiguously char-
acterizes the cellular composition of the tumor microenvironment
and determines the activation status of infiltrating immune cells in
primary tumor tissues from TNBC patients.
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Background
In recent years, cancer immunotherapy research has increasingly lever-
aged knowledge about the tumor microenvironment for the develop-
ment of novel therapeutics and targets. Advancing our current
understanding of the tumor microenvironment will involve continued
characterization of the interactions that occur among immune cells and
cancer cells that reside within the tumor and its periphery. Fluorescent
multiplex immunohistochemistry (mIHC) assays are uniquely suited to
characterizing and quantifying these complex interactions in situ. In re-
sponse, we commercialized manual Opal™ mIHC and Opal™ cancer im-
munology staining kits that are optimized for multispectral imaging.
Here we describe a robust, fully-automated 7-color mIHC procedure
that streamlines Opal™ staining. We coupled this automated staining
procedure with a multispectral imaging system for simultaneous detec-
tion of up to 6 tissue biomarkers plus nuclear counterstain, providing
the ability to visualize interactions between specific immune and
cancer cells within the context of the tumor microenvironment.Methods
Formalin-fixed paraffin-embedded samples of primary tumors were
immunostained using Opal™ reagent kits on a fully automated Leica
BOND RX™ stainer, imaged with a Vectra 3.0® automated imaging
system, and analyzed with inForm® software. Equivalent assays using
manual staining protocols were also performed for comparison.
Results
We developed a fully-automated staining protocol and assessed its
robustness with respect to fluorescence signal degradation, impact
on antigen epitope availability, influence on tissue morphology, and
potential cross-labeling due to incomplete inactivation between stain-
ing steps. We observed minimal degradation of fluorescence signal,
epitope availability, or tissue morphology throughout the automated
staining process. We achieved comparable signal contrast and cross-
talk levels to those obtained with manual protocols while substantially
reducing hands-on time.
Conclusions
The fully-automated staining assay that we developed for Opal™ 7-
color mIHC is a robust method to increase the throughput of multi-
plex tissue staining.
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Background
The EGFR, which is overexpressed in more than 90 % of head and neck
cancers (HNC), activates the Janus kinase 2 (JAK2)/signal transducer
and activator of transcription 3 (STAT3) pathway leading to carcinogen-
esis. STAT3 plays a major role in promoting tumor immune escape, in-
cluding production of immunosuppressive cytokines such as vascular
endothelial growth factor (VEGF), IL-6, IL-10 and TGFβ, which in turn ac-
tivate STAT3 in tumor-associated suppressive immune cells, providing a
feed forward mechanism to ensure a STAT3-dominated microenviron-
ment. Cetuximab, a specific EGFR blocking mAb, downregulates EGFR-
mediated STAT3 activation; however, other STAT3 activating pathways
exist. The IL-6 receptor (IL-6R) constitutes a major EGFR-independent
STAT3 activating pathway in HNC. Given that JAK2 is common signaling
molecule to both EGFR and IL-6R pathways we hypothesized that com-
bined EGFR and JAK2 inhibition may downregulate STAT3-dependent
production of immunosuppressive cytokines.
Methods
mRNA expression for the cytokines analyzed in this study was accessed
and downloaded from the cancer genome atlas (TCGA) repository. Pro-
tein concentration of cytokines in plasma from head and neck cancer
patients enrolled in cetuximab single agent on a neoadjuvant trial
(UPCI #08-013, NCT #01218048) were determined by ELISA. Data ana-
lysis was done using Graphpad v6.0.
Results
Herein we show that tumors of HNC patients annotated in The Cancer
Genome Atlas (TCGA) express higher immunosuppressive cytokines in-
cluding TGFβ, IL-10, VEGFA and IDO than control tissues and have
lower expression of inflammatory cytokines such as IL-12A and IL-17A,
confirming the view of a dominant immunosuppressive tumor micro-
environment that prevents proper immune effector cell activation. In
addition, EGFR and JAK2 inhibition downregulate STAT3 activation and
secretion of these immunosuppressive STAT3-dependent cytokines
in vitro, providing evidence that supports targeting the EGFR/JAK2/
STAT3 mediated suppressive tumor microenvironment.
Conclusions
Importantly, our findings are clinically relevant since HNC patients that
were treated with cetuximab single agent on a neoadjuvant trial (UPCI
#08-013, NCT #01218048) who are resistant to cetuximab therapy have
Fig. 71 (abstract P380). Patient Demographics
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 202 of 221significantly higher TGFβ concentration and a lower immunostimula-
tory cytokine profile in plasma, which endorses the use of combined
therapy in those patients where EGFR blockade is not sufficient to re-
verse production of immunosuppressive cytokines and chemokines
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Background
A major barrier to cancer immunotherapy is lack of selective inhibitors of
the regulatory T cells (Tregs) in the cancer microenvironment. New
methods to directly kill tumors through novel surface oncogenes are also
desirable. Tumor necrosis factor receptor 2 (TNFR2) is a target protein
with restricted expression on the most potent tumor-infiltrating Tregs.
On human tumors, it is a newly-discovered and broadly-expressed hu-
man oncogene.
Methods
We characterized the expression and the functional effects of the
newly-created TNFR2 antibody antagonists on the tumor infiltrating
Tregs of ovarian ascites compared to Tregs of peripheral blood from
patients with ovarian cancer and healthy controls. We also investi-
gated if well-known ovarian tumor cells lines express the TNFR2
oncogene and the effects of the TNFR2 antagonistic antibody on dir-
ect cancer killing.
Results
TNFR2 antagonists inhibited Treg proliferation with exponential po-
tency and selectivity for the tumor microenvironment Tregs. Further-
more, common ovarian cancer cell lines such as OVCAR3 express the
TNFR2 oncogene and were rapidly and completely killed by TNFR2
antagonistic antibodies, even at low concentrations.
Conclusions
Dominant TNFR2 antagonists demonstrate tumor-specific Treg deple-
tion with heightened specificity for the tumor microenvironment
over the Tregs of peripheral blood. Blocking TNFR2 signaling with an-
tagonist antibodies also creates a novel tool to directly eliminate
ovarian tumors expressing the TNFR2 oncogene.
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Background
Precise biomarkers are urgently needed to characterize the tumor im-
mune micro-environment, both for prognostication and to predict the
benefit of immunotherapeutic intervention. Multiplex immunohisto-
chemistry (mIHC) allows for automated quantitation of phenotypes
and spatial distributions of immune cells within formalin-fixed paraffin-
embedded (FFPE) tissues. In early stage melanoma, it has been
established that tumor infiltrating lymphocytes (TILs) confer afavorable prognosis but assessment of TILs is subjective and the
correlation has not been robust enough to incorporate into Ameri-
can Joint Committee on Cancer (AJCC) guidelines.
Methods
In order to test whether mIHC can improve on the accuracy of TIL quanti-
tation for the purpose of biomarker development, we screened data-
bases at the Herbert Irving Cancer Center (HICC) at Columbia University
for early stage melanoma patients with available FFPE primary melanoma
tissue and documented clinical follow up. We identified a preliminary
population of 20 stage II-III melanoma patients diagnosed between 2000
and 2012, with characteristics shown in Fig. 71. At last follow up, 11 pa-
tients were alive and recurrence-free and 9 patients died with melanoma
recurrence. 5 μm slides from either the primary biopsy or subsequent
wide local excision procedure were stained using Opal multiplex IHC for
DAPI, CD3 (LN10, Leica), CD8 (4B11, Leica), CD68 (KP1, Biogenex), SOX10
(BC34, Biocare), HLA-DR (LN-3, Abcam) and Ki67 (MIB1, Abcam) (Fig. 72).
Cell phenotypes within representative fields were pre-selected by a
trained dermato-pathologist and visualized using the Mantra quantitative
pathology workstation (Perkin Elmer), and analysis of spatial distribution
of CD3 + CD8+ cells analyzed as shown in Fig. 73 using inForm® image
analysis software (Perkin Elmer), and Spotfire software (TIBCO).
Results
We find that CD3 + CD8+ cells are closer to CD68+ cells in patients
who were recurrence-free at follow up (p < 0.0001). Conversely,
CD3 + CD8+ cells are further from SOX10 + Ki67- tumor cells in
recurrence-free patients (p < 0.0001). HLA-DR status of CD68+ or
SOX10+ cells did not alter these spatial distributions (Fig. 74). Density
of CD3 + CD8+ cells did not differ significantly between recurrent and
non-recurrent groups in this small patient sample (p > 0.05).
Conclusions
Using proximity as a surrogate for interaction, these data would indi-
cate that contact between T cells and CD68+ antigen presenting cells
is more favorable to protective immunity than is contact between T
cells and tumor cells. Further staining and analysis of 137 annotated
tumor samples from the complete HICC cohort 2000–2012 is on-
going and results will be updated at time of presentation.
Fig. 74 (abstract P380). Spatial Distributions of CD3+CD8+ Cells
Within Primary Melanoma Tumors. 20 primary melanoma tumors
were stained as in Fig. 71 and mean distances between cell
populations are shown with recurrent patients in blue and non-
recurrent patients in green. Mean distances between CD3+CD8+
and CD68+HLA-DR- cells (a), CD3+CD8+ and CD68+HLA-DR+(b),
CD3+CD8+ and SOX10+Ki67-HLA-DR-(c), and CD3+CD8+ and
SOX10+Ki67-HLA-DR+(d) are shown
Fig. 73 (abstract P380). Analysis of images using algorithm’s
within Inform software. a Multiplex IHC image stained for DAPI +
SOX10 (tumor marker, red) + CD3 (T cell marker, cyan) + CD8
(cytotoxic T cell marker, magenta) + CD68 (myeloid marker,
green) + Ki67 (marker of proliferation, yellow) + HLA-DR (marker
of MHC-II, orange). b Phenotyped image with CD68 (green), CD3
(magenta), CD3/CD8 (light pink), HLA-DR (cyan), Tumor (red),
other (blue). c Phenotype Map – data from Inform is exported
to provide an X and Y coordinate for every cell in each image.
d The X and Y coordinates can be analyzed using R Studio for
Nearest Neighbor Analysis. In this image distance between CD3/
CD8 (blue) and HLA-DR (orange) cells are being evaluated. Distance
between cells is illustrated by a line
Fig. 72 (abstract P380). (Multiplex IHC of Melanoma Tumor. Melanoma
tumor stained with DAPI (nuclear cell marker, blue) + CD68
(myeloid, green) + CD3 (T Cells, cyan) + CD8 (cytotoxic T Cells,
magenta) + SOX10 (tumor, red) + Ki67 (proliferation marker, yellow) +
HLA-DR (MHC II, orange)
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Background
In human melanoma, spontaneous T cell infiltration into the tumor
microenvironment (TME) is correlated with a type I interferon (IFN)
transcriptional signature. Induction of IFN-β in this context is
dependent upon activation of stimulator of interferon genes
(STING), a critical component of the cytosolic DNA sensing pathway
of the innate immune system. STING is activated by binding of cyc-
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response to the presence of cytosolic pathogen or tumor-derived DNA.
STING induction of IFN within the TME leads to the priming and activa-
tion of tumor antigen-specific CD8+ T cell immunity. We hypothesized
that direct activation of STING in the TME by intratumoral (IT) injection
of synthetic CDNs would induce potent anti-tumor immunity against a
broad repertoire of an individual’s tumor antigenic milieu.
Methods
Through screening a panel of synthetic CDNs, we selected ADU-S100
(MIW815) for clinical development for its ability to broadly and po-
tently activate all human STING alleles, elicit profound tumor re-
gression of injected and distal lesions in aggressive mouse tumor
models, and promote durable anti-tumor immunity.
Results
A bell-shaped ADU-S100 dose response curve was found to delineate
regression of injected tumor, induction of tumor-specific CD8+ T cell
immunity, and protection against autologous tumor challenge. In vivo
mechanistic studies demonstrate that STING-mediated anti-tumor im-
munity is due in part to an acute pro-inflammatory TNF-α-mediated
cytokine response, as well as a tumor-specific CD8+ T cell response.
Studies in chimeric wild-type and STING−/− mice showed that while
STING signaling in the tumor stromal compartment contributes to
acute tumor rejection, STING signaling in the hematopoietic compart-
ment is required for induction of CD8+ T cell mediated anti-tumor im-
munity. Anti-tumor efficacy is enhanced by combination with immune
checkpoint inhibitors, including α-PD-1 and α-CTLA-4, informing future
clinical development.
Conclusions
The ability to elicit innate and T cell-mediated anti-tumor immunity
via activation of STING in the TME demonstrates that CDNs have high
translational potential for the treatment of patients with advanced/
metastatic solid tumors. To this end, a phase I clinical study is in pro-
gress to evaluate the safety and tolerability and possible anti-tumor
effects in subjects with cutaneously-accessible non UV-induced and





Written informed consent was obtained from the patient for pub-
lication of this abstract and any accompanying images. A copy of
the written consent is available for review by the editor of this
journal.
P382
Modulation of NK cell exhaustion in metastatic melanoma tumors
Elena Gonzalez Gugel1, Charles JM Bell2, Adiel Munk1, Luciana Muniz1,
Nina Bhardwaj1
1Tish Cancer Institute, Icahn School of Medicine at Mount Sinai, New
York, NY, USA; 2Murray Edwards College and School of Clinical Medicine,
University of Cambridge, Cambridge, England, UK
Correspondence: Elena Gonzalez Gugel
(elena.gonzalezgugel@gmail.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P382
Background
Interventions such as checkpoint blockade have made a high impact
in melanoma treatment, but a significant number of patients fail to
respond or become resistant to therapy [1]. The tumor microenviro-
ment in malignant melanoma promotes NK cell exhaustion, a state
characterized by i) up-regulation of inhibitory receptors (TIM-3, KIRB1and KIRNKAT2), ii) down-regulation of activating receptors (NKG2D
and NKp46), IL-2R and transcription factors (T-bet and Eomes) and iii)
loss of IFN-g production, proliferation and cytotoxicity. Interestingly,
this exhaustion can be partially reversed by checkpoint blockade of
Tim-3 [2]. Most strikingly, however, we also found that patients who
have a clinical response to Ipilimumab treatment spontaneously re-
stored their NK cell function, despite the fact that these cells express
little or no CTLA-4 (or PD-1 or PDL-1) [3]. Here we investigate further
aspects of NK cell exhaustion in human and animal models of
melanoma.
Methods
Our results show that NK cells from human melanoma donors
(MDs) are exhausted – a phenotype which is characterized by re-
duction of: (i) cytotoxicity (ii) IFN-γ production and iii) prolifera-
tion. In addition we show that NK cells from healthy donors
(HDs) cultured with IL-2 increase expression levels of epigenetic
modification indicators (HIST1H1C, HIST1H4I, ZNF286B, HIST2H2BE)
whereas IL-2/IL-12 stimulated NK cells up regulated mRNA encod-
ing cytokines (IFN-γ, IL-1β, IL-6 and TNF) and chemokines (CCL3,
CXCL1, CXCL3), as well as the expression of different activating
and inhibitory NK cells receptors. This is consistent with an acti-
vation phenotype that is deficient in MDs samples. We are also
able to demonstrate that NK cells can became exhausted in vitro
through a pathway driven by Ceacam-1 and found evidence of
NK cell exhaustion in a B16BL6 melanoma model.
Results
The methodology used on this study included assays such as Mass
cytometry measurement (CyTOF), Flow cytometry, Poly (A) RNAseq,
Quantitative RT-PCR, Western Blot and tumor melanoma mice model.
Conclusions
We hypothesize that NK cell exhaustion becomes evident as mel-
anomas progress in human and mouse models possibly driven by
specific ligands within the tumor microenviroment. Fully appreci-
ating the factors and immune suppressive mechanisms that con-
tribute towards NK cell exhaustion in these patients will impact
the development of drugs that facilitate effective anti-tumor im-
mune responses.
NK cell exhaustion in murine melanoma modelHere we show how NK cells from B16BL6 tumor bearing mice be-
came dysfunctional in progressive melanoma. NK cells expressed
high levels of Tim-3 and Ceacam-1 when isolated from B16BL6 tu-
mors compared with C57BL/6 J non-tumor mice blood after IL-2
overnight stimulation. In addition, NK cells from tumors showed re-
duced cytotoxicity against YAC-1 target cells compared with NK cells
from blood WT non-tumor bearing mice. These findings of dysfunc-
tional activity are consistent with data obtained in human melanoma
patients.
Fig. 78 (abstract P382). In vitro NK cell exhaustion. CEACAM-1 was
recently discovered as a necessary co-receptor and ligand of Tim-3
on T cells [4] functioning both in cis and in trans to potentiate the
inhibitory activity of Tim-3. Up regulated in primary melanoma, it is
associated with poor prognosis for survival and increased invasive
behavior [5]. CEACAM-1 also increases on IL-2 activated CD56hi NK
cells [6] and functions to inhibit cytolytic activity after exposure
to CEACAM-1-bearing tumor cells [7]. Here we first show high
expression of short cytoplasmic Ceacam-1 isoform in the human
melanoma cell lines m44 and Gmel. Interestingly, we found that
similar to TGFb exposed NK cells, Gmel co-cultured NK cells also
displayed clear signals of exhaustion such as significant loss of
cytotoxic activity and reduced IFN-g production following IL-12
stimulation. Indicating the ability of tumors to suppress NK cells
driven anti-tumor activity. This approach will be useful for
gaining insight into mechanisms of NK cell exhaustion induced
by melanoma cells
Fig. 77 (abstract P382). NK cell Phenotype analysis by CyTOF.
Purified NK cells from HD were isolated and stained with a cocktail
antibody containing a complete panel of 33 activating and
inhibitory NK cell receptors including checkpoint molecules such
as Tim-3, PD-1, DNAM-1, VISTA, LAG-3, TIGIT and Siglec-7 among
others, as represented in this figure. This approach will be useful
to determine the distribution of inhibitory receptors that impact
NK cell exhaustion when the analysis will be repeated in NK cells
from MD as represented in Fig. 75
Fig. 76 (abstract P382). Transcriptome analysis in NK cells. Purified
NK cells from HD were isolated and transcriptome analysis was
performed under two different conditions a) IL-2 stimulated NK cells
that showed evidence of priming through epigenetic modification
indicators (HIST1H1C, HIST1H4I, ZNF286B, HIST2H2BE); b IL-2/IL-12
stimulated NK cells that up-regulated mRNA encoding cytokines
(IFN-γ, IL-1ß, IL-6 and TNF) and chemokines (CCL3, CXCL1, CXCL3)
consistent with an activation phenotype. This approach will be
useful to show which pathways and genes are modulated during NK
cell exhaustion when the analysis will be repeated in NK cells from
MD as represented in Fig. 75
Fig. 75 (abstract P382). Features of exhaustion were detected on
NK cells isolated from fresh melanoma donor (MD) blood. NK cells
from MD show reduced cytotoxicity capacity (expression of LAMP-1/
CD107a in response to co-culture with K562 cells), IFN-γ production
in response to IL-12, and proliferation after IL-2 stimulation,
compared with NK cells isolated from fresh healthy donor (HD)
blood. These reduced functional properties are consistent with
the concept that advanced disease is progressively associated
with systemic immune suppression
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Background
TGF-β is a multifunctional cytokine that suppresses many facets of
cellular immunity. These immunosuppressive properties have led to
the development of immunotherapy regimens to evaluate the ability
of type I TGF-β receptor (TBRI) inhibitors to augment the efficacy of
checkpoint inhibition. The TGF-β cytokine also plays a role in cellular
homeostasis and suppresses fibroblast expansion while promoting
melanoma expression of Wnt5a, a ligand previously associated with
resistance to anti-PD-1 antibody therapy in melanoma.
Methods
Using the BRAFV600EPTEN−/− transgenic melanoma model, we investi-
gated the impact of TBRI inhibition on anti-CTLA-4 antibody and anti-
PD-1 antibody immunotherapy. Primary/metastatic tumor progression
was correlated with the generation of anti-tumor immunity. Immuno-
histochemistry/flow cytometry was performed to assess the effect of
TBRI inhibition on the tumor stroma. Melanoma and melanoma-
associated fibroblast (MAF) lines were generated and utilized in co-
transplant assays to examine the influence of MAFs on anti-PD-1 anti-
body therapy. Melanoma-MAF transwell assays were performed to in-
vestigate the underlying mechanism of anti-PD-1 antibody resistance.
Fig. 81 (abstract P383). TBRI Inhibition Augments anti-PD-1 Antibody
Therapy in a Stroma-poor BRAF(V600E)-PTEN−/− Transplant Model of
Melanoma that is Reversed with MAF Co-Transplantation. A. Anti-PD-1
and Anti-CTLA-4 antibody therapy in combination with TGFBi in a cell
line-derived transplant model of BRAF(V600E)PTEN−/− melanoma. B.
Co-transplantation of MAFs with the BRAF(V600E)PTEN−/− melanoma
cell line suppresses the efficacy of anti-PD-1 antibody therapy
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TBRI inhibition synergistically enhances anti-CTLA-4 antibody im-
munotherapy in the BRAFV600EPTEN−/− transgenic melanoma model
but fails to augment anti-PD-1 antibody therapy in this same model
(Fig. 79). Immunohistochemistry and flow cytometry of TBRI-treated
melanomas reveals an expansion of the MAF population while
in vitro experiments show TBRI inhibition to enhance fibroblast prolif-
eration (Fig. 80). TBRI inhibition augments anti-PD-1 antibody therapy
in a stromal-poor BRAFV600EPTEN−/− transplant tumor model while
the co-transplantation of a BRAFV600EPTEN−/− melanoma-derived MAF
cell line reverses this effect (Fig. 81). MAFs were found to express
high levels of TGF-β which correlates with melanoma expression of
Wnt5a in resected melanoma tissues. Melanoma-MAF co-cultures re-
vealed that TBRI-treated MAFs promote melanoma expression of
Wnt5a and suppress PD-L1 expression both in vitro and in vivo
(Fig. 82). Silencing of Wnt5a expression by the BRAFV600EPTEN−/− mel-
anoma model enhances PD-L1 expression and eliminates the impact
of MAFs on responses to anti-PD-1 antibody therapy.
Conclusions
This work illustrates the importance of the tumor stroma on the effi-
cacy of anti-PD-1 antibody therapy and that pharmacologic modula-
tion of the melanoma microenvironment can have significant effects
on anti-PD-1 antibody therapy outcomes. TGF-β-mediated upregula-
tion of Wnt5a represents an important paracrine signaling pathway
that can impact checkpoint inhibitor efficacy in the melanoma micro-
environment. TBRI inhibition should be further evaluated in combin-
ation with anti-CTLA-4 antibody therapy and Wnt signaling blockade
represents a promising approach for augmenting anti-PD-1 antibody
therapy in future clinical trials.Fig. 80 (abstract P383). TBRI Inhibition Induces Melanoma-
associated Fibroblast (MAF) Expansion. a Immunofluoresence
and immunohistochemical analysis of MAF markers in resected
BRAF(V600E)PTEN−/− tumors treated with vehicle ctrl vs TGFBi. b Flow
cytometry quantitation of MAFs based on the CD45, EpCAM, and
CD90.2 surface markers. c TGFBi promotes MAF proliferation in culture
Fig. 79 (abstract P383). TBRI inhibition augments anti-CTLA-4
antibody but not anti-PD-1 antibody immunotherapy in the
BRAF(V600E)-PTEN−/− transgenic melanoma model. a Assay 1. Short
duration combination TGFBi (TGF-beta inhibitor)-anti-CTLA-4 antibody
therapy. b Assay 2. Longer duration TGFBi-anti-CTLA-4 antibody
therapy. c Combination TGFBi-anti-PD-1 antibody therapy
Fig. 82 (abstract P383). MAFs Suppress PD-L1 Expression and
Promote Melanoma Progression in a Wnt5a-dependent Manner.
a Generation of MAFs from resected BRAF(V600E)PTEN−/− melanoma
tissues. b Transwell cultures of MAFs and BRAF(V600E)PTEN−/−
melanoma cells followed by PD-L1 flow cytometry. c Transwell
culture of MAFs and BRAF(V600E)PTEN−/− melanoma cells +/−
TGFBi followed by Wnt5a Western blot analysis. d Primary tumor
growth of co-transplanted MAFs with control BRAF(V600E)PTEN−/−
melanoma cells (NTC) vs Wnt5a-silenced BRAF(V600E)PTEN−/−
melanoma cells (Wnt5aKD). e qrt-PCR and immunofluorescence
of PD-L1 expression by BRAF(V600E)PTEN−/−NTC melanomas vs
BRAF(V600E)PTEN−/−Wnt5aKD melanomasP384
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Background
Recent findings support a pro-tumorigenic role for regulatory B cells
[1]. B cell signaling is dependent on Bruton's tyrosine kinase (BTK)
and phosphoinositide 3-kinase delta (PI3Kδ) activity. Acalabrutinib is
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 207 of 221a highly selective, potent BTK inhibitor in clinical development for
treatment of hematologic malignancies, solid tumors, and auto-
immune diseases; ACP-319 is a selective inhibitor of PI3Kδ. We hy-
pothesized that these agents, which inhibit B cell activation and alter
myeloid cell signaling, might improve antitumor responses with
checkpoint inhibition (anti-PD-L1 mAb) for tumors containing regula-
tory B cell infiltrates.
Methods
To assess regulatory B cells in the syngeneic ID8 ovarian tumor
model, we adoptively transferred IL-10/GFP reporter B cells into mice
deficient for functional B cells (μMT) then orthotopically implanted
the mice with ID8 cells; GFP expression was analyzed by histology.
Next, C57BL/6 mice orthotopically implanted with luciferase-
transduced ID8 cells were treated with acalabrutinib +/− ACP-319 in
combination with anti-PD-L1. Both oral agents were dosed 15 mg/kg
twice daily; anti-PD-L1 (10 F.9G2) was dosed intraperitoneally 200 μg
every 3 days. Tumor growth was monitored by in vivo biolumines-
cence imaging and ex vivo caliper measurements of ovaries and
fallopian tubes. Tumor-immune infiltrates were characterized by flow
cytometry (peritoneal lavages) and histologic analysis (tumor
sections).
Results
In μMT mice reconstituted with IL-10/GFP, many tumor-infiltrating
cells expressed GFP, consistent with a regulatory B cell phenotype in
the ID8 tumor microenvironment, whereas GFP expression was not
observed in paired spleens. Significant tumor growth reductions
(>50 %) were observed in mice treated for 10 weeks with acalabruti-
nib (p = 0.027), acalabrutinib + anti-PD-L1 (p = 0.037), acalabrutinib/
ACP-319 (p = 0.012) or acalabrutinib/ACP-319 + anti-PD-L1 (p = 0.036),
but not with anti-PD-L1 alone (p = 0.104), compared with vehicle-
treated controls. All anti-PD-L1 groups had increased CD8+ T cells in
peritoneal lavages. Acalabrutinib/ACP-319 treatment decreased B
cells in peritoneal lavages by 70 % compared with vehicle, and aca-
labrutinib synergized with anti-PD-L1 to decrease PD-L1+ macro-
phages in bone marrow (90 %). In mice treated with acalabrutinib/
ACP-319 + anti-PD-L1, histology scores were significantly higher (p ≤
0.031) for immune infiltrates and fibrosis, compared with controls.
Tumor-infiltrating B cells, macrophages, T cells, and FoxP3-positive
cells were decreased in the acalabrutinib/ACP-319 group. Treatment
with acalabrutinib/ACP-319 + anti-PD-L1 increased tumor-infiltrating
CD8+ T cells (p = 0.026).
Conclusions
These results suggest that inhibition of BTK and PI3Kδ targets
both regulatory B cell subsets and myeloid cells in the tumor
microenvironment. Combined with anti-PD-L1, acalabrutinib alone
or with ACP-319 promotes an anti-tumor response against ovar-
ian cancer.
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Background
High levels of extracellular ATP (eATP) have been documented in
many solid tumors. eATP, which enhances activation of antigen-
presenting cells, is efficiently hydrolyzed to adenosine by extra-
cellular CD39 (ATP→ AMP) and CD73 (AMP→ adenosine). Adenosine
is a potent inhibitor of T cell and NK activation. Thus, CD73 has
drawn interest as a next-generation immune-oncology target. We de-
scribe the CT26 tumor model to characterize the effects of CD73inhibition on tumor biology and plasma AMP/adenosine levels as
markers of systemic CD73 inhibition.
Methods
Human PBMC and mouse spleen/blood/tumor leukocytes were iso-
lated using standard methods. Cell markers were quantified by flow
cytometry. Therapeutic treatment of subcutaneous (106 cells) CT26
tumors was initiated at volumes ~100 mm3; Cohorts: vehicle + iso-
type control; CD73i A000830 + isotype control; vehicle + α-PD-1;
A000830 + α-PD-1).
Results
CD73 expression was high in all subsets of human blood CD8+ T
cells, B cells, and Treg, but not Treg-depleted CD4+ T cells. CD39 was
broadly expressed on lymphoid and myeloid cells, with highest levels
on effector Treg, monocytes, neutrophils, B cells, and activated CD8+
T cells. CD73 expression was higher on C57BL/6 than Balb/c mouse
spleen and blood T cells (all subsets). On B and NK cells, CD73 ex-
pression was similar between both mouse strains. In Balb/c mice car-
rying CT26 tumors, CD73 expression in TILs was limited to T cells and
MDSC; CD73 expression was increased on CD8+ TIL relative to
splenic CD8+ T cells from tumor-bearing mice, and both were higher
than in normal splenic CD8+ T cells. Human blood CD8+ T cells ex-
hibit robust CD39 and CD73 activity, which can be blocked by CD39
and CD73 inhibitors, respectively. Mouse spleen CD8+ T cells also
showed a lower but detectable level of CD39 and CD73 activity.
Plasma AMP:adenosine ratios were ~15X higher in CD73 KO than in
gender- and age-matched WT mice. Similarly, plasma AMP:adenosine
ratios were increased in WT mice dosed with a CD73 inhibitor. Ad-
ministration of a novel small-molecule CD73 inhibitor (A000830) to
CT26 tumor-bearing mice resulted in significant reduction in tumor
volume, with an even larger effect observed in combination with α-
PD-1. Co-administration of A000830 with α-PD-1antibody increased
the number of TIL relative to control or single-treatment tumors.
Conclusions
Syngeneic CT26 colon tumors provide an excellent model to assess
the effects of CD73 inhibition on tumor growth and immune infiltra-
tion. Plasma levels of AMP/adenosine provide a simple way of moni-
toring systemic CD73 inhibition.
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Background
A dire prognosis is associated with the metastasis of human melan-
oma. Melanoma invasion and metastasis is coordinated by soluble
signals present within the tumor microenvironment. One soluble sig-
nal is WNT1 inducible signaling pathway protein 1 (WISP1), a se-
creted matricellular protein that is elevated in a variety of cancers.
Functionally, Wisp1 is secreted in response to disruption of adherens
junctions [1], such as occurs during invasion, but also represses anti-
tumor immunity through a paracrine mechanism [2]. Here, our goal
was to parse autocrine, that is the impact on intrinsic tumor cell be-
havior, from paracrine, that is a mediator of intercellular communica-
tion, effects of WISP1 on tumor growth.
Methods
Wisp1 in mouse melanoma B16 cells was knocked out using the
CRISPR/Cas9 system to evaluate its role in melanoma progression
and metastasis using in vitro and in vivo assays. We also knocked out
or over-expressed Wisp1 in mouse fibroblasts to compare the auto-
crine and paracrine effects on in vitro tumor cell invasion assays
using fibroblast conditioned medium.
Results
In vitro, Wisp1 disruption increased tumor cell proliferation and
anchorage-independent growth but repressed its wound healing, mi-
gration and invasion. In vivo, B16 cells without Wisp1 exhibited a
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knockout, certain epithelial–mesenchymal transition (EMT) markers
were down-regulated. This suppression could be partially rescued
by supplementation of Wisp1, suggesting an autocrine mechan-
ism of Wisp1 for EMT gene activation and enhanced tumor inva-
sion. Further work with multiple metastatic melanoma lines using
conditional medium from mouse fibroblast NIH3T3 cells with
Wisp1 knockout or over-expression also supported a paracrine
scenario in which fibroblast-secreted Wisp1 promotes tumor inva-
sion. Wisp1 from fibroblasts activated both Akt and MEK/ERK sig-
naling, repressed E-cadherin, and upregulated certain EMT genes.
Kinase inhibition confirmed the importance of both pathways for
EMT gene regulation.
Conclusions
Collectively, the results support a pleiotropic regulation of melanoma
invasion and metastasis by WISP1 through directly induction of EMT
in tumor cells and indirect promotion of tumor invasion by fibro-
blasts within the tumor microenvironment.
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Background
Pancreatic stellate cells (PSC) are implicated in the pathogenesis of
pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis
(CP). These cells orchestrate fibrosis and contribute to immune sup-
pression in the PDAC microenvironment. As such, PSC may facilitate
resistance to immunotherapy. Soluble factors from these cells can ac-
tivate inflammatory Jak/STAT and MAPK signaling in an autocrine
and paracrine manner. We hypothesized that inhibiting the Jak/STAT
or MAPK pathways may limit features of inflammation and immune
suppression in the diseased pancreas.
Methods
In vitro studies utilized immortalized PSC lines, and primary PSC from
patients with CP and PDAC. Cytokine/chemokine expression was ana-
lyzed in supernatants via multiplex immunoassay. PSC supernatants
were utilized to generate functionally suppressive MDSC in vitro. PSC
were treated with ruxolitinib (Jak1/2 inhibitor), or MEK162 (MEK in-
hibitor) purchased commercially. Cell viability was assessed via MTT
assay. Immunoblot analysis was utilized to evaluate the effect of in-
hibitors on STAT3, MAPK, and apoptotic pathways. To model pancre-
atic inflammation, we used the well-characterized in vivo model of
caerulein-induced pancreatitis. This involved 6 hourly intraperitoneal
injections of 50 μg/kg caerulein 3 days/week for 5 weeks. During the
final week of caerulein, mice received oral gavage of ruxolitinib at
90 mg/kg 2X/day. Pancreata from these mice were stained for H&E,
Masson’s Trichrome, and αSMA.
Results
All PSC displayed constitutive activation of Jak/STAT and MAPK path-
ways. PSC supernatants contained robust levels of soluble factors in-
cluding MCP-1, IL-6, and VEGF (up to 31,000, 19,000, and 800 pg/mL,respectively). Culture of PBMC from healthy human donors with PSC
supernatants promoted differentiation of MDSC (CD33+CD11b+
HLADRlo) that functionally suppressed proliferation of autologous,
CD3/CD28-stimulated T cells. This effect was blocked by adding IL-6
neutralizing antibody or STAT3 inhibitor to culture media, indicating
a role for IL-6/STAT3 signaling in PSC-derived immune suppression.
Treatment of PSC with ruxolitinib reduced STAT3 phosphorylation,
decreased growth (40 % growth after 72 hours) but did not induce
apoptosis. Instead, PSC exhibited a dose-dependent decrease in
αSMA, a marker of PSC activation. In contrast, treatment with
MEK162 had no effect on growth or activation. In a murine model of
caerulein-induced inflammation and pancreatitis, short-term ruxoliti-
nib treatment resulted in significantly less acinar loss and fibrosis.
Conclusions
These data suggest that the Jak/STAT pathway promotes immune
suppressive features via stellate cells in the pancreatic microenviron-
ment. These findings support future studies whereby Jak/STAT inhib-
ition may reduce desmoplasia and augment the response to
immunotherapy.
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Background
We previously reported the presence of a STAT1 associated distinct T
helper type I tumor immune microenvironment (TME) associated
with chemotherapy response in high-grade serous ovarian cancer in
a cohort of chemotherapy naïve tumors from 734 patients. We also
demonstrated that STAT1 enhanced the prognostic relevance of
cytotoxic tumor infiltrating T lymphocytes. The current study was
performed with an aim to elucidate the role of STAT1 induced
CXCL10 in HGSC tumor immune microenvironment in the estab-
lished ID8 mouse model of HGSC.
Methods
ID8 mouse ovarian cancer cells were transduced with lentiviral con-
structs to overexpress CXCL10. In vitro cell proliferation and migra-
tion assays were performed to determine cancer cell intrinsic effects
of increased CXCL10 expression. For in vivo studies, the CXCL10 over-
expressing and control ID8 cells were implanted via intra-peritoneal
injection into immunocompetent C57BL/6 mice. Ascites samples col-
lected at each endpoint were subjected to multiplex cytokine ana-
lysis using a mouse 31-plex assay. RNA isolated from tumor tissues
was subjected to immune transcriptome profiling using the Nano-
String mouse pan cancer immune profiling panel consisting of over
500 immune and 40 reference genes. The effect of CXCL10 on the
tumor vasculature of HGSC TME was evaluated by CD31 immuno-
fluorescence staining.
Results
A significant decrease in tumor progression and metastatic tumor
nodule formation in mice injected with ID8 CXCL10 overexpressing
cells compared to those with ID8 vector control cells was observed.
Multiplex cytokine analysis of malignant ascites showed differential
expression of IL-6, VEGF and CXCL9 between the two groups. CD31
endothelial cell marker staining showed differences in tumor vascula-
ture between the two groups. Immune transcriptomic profiling of tu-
mors from both groups identified distinct expression profiles in
genes associated with cytokines, chemokines, interferons, T cell func-
tion and apoptosis between the two groups.
Conclusions
Our findings provide evidence that the differential expression of
CXCL10 in HGSC tumors potentially contributes to altering tumor
progression and associated tumor immune microenvironment. Find-
ings from this study provide the basis for future studies aimed at
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):73 Page 209 of 221understanding mechanisms underlying differential tumor STAT1 and
CXCL10 expression and its role in pre-existing tumor immunologic di-
versity and aid in design of novel immunomodulatory therapies in
HGSC.
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Background
Embryonic and cancer cell phenotypes share common features.
Whereas during embryogenesis proliferation/differentiation is reg-
ulated, in cancer altered programming leads to invasion and im-
mortality. Our premise is that embryo-derived, immune-regulatory
PIF regulates this process. Synthetic PIF peptide transposes en-
dogenous regulatory features in clinically-relevant models and is
in FDA fast track clinical trial for autoimmune disease
(NCT02239562). Having shown that PIF reduces metastatic melan-
oma (NSG/H199 model), human melanoma cultures were exam-
ined, towards its translation to therapeutic use.
Methods
Following ethical committee approval (ETT TUKEB 1642-02/2010),
minor tissue samples from surgically removed lymph nodes of pa-
tients with metastatic melanoma were investigated. Effect on prolif-
eration was examined in cell cultures with or without PIF and further
analyzed by molecular and immunological assays.
Results
PIF treatment (250 nm) delayed tumor outgrowth in a time-
dependent manner in the 8 investigated cultures. Importantly, PIF
increased the expression of disialylated glycosphingolipid tumor
associated antigens in melanoma cells in the majority of the
tested cases, as evidenced by immunofluorescence FACS cell sort-
ing and confocal laser microscopy (enhanced footprint). Assess-
ment of PIF effect on tumor associated changes in gene
expression is ongoing.
Conclusions
PIF reduces proliferation and may directly or indirectly promote
glycosphingolipid-type tumor associated antigen expression. By
this enhanced tumor footprint visibility, PIF may help trigger
immune-improved anticancer response. Overall, PIF use for tumor
targeting and improved antigen expression may facilitate cancer
treatment.
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Background
Malignant mesothelioma (MM) is an inflammation-associated cancer
that is markedly resistant to “standard-of-care” chemotherapy with
extremely poor prognosis.
Methods
We utilized MM patient biopsies and an immunocompetent MM
mouse model to investigate the role of tumor-infiltrating leukocytes
in regulating response to therapy.
Results
We report herein that chemotherapy leads to increased frequency
of colony stimulating factor-1 receptor (CSF-1R)+ macrophages in
human MM, as well as in an immunocompetent mouse model of
MM. While therapeutic blockade of CSF-1R instigated activation of
CD8+ T cells in primary tumors resulting in ~50 % decreased pri-
mary tumor burden, combined therapy did not improve animal
survival as therapy failed to reduce pulmonary metastasis. To in-
vestigate mechanisms underlying the tissue-specific response to
combined chemo/CSF1R inhibition, we identified programmed
death ligand 1 (PD-L1) as an abundant immune checkpoint mol-
ecule expressed by alveolar macrophages in lung metastases.
Based on this, we hypothesized that combination blockade of
PD-L1 with CSF-1R would improve survival by driving CD8+ T cell
activation and cytotoxicity in both primary and metastatic tumors
thereby extending survival and improving outcome. Indeed, com-
bination therapy using CSF-1R/PD-L1 inhibitors enhanced acti-
vated CD8+ T cell frequency and further reduced tumor burden
at both primary and metastatic sites resulting in increased animal
survival. Activated CD8+ T cells, in both primary and metastatic
tumors, exhibited biomarkers of “reinvigoration” marked by co-
expression of Ki-67 with PD-1 and EOMES. CD8+ T cells were es-
sential for therapeutic benefit of CSF-1R/PD-L1 combination ther-
apy since their depletion subverted therapy response.
Conclusions
Tissue-specific tumor niches pose distinct requirements for gener-
ating adaptive immune responses and/or perturbing/abrogating
tumor growth. Results from these studies highlight a rationale for
combination therapy where individual constituents target differ-
ent immunosuppressive microenvironments to impact BOTH pri-
mary tumor responses as well as thwarting secondary tumor
growth.
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Background
Cholangiocarcinoma (CC) is an uncommon malignancy increasing in
incidence and characterized by rapid progression. The tumor im-
mune microenvironment (TME) has been extensively studied in a var-
iety of cancers, but characterization of the CC TME is not well
understood. We aimed to perform a comprehensive analysis of the
TME of CC in order to identify new potential immunotherapy targets.
Methods
A retrospective analysis was conducted of CC tumor samples at the
University of Virginia from 2000–2014. Tissue microarrays (TMAs)
were constructed of 3–4 cores from each tumor and were stained by
immunohistochemistry (IHC) for a number of immune cells and
markers of immune activation or inhibition (17 total). These were
grouped into a positive effector signal (CD4, CD8, CD14, CD40, CD45,
CD45RO, CD56, CD68, CD69, CD83, granzyme, and OX40) and a nega-
tive suppressor signal (FoxP3, CD163, TIM3, LAG3, and IDO). TMAs
were scanned using the Leica SCN400 and was analyzed using the
Digital Image Hub software. Stain intensity thresholds for determin-
ing positive cells were determined by two users and recorded as an
average of all cores from each tumor. Correlation with overall survival
was assessed using Cox-proportional hazard with p-values < 0.05 be-
ing considered as statistically significant.
Results
Ninety-nine CC tumors were available for analysis. Median age was
68 years old with 26 intrahepatic, 37 hilar and 36 distal CC. In univari-
ate analysis, increasing CD56+ (HR: 1.75; CI: 1.24-2.46), p + (HR: 1.07;
CI: 1.02-1.12, p = 0.007) infiltrations significantly correlated with worse
survival. CD163+ infiltration trended towards a significant decrease in
survival (HR: 1.19; CI: 0.9-1.43, p = 0.06) while CD40+ infiltration
trended towards a significant increase in survival (HR: 0.66; CI: 0.42-
1.05, p = 0.08).
Conclusions
CD56+ cell infiltration into cholangiocarcinoma correlates with a
worse prognosis. Further studies including a multivariate analysis and
multicolored IHC are planned to better understand to the role of
CD56+ cells in CC.
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Background
The aim of our project is to identify the phenotypic and functional
status of immune cells in the bone marrow of patients with acute
myeloid leukemia (AML). The goal of the immunophenotyping is to
identify the relevant myeloid and lymphoid cell subsets present in
the marrow of patients with AML, understand their differentiation
and activation status, and to quantify the density of immune modi-
fiers on cells of interest. The goal of the functional assays is to furtherdefine the status of T cells in the AML microenvironment by evaluat-
ing the responsiveness of these cells to stimulation. Additionally,
these studies assess the impact of costimulatory or immune check-
point inhibitors on the proliferative and cytokine production capacity
of T cells, as well as tumor cells, resident in AML bone marrow.
Methods
Immunophenotyping was performed using mass cytometry (CyTOF).
Primary AML bone marrow samples were stained with four distinct
antibody panels to identify the status of over 70 cell surface and
intracellular proteins and cytokines. Functional assays measured both
the proliferative capacity and cytokine production profile of AML
bone marrow T cells in response to CD3 stimulation in the context of
the tumor microenviroment. Analysis of the changes to the baseline
T cell functional profile in the presence of various checkpoint inhibi-
tors and immune stimulatory antibodies was measured.
Results
Our initial studies have begun to identify the major myeloid and
lymphoid subsets present in the marrow of patients with AML with a
focus on the detailed description of T cell subsets and activation sta-
tus. We have identified the cellular expression of various immune
checkpoint proteins and inhibitory cytokines on both myeloid and
lymphoid cellular subsets. The functional studies have identified a
subset of AML patient samples where T cells are impaired in their
ability to proliferate in response to CD3 ligation. We have found dif-
ferential effects of several immune checkpoint inhibitor antibodies
on T cell proliferation and cytokine production.
Conclusions
These results provide the beginning of a functional and phenotypic
description of the immune status in the marrow of patients with
AML. We have identified potential immune targets in AML. This is a
report of initial findings of our study; accrual of patient samples is
ongoing to expand the power of our observations.
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Background
Regulatory T (Treg) cells are essential for maintenance of immune
homeostasis, and are important suppressive cells among tumor infil-
trating lymphocytes (TIL). Tim-3 was first identified on Th1 T cells as
a negative regulator of type 1 immunity. Tim-3 can also be expressed
by some Tregs, but the functional status of human Tregs expressing
Tim-3 remains unclear.
Methods
Treg were sorted from fresh HNSCC TIL based on Tim-3 expression.
Gene expression profiling and NanoString RNA analysis were used to
compare differences between these populations. Functional and
phenotypic features of Tim-3+ and Tim-3− Treg in freshly isolated
HNSCC patient TILs were tested by multi-color flow cytometry.
Results
Tim-3+ Treg from human HNSCC TIL display a more effector-like
phenotype, based on gene expression profiling and NanoString ana-
lysis. Compared with Tim-3− Treg, Tim-3+ Treg exhibited more robust
expression of CD39, CTLA-4, PD-1, granzyme B, IFN-γ receptor and
IFN-γ by flow cytometry. Despite this phenotype, Tim-3+ TIL Treg dis-
played a greater capacity for inhibiting naïve CD8+ T cell proliferation
and subsequent cytokine production than Tim-3− Treg. In addition,
suppression mediated by Tim-3+ Treg was partially reversed by ex-
ogenous IFN-g treatment.
Conclusions
Tim-3 expression on HNSCC TIL Treg cells identifies a phenotypically
and functionally distinct population of cells that is highly effective in
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IFN-g by successful immunotherapy may overcome suppressive fea-
tures of this Treg population. Anti-Tim-3 directed therapies may yield
immunotherapeutic benefits.Fig. 84 (abstract P394). * p<0.05, ** p<0.01, *** p<0.001, ****
p<0.0001 Data expressed as mean ± standard deviation (SD)
Fig. 83 (abstract P393). * p<0.05, ** p<0.01, *** p<0.001 Data
expressed as mean ± standard deviation (SD)P394
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Background
FOXP3+ regulatory T cells (Tregs) are central for the maintenance of
self-tolerance and are important suppressive components in the
tumor microenvironment. The aim of this study was to investigate
the phenotypic and functional characteristics of tumor infiltrating
lymphocytes (TIL) with multiple immune checkpoint receptor expres-
sion, including PD-1 and OX40, directly from head and neck squa-
mous carcinoma (HNSCC) tumors.
Methods
Lymphocytes were extracted from freshly excised HNSCC tumors and
matched peripheral blood. Flow cytometry was conducted using
HNSCC lymphocytes and in vitro functional assays were performed
using sorted TIL or circulating T cells.
Results
CD4+CD25hiFOXP3+ Tregs were more frequent in HNSCC TIL vs PBL
(52.7 % vs 11.5 % of CD4+CD25hi immune infiltrate, n = 10) (Fig. 84a).
HNSCC Tregs expressed significantly higher levels of OX40 (70.8 % of
FOXP3+ cell population, n = 10 tumors) and PD-1 (26.6 %, n = 9)
than Tregs from peripheral blood (p = 0 · 01). We found a signifi-
cant positive correlation (p + CD25high) (Fig. 84b). Double-positive
(PD-1+OX40+) TIL Tregs had a more suppressive phenotype than
single-positive (PD-1+ or OX40+) TIL Tregs (Fig. 84c, 84d), including the
ability to proliferate and to express IL-10 and TGF-b–associated LAP
(Fig. 84e). Double-positive (PD-1+OX40+) TIL Tregs also significantly
inhibited effector T cells. Triggering OX40 with the an agonistic mAb
(MEDI0562) overcame the suppression exerted by Tregs, leading to in-
creased effector CD4+ or CD8+ T cell proliferation.Conclusions
These findings contribute to ongoing efforts to improve PD-1 or
OX40-based immunotherapy in HNSCC patients, and suggest that
dual targeting of these pathways may reverse suppressive function
of Tregs in the clinic.P395
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Background
Lymphatic vessel remodeling is correlated with melanoma progres-
sion and lymph node metastasis. While lymphatic vessels provide an
important route for disseminating tumor cells, their role in respond-
ing to immunological challenge has yet to be appreciated with re-
spect to tumor progression. We recently published that in the
absence of dermal lymphatic vessels, the tumor microenvironment
of murine melanoma remains completely uninflamed and fails to in-
duce a robust T cell response. Consistently, in an analysis of human
cutaneous metastatic melanoma (TCGA), we identified positive corre-
lations between lymphatic endothelial cell gene expression and im-
mune genes suggesting a relationship between lymphatic vessel
remodeling and local immunity. We therefore hypothesize that
lymphatic vessels are a biomarker of in situ immune responsiveness
and response to therapy.
Methods
In this work, we present the simultaneous evaluation of immune and
vascular components in human primary melanoma samples using a
multiplex-immunohistochemistry-based approach. We have optimized
a staining panel for simultaneous detection of 10 biomarkers (S-100,
CD8a, CD68, CD31, D2-40, Lyve1, Prox1, FasL, PD-L1, PD-1) within a sin-
gle FFPE section. Tissue regions that include tumor/stroma borders and
show high CD8+ T cell infiltrates are selected for analysis, followed by
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within intra-tumoral regions and stroma. We have identified a cohort of
18 human primary cutaneous melanomas with clinical annotation for
protocol optimization and validation of hypotheses.
Results
Multiplexed immunohistochemistry of the validation cohort has iden-
tified poorly inflamed and inflamed primary melanomas. Interest-
ingly, those tumors with enhanced hematopoietic infiltrate (CD68
and CD8) also appear to demonstrate increased vasculature, both
blood and lymphatic. Preliminary data demonstrates that lymphatic
vessels, blood vessels and CD8+ T cells are enriched in stroma, while
CD68+ cells are homogenously distributed throughout tissue. Fur-
thermore, blood and lymphatic endothelial cells are positively corre-
lated in stroma as are, interestingly, intratumoral CD8+ T cells and
stromal lymphatic vessels.
Conclusions
Intratumoral CD8+ T cells are predictive of survival. Lymphatic ves-
sels, however, are required for transport of antigen-bearing cells to
lymph nodes for induction of adaptive immunity and as such may be
a prerequisite to antigen-specific T cell infiltrates and the in situ anti-
tumor response. Our data, across multiple model systems, provides
strong experimental evidence to indicate that the lymphatic vascula-
ture is an important, active component of the anti-tumor immune re-
sponse. Furthermore, lymphatic remodeling and local dysfunction
may represent a biomarker to stratify patient response and survival
for effective clinical immunotherapy.
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Background
Tissue resident memory (TRM) cells are found in certain peripheral tis-
sues long after resolution of infections that generate them. TRM forma-
tion is induced by TGFβ and has been associated with upregulation of
CD103 and CD49a. Interaction of CD103 and CD49a with their respect-
ive ligands is thought to allow long term persistence of TRM cells in
peripheral tissues. In melanoma patients, increased expression of
CD103 and CD49a has been observed on tumor infiltrating lympho-
cytes (TIL) compared to PBMCs. These phenotypic similarities suggest
that a subset of TIL might function as TRM. However, the impact of con-
tinuous antigen presentation and/or differential TGFβ expression levels
on this property of TIL is currently unknown.
Methods
For in vivo tumor studies C57BL/6 mice were injected with 4x105
B16-OVA or B16-F1-shTGFb/shNEG cells, either subcutaneous or intra-
peritoneal. Tumors were grown for 14 days, harvested, processed in
single cell suspensions and stained for multicolor flow cytometry. Hu-
man tumors were recovered from frozen single cell suspensions,
counted and stained for multicolor flow cytometry. For in vitro stud-
ies, bulk splenocytes (OT-1 mice) or PBMC (human normal donor)
were cultured for 2–7 days in presence of CD3 and CD28 stimulating
antibodies and/or 5 ng/ml recombinant TGFβ.
Results
Here, we demonstrate that, in murine B16-OVA and human melan-
oma tumors, CD8+ TIL co-express CD49a and CD103. Additionally,
relative expression of CD49a and CD103 differs on TIL in subcutane-
ous versus intraperitoneal murine tumors, as well as between skin
and small bowel human melanoma metastases. Furthermore, we
identified a small subset of CD103pos CD8+ TIL that express CD127
and CD69. However, the majority of CD103pos CD8+ TIL express noCD127. Lastly, we show that, despite established knowledge on the
induction of CD103 expression by TGFβ, secretion of this cytokine by
tumor cells is not required for CD103 expression.
Conclusions
Our data indicate that the capacity of T cells to persist in tumors po-
tentially changes based on tumor location, which may be dependent
on TGFβ levels. Furthermore, we showed that a small subset of
CD103pos CD8+ TIL appear to be authentic TRM, however the major-
ity may be either terminal effectors or inactive, potentially anergic/
exhausted, TIL. Taken together, our results raise important questions
about the role of CD103 on non-TRM-like TIL and the importance of
TGFβ in the establishment of these TIL.
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Background
The role of TGF-β in oncogenesis and immune evasion is well recog-
nized [1]. Membrane Latent TGF-β is highly expressed on the surface
of regulatory T cells and platelets by binding its receptor
Glycoprotein-A Repetitions Predominant Protein (GARP). Several lines
of evidence suggest that GARP enhances the conversion of the
membrane Latent TGF-β in its active form [2].
Methods
We performed an immunohistochemistry evaluation of human
breast, prostate, colon, prostate, head and neck cancer tissue micro-
arrays and correlation with disease stage and survival. Analysis of hu-
man serum was performed by ELISA. GARP function in metastatic
and non-metastatic breast cancer was evaluated by preclinical
models where GARP expression was either enforced or knocked
down. Therapeutic role of anti-GARP antibody was assessed using
metastatic 4 T1 breast cancer model.
Results
We herein report that GARP is aberrantly expressed by human cancers,
including colon, prostate, head and neck, and breast cancer, in addition
to a well-characterized murine prostate cancer model. Importantly, ex-
pression of GARP inversely correlates with overall survival. We also
identified the presence of soluble GARP in prostate cancer patients and
observed that the concentration of soluble GARP is higher in cancer pa-
tients compared to healthy controls. Through genetic strategies, we
found that GARP expression in multiple animal tumor models increases
the bioavailability of active TGF-β, promoted regulatory T lymphocytes
in tumor environment, favored the immune evasion of cancer cells,
and contributed to the formation of secondary tumors. Finally, we
tested a panel of anti-GARP antibodies, alone and in combination with
cyclophosphamide, in a mouse model of mammary carcinoma, and we
found that they have significant anti-tumor activity especially by inhi-
biting the formation of lung metastasis.
Conclusions
We conclude that GARP is expressed on several human cancers, and
its expression correlates with poor prognosis. Mechanistically, GARP
increases the availability of active TGF-β that promotes an immune
tolerant tumor environment. Based on these observations, we
propose GARP-TGF-β as a novel oncogenic axis that can be exploited
for diagnosis, prognosis and treatment of cancer.
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Background
We reported a cooperative interaction between local radiation (RT)
and intratumoral (IT) injection of hu14.18-IL2 immunocytokine (IC,
anti-GD2 antibody linked to IL2) in mice bearing a single subcutane-
ous tumor, resulting in 71 % complete regression [1]. However, when
two tumors of the same type are present and one is treated with RT
and IT-IC, the enhanced response is not seen. The non-treated tumor
induces a systemic suppressive effect on the efficacy of RT and IT-IC.
We hypothesize that this “concomitant immune tolerance” is a
tumor-specific effect of regulatory T cells (Tregs).
Methods
C57BL/6 mice were implanted with one or two syngeneic B78(GD2+)
melanomas or Panc02(GD2- & GD2+ subclones) pancreatic tumors.
Five weeks later, mice were treated at one tumor site with single
fraction (12 Gy) RT followed by IT-IC or IT-control IgG (50 μg days 6–
10 after RT). C57BL/6 DEREG mice were used to test the necessity of
Tregs for concomitant immune tolerance by specific depletion using
intraperitoneal injection of diphtheria toxin. Tumor volumes were
measured and mixed-effect-models were used to estimate and com-
pare the tumor growth curves.
Results
In mice bearing single B78(GD2+) or Panc02(GD2+) tumors, com-
bined treatment with RT and IT-IC resulted in markedly improved
tumor response compared to single modality treatments. In contrast,
in mice bearing two B78 tumors or two Panc02 tumors, treatment
with RT and IT-IC to the GD2+ tumor did not improve tumor re-
sponse compared to RT alone. This effect was tumor-specific and
was not observed in mice bearing a treated B78 tumor and an un-
treated distant Panc02(GD2-) tumor or those bearing a treated
Panc02(GD2+) tumor and an untreated distant B78(GD2+) tumor. In
these mice with two histologically distinct types of tumors, response
of the treated tumor to combined RT and IT-IC was similar to that
observed in mice bearing a single tumor treated with RT and IT-IC. In
mice bearing two B78 tumors, one treated with RT and IT-IC, deple-
tion of Tregs (in DEREG mice or by anti-CTLA-4 IgG2a mAb in C57Bl/
6 mice) facilitated a response at the treated tumor comparable to
that observed with RT and IT-IC in mice bearing a single B78 tumor.
Conclusions
Our findings suggest that concomitant immune tolerance is a tumor-
specific, Treg-dependent, suppressive effect of distant, untreated tu-
mors on the anti-tumor efficacy of RT and IT-IC treatment of a separ-
ate tumor.
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Patients with cancer are at increased risk of infections; however,
there is a paucity of information available regarding the effects of
concomitant local or distant non-oncogenic infection on cancer and
response to therapy. Further, studies interrogating the antigen-
specificity of tumor-infiltrating T cells have demonstrated the exist-
ence of CD8+ T cells within the tumor that are not specific to the an-
tigens expressed by the tumor. A portion of these CD8+ T cells are
specific to antigens expressed by pathogens to which patients are
commonly exposed. However, how such cells effect tumor growth is
not well understood.
Methods
Therefore, we challenged C57BL/6 mice with B16-F10 (105) tumor
cells via intradermal injection of the right flank (for tumor growth
distal to the infection) or via intravenous injection (for tumor growth
local [within the lung] to the infection). B6 mice were infected with
influenza (A/H1N1/PR8) expressing OVA257–264 (FLU-OVA; 10,000 pfu;
intranasal administration). Every 2–3 days tumor growth was moni-
tored by caliper measurement and influenza infection was monitored
by body weight measurement. Tumors were harvested at various
times and analyzed by flow cytometry for OVA-specific CD8+ T cells
(representing influenza-specific cells) using tetramer staining. Statis-
tics were determined using the Student’s t test and comparisons with
P < 0.05 were considered statistically significant.
Results
Infection of the lung with FLU-OVA expectedly lead to the expansion
of CD8+ T cells specific for OVA257–264 in the lung. Unexpectedly,
such infection likewise led to the distal accumulation of OVA257–264-
specific T cells (up to 23 % of all CD8+ T cells; P < 0.01) in the tumor
microenvironment (skin of the flank) and accelerated of tumor
growth (P < 0.001). Importantly, in the context of B16 melanoma in
the lung, infection of the lung with FLU-OVA resulted in reduced B16
melanoma foci compared to no infection (38 % reduction; P < 0.01).
Melanoma foci were further reduced (81 %) in the lung with combin-
ation FLU-OVA and PD-1 blocking anybody (P < 0.01).
Conclusions
Infection local to the tumor site (lung infection in the context of lung
melanoma) but not distal to the site (lung infection in the context of
skin melanoma) improves cancer outcome. This finding may have im-
plications for viral infections used as immunotherapeutic strategies
(including oncolytic viruses), which may demonstrate maximum effi-
cacy when administered local to the tumor and when offsite distant
infection is minimized. Further studies utilizing the engagement of
pathogen-specific CD8+ T cells in the tumor microenvironment as a
novel immunotherapeutic approach are currently underway.
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Background
Clear cell renal cell carcinoma (ccRCC) is considered immuno-
sensitive and tumors typically show a strong immune cell infiltrate.
Fig. 85 (abstract P401). T cell population in NPES-treated and
untreated tumors. There is a 50% reduction in Tregs in tumors
treated with NPES
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that infiltrating CD8+ T effector cells and NK cells are unresponsive to
stimulation with a signature of anergy and cell cycle arrest [1, 2].
These features were caused by the tumor microenvironment as they
were not observed in cells from non-tumor kidney (NKC). Many T
cells in the tumor tissue were in close contact with CD209+ myeloid
cells, which is suggestive of intense intercellular communication. Fur-
ther analysis revealed unusual co-expression of DC and macrophage
markers. Those unusual cells were highly enriched in tumor tissue
compared to non-tumor kidney cortex (NKC), thus they were referred
to as “enriched-in-renal-carcinoma DCs” (ercDCs) [3]. For a deeper un-
derstanding of the role which this unusual myeloid subset might play
and to potentially identify targets for therapeutic intervention we
conducted genome-wide transcriptional profiling of sorted ercDCs.
Methods
In situ analysis using triple-marker immunofluorescence with confocal
microcopy; ex vivo analysis using polychromatic flow cytometry; cell
sorting from ccRCC tissue suspensions and blood; in vitro generation
of reference myeloid subsets; transcriptional profiling using Affyme-
trix microarrays; bioinformatics using data from sorted cells and pub-
licly available repositories, including The Cancer Genome Atlas
(TCGA; http://cancergenome.nih.gov/).
Results
ErcDCs were found to strongly express macrophage core genes,
macrophage-associated transcription factors and growth factor re-
ceptors. They combined characteristics of M1- and M2-macrophages
and exhibited a pro-angiogenic and invasive gene expression profile.
A unique transcriptional signature could be identified that distin-
guished ercDCs from all other analyzed myeloid subsets except in-
flammatory macrophages from ascites of ovarian cancer. Applying
the gene signature to TCGA ccRCC expression data (RNA Seq) re-
vealed a significant association between a high ercDC score and ad-
vanced tumor grade and shorter patient survival. The gene
expression profile contains targets with promise for repolarization of
ercDCs into an immunocompetent cell type.
Conclusions
The transcriptional profile of ercDCs identified them as a unique
myeloid subset within the macrophage spectrum. A high ercDC score
is associated with poor patient survival. The gene expression profile
contains promising targets for intervention.
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Background
Nano-Pulse Electro-Signaling (NPES) refers to the application of ultra-
short electric pulses in the nanosecond range and can be used to ini-
tiate a variety of cellular responses. This physical treatment is drug-
free, non-thermal and highly localized between electrodes. We have
previously found that murine cells and tumors exposed to the appro-
priate NPES can be stimulated to undergo immunogenic apoptosis.
When these mice are injected with a challenge secondary tumor they
reject that tumor in a CD8-dependent manner. In addition, we can
vaccinate a mouse against specific tumors with a sub-dermalinjection of NPES-treated tumor cells [1]. We are using flow cytome-
try to examine changes in the T cell population in the primary and
challenge tumor microenvironment before and after NPES treatment.
Methods
Murine MCA205 fibrosarcoma cells were injected subdermally into
syngeneic B6 mice to form a tumor. Once the tumor reached a
diameter of 5 mm, we treated it in vivo with NPES (1300 pulses,
300 ns, 30 kV/cm). Some of these tumors were removed surgi-
cally and dissociated into single cells for analysis by flow cytome-
try. Others were allowed to undergo apoptosis and three weeks
later a challenge tumor was injected into the contralateral flank
of the mouse. 2 weeks later, those mice were sacrificed and their
spleens and lymph nodes were removed and dissociated for flow
cytometry analysis.
Results
Tumor treatment by NPES results in a significant reduction in both
Tregs and CD8+ T cells within the tumor (Fig. 85). In contrast, the
spleen and lymph nodes of the treated mice had slightly higher
levels of Treg and CD8+ T cells than those with untreated tumors.
Ongoing flow cytometry studies of the changes in the secondary
challenge tumors will be also be presented.
Conclusions
We conclude that NPES treatment reduces the number of regulatory
T cells in the treated primary tumor and are currently examining the
changes in the T cell population in challenge tumors.
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Background
CSF-1R is expressed on immunosuppressive tumor associated macro-
phages (TAMs) that accumulate within the tumor microenvironment.
High levels of TAMs correlate with poor prognosis for certain cancers
and inhibition of TAMs can enhance anti-tumor immune responses.
SNDX-6352 is a humanized IgG4 monoclonal antibody with high af-
finity against CSF-1R under investigation for the treatment of neo-
plastic diseases.
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In vitro binding studies, functional cell based assays, and mouse
tumor models were utilized to characterize SNDX-6352 and a surro-
gate rodent antibody, Ab535. Reported toxicology and pharmaco-
dynamics studies for SNDX-6352 were in cynomolgus monkeys.
Results
SNDX-6352 binds to human CSF-1R (KD 4-8pM, Fc-tagged construct)
and cross reacts with cynomolgus monkey CSF-1R but not rodent
CSF-1R. SNDX-6352 has been shown to inhibit both CSF-1 (IC50
270pM) and IL-34 (IC50 100pM) induced MCP-1 release from human
monocytes) and the viability of macrophages during tCSF-1-
mediated differentiation process in vitro (IC50 455pM). A dual ligand
blocking surrogate rodent antibody, Ab535, was generated for pre-
clinical studies in mice and shown to inhibit tumor growth in colon
(MC38), breast (MCF-7, MDA-MB-231) and prostate (PC-3) cancer
models and enhance immune checkpoint blockade in the MC38
model. A 13-week toxicology study in cynomolgus monkeys indi-
cated that weekly intravenous administration of SNDX-6352 at 10, 30,
and 100 mg/kg was well tolerated. Swelling around the eyes was ob-
served at the mid and high dose groups, occurring from Day 85 on-
ward and may be related to CSF-1R pharmacology, as it has been
observed with other anti-CSF-1R molecules, including in clinical trials
at supra-therapeutic doses. Other changes were also all related to
the mode of action of SNDX-6352. Clinical pathology changes in-
cluded dose-related increases in aspartate transferase, alanine trans-
ferase and glutamate dehydrogenase levels correlating with SNDX-
6352 exposure but not translating into histopathological liver
changes. These changes resulted from pharmacological inhibition of
CSF-1R on Kupffer cells within the liver, which are involved in the
clearance of these hepatic enzymes and as such, considered to be
non-adverse. Dose-related increases in CSF-1 plasma concentration
and decreases in non-classical (CD14 + CD16+) monocytes and
markers of bone formation and resorption were observed during the
treatment phase and were rapidly reversible upon SNDX-6352 clear-
ance. Changes in bone markers were not associated with histological
changes or changes in bone densitometry in the context of this
study. Upon SNDX-6352 clearance, all parameters rapidly returned to
control values.
Conclusions
SNDX-6352 is a novel, high affinity humanized IgG4 anti-CSF-1R anti-
body available for initiation of first-in-human studies.
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Background
CD47 has been identified as a tumor antigen on human ovarian can-
cer cells and is expressed on multiple tumor types. CD47 negatively
regulates phagocytosis by interacting with signal regulatory protein
alpha (SIRPα), an inhibitory protein expressed on macrophages. High
expression of CD47 on tumors contributes to tumor immune evasion
by blocking phagocytic uptake. Agents that block the CD47-SIRPα
interaction are promising therapeutics in that they restore phagocytic
uptake of CD47+ tumor cells in vitro and attenuate tumor growth
in vivo. Here we characterize SRF231, one of a panel of fully human
CD47 antibodies, and demonstrate that it displays the desired criteria
for development as a therapeutic.
Methods
Anti-CD47 antibodies were generated using transgenic mice carrying
human V regions and SRF231 was subsequently engineered as sev-
eral Fc-region variants. In vitro phagocytosis assays were performed
using primary human macrophages differentiated from peripheralblood-derived monocytes. Phagocytosis was measured by flow cyto-
metric analysis of CFSE-labeled target cells after incubation with
CD14+ macrophages. For in vivo studies, SCID mice were injected
subcutaneously with tumor cells and treated with the indicated
antibodies.
Results
SRF231 binds with high affinity to human CD47 and is a potent
blocker of the CD47-SIRPα interaction. SRF231 enhances phagocytic
uptake of primary tumor cells and tumor cell lines in vitro, and does
so irrespective of macrophage polarization. SRF231-mediated tumor
cell phagocytosis is also enhanced in the presence of opsonizing
antibodies. Importantly, since loss of CD47 expression serves as a
marker of aged/damaged red blood cells (RBC) and promotes their
phagocytic clearance, SRF231 does not enhance phagocytosis or in-
duce hemagglutination of human or cynomolgus RBC, despite bind-
ing to these cells. To better understand the relative contribution of
Fc receptor (FcR) interactions on SRF231 mediated activity, we gener-
ated and characterized SRF231 isotypes both with and without ef-
fector function. Potency in the phagocytosis assay is mildly
decreased in isotypes with lower or no ability to bind FcR. In a tumor
xenograft model, antibodies display isotype-specific differences in
anti-tumor activity despite having equivalent systemic exposures.
Conclusions
SRF231 binds with high affinity to CD47 and potently disrupts the
CD47-SIRPα interaction. SRF231 is unique in its ability to promote ro-
bust tumor cell phagocytosis without inducing RBC phagocytosis or
hemagglutination. In addition, SRF231 shows potent in vivo anti-
tumor efficacy in preclinical models either as monotherapy or in
combination settings. SRF231 is currently in IND-enabling studies
and is expected to enter clinical trials in 2017.
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Background
In the tumor micro-environment extracellular ATP is sequentially hy-
drolyzed to adenosine by the ecto-nucleotidases CD39 (ATP→ AMP)
and CD73 (AMP→ adenosine). Adenosine is a potent inhibitor of T
cell activation, resulting in an immunosuppressed phenotype, and
thus inhibition of CD73 has recently generated much interest in
immuno-oncology. We present here novel, selective, and highly po-
tent small molecule inhibitors of CD73.
Methods
CD73 inhibitor in vitro potency was assessed by measuring the hy-
drolysis of AMP to adenosine in the presence of varying amounts of
inhibitors in endogenously expressing (hCD73/SKOV-3; mCD73/E771)
and stably over-expressing (hCD73/CHO; hCD39/CHO) cells. Selectiv-
ity was assessed in transiently expressing CHO cells (mCD73,
NTPDase2, NTPDase3, and NTPDase8). Activity in a CD8+ T cell func-
tional assay was assessed in human and mouse CD8+ T cells which
were pretreated with inhibitor, buffer control, or CD73-inactive con-
trol followed by stimulation (3 days; CD3/CD28 ± 50 mM AMP). Cell
activation, proliferation, and effector function were quantified by
flow cytometry. CD73 inhibition in a tumor setting was assessed in a
subcutaneous CT26 tumor model in Balb/c mice. Treatment was initi-
ated when tumor volumes reached ~100 mm3 and mice were di-
vided into four cohorts (vehicle control + isotype control, CD73
inhibitor A000830 + isotype control, vehicle control + anti-PD-1 Ab,
and A000830 + anti-PD-1 Ab.
Results
A000830 and A001190 are representative members of a series of po-
tent and selective inhibitors of CD73 (hCD73/CHO IC50 = 1 nM and
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version of AMP to adenosine in human CD8+ T cells (IC50 = 0.2 and 0.008
nM respectively) and robustly reversed adenosine-mediated inhibition of
proliferation, CD25 expression, and IFN-g and granzyme B production in
human CD8+ T cells. The compounds are highly selective (>10,000-fold)
against related ecto-nucleotidases (CD39, NTPDases2/3/8) as well as a
large panel of unrelated targets. In vivo, A000830 was well tolerated in
mice at plasma concentrations sustained well over IC90 (21 days). Thera-
peutic dosing of A000830 in mice in combination with an anti-PD-1 anti-
body resulted in robust inhibition of CT26 tumor growth, greater than
either treatment alone.
Conclusions
We have designed a series of potent and selective small molecule in-
hibitors of mouse and human CD73 exemplified by A000830 and
A001190. These inhibitors block the generation of adenosine from
AMP, reverse adenosine-mediated inhibition of human and mouse T
cell activation, and demonstrate promising anti-tumor activity when
dosed in combination with PD-1 blockade.Fig. 86 (abstract P405). Discrepancy of CD8+TILs in mucosal
melanoma (BOR: Best Overall Response, DOR: Duration of Response)P405
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Background
Both increased number of pre-treatment CD8+ T lymphocytes and
PD-L1 expression at the invasive tumor margin of advanced cutane-
ous melanoma metastases predicted improved treatment outcome
in patients receiving single agent therapy with the PD-1 inhibitor,
pembrolizumab [1, 2]. Association between CD8+ T cell numbers or
PD-L1 expression and response to combined immune-checkpoint
blockade in mucosal melanoma has not been established.
Methods
Four cases of advanced mucosal melanoma were each stained
with antibodies against CD8, and PD-L1 (SP-142; rabbit monoclo-
nal antibody, Spring Bioscience). A pan-melanoma (HMB-45,
MART-1, and tyrosinase), mouse monoclonal antibody (Biocare)
was used to identify the tumor area and margins. The pathologist
was blinded to the diagnosis and clinical information. Intensity of
immunostaining was measured with average optical density (OD).
CD8+ T cells and PD-L1 cells density were measured using ImageJ with
semi-automated Nuclei Segmentation-IHC Tool Box plugin developed
by Shu, et al. [3].
Results
The breakdown of PD-L1 and CD8 immunohistochemistry (IHC) from
three anorectal melanoma and one paranasal melanoma are de-
scribed in Fig. 86. Tumor PD-L1 staining was negative in all tumors
measured. CD8+ T cells are non-brisk in all tumors measured. There
is a discrepancy in density of total CD8+ T cells. CD8+ T cells at the
invasive margin are scarce.
Conclusions
This preliminary data is unable to demonstrate any definitive pat-
tern of CD8+ T cells or PD-L1 expression in a small case series of
mucosal melanoma. To further address the immunobiology of
mucosal melanoma and its microenvironment, the Melanoma Re-
search Foundation Breakthrough Consortium, is conducting, “A
Study to Estimate the Anti-tumor Activity and Identify Potential
Predictors of Response in Patients with Advanced Mucosal or
Acral Lentiginous Melanoma Receiving Standard Nivolumab in
Combination with Ipilimumab Followed by Nivolumab Monother-
apy.” The study will assess whether pre-existing immune cell infil-
trates and PD-L1-expressing cells at the invasive tumor margin
correlate with clinical response to combination checkpoint block-
ade in these uncommon melanoma subtypes.References
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Background
The balance between anti-tumor effector and immunosuppressive
immune cells in the tumor microenvironment (TME) is a key
determinant of response to cancer treatment. Phosphatase and
tensin homolog (PTEN) modulation can directly affect T cell medi-
ated immunotherapies. Specifically, the loss of PTEN has been
shown to promote resistance to this type of immunotherapy, sup-
porting the significance of this oncogenic pathway in immuno-
therapy responses and suggesting upregulation of PTEN activity
may have a favorable impact. Chemerin (RARRES2; retinoic acid
receptor responder 2) is a recently identified endogenous
leukocyte chemoattractant shown to recruit innate immune cells.
Previous studies in mouse tumor models suggest that chemerin
is a tumor suppressive chemoattractant cytokine, capable of
recruiting immune effector cells into the TME. RARRES2 is com-
monly downregulated across multiple tumor types compared to
normal tissue counterparts in microarray studies. Several methylome-
wide studies in various tumor types have identified RARRES2 as
one of the most hypermethylated genes, potentially leading to
decreased chemerin expression. Therefore, we hypothesized that
augmentation of chemerin in the TME might inhibit tumor pro-
gression and activity.
Methods
To test this, we exposed human cancer cell lines to exogenous che-
merin in vitro.
Results
Surprisingly, we found recombinant chemerin was able to upregulate
PTEN expression, a key cell survival and proliferation checkpoint. Spe-
cifically, mRNA and protein analyses show a significant upregulation
of PTEN after 48 hour chemerin exposure, without significant
changes in tumor cell proliferation or apoptosis. Additionally, we
found that treatment with chemerin was also able to significantly de-
crease tumor cell migration. Using siRNA, we found that knockdown
of CMKLR1 – the main chemerin receptor that mediates leukocyte
chemotaxis – abrogated chemerin-induced upregulation of PTEN,
suggesting chemerin’s effect on PTEN expression in tumor cells is
mediated through this G-protein coupled receptor. These studies
help delineate the role of chemerin/RARRES2 suppression within the
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pathway that may have implications on tumor progression and mi-
gration. Importantly, these effects of chemerin are independent of its
ability to recruit leukocytes into the TME, suggesting chemerin has
multiple mechanisms of anti-tumor action.
Conclusions
Overall, our studies show a novel finding that chemerin augments PTEN ac-
tivity via CMKLR1. Thus, chemerin-driven increased PTEN expression and ac-
tivity may help facilitate improved immunotherapy, not only by recruiting
immune effector cells into, but also by augmenting PTEN expression within
the TME. Future experimental studies will focus on the chemerin-driven up-
regulation of PTEN activity and its effects on immunotherapy strategies.
P407
Regulation of IL-15 in the tumor microenvironment by the STING
pathway
Rosa M. Santana Carrero1, Sarai Rivas2, Figen Beceren-Braun2, Scott
Anthony3, Kimberly S Schluns2
1The University of Texas Graduate School of Biomedical Sciences at
Houston, Houston, TX, USA; 2Department of Immunology, University of
Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of
Microbiology, University of Iowa, Iowa City, IA
Correspondence: Rosa M. Santana Carrero
(rosa.santanacarrero@uth.tmc.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P407
Background
Expression of IL-15 within the tumor correlates with increased tumor infiltrat-
ing T cells, decreased metastasis and increased patient survival [1]. Unfortu-
nately, the regulation of IL-15 within the tumor microenvironment is not
clear. In our recent study we showed that agonists of the Stimulator of Inter-
feron Genes (STING) pathway are potent inducers of soluble IL-15 complexes
(sIL-15c) in vivo [2]. Since the STING pathway is important for regulation of
type I interferons (IFNs) in tumors, we set out to determine if sIL-15c are pro-
duced in the tumormicroenvironment and are regulated by STING signaling.
Methods
C57BL/6, IL-15Ra−/−, IFNAR1−/− and Tmem173−/− mice were chal-
lenged with 300,000 B16-F10 melanoma cells by s.c. injection. Tumors
of various sizes were isolated and sIL-15c were measured in homoge-
nates from tumors and spleens using ELISAs. For stimulation of STING
pathway, mice were administered c-di-GMP (25ug/mouse) via intratu-
moral injection every three days. To measure proliferation, OT-I CD8+ T
cells were CFSE labelled and adoptively transferred into wild-type and
IL-15Ra−/− mice. Tumors, spleens and tumor-draining lymph nodes
were processed and stained for analysis via flow cytometry.
Results
Levels of sIL-15cwere high in homogenates from small tumors and low in lar-
ger tumors, but were absent in homogenates from IL-15Ra −/−mice indicat-
ing sIL-15c were produced by the tumor stroma. Tumors isolated from
IFNAR1−/− mice contained decreased levels of sIL-15c, but interestingly,
those isolated frommice with a defective STING pathway had normal levels
of sIL-15c suggesting that type I IFN-dependent, but STING-independent
pathwaywas required for intratumoral IL-15 regulation. Nonetheless, intratu-
moral delivery of STING agonists enhanced production of sIL-15c in B16 tu-
mors. Whereas treatment of tumors with STING agonists promoted tumor
regression and enhanced proliferation of tumor-specific CD8+ T cells, these
effectswere severely blunted in IL-15Ra−/−mice.
Conclusions
These findings indicate that IL-15 is a critical factor mediating the
anti-tumor responses induced by STING signaling.
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Background
Regulatory T cells (Tregs) are a specialized suppressive CD4
+ T cell sub-
population capable of restricting deleterious immune responses to self
and foreign antigens that underlie autoimmune and chronic inflamma-
tion. Conversely, Tregs block beneficial anti-tumor immune responses
and thereby pose severe impediment to effective tumor immunother-
apies. Although Treg depletion reduces tumor burden, the ensuing
autoimmune sequelae limits its utility in the clinic. Thus targeted ap-
proaches limiting Treg cell activity specific to the tumor microenviron-
ment are warranted. One of the major mechanism by which Tregs exert
their suppressive effects is via secretion of inhibitory cytokines. How-
ever, the physiological relevance of this mode of suppression to the
tumor microenvironment remains largely unclear.
Methods
To interrogate the role of the two predominant Treg suppressive cyto-
kines, IL35 and IL10, in the tumor setting, we injected B16F10 tumors
intradermally into Foxp3Cre-YFP mice bearing reporters for IL35 and
IL10 (Foxp3CreYFP.Ebi3tdTom.IL10GFP). This enabled tracking of Tregs ex-
pressing/co-expressing IL35 and IL10 in the tumor microenvironment.
We also performed tumor experiments in mice bearing IL35-deficient
Tregs (Foxp3
Cre-YFP.Ebi3L/L) and IL10-deficient Tregs (Foxp3
Cre-YFP.IL10L/L)
to assess the impact of Treg-specific deletion of the two suppressive
cytokines on tumor growth and CD8+ T cell effector function.
Results
Preliminary studies using the dual cytokine reporter mice reveal dis-
tinct populations of Tregs expressing IL35 and IL10 in the B16 tumor
microenvironment, with a preferential enrichment of IL35+ Tregs and
little to no co-expression of the two cytokines on Tregs. Reduced
tumor burden was noted in both Foxp3Cre-YFP.Ebi3L/L and Foxp3Cre-
YFP.IL10L/L mice. Interestingly, this was associated with a significant
loss of multiple inhibitory receptors (IRs) on CD8+ T cells in both
floxed environments. These findings suggest a potential role for the
Treg-derived inhibitory cytokines in inducing multi-IR
+ exhausted
state on CD8+ T cells in tumors.
Conclusions
The dramatic loss of IR+ T cells in mice bearing IL35 and IL10-
deficient Tregs highlights the possibility of targeting these inhibitory
cytokines to limit T cell exhaustion in tumors. Our study uncovers a
novel mechanism of Treg suppression within the tumor microenviron-
ment wherein Treg-derived inhibitory cytokines induce a state of dys-
function on the effector T cells thereby contributing to tumor
immune evasion.
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Immune signatures of T cell infiltration for melanoma and ovarian
cancer are associated with improved survival. Mechanisms enabling
and regulating T cell infiltration in the tumor microenvironment are
being elucidated. We hypothesized that genes overexpressed in tu-
mors without T cell infiltration may limit T cell infiltration and have
prognostic implications.
Methods
Gene expression profiling of 44 human melanoma metastases had
previously identified subsets with or without Th1 immune signatures.
We identified genes overexpressed five-fold or more in tumors lack-
ing immune signatures, at a significance level of p < 0.01. These find-
ings were further validated in gene expression data from melanoma
metastases and ovarian cancers. To assess associations with survival,
RNAseq data and patient survival data from The Cancer Genome
Atlas (TCGA) were assessed with Kaplan-Meier curves, and log-rank
tests.
Results
We identified 8 genes overexpressed in human melanomas and
ovarian cancers lacking Th1 immune signatures, and which en-
code molecules with mechanical barrier function in normal tis-
sues: filaggrin (FLG), tumor-associated calcium signal transducer 2
(TACSTD2), and 6 desmosomal proteins (DST, DSC3, DSP, PPL,
PKP3, and JUP). This association was validated in another 114
melanoma metastases, where DST expression alone was sufficient
to identify melanomas without immune signatures, while FLG and
the other 6 putative barrier molecules were overexpressed in a
different subset of melanomas lacking immune signatures. Similar
associations were identified in a set of 186 ovarian cancers. RNA-
seq data from 471 melanomas and 307 ovarian cancers in the
TCGA further supported these findings and also revealed that
overexpression of barrier molecules was largely independent of
β-catenin/WNT and endothelin receptor B gene expression. Over-
expression of barrier molecules was associated with early patient
mortality for melanoma (p = 0.0002) and ovarian cancer (p < 0.01).
This was true for FLG for melanoma (p = 0.012) and ovarian can-
cer (p = 0.006), whereas DST overexpression was negatively associ-
ated with CD8 gene expression, but not with patient survival.
Conclusions
Overexpression of FLG or DST identifies 2 distinct patient popula-
tions with low immune cell infiltration in melanoma and ovarian
cancers, but with different prognostic implications for each. These
data raise the possibility that molecules with mechanical barrier
function in skin and other tissues may be used by cancer cells to
protect them from immune cell infiltration and immune-mediated
destruction.
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Background
CD8+ T cell infiltration into the tumor microenvironment appears to
be correlative for clinical response to checkpoint blockade immuno-
therapy. Understanding the molecular mechanisms which cause lack
of T cell infiltration will be instrumental for the development of novel
treatment combinations to expand clinical efficacy. Recent studies
have demonstrated that tumor cell-intrinsic signaling pathways,including the Wnt/β-catenin pathway, result in a lack of T cell infiltra-
tion in patients and genetically engineered mouse (GEM) models.
Mechanistically, activation of the Wnt/β-catenin signaling pathway in
the primary tumor mediates inhibition of priming of tumor-antigen-
specific T cells through failed recruitment of Batf3-lineage DCs. How-
ever, it was not clear whether activation of a tumor cell-intrinsic sig-
naling pathway could also mediate secondary resistance in the
presence of a systemic anti-tumor immune response. In addition, it
was not known whether adoptive T cell transfer would be a potential
therapeutic option for non-T cell inflamed tumors.
Methods
To address those questions we used GEMs for murine melanoma
with or without activation of the Wnt/β-catenin signaling pathway
and engineered to expresses the model antigen SIY (SIYRYYGL).
Results
By using these GEMs we now show that tumor cell-intrinsic activa-
tion of β-catenin was capable to mediate secondary resistance by ex-
cluding effector T cell from the tumor microenvironment. Effector T
cell infiltration in β-catenin negative tumors was further associated
with the emergence of immuno-edited tumor escape variants, which
were never observed in β-catenin positive non-T cell inflamed tu-
mors. Consistently, adoptive T cell transfer of antigen-specific T cells
failed to provide therapeutic benefit in tumors with activated β-
catenin signaling. Using intravital-microscopy we found that, while
effector T cells in β-catenin negative tumors made direct tumor cell
contact and showed a dynamic and directed migratory behavior, the
few effector T cells found in β-catenin positive tumor failed to en-
gage close contact with tumor cells and were immobile within areas
having the appearance of stroma. Mechanistically, we identified a
lack of expression of the chemokines CXCL9 and CXCL10 in tumor
with activated b-catenin signaling, which a are normally produced by
CD103+ Batf3-driven DCs.
Conclusions
Our data support the notion that CD103+ dendritic cells within the
tumor microenvironment are essential for effector CD8+ T cell recruit-
ment and mobility. Strategies to promote CD103+ dendritic cell
accumulation and activation within the tumor microenvironment
could be essential for expanding efficacy to checkpoint blockade
immunotherapy.
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Background
Previously, we have reported that cysteamine, an anti-oxidant
aminothiol, inhibited the tumor invasion in vitro and metastasis of
pancreatic cancer in vivo in mouse models of human pancreatic can-
cer. We have also shown that subcutaneous cysteamine treatment
improves the survival of mice bearing orthotopically transplanted
pancreatic tumors. Herein, we examined whether cysteamine can in-
hibit invasion and metastasis of other human cancers.
Methods
We examined cysteamine’s anti-invasion effects in 6 human ovarian
cancer cell lines by a matrigel invasion assay. To study the mechan-
ism of action, we evaluated the cytotoxic activity of cysteamine
in vitro and measured the effect of cysteamine on matrix metallopro-
teinases (MMP), which are known to be involved in metastasis. We
examined the anti-metastatic effect of cysteamine in two orthotopic
murine models of human ovarian cancer by monitoring peritoneal
metastases. A2780 and IGROV-1 ovarian cancer cells were surgically
implanted orthotopically in the ovary followed by monitoring tumor
growth and peritoneal metastasis using a high-resolution ultrasound
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teamine (0, 100, or 250 mg/kg/day) were subcutaneously injected
twice a day until the end of the experiment.
Results
We observed that cysteamine inhibited cell invasion in vitro in a
concentration-dependent manner. Similar to invasion, MMP activity
was inhibited by cysteamine in a concentration-dependent manner.
We next examined the anti-metastatic effect of cysteamine on peri-
toneal metastasis in two orthotopic murine models of human ovarian
cancer. Cysteamine significantly decreased the number of metastases
and total weight of metastatic lesions in these mice (p < 0.01 in
A2780 and p < 0.05 in IGROV-1 xenografts compared to untreated
control mice), while the primary tumor volumes and weights were
not changed. We did not observe any symptoms of general toxicity
(such as general appearance, body weight, or mortality) in animals
treated at the highest dose of cysteamine. Similar to the in vitro
results, MMP activity was significantly decreased in primary tu-
mors in both A2780 & IGROV-1 xenograft models treated with
cysteamine (p < 0.05). Tumor growth was also monitored weekly
by ultrasound volumetric analyses. We observed that tumor vol-
umes measured by ultrasound imaging correlated positively with
the ex vivo tumor weight measurements following dissection of
the primary tumor at the end of experiment (Spearman r = 0.7870
in A2780 and 0.9800 in IGROV-1 xenografts).
Conclusions
Based on these results, we conclude that cysteamine may be a useful
therapeutic option for ovarian cancer as a mono- or combination-
therapy with other anti-cancer agents such as cancer vaccines and
immunotherapy.
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Background
Immune checkpoint therapy recently led to the first regulatory ap-
proval in metastatic bladder cancer in well over a decade. Despite re-
markable responses observed in some patients, the objective
response rate remains 15 %. We recently reported a characterization
of bladder cancers lacking a T cell-inflamed tumor microenviron-
ment, which has been associated with lack of response to immune
checkpoint therapy. We observed that FGFR3 activating mutations
were exclusively present in non-T cell-inflamed tumors. In order to
further substantiate our findings, we analyzed an independent cohort
of non-T cell inflamed bladder cancers.
Methods
Ninety-three samples were analyzed from a validation data set (GSE
31684) with gene expression profiling. Affymetrix microarray files
were downloaded from the GEO database and preprocessed to gen-
erate normalized gene expression values for 20,390 genes. Consen-
sus clustering of samples was conducted using 725 genes from our
prior TCGA analysis, and repeated using a refined 160 gene set de-
veloped across multiple cancer types by Methods previously de-
scribed. Immune subtypes were called based on gene expression.
Differentially expressed genes were filtered by FDR-adjusted P-
value < 0.01 and fold change ≥ 1.5.
Results
We first evaluated the performance of our refined gene expression
signature, which has recently been adapted for application across all
solid tumor types. Comparing previous and current gene sets derived
from our 13 gene T cell-inflamed signature, we found ourclassification to be robust with 89 % (83/93) concordance in immune
subtype calling. We noted a higher proportion of samples were non-
T cell-inflamed compared with bladder cancers in TCGA (48 % vs.
33 %). We confirmed a strong inverse correlation between expression
of CD8A and FGFR3 (P < 0.0001). Furthermore, FGFR3 overexpressing
tumors by median dichotomization had significantly lower expression
of PD-L1, IDO1, LAG3, and TIM3 (all P ≤ 0.01). The association be-
tween FGFR3 and FOXP3 was not significant (P = 0.41). CD8A was
concordantly expressed with PD-L1, IDO1, LAG3, FOXP3, and TIM3
(P < 0.0001), consistent with data from TCGA. Finally, differentially
expressed genes were compiled and enriched pathways were
identified by Ingenuity Pathway Analysis. In non-T cell-inflamed
tumors from this data set, activation of β-catenin, PPARG and
SMARCA4 pathways was observed (P < 0.0001).
Conclusions
In summary, we confirm the fidelity of our gene expression classifica-
tion of non-T cell-inflamed bladder cancers across different gene ex-
pression platforms and data sets. In addition to activating mutations,
FGFR3 overexpression occurs preferentially in the non-T cell-inflamed
immune subtype lacking PD-L1 expression.
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Background
Despite aggressive surgery and chemotherapy, the 5-year survival
rate for patients with ovarian cancer is very low, 37 % for stage
III and 25 % for stage IV [1]. Previously, we have demonstrated a
high level of synergy among TLR-3 ligands, IFNa and COX-2
blockers in inducing chemokines, which attract the desirable
cytotoxic T cells, Th1-cells and NK cells in colorectal cancer mi-
croenvironments and limited local production of CCL22, the che-
mokine implicated in the accumulation of T regulatory cells [2].
In this study, we investigated an optimized combinatorial adju-
vant to reprogram the tumor microenvironment (TME) of ovarian
cancer.
Methods
Ovarian cancer specimens were divided into 4-mm biopsies and cul-
tured for 24 hours in the presence of IFNa, indomethacin (COX-1/2
inhibitor) or/and one of two synthetic TLR3 ligands Poly-I:C (non-
selective activator of TLR3) rintatolimod (Ampligen), or their com-
binations. Biopsies were harvested for mRNA as well as for con-
focal microscopy and culture supernatants were analyzed for
CCL5, CXCL10 and CCL22 concentration. Alternatively, established
ovarian cancer cell lines (PE01 and PE04) or monocyte-derived
macrophages were used in analogous experiments. Chemotaxis assays
were performed using pre-activated CD8+ T cells and supernatants
from the differentially treated ovarian cancer specimens.
Results
We observed that the combination of TLR-3 ligands, IFNa and COX1/
2 blockers selectively induce the desirable chemokines CCL5 and
CXCL10 and suppressed CCL22 in ovarian cancer with similar results
in the macrophages and ovarian cancer cell lines. Unexpectedly,
IFNa + poly-I:C but not IFNa + rintatolimod, also promoted the
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through addition of COX-2 inhibitors. Furthermore, the induction of
CCL5 was enhanced by the addition of COX1/2 inhibitor. Compared
to poly-I:C, the positive effects of the selective TLR-3 ligand, rintatoli-
mod, were not dependent on the addition of indomethacin.
Conclusions
We demonstrate the feasibility of selective modulation of the ovarian
TME, using combinations of different clinical reagents, in order to im-
prove the local balance between tumor-infiltrating T effector and T
regulatory cells. We show for the first time, that poly-I:C induces un-
desirable COX2-dependent suppressive factors, which can be elimi-
nated through addition of the COX-1/2 inhibitor, indomethacin, or
through usage of the selective TLR-3 ligand, rintatolimod.
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Background
Inflammation plays pivotal roles in carcinogenesis and formation of
the immunosuppressive microenvironment of prostate tumors. How-
ever, molecular mechanisms of crosstalk between cancer cells and
immune cells at the tumor site are only partly understood. Our re-
cent study demonstrated that advanced, castration-resistant prostate
cancer (CRPC) cells express innate immune receptor, Toll-Like Recep-
tor 9 (TLR9). TLR9 signaling through NF-kB/RELA and STAT3 pro-
moted tumor propagating potential and self-renewal of prostate
cancer cells. Here, we evaluated the effect of cancer cell-intrinsic
TLR9 signaling on the composition of tumor microenvironment.
Methods
For temporal control of TLR9 expression, we introduced tetracycline-
inducible TLR9 expression system (Tet-On) into mouse Ras/Myc-
driven (RM9) prostate cancer cells.
Results
The induction of TLR9 expression in RM9 tumors in vivo correlated
with the accumulation of polymorphonuclear myeloid-derived sup-
pressor cells (PMN-MDSCs; CD11b+Ly6CINTLy6GHI). The PMN-MDSC in
TLR9HI-tumors showed elevated levels of activated STAT3, a master
regulator of immunosuppressive MDSC activities. Accordingly, tumor-
associated PMN-MDSCs isolated from TLR9HI-, but not from TLR9LO-
RM9 tumors, expressed high level of immunosuppressive mediators
such as Arginase-1 and IL-10, and showed augmented suppressive
effects on T cell proliferation. TLR9 expression in mouse and human
(LNCaP and PC3) prostate cancer cells resulted in altered cytokine/
chemokine secretion with significant upregulation of an IL-6 family
cytokine, leukemia inhibitory factor (LIF). Our preliminary analysis
confirmed elevated levels of LIF in plasma from prostate cancer pa-
tients compared to healthy subjects. On molecular level, TLR9 trig-
gered direct binding of the NF-kB and STAT3 to the LIF promoter as
verified by chromatin immunoprecipitation (ChIP) assays. The
antibody-mediated neutralization of LIF significantly inhibited tumorgrowth in vivo with concomitant reduction in the accumulation of
pSTAT3+ PMN-MDSCs. Finally, we used an oligonucleotide-based ap-
proach to inhibit STAT3 in TLR9 expressing RM9 tumor cells and in
tumor-associated myeloid cells such as PMN-MDSCs. Local injection
of CpG-STAT3 inhibitor reduced growth of RM9 prostate tumors at
the treated and in the distant site suggesting generation of systemic
antitumor immune responses.
Conclusions
Collectively, TLR9 signaling in prostate cancer cells induces tolero-
genic tumor microenvironment through altering cytokine and che-
mokine and subsequent activation of STAT3 in tumor-infiltrated
myeloid cells. In addition, the results suggest therapeutic potential of
targeting TLR9+ prostate cancer cells and tumor-associated PMN-
MDSC to eliminate both tumorigenic and tolerogenic effects of
STAT3 signaling in the tumor microenvironment.
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Background
To enhance the anti-tumor effects of current immunotherapies in-
cluding immune checkpoint blockade therapies, it is important to
reverse the cancer-induced immunosuppression. Ovarian clear cell
carcinoma (OCCC), the second most major subtype of ovarian
cancer in Japan, produces high amounts of immunosuppressive
cytokines such as IL-6 and IL-8, which were correlated with poor
prognoses. A transcriptional factor HNF-1β preferentially activated
in human OCCC contributes to various malignant phenotypes in-
cluding chemoresistance and glucose metabolism. In this study,
we have investigated roles of HNF-1β in the immunosuppressive
activity of human OCCC.
Methods
We have evaluated the number of tumor-infiltrating T cells in human
OCCC tissues. We have evaluated the contribution of HNF-1β activa-
tion in OCCC to the suppression of DC function through the produc-
tion of IL-6 in vitro and in vivo. Finally, we have screened an existing
drug library for agents which have an activity to suppress IL-6 pro-
duction from OCCC and evaluated their effects in vivo.
Results
Tumor-infiltrating T cells in OCCC were significantly fewer than those
in other types of cancers including serous ovarian cancers. HNF-1β
knockdown and overexpression experiments revealed that HNF-1β
induced IL-6 and IL-8 production via NF-κB and STAT3 activation in
OCCC. Suppressive activities of human OCCC cell line culture super-
natants on human monocyte-derived dendritic cells (DC) were re-
duced in vitro by knockdown of HNF-1β partly through decrease of
IL-6. Knockdown of HNF-1β in a human OCCC cell line resulted in the
restoration of T cell stimulatory activity of murine DC in nude mice
implanted with human OCCC partly through decrease of human IL-6
in vivo. From the drug screening, various existing drugs having activ-
ity to inhibit STAT-3 or NF-κB were found to suppress IL-6 production
from OCCC and to restore immuno-competence of cancer-bearing
mice.
Conclusions
HNF-1β activation in human OCCC is a possible upstream event for
induction of immunosuppression by IL-6 and IL-8 production via NF-
κB and STAT3 activation and that combination of drugs targeting
HNF-1β/STAT3/NF-kB pathway may enhance the efficacy of current
immunotherapies for OCCC patients.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fi-
brotic stroma and poor immune infiltrate, in part driven by can-
cer-associated fibroblasts (CAFs). CAFs, which selectively express
fibroblast activation protein (FAP), contribute to immune escape
via sequestration of anti-tumor CD8+ T cells, upregulation of im-
mune checkpoint ligand expression, and immunosuppressive
cytokine production and polarization of tumor infiltrating immune
cells.
Methods
We established syngeneic pancreatic tumors in immune competent
C57BL/6 mice using Panc02 cells. From days 7-20, mice were treated
with FAP inhibitor UAMC-1110 or control. Radiation (RT) was deliv-
ered exclusively to the tumor using a 1cm collimator on the Small
Animal Radiation Research Platform, 10Gy x 3 daily fractions on day
14, 15, and 16. FAP knockout mice were challenged with Panc02 or
Panc02-SIY cells and radiated 10Gy x 3 on days 14-16. Tumors were
measured, and mice followed for survival. Using the same treatment
groups above, tumors were harvested for flow cytometry and multi-
parameter immunofluorescence on day 14, 23, and 43. Splenocytes
were harvested and pulsed with SIY peptide and tested for intracellu-
lar cytokine production on day 14 and 23. Tumor infiltrating macro-
phages were FACs sorted and western blot was performed to
determine M1 vs M2 polarization. Tumor cytokines were assessed
using cytokine bead assay.
Results
UAMC-1110 alone had no effect on tumor growth or survival. RT
caused a transient growth delay, resulting in a survival advan-
tage. Combination treatment with radiation and UAMC-1110 re-
sulted in two temporally distinct growth delays: an initial tumor
growth delay significant over radiation alone at day 22, and a
second late response at day 43; but did not translate to a sur-
vival advantage over RT. At day 14, UAMC-1110 treatment re-
sulted in fewer macrophages. At day 23, RT increased CD11b+
tumor infiltrates, MDSCs, and CD3+ infiltrates. Tumor immune in-
filtrates were equivalent at day 43. Radiation and combination
treatment with UAMC-1110 increased collagen deposition. FAP
knockout mice had equivalent response to radiation compared to
wildtype control. FAP KO tumors had fewer macrophages and
MDSCs, and more antigen-specific T cells following radiation, but
not prior to radiation.
Conclusions
We tested a novel specific FAP inhibitor with radiation in a mur-
ine PDAC model. We found FAP inhibition favorably altered
tumor immune infiltrate, and increase antigen-specific T cells fol-
lowing radiation, but was insufficient to result in a survival ad-
vantage. While FAP may be selectively expressed by CAFs,
inhibition of its function is not seem sufficient to influence in
vivo radiosensitivity. We propose a more comprehensive targeting
of CAFs may be required to influence radiation response.Acknowledgements
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Background
Tumors may evade the immune system, in part by exploiting interac-
tions between T cells and the tumor. Renal cell carcinoma (RCC) is a
poorly responsive tumor to conventional cytotoxic chemotherapies,
although it is sensitive to IL-2, which still remains as the treatment of
choice. The FDA has approved novel PD-1 immunotherapies, which
have shown survival benefits for patients with metastatic RCC. How-
ever, preclinical studies and early phase clinical trials suggest that re-
sistance mechanisms exploited by tumors may limit the effectiveness
of these therapies. We believe that the heterogeneity of RCC tumors
can contribute to the poor responses in RCC. In this work, we are
studying the role the enzyme arginase 2 (ARG2) plays in the expres-
sion of PD-L1 in RCC tumors. Different levels of ARG2 expression in
RCC contributes proportionally to the generation of T cell dysfunc-
tion. The understanding of this mechanism will be crucial for probing
human immune responses and tumor biology in order to understand
what distinguishes responder vs. non-responder patients. Therefore,
our hypothesis is that the expression of PD-L1 in RCC tumors is regu-
lated by ARG2 and blocking this enzyme will reduce its expression,
resulting in improved antitumor activity.
Methods
Three murine RCC cell lines, CL-2 (low-ARG2), CL-19 (high-ARG2), and
Renca (median-ARG2) were cultured at different time points: 1, 3, 6,
and 24 h in the presence or absence of IFNγ and ARG2 inhibitor BEC.
Expression of PD-L1 was assessed by flow cytometry, tumor cell sur-
vival by MTT assay, ARG activity by enzymatic assays and superna-
tants for L-arginine by HPLC.
Results
PD-L1 expression was similar between CL-2 and CL-19 cell lines (17-
20 %) that significantly increased up to 95 % after 6 h of IFNγ stimu-
lation (2.5 U/ML). Interestingly, we observed a constitutive high ex-
pression of PD-L1 in Renca cells (85-90 %) in non-stimulated cells.
When cells were treated with ARG2 inhibitor, PD-L1 expression de-
creased 5 fold in CL-2 and CL19 cells but had not effect on Renca
cells. High concentrations of IFNγ (10U/ML) had cytotoxic effects in
CL-2 and CL-19 but not in Renca cells.
Conclusions
These results suggest that 1) RCC heterogeneity plays an import-
ant role in the expression of immune checkpoints and in path-
ways that can disable T cells. This finding can contribute to
determine what patients may benefit or not from anti PD-1 ther-
apy. 2) The role of IFNγ in this process is unclear and is currently
being investigated.
